

TITLE: SPIRO AND DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS

CROSS-REFERENCE TO RELATED APPLICATION

This invention is a continuation-in-part of co-pending patent application number
5 PCT/US02/19767 filed June 21, 2002, which claims priority to U.S. Pat. No. 6,486,199, the disclosures of which are hereby expressly incorporated by reference.

FIELD OF THE INVENTION

This invention relates to compositions and methods for treating malaria.
Specifically, this invention relates to pharmaceutical compositions including spiro and
10 dispiro trioxolanes, and methods of their use and manufacture.

BACKGROUND OF THE INVENTION

Malaria is an acute and often chronic infectious disease resulting from the presence
of protozoan parasites within red blood cells. Caused by single-celled parasites of the
genus *Plasmodium*, malaria is transmitted from person to person by the bite of female
15 mosquitos.

Although once prevalent in North America and other temperate regions of the world, today malaria occurs mostly in tropical and subtropic countries. Each year, between 400 million and 600 million people contract the disease, and 1.5 million to 2.7 million die of the disease.

20 Four species of *Plasmodium* protozoan parasites are generally responsible for malaria, including *Plasmodium vivax*, *Plasmodium falciparum*, *Plasmodium malariae*, and *Plasmodium ovale*. Of the four, *Plasmodium falciparum* is the most dangerous, accounting for half of all clinical cases of malaria and 90% of deaths from the disease.

The transmission of malaria begins when a female mosquito bites a human already
25 infected with the malaria parasite. When the infected mosquito bites another human, sporozoites in the mosquito's saliva are transferred into the blood, which then travel to the liver. In the liver, the sporozoites divide rapidly, then enter the bloodstream where they invade red blood cells. Inside these blood cells, the merozoites multiply rapidly until they cause the red blood cells to burst, releasing into the blood stream a new generation of
30 merozoites that then infect other red blood cells.

The symptoms associated with malaria are generally associated with the bursting of the red blood cells. The destruction of the red blood cells spills wastes, toxin, and other

debris into the blood. This in turn causes an intense fever that can leave the infected individual exhausted and bedridden. More severe symptoms associated with repeat infections and/or infection by *Plasmodium falciparum* include anemia, severe headaches, convulsions, delirium and, in some instances, death.

5 The treatment of malaria has been especially difficult due to the ability of malaria parasites to develop resistance to drugs. Quinine, an antimalarial compound that is extracted from the bark of the South American cinchona tree, is one of the oldest and most effective pharmaceuticals in existence. The downside to quinine is that it is short-acting, and fails to prevent disease relapses. Further, quinine is associated with side effects
10 ranging from dizziness to deafness.

Chloroquine is a synthetic chemical similar to quinine. It became the drug of choice for malaria when it was developed in the 1940s due to its effectiveness, ease of manufacture, and general lack of side effects. However, in the last few decades, malaria parasites in many areas of the world have become resistant to chloroquine.

15 Mefloquine is another synthetic analog of quinine that has been used in the treatment of malaria. Malaria parasites have also developed resistance to mefloquine, however. Mefloquine is also associated with undesirable central nervous side effects in some patients, including hallucinations and vivid nightmares.

20 Antifolate drugs are effective against malaria parasites by inhibiting their reproduction. Although the parasites have also developed a resistance to antifolate drugs, the drugs can still be used effectively in combination with other types of antimalarials. The use of combination therapies in treating malaria has the drawbacks of being inconvenient and expensive, however.

25 More recent developments in the treatment of malaria have involved the use of the peroxide functional group, as exemplified by the drug artemisinin, which contains a unique 1,2,4-trioxane heterocyclic pharmacophore. The antimalarial action of artemisinin is due to its reaction with the iron in free heme molecules in the malaria parasite with the generation of free radicals leading to cellular destruction.

30 The discovery of artemisinin (qinghaosu), a naturally occurring endoperoxide sesquiterpene lactone (Meshnick et al., 1996; Vroman et al. 1999; Dhingra et al., 2000) initiated a substantial effort to elucidate its molecular mechanism of action (Jefford, 1997;

Cumming et al., 1997) and to identify novel antimalarial peroxides (Dong and Vennerstrom, 2001). Many synthetic 1,2,4-trioxanes, 1,2,4,5-tetraoxanes, and other endoperoxides have been prepared.

Although the clinically useful semisynthetic artemisinin derivatives are rapid acting and potent antimalarial drugs, they have several disadvantages including recrudescence, neurotoxicity, (Wesche et al., 1994) and metabolic instability. (White, 1994). A fair number of these compounds are quite active *in vitro*, but most suffer from low oral activity. (White, 1994; van Agtmael et al., 1999). Although many synthetic antimalarial 1,2,4-trioxanes have since been prepared (Cumming et al., 1996; Jefford, 1997), there exists a need in the art to identify new peroxide antimalarial agents, especially those which are easily synthesized, are devoid of neurotoxicity, and which possess improved pharmacokinetic properties, e.g. improved stability, oral absorption, etc.

Accordingly, it is a primary objective of the present invention to provide compositions and methods for prophylaxis and treatment of malaria using spiro and dispiro 1,2,4-trioxolanes.

It is a further objective of the present invention to provide a composition and method for prophylaxis and treatment of malaria using spiro and dispiro 1,2,4-trioxolanes that is nontoxic.

It is a further objective of the present invention to provide a composition and method for prophylaxis and treatment of malaria using spiro and dispiro 1,2,4-trioxolanes that is metabolically stable and orally active.

It is yet a further objective of the present invention to provide a composition and method for prophylaxis and cost-effective treatment of malaria using spiro and dispiro 1,2,4-trioxolanes that do not involve a treatment regimen of more than three days.

It is a further objective of the present invention to provide compositions and methods for prophylaxis and treatment of malaria using spiro and dispiro 1,2,4-trioxolanes that can be used either as stand-alone medicaments or in combination with other agents.

It is still a further objective of the present invention to provide novel intermediates for synthesizing compositions for prophylaxis and treatment of malaria.

The method and means of accomplishing each of the above objectives as well as others will become apparent from the detailed description of the invention which follows hereafter.

SUMMARY OF THE INVENTION

5 The invention describes a method and composition for treating malaria with spiro and dispiro 1,2,4-trioxolanes, their prodrugs and analogues. The trioxolanes of this invention are sterically hindered on one side of the trioxolane heterocycle in order to provide chemical and metabolic stability to the trioxolane ring for better *in vivo* activity. In one embodiment, the spiro and dispiro trioxolanes are sterically hindered with an
10 unsubstituted, mono-, di-, or poly-substituted C₅-C₁₂ spiro cycloalkyl group, which may be spiroadamantane. In this embodiment, the spiro and dispiro trioxolanes may include a spirocyclohexyl that is functionalized or substituted at the 4-position or a spiropiperidyl ring that is functionalized or substituted at the nitrogen atom. In another embodiment, the trioxolanes of this invention include an alkyl bridge from the 4-position of the
15 spirocyclohexyl ring connecting a substituent that is most preferably a weak base. The invention embraces achiral, achiral diastereomers, racemic mixtures, as well as enantiomeric forms of the compounds.

20 The trioxolanes of this invention possess excellent potency and efficacy against *Plasmodium* parasites, and a low degree of neurotoxicity. In addition, several of the trioxolanes are suitable for both oral and non-oral administration. Moreover, in comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy and inexpensive to synthesize, and can be used effectively alone or in conjunction with other antimalarials.


DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

25 The present invention relates to the development of spiro and dispiro 1,2,4-trioxolanes for use in the prophylaxis and treatment of malaria. The present invention is predicated upon the unexpected discovery that trioxolanes that are relatively sterically hindered on at least one side of the trioxolane heterocycle provide metabolic and chemical stability to the trioxolane ring, thereby providing better *in vivo* activity, especially with
30 respect to oral administration.

As used herein the term "prophylaxis-effective amount" refers to a concentration of compound of this invention that is effective in inhibiting or preventing infection and subsequent disease by malarial parasites. Likewise, the term "treatment-effective amount" refers to a concentration of compound that is effective in treating malaria in terms of preventing an increase in the concentration of malarial parasites, decreasing the concentration of malarial parasites, and/or "curing" a malaria infection, i.e. survival for 30 days post-infection.

Tetrasubstituted trioxolanes are relatively stable peroxidic compounds based on literature precedent (Griesbaum et al., 1997a; 1997b). This may be due, in part, to the lack of α -hydrogen atoms. The present inventors have synthesized new compounds in the trioxolane class having both superior antimalarial potency and oral efficacy. Furthermore, the compounds of this invention have low toxicity, and half-lives conducive to treatment of malaria which are believed will permit short-term treatment regimens comparing favorably to other artemisinin-like drugs. These compounds may also be used in malaria prophylaxis.


In previous application, the present inventors disclosed certain novel tetrasubstituted trioxolanes having the following structural formula:



wherein R₁, R₂, R₃, and R₄ represent combinations of ring systems, acyclic systems, and functional groups that provide sufficient steric hindrance about the trioxolane ring in order to give the ring chemical and metabolic stability. R₁, R₂, R₃ and R₄ may be the same or different, and may be a linear or branched alkyl, aryl, or alkaryl group which is optionally substituted. In the alternative, R₁ and R₂ taken together and/or R₃ and R₄ taken together may form an alicyclic group which is optionally interrupted by one or more oxygen, sulfur or nitrogen atoms and which group is optionally substituted. In no event may any of R₁, R₂, R₃ or R₄ be hydrogen.

In one embodiment, the compounds include those whereby R₁ and R₂ taken together and/or R₃ and R₄ taken together is a mono- or di-substituted C₅-C₁₂ spirocycloalkyl group which is optionally interrupted by one or more oxygen, sulfur, or nitrogen atoms, and which group is optionally substituted. In another embodiment, R₁ and R₂ taken together or R₃ and R₄ is spiroadamantane.

The present invention discloses a new embodiment of trioxolane compounds having the following structure:




10

The spirocyclohexyl ring may be optionally interrupted by one or more oxygen, sulfur or nitrogen atoms. In this regard, R₁ and R₂ may be the same or different, and may be hydrogen, substituted or unsubstituted linear or branched alkyl, aryl, and alkaryl groups and 15 substituted or unsubstituted alicyclic groups that may be interrupted by one or more oxygen, sulfur or nitrogen atoms, substituted or unsubstituted aromatic or heterocyclic groups that may be interrupted by one or more oxygen, sulfur or nitrogen atoms, a hydroxy group, or a halogen. In one embodiment, R₁ or R₂ is an amide. It has been unexpectedly found that amide-containing substituents at the 4-position provide antimalarial compounds 20 with good oral absorption, good antimalarial activity, and good pharmacokinetics, i.e. rates of absorption, metabolism, and elimination that are suitable and advantageous for the prophylaxis and treatment of malaria.



In another embodiment, the compounds of this invention have the following structural formula:

25



whereby R_3 is $(CH_2)_n-Y$. In this formula, Y represents a functional group that, in one embodiment, is non-acidic, and in another embodiment is a weak base. The Y functional group may be an alkyl, ketone, acid, alcohol, amine, amide, sulfonamide, guanidine, ether, ester, oxime, urea, oxime ether, sulfone, lactone, carbamate, semicarbazone, phenyl, or heterocycle. In one embodiment, $n = 1$. The alkyl "bridge" group has been found to improve the metabolically stability (i.e. oral activity and pharmacokinetics) of the 10 antimarial compounds of this invention.

In another embodiment of the invention, the trioxolanes are weak bases, which provide an ideal combination of high intrinsic potency and good oral activity. Two promising trioxolane structural subtypes are weak base amides of trioxolane amine OZ209 and trioxolane acid OZ78. These compounds have one of the following two structural 15 formulas:




20

Other substituents at the 4-position of the spirocyclohexyl ring are also possible that fall within the scope of this invention. The spirocyclohexyl ring may also be substituted at other positions besides the 4-position. For instance, the inventors have synthesized several compounds substituted at the 2-position of the spirocyclohexyl ring that provide excellent 25 antimarial potency.

In another embodiment of this invention, the compounds include an alkyl group connecting the substituent at the 4-position to the spirocyclohexyl ring. In one

embodiment, the alkyl group is methyl or ethyl. In another embodiment, the alkyl group is methyl. The substituent may also be directly attached to the 4-position of the spirocyclohexyl ring.

The present inventors have identified two orally active lead dispiro-1,2,4-trioxolanes, OZ03 and OZ05:




These trioxolanes have IC₅₀s between 1 and 5 ng/ml against *P. falciparum* *in vitro*, and presumably possess good therapeutic indices as no toxicity is evidence for either compound 10 in a neuroblastoma cell line or at single 640 mg/kg doses in mice in the Rane test. These results contrast with published data (de Almeida Barbosa et al., 1992; 1996) disclosing the weak in vitro antimalarial potency of several tricyclic trioxolanes, the best of which has an IC₅₀ of 2000 ng/ml against *P. falciparum* *in vitro*.


A notable feature of these trioxolanes in comparison to the artemisinin 15 semisynthetic derivatives is their structural simplicity. A potential advantage of trioxolanes over both trioxanes (Jefford, 1997; Cumming et al., 1997) and tetraoxanes (Vennerstrom et al., 2000) is a more convenient access to structurally diverse, non-symmetrical, and in many cases, achiral compounds.

Below are several dispiro 1,2,4-trioxolanes synthesized in accordance with the 20 teachings of this invention. "OZ" is an internal designation for these compounds that will be used throughout the remainder of the application for convenience. The structures of OZ01-OZ90 have been previously disclosed in prior application U.S. Serial No. 09/886,666 (U.S. Patent No. 6,486,199), and are therefore not repeated here.


OZ Series 11 (OZ91–OZ99)




OZ Series 12 (OZ100–OZ108)




OZ Series 13 (OZ109–OZ117)




OZ Series 14 (OZ118–OZ126)




OZ Series 15 (OZ127–OZ135)




OZ Series 16 (OZ136–OZ144)



OZ Series 17 (OZ145–OZ153)




25
OZ Series 18 (OZ154–OZ162)




50


OZ Series 19 (OZ163–OZ171)




OZ Series 20 (OZ172–OZ180)



OZ Series 21 (OZ181–OZ189)




OZ Series 22 (OZ190–OZ198)




50


OZ Series 23 (OZ199–OZ207)




OZ Series 24 (OZ208–OZ216)




OZ Series 25 (OZ217–OZ225)



25 **OZ Series 26 (OZ226–OZ234)**




OZ Series 27 (OZ235–OZ243)




25


OZ Series 28 (OZ244–OZ252)



OZ Series 29 (OZ253–OZ261)




25
OZ Series 30 (OZ262–OZ270)



50

OZ Series 31 (OZ271–OZ279)


5



10

OZ Series 32 (OZ280–OZ288)




15






20

OZ Series 33 (OZ289–OZ297)




5

OZ289
MW 365.46OZ290
MW 475.60OZ291
MW 364.48

10

OZ292
MW 576.73OZ293
MW 370.49OZ294
MW 418.53










15

OZ295
MW 508.63OZ296
MW 404.50OZ297
MW 405.53

20

OZ Series 34 (OZ298–OZ306)


25

OZ298
MW 448.58OZ299
MW 420.52OZ300
MW 393.47OZ301
MW 467.58OZ302
MW 371.47OZ303
MW 390.52OZ304
MW 398.50OZ305
MW 536.68OZ306
MW 378.46


30

35

OZ Series 35 (OZ307–OZ315)



OZ Series 36 (OZ316–OZ324)




15

20

21

OZ Series 37 (OZ325–OZ333)


5



10

OZ Series 38 (OZ334–OZ342)

15




20

The prototype trioxolanes of this invention are OZ03 and OZ05. Preferred

compounds identified thus far include OZ03, OZ05, OZ11, OZ25, OZ27, OZ61, OZ71, OZ78, OZ127, OZ145, OZ156, OZ163, OZ175, OZ177, OZ179, OZ181, OZ189, OZ205, OZ207, OZ209, OZ210, OZ219, OZ227, OZ229, OZ235, OZ255, OZ256, OZ257, OZ263, OZ264, OZ265, OZ266, OZ267, OZ268, OZ269, OZ270, OZ271, OZ277, OZ281, OZ279, 5 OZ288, OZ289, OZ290, OZ296, OZ297, OZ298, OZ301, OZ305, OZ309, OZ315, OZ317, OZ319, OZ320, OZ323, OZ329, OZ333, OZ335, OZ336, OZ337, OZ338, and OZ339. The most preferred compounds are OZ78, OZ163, OZ181, OZ207, OZ209, OZ255, OZ256, OZ257, OZ263, OZ264, OZ267, OZ271, OZ277, OZ279, OZ301, OZ305, OZ315, OZ317, OZ319, OZ323, OZ329, OZ338, and OZ339, with OZ277 and OZ279 being the 10 best of those compounds identified thusfar. In general, the highest *in vitro* potency against malarial parasites is obtained for trioxolanes functionalized or substituted at the 4-position of the spirocyclohexyl ring. As a general rule, non-symmetrical, achiral trioxolanes are also preferred.

Notable features of these spiro and dispiro 1,2,4-trioxolanes in comparison to the 15 artemisinin semisynthetic derivatives are their structural simplicity and ease of synthesis. For example, dispiro trioxolanes may be easily synthesized by the coozonolysis of the *O*-methyl oximes of cycloalkanones in the presence of the requisite cycloalkanone derivatives according to the method of Griesbaum et al. (1997a; 1997b) as illustrated below for the symmetrical dispiro cyclohexyl trioxolane:

20




25

If yields are low in this coozonolysis reaction, yields can improve dramatically when the *O*-methyloxime and ketone are "reversed." This novel procedure provides a 30 uniquely convenient method to synthesize spiro and dispiro trioxolanes. The trioxolanes may be purified by crystallization or by flash column chromatography. Their structures and

purity may be confirmed by analytical HPLC, ^1H and ^{13}C NMR, IR, melting point and elemental analysis.

Recently, Griesbaum et al. (1997b) discovered that tetrasubstituted 1,2,4-trioxolanes are conveniently obtained by ozonolysis of *O*-alkyl ketone oximes in the presence of carbonyl compounds. Advantages of the oxime ether route over the alkene approach include convenient synthesis of starting materials (oxime ethers vs. 5 tetrasubstituted alkenes), higher yield and selectivity of formation of desired trioxolanes by the judicious selection of paired reaction substrates.

Formation of a trioxolane from an oxime ether and a ketone is presumed to be a 10 three-step process. The sequence begins by the electrophilic addition of ozone to the oxime double bond to form a primary ozonide. Second, the very unstable primary adduct fragments to a reactive carbonyl oxide driven in part by the concomitant expulsion of the relatively stable methyl nitrite. Third, the carbonyl oxide undergoes a [3 + 2] cycloaddition with a ketone to give the secondary ozonide or 1,2,4-trioxolane. It remains to be 15




determined whether this is a stepwise or a concerted recombination process.


As illustrated above by the synthesis of OZ03, all of the new target dispiro 20 trioxolanes contain a spiroadamantane and can be synthesized by the coozonolysis of adamantanone *O*-methyl oxime in the presence of the requisite cycloalkanone derivative. The preferred reaction solvents for the coozonolysis reactions are hydrocarbon solvents such as pentane or cyclohexane; more polar solvents tend to decrease the yield of the reaction. When ketones are not readily soluble in pentane or cyclohexane, a mixed solvent (pentane/methylene chloride) or methylene chloride alone may be used. Several factors govern the ratio of oxime ether to ketone. In some reactions, in order to avoid diperoxide 25 (1,2,4,5-tetraoxane) formation, to preclude diozonide formation from diketones, and to promote the reaction with readily pentane soluble ketones, excess ketone (2:1) is used. Most commonly in the discovery synthesis stage, and especially in cases where ketones are not readily soluble in pentane, expensive, or difficult to remove in the reaction workup, a

1:1 ratio of ketone to oxime ether may be used. In large scale trioxolane syntheses, a 1.5-fold excess of oxime ether can be used to achieve higher conversions of ketones into the desired product trioxolanes without causing purification problems.

There are several examples of where post-ozonolysis transformations were used to obtain trioxolane target compounds difficult, or in some cases, impossible to obtain directly (Kashima et al., 1987) by the coozonolysis method. Trioxolane tertiary alcohols OZ90 and




OZ108 can be obtained by methylolithium treatment of trioxolane ketone OZ05 and trioxolane ester OZ70, respectively. In other reactions, trioxolane lactone OZ17 and trioxolane alcohol OZ32 were obtained by treatment of OZ05 with *m*-CPBA and sodium borohydride, respectively. In addition, various oxime ethers, hydrazones, ketals, and amines (reductive amination with sodium triacetoxyborohydride) were also obtained from trioxolane ketone OZ05 in good to excellent yields. In the examples noted above, it is evident that trioxolane ketone OZ05 is a key intermediate as its ketone functional group provides a convenient means for functional group transformation.



15


Further evidence of the stability of these trioxolanes to reducing agents is shown by the reduction of trioxolane esters OZ70 and OZ61 into their corresponding trioxolane

alcohols OZ119 and OZ89 with a mixture of lithium borohydride and lithium triethylborohydride, and the hydrazinolysis of the trioxolane phthalimides OZ136 and




5 OZ146 into their corresponding trioxolane amines OZ137 and OZ209.

As shown in the examples below, trioxolane esters can be conveniently converted into their corresponding trioxolane acids.



In addition to trioxolane ketone OZ05, trioxolane amine mesylate OZ209, trioxolane ester OZ61 and trioxolane acid OZ78, trioxolane alcohols OZ119 and OZ89 have and will continue to be key intermediates for post-ozonolysis synthetic transformations. A recent example is the




5 synthesis of trioxolane triazole OZ177 in a reaction between the mesylate derivative of OZ119 and the sodium salt of 1,2,4-triazole.

It has been found that the coozonolysis method using oxime methyl ethers offers a rapid, flexible, and predictable access to structurally diverse trioxolanes. In fact, several key trioxolanes that have served as important building blocks have been prepared in large scale including OZ05 (100 mmol), OZ61 (100 mmol), and OZ146 (60 mmol), with no decrease in reaction yields over the usual 5-10 mmol scale. Furthermore, both OZ61 and OZ146 can be conveniently isolated as white solids by addition of ethanol to the crude reaction mixtures.

Differential scanning calorimetry (DSC) experiments (Cammenga, and Epple, 15 1995) reveal that these compounds have good thermal stability, comparable to artemisinin. The average T_m, dec was 160 ± 15°C compared to a T_m, dec of 181 °C for artemisinin. It is presumed that thermal decomposition of these trioxolanes was initiated by formation of a 1,5 diradical produced by homolytic cleavage of the peroxide bond of the trioxolane ring.

Since most of the target trioxolanes contain the symmetrical spiroadamantane structural framework, their stereochemistry is largely a function of the starting material ketone structure or reagents used in post-ozonolysis reactions. For OZ27 and other similarly 1,4-substituted trioxolanes, two achiral diastereomers are possible. However, as exemplified by OZ27, the majority of these trioxolanes were isolated as single achiral diastereomers rather than as mixtures of two achiral diastereomers. For example, in OZ27, 20 no chirality is present since the trioxolane ring and phenyl substituent are in a 1,4 relationship in a six membered ring. Such compounds possess a plane of symmetry.



As determined by X-ray crystallography, the assignment of stereochemistry for OZ78, OZ209 and their derivatives was determined to be *cis* where the peroxide oxygens are in an axial position.

The starting material 2-adamantanone may be obtained from Aldrich Chemical Co.
5 or from TCI American Organic Chemicals or may also be synthesized. Persons skilled in the art can readily ascertain other appropriate means of synthesizing the starting materials and compounds in accordance with this invention.

The spiro and dispiro trioxolane compositions of the present invention may be generally used for the prophylaxis and treatment of malaria. The trioxolane compositions
10 of the present invention are administered along with a pharmaceutically acceptable carrier. Any pharmaceutically acceptable carrier may be generally used for this purpose, provided that the carrier does not significantly interfere with the stability or bioavailability of the trioxolane compounds of this invention.

The trioxolanes of this invention can be administered in any effectively
15 pharmaceutically acceptable form to warm blooded animals, including human and other animal subjects, e.g. in topical, lavage, oral, suppository, parenteral, or infusible dosage forms, as a topical, buccal, sublingual, or nasal spray or in any other manner effective to deliver the agents. The route of administration will preferably be designed to optimize delivery and/or localization of the agents to target cells.

In addition to the active compounds i.e. the trioxolanes, the pharmaceutical compositions of this invention may contain suitable excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Oral dosage forms encompass tablets, capsules, and granules.
20 Preparations which can be administered rectally include suppositories. Other dosage forms include suitable solutions for administration parenterally or orally, and compositions which can be administered buccally or sublingually.

The pharmaceutical preparations of the present invention are manufactured in a manner which is itself well known in the art. For example the pharmaceutical preparations may be made by means of conventional mixing, granulating, dragee-making, dissolving,

lyophilizing processes. The processes to be used will depend ultimately on the physical properties of the active ingredient used.

Suitable excipients are, in particular, fillers such as sugars for example, lactose or sucrose mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example, tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch, paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, disintegrating agents may be added, such as the above-mentioned starches as well as carboxymethyl starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate. Auxiliaries are flow-regulating agents and lubricants, for example, such as silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate and/or polyethylene glycol. Oral dosage forms may be provided with suitable coatings which, if desired, may be resistant to gastric juices.

For this purpose concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate, dyestuffs and pigments may be added to the tablet coatings, for example, for identification or in order to characterize different combination of compound doses.

Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain the active compounds in the form of granules which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition stabilizers may be added. Possible pharmaceutical preparations which can be used rectally include, for example, suppositories, which consist of a combination of the active compounds with the suppository base. Suitable suppository bases are, for example, natural or synthetic

triglycerides, paraffin hydrocarbons, polyethylene glycols, or higher alkanols. In addition, it is also possible to use gelatin rectal capsules which consist of a combination of the active compounds with a base. Possible base material include for example liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.

5 Suitable formulations for parenteral administration include aqueous solutions of active compounds in water-soluble or water-dispersible form. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides. Aqueous injection
10 suspensions may contain substances which increase the viscosity of the suspension, including for example, sodium carboxymethyl cellulose, sorbitol and/or dextran. Such compositions may also comprise adjuvants such as preserving, wetting, emulsifying, and dispensing agents. They may also be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents into the compositions. They
15 can also be manufactured in the form of sterile solid compositions which can be dissolved or suspended in sterile water, saline, or other injectable medium prior to administration.

In addition to administration with conventional carriers, active ingredients may be administered by a variety of specialized delivery drug techniques which are known to those of skill in the art, such as portable infusion pumps.

20 The trioxolane compositions of the present invention are administered along with a pharmaceutically acceptable carrier in an amount sufficient to prevent malarial infection and/or treat an active infection. The trioxolane compounds of this invention have extremely low toxicity and a low degree of side effects even at high doses. The dosing range of the trioxolane compositions will vary depending on a number of factors, such as
25 whether it is used for prophylaxis or treatment of an active infection, route of administration, dosing schedule, etc. In general, the therapeutic dose of trioxolane may range between about 0.1-1000 mg/kg/day, with between about 1-100 mg/kg/day being preferred. The foregoing doses may be administered as a single dose or may be divided into multiple doses for administration. The trioxolane compositions may be administered
30 once to several times daily. For malaria prevention, a typical dosing schedule could be, for

example, 2.0-1000 mg/kg weekly beginning 1-2 weeks prior to malaria exposure taken up until 1-2 weeks post-exposure.

The spiro and dispiro trioxolanes of this invention have been found to be effective in the treatment of schistosomiasis. Schistosomiasis ranks second behind malaria in terms of socioeconomic and public health importance in tropical and subtropical areas. The disease is endemic in 74 developing countries, infecting more than 200 million people in rural agricultural and peri-urban areas. An estimated 500-600 million people worldwide are at risk from the disease.

The major forms of human schistosomiasis are caused by five species of water-borne flatworm, or blood flukes, called schistosomes. One of these species is *Schistosoma mansoni*, which has been reported in 53 countries in Africa, the Eastern Mediterranean, the Caribbean, and South America. The parasites enter the body through contact with infested surface water, primarily among people engaged in agriculture and fishing. The parasites normally infect the host during the cercaria, or larval stage. Once inside the host, the cercaria develop into adults or schistosomes.

Current treatments for schistosomiasis have focused primarily on prophylaxis, i.e. prevention of host infection by cercaria. Currently, praziquantel is the most widely used drug for treatment of schistosomiasis. While artemether has demonstrated activity in the prophylaxis of schistosomiasis, it has not shown any activity against adult *S. mansoni*.

It has now been unexpectedly discovered that the spiro and dispiro trioxolanes of this invention are active against both cercaria and adult *S. mansoni*, *S. japonicum* when administered in the dosages and manner outlined above with respect to treatment of malarial parasites. It is also believed the trioxolanes of this invention will be active against *S. haematobium*. Preferred compounds identified for use in the treatment of schistosomiasis include OZ05, OZ11, OZ23, OZ25, OZ28, OZ32, OZ71, OZ78, OZ89, OZ90, OZ119, OZ145, OZ179, OZ205, OZ207, and OZ209. Most preferred compounds are OZ78, OZ207, and OZ209. Preferred dosing levels of the spiro and dispiro trioxolanes are about 100-200 mg/kg/day orally. The prototype trioxolanes of this invention are OZ03 and OZ05.

The spiro and dispiro trioxolanes of this invention may also have effectiveness in the treatment of cancer. Compounds having an endoperoxide moiety that is reactive with

heme and iron have shown an ability to kill cancer cells. (See e.g. U.S. Pat. No. 5,578,637, the disclosure of which is hereby incorporated by reference). As noted with respect to artemisinin, trioxolanes' mechanism of action against malarial parasites is based on the ability of trioxolane compounds to react with the iron in free heme molecules in malaria parasites, with the generation of free radicals leading to cellular destruction. Similarly, trioxolanes are selective against cancer cells due to the higher concentration of transferrin receptors on cancer cell membranes that pick up iron at a higher rate than normal cells. In the presence of the trioxolanes of this invention, the cancer cells will accumulate high concentrations of free radicals, leading to cell death. For cancer treatment, the trioxolanes of this invention may be administered in the doses and manner outlined above.

Other drugs besides trioxolanes which are compatible with the carrier ingredients may also be incorporated into the carrier. Such drugs may be readily ascertained by those of ordinary skill in the art and may include, for instance, antibiotics, other antimalarials, antiinflammatory agents, etc.

It is understood that the present invention contemplates the use of not only the above-stated trioxolane compounds themselves, but their prodrugs which metabolize to the compound and the analogues and biologically active salt forms thereof, as well as optical isomers which provide the same pharmaceutical results.

The following examples are offered to illustrate but not limit the invention. Thus, they are presented with the understanding that various formulation modifications as well as method of delivery modifications may be made and still be within the spirit of the invention.

EXAMPLE 1

General Procedure for the Preparation of 1,2,4-Trioxolanes

In the priority applications (U.S. Pat. No. 6,486,199 and PCT App. No. US02/19767, the disclosures of which have been expressly incorporated by reference), detailed information regarding the synthesis of the starting materials for the OZ compounds was provided. This information is therefore not repeated herein.

General procedure for the preparation of 1,2,4-trioxolanes. Ozone was produced with an OREC ozone generator (0.6 L/min O₂, 60 V), passed through an empty

gas washing bottle that was cooled to -78°C , and bubbled through a solution of an *O*-methyl ketone oxime and a ketone in pentane/CH₂Cl₂ at 0°C . The *O*-methyl oxime of 2-adamantanone was consumed within 3 min. After completion, the solution was flushed with oxygen for 5 min before being concentrated in vacuo at room temperature to give a residue that was purified by crystallization or flash chromatography.

In the priority applications (U.S. Pat. No. 6,486,199 and PCT App. No. US02/19767), the disclosures of which have been expressly incorporated by reference), detailed information regarding the synthesis of OZ01-OZ90 has already been provided. This information is therefore not repeated herein.

10

Adamantane-2-spiro-3'-8'-(1'S)-10'-camphorsulfonyl]-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ91). A solution of *O*-methyl 2-adamantanone oxime (895 mg, 5 mmol) and 1-[(1S)-10-camphorsulfonyl]-4-piperidone (1.56 g, 4.98 mmol) in pentane (50 ml) and CH₂Cl₂ (50 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 30% ether in hexanes) to afford trioxolane **OZ91** (860 mg, 36%) as a colorless solid. mp 72–74 °C (methanol); ¹H NMR (500 MHz, CDCl₃) δ 0.88 (s, 3H), 1.13 (s, 3H), 1.38–1.51 (m, 1H), 1.55–2.21 (m, 22H), 2.32–2.46 (m, 1H), 2.47–2.61 (m, 1H), 2.76 (d, J = 14.6 Hz, 1H), 3.35 (d, J = 14.6 Hz, 1H), 3.34–3.59 (m, 4H); ¹³C NMR (125.7 MHz, CDCl₃) δ 19.72, 19.94, 25.12, 26.46, 26.84, 26.89, 34.49, 34.72, 34.80, 36.40, 36.71, 42.54, 42.91, 43.84, 43.86, 45.84, 47.82, 58.25, 106.16, 112.26, 214.78. Anal. Calcd for C₂₅H₃₇NO₆S: C, 62.60; H, 7.78; N, 2.92. Found: C, 62.80; H, 7.60; N, 2.92.

15

20

Adamantane-2-spiro-3'-8'-(1'-butanesulfonyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ92). A solution of *O*-methyl 2-adamantanone oxime (895 mg, 5 mmol) and 1-(1-butanesulfonyl)-4-piperidone (1.12 g, 5.11 mmol) in pentane (50 ml) and CH₂Cl₂ (50 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 30% ether in hexanes) to afford trioxolane **OZ92** (700 mg, 36%) as a colorless solid. mp 62–64 °C (methanol); ¹H NMR (500 MHz, CDCl₃) δ 0.95 (t, J = 7.6 Hz, 3H), 1.32–1.57 (m, 2H), 1.59–2.21 (m, 20H), 2.81–3.02 (m, 2H), 3.22–3.59 (m, 4H); ¹³C NMR (125.7 MHz, CDCl₃) δ 13.48, 21.68,

25

30

25.24, 26.50, 26.90, 34.67, 34.78, 34.87, 36.48, 36.75, 43.94, 50.09, 106.20, 112.38. Anal.
Calcd for C₁₉H₃₁NO₅S: C, 59.19; H, 8.10; N, 3.63. Found: C, 59.38; H, 7.99; N, 3.45.

Adamantane-2-spiro-3'-8'-(phthalimidoacetyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ93). To a solution of **OZ87** (342 mg, 1 mmol) in acetonitrile (10 ml) was added potassium phthalimide (200 mg, 1.08 mmol). The reaction solution was heated at 60–65 °C for 36 h and cooled to rt. The solvent was removed by evaporation, and the residue was triturated with water (20 ml) and filtered. Recrystallization of the solid from methanol gave trioxolane **OZ93** (379 mg, 84%) as a colorless solid. mp 152–154 °C (methanol); ¹H NMR (500 MHz, CDCl₃) δ 1.59–2.11 (m, 18H), 3.45–3.71 (m, 3H), 3.72–3.89 (m, 1H), 4.51 (s, 2H), 7.65–7.79 (m, 2H), 7.82–7.97 (m, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.47, 26.86, 33.94, 34.75, 36.44, 36.72, 38.96, 40.38, 42.62, 106.49, 112.36, 123.43, 132.38, 133.93, 163.88, 167.87. Anal. Calcd for C₂₅H₂₈N₂O₆: C, 66.36; H, 6.24; N, 6.19. Found: C, 66.19; H, 6.07; N, 6.19.

Adamantane-2-spiro-3'-1',2',4'-trioxolane-5'-spiro-9''-fluorene (OZ94). A solution of *O*-methyl 2-adamantanone oxime (895 mg, 5 mmol) and 9-fluorenone (1.80 g, 10 mmol) in pentane (80 ml) and CH₂Cl₂ (20 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 1% ether in hexanes) to afford trioxolane **OZ94** (650 mg, 38%) as a colorless solid. mp 150–152 °C (methanol/ether 9:1); ¹H NMR (500 MHz, CDCl₃) δ 1.62–2.25 (m, 12H), 2.47 (s, 2H), 7.27 (dd, J = 7.6, 7.6 Hz, 2H), 7.38 (dd, J = 7.6, 7.6 Hz, 2H), 7.53 (d, J = 7.3 Hz, 2H), 7.57 (d, J = 7.3 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.61, 26.99, 34.89, 35.10, 36.51, 36.87, 111.76, 112.99, 120.02, 125.22, 128.42, 130.81, 140.29, 140.99. Anal. Calcd for C₂₃H₂₂O₃: C, 79.74; H, 6.40. Found: C, 79.56; H, 6.23.

Adamantane-2-spiro-3'-5'-(4'-nitrophenyl)-5'-phenyl-1',2',4'-trioxolane (OZ95). A solution of *O*-methyl 2-adamantanone oxime (1.79 g, 10 mmol) and 4-nitrobenzophenone (2.27 g, 10 mmol) in pentane (70 ml) and CH₂Cl₂ (80 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 10% ether in hexanes) to afford trioxolane **OZ95** (1.60 g, 41%) as a colorless solid. mp 114–116 °C (ether); ¹H NMR (500 MHz, CDCl₃) δ 1.60–2.26 (m, 14H), 7.32–7.41 (m, 3H), 7.42–7.49 (m, 2H), 7.75 (d, J = 8.8 Hz, 2H), 8.22 (d, J = 8.8 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.46, 26.88, 34.61, 34.78, 34.81, 35.42, 36.04,

36.24, 36.71, 108.77, 114.65, 123.37, 126.86, 127.62, 128.43, 129.39, 137.62, 148.00, 148.26. Anal. Calcd for C₂₃H₂₃NO₅: C, 70.21; H, 5.89; N, 3.56. Found: C, 70.12; H, 5.66; N, 3.58.

Adamantane-2-spiro-3'-5',5'-bis(4'-chloro-3'-nitrophenyl)-1',2',4'-trioxolane (OZ96).

5 A solution of *O*-methyl 2-adamantanone oxime (1.79 g, 10 mmol) and 4,4'-dichloro-3,3'-dinitrobenzophenone (2.09 g, 10 mmol) in pentane (80 ml) and CH₂Cl₂ (75 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 10% ether in hexanes) to afford trioxolane OZ96 (2.03 g, 40%) as a pale yellow solid. mp 113–115 °C (ether); ¹H NMR (500 MHz, CDCl₃) δ 1.60–2.25 (m, 14H), 7.50–7.71 (m, 4H), 8.04 (d, J = 2.0 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.30, 26.68, 34.75, 34.92, 36.06, 36.49, 106.72, 116.10, 123.73, 128.27, 131.00, 132.31, 139.19, 148.02. Anal. Calcd for C₂₃H₂₀Cl₂N₂O₇: C, 54.45; H, 3.97; N, 5.52. Found: C, 54.46; H, 4.09; N, 5.53.

10

Adamantane-2-spiro-3'-8'-phenyl-8'-phthalimidomethyl-1',2',4'-trioxaspiro[4.5]decane (OZ97).

15 A solution of *O*-methyl 2-adamantanone oxime (0.75 g, 4.2 mmol) and 4-phenyl-4-phthalimidomethylcyclohexanone (1.40 g, 4.2 mmol) in pentane (100 ml) and CH₂Cl₂ (50 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 12% ethyl acetate in hexanes) to afford trioxolane OZ97 (0.62 g, 30%) as a colorless solid. mp 150–152 °C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.50–1.99 (m, 20H), 2.40 (app d, J = 14.2 Hz, 2H), 3.63 (s, 2H), 7.18–7.30 (m, 1H), 7.31–7.40 (m, 2H), 7.41–7.50 (m, 2H), 7.65–7.72 (m, 2H), 7.73–7.85 (m, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.52, 26.88, 30.80, 30.88, 34.79, 36.43, 36.82, 43.90, 108.57, 111.33, 123.22, 126.67, 127.10, 128.78, 132.02, 133.84, 141.13, 168.44. Anal. Calcd for C₃₁H₃₃NO₅: C, 74.53; H, 6.66; N, 2.80. Found: C, 74.54; H, 6.71; N, 2.80.

20

25

Adamantane-2-spiro-3'-8'-methoxycarbonyl-8'-phenyl-1',2',4'-trioxaspiro[4.5]decane (OZ98).

30 A solution of *O*-methyl 2-adamantanone oxime (2.15 g, 12 mmol) and 4-methoxycarbonyl-4-phenylcyclohexanone (2.79 g, 12 mmol) in pentane (100 ml) and CH₂Cl₂ (50 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 10% ether in hexanes) to afford trioxolane OZ98 (1.07 g, 22%) as a colorless solid. mp 127–129 °C

(ethanol/CH₂Cl₂ 9:1); ¹H NMR (500 MHz, CDCl₃) δ 1.62–2.15 (m, 20H), 2.53 (app d, J = 13.2 Hz, 2H), 3.67 (s, 3H), 7.20–7.44 (m, 5H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.54, 26.94, 31.93, 31.98, 34.82, 34.87, 36.48, 36.85, 50.06, 52.22, 108.03, 111.58, 125.78, 127.06, 128.59, 142.39, 174.86. Anal. Calcd for C₂₄H₃₀O₅: C, 72.34; H, 7.59. Found: C, 5 72.12; H, 7.48.

Adamantane-2-spiro-3'-8'-carboxy-8'-phenyl-1',2',4'-trioxaspiro[4.5]decane (OZ99). A mixture of **OZ98** (0.42 g, 1.05 mmol), KOH (1.00 g, 17.85 mmol), ethanol (30 ml), THF (25 ml), and water (10 ml) was heated at 50 °C for 5 h. The reaction mixture was cooled to rt, concentrated to 10 ml, diluted with water (20 ml), acidified with conc. HCl 10 (2.0 ml), and extracted with CHCl₃ (3 x 25 ml). The combined extracts were dried over MgSO₄, filtered, and concentrated. Recrystallization of the residue from hexanes/CH₂Cl₂ (7:3) afforded trioxolane **OZ99** (0.31 g, 77%) as a colorless solid. mp 153–156 °C (hexanes/CH₂Cl₂ 7:3); ¹H NMR (500 MHz, CDCl₃) δ 1.62–2.19 (m, 20H), 2.54 (app d, J = 11.7 Hz, 2H), 7.20–7.53 (m, 5H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.58, 26.98, 31.54, 15 31.83, 34.84, 34.90, 36.51, 36.88, 49.62, 107.96, 111.67, 126.04, 127.34, 128.68, 141.44, 180.55. Anal. Calcd for C₂₃H₂₈O₅: C, 71.85; H, 7.34. Found: C, 71.66; H, 7.32.

Adamantane-2-spiro-3'-8'-(4'-pyridinylcarbonyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ100). To a solution of **OZ80** (225 mg, 0.85 mmol) in CH₂Cl₂ (10 ml) was added triethylamine (258 mg, 2.55 mmol). The solution was then cooled to 0–5 °C, and isonicotinoyl hydrochloride (180 mg, 1.01 mmol) was added. The resulting mixture was stirred at rt for 16 h before evaporation to dryness. The residue was triturated with water and filtered. Recrystallization of the solid from methanol at –20 °C gave trioxolane **OZ100** (190 mg, 69%) as a colorless solid. mp 140–142 °C (methanol); ¹H NMR (500 MHz, CDCl₃) δ 1.58–2.16 (m, 18H), 3.31–3.58 (m, 2H), 3.68–3.85 (m, 1H), 25 3.86–4.06 (m, 1H), 7.19–7.37 (m, 2H), 8.60–8.80 (m, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.47, 26.87, 34.13, 34.76, 34.87, 35.18, 36.45, 36.71, 40.03, 45.20, 106.47, 112.49, 120.96, 143.47, 150.37, 167.77. Anal. Calcd for C₂₁H₂₆N₂O₄: C, 68.09; H, 7.07; N, 7.56. Found: C, 68.22; H, 7.06; N, 7.68.

Adamantane-2-spiro-3'-8'-(4'-chlorophenoxyacetyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ101). A solution of *O*-methyl 2-adamantanone oxime (895 mg, 5 mmol) and 1-(4-chlorophenoxyacetyl)-4-piperidone (1.34 g, 5 mmol) in pentane (50 ml)

and CH_2Cl_2 (50 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 30% ether in hexanes) to afford trioxolane **OZ101** (300 mg, 14%) as a colorless solid. mp 148–150 °C (methanol); ^1H NMR (500 MHz, CDCl_3) δ 1.59–2.19 (m, 18H), 3.48–3.71 (m, 3H), 3.72–3.87 (m, 1H), 4.67 (AB system, 2H), 6.80–6.95 (m, 2H), 7.15–7.35 (m, 2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.47, 26.86, 34.15, 34.75, 34.93, 35.19, 36.43, 36.71, 40.21, 43.13, 68.16, 106.54, 112.38, 115.99, 126.80, 129.55, 156.57, 166.03. Anal. Calcd for $\text{C}_{23}\text{H}_{28}\text{ClNO}_5$: C, 63.66; H, 6.50; N, 3.23. Found: C, 63.82; H, 6.46; N, 3.30.

Adamantane-2-spiro-3'-8'-(phenylaminocarbonyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ102).

To a solution of **OZ80** (301 mg, 1 mmol) and triethylamine (101 mg, 1 mmol) in CH_2Cl_2 (10 ml) at 0–5 °C was added phenyl isocyanate (140 mg, 1.2 mmol). The reaction mixture was stirred at rt for 3 h, diluted with CH_2Cl_2 (10 ml), and washed with water (10 ml), 10% aq. NaHCO_3 (10 ml), 2 M HCl (10 ml), water (10 ml) and brine (10 ml). The organic layer was dried over MgSO_4 and concentrated. The residue was triturated with hexanes (20 ml), filtered, and dried to afford trioxolane **OZ102** (370 mg, 96%) as a colorless solid. mp 146–148 °C (hexanes); ^1H NMR (500 MHz, CDCl_3) δ 1.62–2.11 (m, 18H), 3.42–3.76 (m, 4H), 6.46 (s, 1H), 7.04 (dd, J = 7.3, 7.3 Hz, 1H), 7.15–7.44 (m, 4H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.52, 26.91, 34.42, 34.80, 34.89, 36.49, 36.77, 42.44, 106.80, 112.28, 120.13, 123.29, 128.91, 139.00, 154.88. Anal. Calcd for $\text{C}_{22}\text{H}_{28}\text{N}_2\text{O}_4$: C, 68.73; H, 7.34; N, 7.29. Found: C, 68.78; H, 7.14; N, 7.50.

Adamantane-2-spiro-3'-8'-(1'H-imidazol-1'-ylacetyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ103).

To a solution of **OZ87** (342 mg, 1 mmol) in acetonitrile (10 ml) was added imidazole (201 mg, 3 mmol). The mixture was heated at 60–65 °C for 36 h before evaporation to dryness. The crude product was purified by flash chromatography (silica gel, 5% methanol in dichloromethane) and by subsequent recrystallization from hexanes/ether (9:1) to give trioxolane **OZ103** (132 mg, 35%) as a colorless solid. mp 138–140 °C (hexanes/ether 9:1); ^1H NMR (500 MHz, CDCl_3) δ 1.59–2.21 (m, 18H), 3.43–3.60 (m, 2H), 3.61–3.72 (m, 1H), 3.73–3.91 (m, 1H), 4.79 (s, 2H), 6.97 (br s, 1H), 7.12 (br s, 1H), 7.52 (br s, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.46, 26.86, 33.98, 34.76, 34.95, 36.44, 36.70, 40.41, 43.02, 48.09, 106.22, 112.54, 120.04 (br s),

129.67, 138.10 (br s), 164.47. Anal. Calcd for C₂₀H₂₇N₃O₄: C, 64.32; H, 7.29; N, 11.25. Found: C, 64.12; H, 7.02; N, 11.09.

Adamantane-2-spiro-3'-8'-[4-(acetylamino)phenylsulfonyl]-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ104). To a solution of **OZ80** (300 mg, 1 mmol) in CH₂Cl₂ (10 ml) was added triethylamine (303 mg, 3 mmol). The solution was then cooled to 0–5 °C, and 4-acetamidobenzenesulfonyl chloride (280 mg, 1.2 mmol) was added. The resulting mixture was stirred at rt for 16 h before evaporation to dryness. The residue was triturated with water (15 ml) and filtered. Recrystallization of the solid from methanol/CH₂Cl₂ (9:1) at –20 °C gave trioxolane **OZ104** (300 mg, 65%) as a colorless solid. mp 122–124 °C (methanol/CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 1.50–2.12 (m, 18H), 2.19 (s, 3H), 2.90–3.08 (m, 2H), 3.15–3.37 (m, 2H), 7.65 (d, J = 8.8 Hz, 2H), 7.68 (d, J = 8.8 Hz, 2H), 7.93–8.16 (m, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 24.51, 26.46, 26.83, 34.05, 34.74, 34.76, 36.39, 36.70, 44.26, 105.86, 112.41, 119.44, 128.73, 131.51, 142.35, 168.72. Anal. Calcd for C₂₃H₃₀N₂O₆S: C, 59.72; H, 6.54; N, 6.06. Found: C, 59.58; H, 6.60; N, 5.81.

Adamantane-2-spiro-3'-5',5'-bis(3'-nitrophenyl)-1',2',4'-trioxolane (OZ105). A solution of *O*-methyl 2-adamantanone oxime (1.79 g, 10 mmol) and 3,3'-dinitrobenzophenone (2.72 g, 10 mmol) in pentane (60 ml) and CH₂Cl₂ (40 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 90% ether in hexanes) to afford trioxolane **OZ105** (0.90 g, 21%) as a colorless solid. mp 131–134 °C (ether); ¹H NMR (500 MHz, CDCl₃) δ 1.60–2.45 (m, 14H), 7.59 (dd, J = 7.8, 7.8 Hz, 2H), 7.81–7.88 (m, 2H), 8.22–8.28 (m, 2H), 8.41 (dd, J = 2.0, 2.0 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.37, 26.76, 34.77, 34.95, 36.09, 36.58, 107.55, 115.64, 121.71, 124.10, 129.67, 132.47, 141.33, 148.46. Anal. Calcd for C₂₃H₂₂N₂O₇: C, 63.01; H, 5.06; N, 6.39. Found: C, 63.26; H, 5.00; N, 6.47.

Adamantane-2-spiro-3'-5',5'-bis[3',4'-di(methoxycarbonyl)phenyl]-1',2',4'-trioxolane (OZ106). A solution of *O*-methyl 2-adamantanone oxime (1.79 g, 10 mmol) and 3,3',4,4'-tetra(methoxycarbonyl)benzophenone (4.14 g, 10 mmol) in pentane (70 ml) and CH₂Cl₂ (80 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 80% ether in hexanes) to afford trioxolane **OZ106** (2.03 g, 35%) as a colorless solid. mp 52–54 °C (ether); ¹H NMR (500 MHz, CDCl₃) δ 1.60–2.35 (m, 14H), 3.907 (s, 6H), 3.909 (s, 6H), 7.66 (dd, J = 8.0, 1.5 Hz,

2H), 7.70 (d, J = 8.0 Hz, 2H), 7.87 (d, J = 1.5 Hz, 2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.38, 26.77, 34.75, 34.91, 35.99, 36.62, 52.64, 52.66, 107.85, 115.18, 127.10, 129.03, 129.29, 132.05, 132.71, 142.41, 167.29, 167.55. Anal. Calcd for $\text{C}_{31}\text{H}_{32}\text{O}_{11}$: C, 64.13; H, 5.56. Found: C, 64.28; H, 5.46.

5 **Adamantane-2-spiro-3'-8'-(aminocarbonyl)oxy]-1',2',4'-**

trioxaspiro[4.5]decane (OZ107). A solution of trichloroacetyl isocyanate (0.44 g, 2.25 mmol) and **OZ32** (0.42 g, 1.50 mmol) in CH_2Cl_2 (5 ml) was stirred at 0 °C for 4 h. The reaction mixture was warmed up to rt, concentrated, dissolved in methanol (20 ml), and cooled to 0°C. To this cooled solution was added 5% aq. Na_2CO_3 solution (20 ml). The resulting mixture was stirred at 0°C for 1 h, warmed up to rt, and stirred at rt overnight. The reaction solution was diluted with water (50 ml) and extracted with CHCl_3 (3 x 40 ml). The combined organic layers were washed with water (30 ml) and brine (30 ml), dried over MgSO_4 , and concentrated. Recrystallization of the residue from hexanes/chloroform (3:1) gave trioxolane **OZ107** (250 mg, 52%, 10:1 mixture of two diastereomers) as a colorless solid. mp 160–162°C (hexanes/chloroform 3:1); ^1H NMR (500 MHz, CDCl_3) δ 1.50–2.25 (m, 22H), 4.72–4.98 (m, 3H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.52, 26.93, 28.60, 31.01, 34.80, 34.88, 36.39, 36.82, 70.81, 107.85, 111.69, 156.34. Anal. Calcd for $\text{C}_{17}\text{H}_{25}\text{NO}_5$: C, 63.14; H, 7.79; N, 4.33. Found: C, 62.91; H, 7.56; N, 4.31.

10 **cis-Adamantane-2-spiro-3'-8'-(1'-hydroxy-1'-methylethyl)-1',2',4'-**

15 **trioxaspiro[4.5]decane (OZ108).** To a solution of methylolithium (3.80 ml, 1.4 M in ether, 5.4 mmol) in ether (5 ml) at –78°C was added a solution of **OZ70** (0.70 g, 2.1 mmol) in ether (20 ml). The reaction was stirred at –78°C for 3 h before being quenched with saturated aq. ammonium chloride (20 ml). The mixture was extracted with ether (3 x 30 ml), and the organic layers were washed with water (30 ml) and brine (30 ml), dried over MgSO_4 , filtered, and concentrated. The crude product was purified by flash chromatography (silica gel, 20% ether in hexanes) to afford trioxolane **OZ108** (0.42 g, 62%) as a colorless solid. mp 126–128 °C (ethanol/ H_2O 4:1); ^1H NMR (500 MHz, CDCl_3) δ 1.17 (s, 6H), 1.06–1.55 (m, 3H), 1.58–2.30 (m, 20H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 24.85, 26.59, 26.99, 27.02, 34.50, 34.85, 36.50, 36.90, 47.76, 72.51, 108.70, 111.28. Anal. Calcd for $\text{C}_{19}\text{H}_{30}\text{O}_4$: C, 70.77; H, 9.38. Found: C, 70.64; H, 9.15.

Adamantane-2-spiro-3'-8'-(3'-carboxypyrazinyl)carbonyl]-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ109). To a solution of **OZ80** (301 mg, 1 mmol) in CH₂Cl₂ (5 ml) at 0–5 °C were added triethylamine (101 mg, 1 mmol) and 2,3-pyrazinedicarboxylic anhydride (156 mg, 1 mmol). The resulting mixture was stirred at rt for 16 h before evaporation to dryness. The residue was triturated with water (10 ml) and filtered. Recrystallization of the solid from methanol gave trioxolane **OZ109** (300 mg, 72%) as a colorless solid. mp 128–130°C (methanol); ¹H NMR (500 MHz, CDCl₃) δ 1.52–2.21 (m, 18H), 3.21–3.43 (m, 2H), 3.79–3.96 (m, 1H), 3.97–4.14 (m, 1H), 8.71 (s, 1H), 8.79 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.54, 26.92, 33.73, 34.32, 34.78, 34.83, 34.84, 34.96, 10.48, 36.52, 36.79, 39.94, 44.80, 106.79, 112.42, 140.16, 143.16, 146.96, 151.73, 163.03, 165.23. Anal. Calcd for C₂₁H₂₅N₃O₆: C, 60.71; H, 6.07; N, 10.11. Found: C, 60.46; H, 5.93; N, 9.96.

Adamantane-2-spiro-3'-1',2',4'-trioxolane-5'-spiro-3"-8"-ethoxycarbonyl-8"-azabicyclo[3.2.1]octane (OZ110). A solution of *O*-methyl 2-adamantanone oxime (895 mg, 5.0 mmol) and *N*-carboethoxytropinone (1.01 g, 5.2 mmol) in pentane (80 ml) and CH₂Cl₂ (20 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 15% ether in hexanes) to afford trioxolane **OZ110** (300 mg, 17%, 2:1 mixture of two diastereomers) as a colorless solid. mp 98–100 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.27 (t, J = 7.1 Hz, 3H), 1.58–2.39 (m, 22H), 4.15 (q, J = 6.8 Hz, 2H), 4.18–4.45 (m, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 14.67, 26.45, 26.50, 26.86, 26.89, 27.16, 27.60 (br s), 33.22, 34.68, 34.82, 35.06, 36.37, 36.41, 36.74, 36.77, 37.05, 40.42 (br s), 52.44, 52.75, 52.78, 60.88, 60.93, 60.96, 106.98, 107.71, 110.39, 112.46, 153.70. Anal. Calcd for C₂₀H₂₉NO₅: C, 66.09; H, 8.04; N, 3.85. Found: C, 66.12; H, 7.90; N, 3.82.

Adamantane-2-spiro-3'-8'-(3',3'-dimethylbutanoyl)-1',2',4'-trioxo-8'-azaspiro[4.5]decane (OZ111). To a solution of **OZ80** (302 mg, 1 mmol) in CH₂Cl₂ (10 ml) at 0–5 °C were added triethylamine (303 mg, 3 mmol) and trimethylacetyl chloride (185 mg, 1.5 mmol). The resulting mixture was stirred at rt for 16 h, then diluted with CH₂Cl₂ (10 ml), and washed with water (10 ml) and brine (10 ml). The organic phase was separated, dried over MgSO₄, and concentrated. Crystallization of the residue from methanol gave trioxolane **OZ111** (140 mg, 39%) as a colorless solid. mp 98–100°C

(methanol); ^1H NMR (500 MHz, CDCl_3) δ 1.05 (s, 9H), 1.58–2.11 (m, 18H), 2.27 (AB system, 2H), 3.46–3.69 (m, 3H), 3.75–3.90 (m, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.60, 26.99, 30.06, 31.39, 34.37 (br s), 34.85, 35.34 (br s), 36.57, 36.85, 39.44 (br s), 44.40 (br s), 44.75, 106.92, 112.25, 170.30. Anal. Calcd for $\text{C}_{21}\text{H}_{33}\text{NO}_4$: C, 69.39; H, 9.15; N, 3.85. Found: C, 69.52; H, 8.89; N, 3.72.

Adamantane-2-spiro-3'-8'-(carboxymethoxy)acetyl]-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ112). To a solution of **OZ80** (302 mg, 1 mmol) in CH_2Cl_2 (10 ml) was added triethylamine (101 mg, 1 mmol). The solution was then cooled to 0–5 °C, and diglycolic anhydride (116 mg, 1 mmol) was added. The resulting mixture was stirred at rt for 16 h before evaporation to dryness. The residue was triturated with water (10 ml) and filtered. Recrystallization of the solid from methanol gave trioxolane **OZ112** (250 mg, 66%) as a colorless solid. mp 126–128 °C (methanol); ^1H NMR (500 MHz, CDCl_3) δ 1.59–2.18 (m, 18H), 3.29–3.49 (m, 2H), 3.63–3.77 (m, 1H), 3.79–3.91 (m, 1H), 4.22 (s, 2H), 4.42 (s, 2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.44, 26.84, 33.91, 34.72, 34.80, 34.97, 36.45, 36.68, 40.56, 42.21, 70.94, 72.00, 106.08, 112.64, 169.20, 171.40. Anal. Calcd for $\text{C}_{19}\text{H}_{27}\text{NO}_7$: C, 59.83; H, 7.14; N, 3.67. Found: C, 59.67; H, 7.16; N, 3.56.

Adamantane-2-spiro-3'-8'-methoxyacetyl-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ113). To a solution of **OZ80** (301 mg, 1 mmol) in CH_2Cl_2 (10 ml) was added triethylamine (303 mg, 3 mmol). The solution was then cooled to 0–5 °C, and methoxyacetyl chloride (163 mg, 1.5 mmol) was added. The resulting mixture was stirred at rt for 16 h and washed with water (5 ml) and brine (5 ml). The organic phase was separated, dried over MgSO_4 , and concentrated to give trioxolane **OZ113** (325 mg, 96%) as a colorless solid. mp 76–78 °C; ^1H NMR (500 MHz, CDCl_3) δ 1.59–2.17 (m, 18H), 3.42 (s, 3H), 3.43–3.73 (m, 3H), 3.75–3.89 (m, 1H), 4.11 (AB system, 2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.57, 26.97, 34.32 (br s), 34.83, 34.92, 35.25 (br s), 36.55, 36.82, 39.98 (br s), 42.87 (br s), 58.96, 72.21, 106.78, 112.30, 167.54. Anal. Calcd for $\text{C}_{18}\text{H}_{27}\text{NO}_5$: C, 64.07; H, 8.07; N, 4.15. Found: C, 63.94; H, 8.03; N, 4.30.

Adamantane-2-spiro-3'-8'-(8'-quinolinesulfonyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ114). To a solution of **OZ80** (151 mg, 0.5 mmol) in CH_2Cl_2 (5 ml) was added triethylamine (150 mg, 1.49 mmol). The solution was then cooled to 0–5 °C, and 8-quinolinesulfonyl chloride (115 mg, 0.5 mmol) was added. The resulting mixture

was stirred at rt for 12 h before evaporation to dryness. The residue was triturated with water (5 ml) and filtered. Recrystallization of the solid from methanol gave trioxolane **OZ114** (215 mg, 94%) as a colorless solid. mp 142–144 °C (methanol); ¹H NMR (500 MHz, CDCl₃) δ 1.55–2.21 (m, 18H), 3.40–3.61 (m, 2H), 3.62–3.85 (m, 2H), 7.51 (dd, J = 8.2, 3.9 Hz, 1H), 7.61 (dd, J = 8.2, 8.2 Hz, 1H), 8.02 (d, J = 7.8 Hz, 1H), 8.23 (dd, J = 8.3, 1.5 Hz, 1H), 8.47 (dd, J = 7.3, 1.5 Hz, 1H), 9.05 (dd, J = 3.9, 1.5 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.58, 26.97, 34.82, 34.88, 34.90, 36.54, 36.83, 44.37, 106.74, 112.16, 121.98, 125.47, 129.12, 132.68, 133.24, 136.30, 137.86, 144.33, 151.10. Anal. Calcd for C₂₄H₂₈N₂O₅S: C, 63.14; H, 6.18; N, 6.14. Found: C, 62.94; H, 6.16; N, 6.00.

Adamantane-2-spiro-3'-8'-(1'-octanesulfonyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ115). To a solution of **OZ80** (200 mg, 0.66 mmol) and triethylamine (200 mg, 1.98 mmol) in CH₂Cl₂ (5 ml) at 0–5 °C was added 1-octanesulfonyl chloride (170 mg, 0.8 mmol). The resulting mixture was stirred at rt for 12 h before evaporation to dryness. The residue was triturated with water (10 ml) and filtered.

Recrystallization of the solid from methanol gave trioxolane **OZ115** (160 mg, 55%) as a colorless solid. mp 54–56 °C (methanol); ¹H NMR (500 MHz, CDCl₃) δ 0.88 (t, J = 6.8 Hz, 3H), 1.17–1.49 (m, 10H), 1.61–2.21 (m, 20H), 2.90 (t, J = 8.1 Hz, 2H), 3.24–3.39 (m, 2H), 3.41–3.57 (m, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 13.95, 22.56, 23.26, 26.55, 26.95, 28.49, 28.93, 29.04, 31.71, 34.71, 34.82, 34.91, 36.53, 36.79, 43.97, 50.46, 106.24, 112.41. Anal. Calcd for C₂₃H₃₉NO₅S: C, 62.55; H, 8.90; N, 3.17. Found: C, 62.38; H, 8.76; N, 3.25.

cis-Adamantane-2-spiro-3'-8'-(hydroxyamino)carbonyl]-1',2',4'-trioxaspiro[4.5]decane (OZ116). A solution of ethyl chloroformate (0.26 g, 2.4 mmol), **OZ72** (0.62 g, 2.0 mmol), and triethylamine (0.27 g, 2.6 mmol) in ether (6 ml) was stirred at 0°C for 10 min. The solid was removed by filtration, and the filtrate was added to a freshly prepared solution of hydroxylamine. [To a suspension of KOH (168 mg, 3.0 mmol) in methanol (1 ml) at 0 °C was added a solution of hydroxylamine hydrochloride (0.20 g, 3 mmol) in methanol (3 ml). The reaction mixture was stirred at 0°C for 15 min and filtered to remove solid by-products. The filtrate was used as such.] The resulting mixture was stirred at rt for 1 h and concentrated. The crude product was purified by flash chromatography (silica gel, 8% methanol in chloroform) to afford trioxolane **OZ116** (0.23

g, 36%) as a colorless solid. mp 130–132 °C (ethanol/water 1:2); ^1H NMR (500 MHz, DMSO- d_6) δ 1.40–2.19 (m, 23H), 8.60 (s, 1H), 10.35 (s, 1H); ^{13}C NMR (125.7 MHz, DMSO- d_6) δ 25.87, 26.27, 26.50, 33.03, 34.28, 34.30, 35.84, 36.15, 39.04, 107.85, 110.64, 171.30. Anal. Calcd for $\text{C}_{17}\text{H}_{25}\text{NO}_5$: C, 63.14; H, 7.79; N, 4.33. Found: C, 62.97; H, 7.57; N, 4.26.

Adamantane-2-spiro-3'-8'-(aminomethyl)-8'-phenyl-1',2',4'-trioxaspiro[4.5]decane hydrochloride (OZ117). A solution of **OZ97** (1.60 g, 3.2 mmol) and hydrazine monohydrate (325 mg, 6.5 mmol) in chloroform (27 ml) and methanol (3 ml) was heated at 50 °C for 36 h. The reaction mixture was cooled to rt and filtered to remove solid by-products. The filtrate was washed with water (20 ml) and brine (20 ml), dried over MgSO_4 , filtered, and concentrated. The solid was dissolved in ether (30 ml), treated with 1 M ethereal HCl (6 ml), and filtered. Recrystallization from hexanes/chloroform (2:1) gave trioxolane **OZ117** (0.22 g, 17%) as a colorless solid. mp 156 °C dec (hexanes/chloroform 2:1); ^1H NMR (500 MHz, DMSO- d_6) δ 1.42–2.05 (m, 20H), 2.32 (apparent d, J = 13.7 Hz, 2H), 2.89 (s, 2H), 7.26–7.39 (m, 1H), 7.41–7.62 (m, 4H), 7.80 (br s, 3H); ^{13}C NMR (125.7 MHz, DMSO- d_6) δ 25.82, 26.19, 30.08, 34.24, 35.76, 36.09, 49.37, 107.89, 110.70, 126.97, 127.14, 128.98, 139.82. Anal. Calcd for $\text{C}_{23}\text{H}_{32}\text{ClNO}_3$: C, 68.05; H, 7.95; N, 3.45. Found: C, 67.92; H, 7.69; N, 3.72.

cis-Adamantane-2-spiro-3'-8'-acetoxymethyl-1',2',4'-trioxaspiro[4.5]decane (OZ118). A solution of *O*-methyl 2-adamantanone oxime (1.34 g, 7.5 mmol) and 4-acetoxymethylcyclohexanone (1.28 g, 7.5 mmol) in pentane (100 ml) and CH_2Cl_2 (20 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 10% ether in hexanes) to afford trioxolane **OZ118** (1.15 g, 46%) as a colorless solid. mp 39–41 °C (ethanol/ H_2O 7:3); ^1H NMR (500 MHz, CDCl_3) δ 1.18–1.31 (m, 2H), 1.59–2.19 (m, 21H), 2.05 (s, 3H), 3.90 (d, J = 6.3 Hz, 2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 20.77, 26.62, 26.77, 27.02, 33.71, 34.86, 34.88, 35.67, 36.54, 36.91, 68.49, 108.57, 111.40, 170.90. Anal. Calcd for $\text{C}_{19}\text{H}_{28}\text{O}_5$: C, 67.83; H, 8.39. Found: C, 67.70; H, 8.32.

cis-Adamantane-2-spiro-3'-8'-hydroxymethyl-1',2',4'-trioxaspiro[4.5]decane (OZ119). A solution of **OZ70** (0.81 g, 2.4 mmol), lithium borohydride (1.2 ml, 2.4 mmol, 2 M in THF), and lithium triethylborohydride (0.24 ml, 0.24 mmol, 1 M in THF) in ether

(2.5 ml) was stirred at rt for 3 h. The reaction mixture was diluted with ether (5 ml), washed with 3 M aq. NaOH (2 x 5 ml), water (2 x 5 ml) and brine (5 ml), dried over MgSO₄, filtered, and concentrated in vacuo to afford trioxolane **OZ119** (0.68 g, 96%) as a colorless solid. mp 97–99 °C (ethanol/H₂O 1:1); ¹H NMR (500 MHz, CDCl₃) δ 1.09–1.27 (m, 2H), 1.42–2.19 (m, 21H), 3.47 (d, J = 6.5 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.63, 26.66, 27.03, 33.86, 34.87, 34.90, 36.56, 36.93, 38.97, 67.63, 108.91, 111.32. Anal. Calcd for C₁₇H₂₆O₄: C, 69.36; H, 8.90. Found: C, 69.58; H, 8.63.

Adamantane-2-spiro-3'-11',11'-bis(ethoxycarbonyl)-1',2',4',9',13'-pentaoxadispiro[4.2.5.2]pentadecane (OZ120). A solution of *O*-methyl 2-adamantanone oxime (2.69 g, 15 mmol) and 3,3-bis(ethoxycarbonyl)-1,5-dioxaspiro[5.5]undecan-9-one (4.71 g, 15 mmol) in pentane (100 ml) and CH₂Cl₂ (50 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 10% ether in petroleum ether) to afford trioxolane **OZ120** (3.60 g, 50%) as a colorless solid. mp 74–77 °C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.27 (t, J = 7.1 Hz, 6H), 1.61–2.18 (m, 22H), 4.24 (q, J = 7.2 Hz, 4H), 4.28 (s, 4H); ¹³C NMR (125.7 MHz, CDCl₃) δ 13.91, 26.55, 26.95, 29.35, 30.45, 34.77, 34.87, 36.43, 36.83, 39.26, 53.95, 61.77, 62.10, 97.54, 108.22, 111.56, 167.84. Anal. Calcd for C₂₅H₃₆O₉: C, 62.48; H, 7.55. Found: C, 62.62; H, 7.32.

Adamantane-2-spiro-3'-11',11'-bis(hydroxymethyl)-1',2',4',9',13'-pentaoxadispiro[4.2.5.2]pentadecane (OZ121). A solution of **OZ120** (1.00 g, 2.18 mmol), lithium borohydride (2.10 ml, 4.20 mmol, 2 M in THF), and lithium triethylborohydride (0.42 ml, 0.42 mmol, 1 M in THF) in ether (5 ml) was stirred at rt for 3 h. The reaction mixture was diluted with ether (10 ml) and washed with 3 M aq. NaOH (2 x 10 ml), water (2 x 10 ml), and brine (10 ml). The combined aqueous layers were extracted with CHCl₃ (3 x 50 ml), and the chloroform extract was washed with water (2 x 50 ml) and brine (50 ml). The ether extract and chloroform extract were combined, dried over MgSO₄, filtered, and concentrated. The residue was purified by flash chromatography (silica gel, 5% methanol in chloroform) to afford trioxolane **OZ121** (0.40 g, 46%) as a colorless solid. mp 146–148 °C (ethanol/H₂O 3:2); ¹H NMR (500 MHz, DMSO-d₆) δ 1.60–2.15 (m, 22H), 3.36 (d, J = 4.9 Hz, 4H), 3.61 (s, 2H), 3.62 (s, 2H), 4.49 (t, J = 5.4 Hz, 2H); ¹³C NMR (125.7 MHz, DMSO-d₆) δ 25.86, 26.26, 29.34, 30.21, 34.27, 34.36, 35.77,

36.13, 39.07, 60.69, 61.44, 61.48, 96.00, 108.15, 110.84. Anal. Calcd for C₂₁H₃₂O₇•0.077CHCl₃: C, 62.40; H, 7.97. Found: C, 62.76; H, 7.77.

Adamantane-2-spiro-3'-11',11'-dicarboxy-1',2',4',9',13'-pentaoxadispiro[4.2.5.2]pentadecane (OZ122).

A solution of **OZ120** (0.73 g, 1.5 mmol),

5 15% aq. KOH (4.2 ml) in methanol (30 ml) was heated at 50 °C for 2 h. After being cooled to rt, the reaction mixture was concentrated to 5 ml, acidified with conc. HCl, and extracted with CHCl₃ (5 x 50 ml). The combined organic layers were washed with water (2 x 50 ml)

and brine (50 ml), dried over MgSO₄, filtered, and concentrated to afford trioxolane **OZ122**

(0.38 g, 58%) as a colorless solid. mp 151–153 °C (water); ¹H NMR (500 MHz, DMSO-d₆)

10 δ 1.51–2.14 (m, 22H), 4.13 (s, 2H), 4.15 (s, 2H); ¹³C NMR (125.7 MHz, DMSO-d₆) δ

25.86, 26.26, 29.16, 30.16, 34.27, 34.37, 35.77, 36.13, 52.89, 61.65, 96.49, 107.99, 110.92,

116.11. Anal. Calcd for C₂₁H₂₈O₉: C, 59.43; H, 6.65. Found: C, 59.42; H, 6.66.

cis-Adamantane-2-spiro-3'-8'-bromomethyl-1',2',4'-trioxaspiro[4.5]decane

(OZ123). A solution of *O*-methyl 2-adamantanone oxime (2.15 g, 12 mmol) and 4-

15 bromomethylcyclohexanone (2.30 g, 12 mmol) in pentane (100 ml) and CH₂Cl₂ (50 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 3% ether in hexanes) to afford trioxolane **OZ123** (1.62 g, 38%) as a colorless solid. mp 138–140 °C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ

1.21–1.41 (m, 2H), 1.51–2.21 (m, 21H), 3.28 (d, J = 6.3 Hz, 2H); ¹³C NMR (125.7 MHz,

20 CDCl₃) δ 26.64, 27.04, 28.83, 33.73, 34.88, 34.90, 36.55, 36.93, 38.63, 38.76, 108.41,

111.47. Anal. Calcd for C₁₇H₂₅BrO₃: C, 57.15; H, 7.05. Found: C, 57.20; H, 6.99.

Adamantane-2-spiro-3'-5'-(4'-cyanophenyl)-5'-phenyl)-1',2',4'-trioxolane

(OZ124). A solution of *O*-methyl 2-adamantanone oxime (0.86 g, 4.80 mmol) and 4-

cyanobenzophenone (1.00 g, 4.80 mmol) in pentane (50 ml) and CH₂Cl₂ (60 ml) was

25 treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 10% ether in hexanes) to afford trioxolane **OZ124** (0.30 g, 17%) as a colorless solid. mp 136–137 °C (ether); ¹H NMR (500 MHz, CDCl₃) δ 1.60–

2.35 (m, 14H), 7.31–7.39 (m, 3H), 7.40–7.48 (m, 2H), 7.62–7.73 (m, 4H); ¹³C NMR (125.7

MHz, CDCl₃) δ 26.50, 26.92, 34.70, 34.80, 34.84, 35.39, 36.08, 36.25, 36.76, 108.84,

30 112.50, 114.57, 118.43, 126.85, 127.42, 128.38, 129.27, 131.97, 137.97, 146.30. Anal.

Calcd for C₂₄H₂₃NO₃: C, 77.19; H, 6.21; N, 3.75. Found: C, 77.58; H, 6.32; N, 3.76.

Adamantane-2-spiro-3'-5',5'-bis[4'-(ethoxycarbonyl)phenyl]-1',2',4'-trioxolane (OZ125). A solution of *O*-methyl 2-adamantanone oxime (1.79 g, 10 mmol) and 4,4'-bis(ethoxycarbonyl)benzophenone (3.26 g, 10 mmol) in pentane (60 ml) and CH₂Cl₂ (40 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 10% ether in hexanes) to afford trioxolane OZ125 (1.77 g, 36%) as a colorless solid. mp 143–145 °C (ether); ¹H NMR (500 MHz, CDCl₃) δ 1.38 (t, J = 7.1 Hz, 6H), 1.60–2.07 (m, 12H), 2.20 (app d, J = 12.2 Hz, 2H), 4.37 (q, J = 7.2 Hz, 4H), 7.58 (d, J = 8.3 Hz, 4H), 8.03 (d, J = 8.3 Hz, 4H); ¹³C NMR (125.7 MHz, CDCl₃) δ 14.28, 26.52, 26.94, 34.84, 35.06, 36.17, 36.78, 61.01, 108.84, 114.60, 126.69, 129.52, 131.10, 144.22, 166.06. Anal. Calcd for C₂₉H₃₂O₇: C, 70.71; H, 6.55. Found: C, 70.52; H, 6.32.

cis-Adamantane-2-spiro-3'-8'-(2'-(diethylamino)ethyl)-1',2',4'-trioxaspiro[4.5]decane hydrobromide (OZ126). Step 1. A solution of *O*-methyl 2-adamantanone oxime (716 mg, 4 mmol) and 4-(2-bromoethyl)cyclohexanone (820 mg, 4 mmol) in pentane (72 ml) and CH₂Cl₂ (8 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 1% ether in hexanes) to afford **cis-Adamantane-2-spiro-3'-8'-(2'-bromoethyl)-1',2',4'-trioxaspiro[4.5]decane** (800 mg, 54%) as a colorless solid. mp 62–64 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.18–1.22 (m, 2H), 1.72–2.10 (m, 23H), 3.42 (t, 2H, J = 6.8 Hz). **Step 2.** To a solution of the above bromide (371 mg, 1 mmol) in acetonitrile (5 ml) were added diethylamine (140 mg, 2 mmol) and triethylamine (101 mg, 1 mmol). The mixture was heated at 60–65 °C for 60 h before removal of solvents. The residue was triturated with water (5 ml) and filtered. Recrystallization of the solid from ethanol gave trioxolane OZ126 (170 mg, 43%) as a colorless solid. mp 152–154 °C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.20–1.34 (m, 2H), 1.41 (t, J = 7.3 Hz, 6H), 1.60–2.25 (m, 23H), 2.95–3.04 (m, 2H), 3.05–3.19 (m, 4H), 12.17 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 8.69, 26.61, 27.00, 29.13, 29.84, 33.90, 34.34, 34.86, 34.88, 36.54, 36.90, 46.55, 49.51, 108.27, 111.54. Anal. Calcd for C₂₂H₃₇NO₃•0.5HBr: C, 65.41; H, 9.36; N, 3.47. Found: C, 65.24; H, 9.54; N, 3.46.

trans-Adamantane-2-spiro-3'-8'-(hydroxyamino)carbonyl]-1',2',4'-trioxaspiro[4.5]decane (OZ127). A solution of ethyl chloroformate (0.13 g, 1.2 mmol),

OZ71 (0.31 g, 1.0 mmol), and triethylamine (0.13 g, 1.3 mmol) in ether (5 ml) was stirred at 0 °C for 10 min. The solid was removed by filtration, and the filtrate was added to a freshly prepared solution of hydroxylamine. [To a suspension of KOH (84 mg, 1.5 mmol) in methanol (1 ml) at 0 °C was added a solution of hydroxylamine hydrochloride (0.10 g, 1.5 mmol) in methanol (2 ml). The reaction mixture was stirred at 0 °C for 15 min and filtered to remove solid by-products. The filtrate was used as such.] The resulting mixture was stirred at rt for 1 h and concentrated. The crude product was purified by crystallization from hexanes/chloroform (5:1) to afford trioxolane **OZ127** (0.15 g, 47%) as a colorless solid. mp 136–138 °C (hexanes/chloroform 5:1); ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.42–2.23 (m, 23H), 8.60 (s, 1H), 10.36 (s, 1H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 25.87, 26.26, 26.40, 32.95, 34.26, 34.42, 35.81, 36.13, 39.26, 107.88, 110.95, 171.35. Anal. Calcd for C₁₇H₂₅NO₅: C, 63.14; H, 7.79; N, 4.33. Found: C, 62.89; H, 7.59; N, 4.40.

Adamantane-2-spiro-3'-11'-methylene-1',2',4',9',13'-pentaoxadispiro[4.2.5.2]pentadecane (OZ128). **Step 1.** A mixture of **OZ05** (1.12 g, 4 mmol), TFA (0.70 ml), CH₂Cl₂ (10 ml), and methanol (70 ml) was stirred at rt for 16 h. The reaction was quenched with NaHCO₃ (2.0 g) and stirred for additional 1 h before evaporation to dryness. The residue was dissolved in CH₂Cl₂ (20 ml), washed with water and brine, dried over MgSO₄, filtered, and concentrated to afford dimethyl ketal of **OZ05** (1.31 g, 100%) as a colorless oil. ¹H NMR (500 MHz, CDCl₃) δ 1.66–2.02 (m, 22H), 3.18 (s, 3H), 3.19 (s, 3H). **Step 2.** A mixture of the above ketal (1.30 g, 4 mmol), 2-methylene-1,3-propanediol (0.70 g, 8 mmol), and *p*-TsOH (0.5 g) in CH₂Cl₂ (70 ml) and THF (10 ml) was stirred at rt for 16 h. The reaction was quenched with NaHCO₃ (1.0 g), stirred for additional 1 h, and diluted with water (70 ml). After separation of the organic layer, the aqueous layer was extracted with CH₂Cl₂ (2 x 50 ml). The combined organic layers were washed with water and brine, dried over MgSO₄, filtered, and concentrated. The crude product was purified by flash chromatography (silica gel, 8% ether in hexanes) to afford trioxolane **128** (0.87 g, 63%) as a colorless solid. mp 58–59 °C (hexanes); ¹H NMR (500 MHz, CDCl₃) δ 1.59–2.21 (m, 22H), 4.31 (s, 4H), 4.86 (s, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.60, 27.02, 29.97, 30.69, 34.84, 34.94, 36.49, 36.90, 63.63, 97.60, 107.92, 108.38, 111.59, 141.15. Anal. Calcd for C₂₀H₂₈O₅: C, 68.94; H, 8.10. Found: C, 68.77; H, 7.93.

cis-Adamantane-2-spiro-3'-8'-(2'-hydroxy-1',1'-dimethylethylamino)carbonyl]-1',2',4'-trioxaspiro[4.5]decane (OZ129). A solution of **OZ72** (0.77 g, 2.50 mmol), DCC (0.78 g, 3.75 mmol), HOBT (0.51 g, 3.75 mmol), and 2-amino-2-methyl-1-propanol (0.33 g, 3.75 mmol) in DMF (20 ml) was heated at 50–60 °C for 6 h. After being cooled to rt, the reaction mixture was acidified with 1 M aq. HCl (100 ml) and extracted with ethyl acetate (4 x 60 ml). The combined extracts were washed with water and brine, dried over MgSO₄, filtered, and concentrated. The crude product was purified by flash chromatography (silica gel, 50% ethyl acetate in hexanes) to afford trioxolane **129** (0.44 g, 46%) as a colorless solid. mp 163–164 °C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.27 (s, 6H), 1.60–2.24 (m, 23H), 3.56 (s, 2H), 4.80 (s, 1H), 5.47 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 24.77, 26.62, 27.03, 27.21, 33.64, 34.86, 34.90, 36.55, 36.91, 44.24, 55.95, 70.66, 107.78, 111.60, 175.63. Anal. Calcd for C₂₁H₃₃NO₅: C, 66.46; H, 8.76; N, 3.69. Found: C, 66.41; H, 8.56; N, 3.76.

Adamantane-2-spiro-3'-11'-oxo-1',2',4',9',13'-pentaoxadispiro[4.2.5.2]pentadecane (OZ130). A solution of **OZ128** (0.65 g, 1.9 mmol) in CH₂Cl₂ (80 ml) at –78 °C was treated with ozone for 10 min, flashed with oxygen for 5 min before addition of triphenylphosphine (0.49 g, 1.9 mmol). The reaction mixture was warmed up to rt and stirred at rt for 1 h before evaporation to dryness. The crude product was purified by flash chromatography (silica gel, 10% ether in hexanes) to afford trioxolane **OZ130** (0.37 g, 57%) as a colorless solid. mp 76–79 °C (hexanes); ¹H NMR (500 MHz, CDCl₃) δ 1.61–2.21 (m, 22H), 4.17 (s, 4H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.61, 27.03, 29.80, 30.81, 34.85, 34.96, 36.52, 36.89, 66.92, 66.94, 99.14, 107.96, 111.82, 207.00. Anal. Calcd for C₁₉H₂₆O₆: C, 65.13; H, 7.48. Found: C, 65.38; H, 7.58.

Adamantane-2-spiro-3'-8'-phenylmethanesulfonyl-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ131). To a solution of **OZ80** (301 mg, 1.0 mmol) and *p*-toluenesulfonyl chloride (192 mg, 1.0 mmol) in CH₂Cl₂ (10 ml) at 0–5 °C was added triethylamine (303 mg, 3.0 mmol). The resulting mixture was stirred at rt for 16 h before evaporation to dryness. The residue was triturated with water, filtered, and crystallized from ethanol to give trioxolane **OZ131** (320 mg, 76%) as a colorless solid. mp 148–150 °C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.59–2.21 (m, 18H), 3.06–3.24 (m, 2H), 3.25–3.41 (m, 2H), 4.22 (s, 2H), 7.27–7.60 (m, 5H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.53,

26.94, 34.77, 34.79, 34.89, 36.50, 36.78, 44.20, 57.79, 106.20, 112.28, 128.79, 129.12, 130.67. Anal. Calcd for C₂₂H₂₉NO₅S: C, 62.98; H, 6.97; N, 3.34. Found: C, 63.16; H, 6.79; N, 3.46.

Adamantane-2-spiro-3'-8'-(2'-carboxybenzoyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ132).

To a solution of **OZ80** (301 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in CH₂Cl₂ (10 ml) at 0–5°C was added phthalic anhydride (148 mg, 1.0 mmol). The resulting mixture was stirred at rt for 24 h before evaporation to dryness. The residue was triturated, filtered, and crystallized from ethanol to give trioxolane **OZ132** (285 mg, 69%) as a colorless solid. mp 162–164 °C (ethanol); ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.57–2.21 (m, 18H), 3.01–3.32 (m, 2H), 3.35–4.04 (m, 2H), 7.33 (d, J = 7.3 Hz, 1H), 7.52 (dd, J = 7.8, 7.8 Hz, 1H), 7.64 (dd, J = 7.3, 7.3 Hz, 1H), 7.93 (d, J = 7.8 Hz, 1H), 13.14 (br s, 1H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 25.84, 26.23, 33.29, 33.54, 34.25, 34.34, 35.74, 35.79, 36.07, 38.82, 44.26, 107.05, 111.35, 126.62, 128.43, 128.63, 130.03, 132.42, 138.38, 166.90, 168.45. Anal. Calcd for C₂₃H₂₇NO₆: C, 66.81; H, 6.58; N, 3.39. Found: C, 67.02; H, 6.65; N, 3.40.

Adamantane-2-spiro-3'-8'-[dimethylamino]carbonyl]-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ133).

To a solution of **OZ80** (301 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in CH₂Cl₂ (10 ml) at 0–5°C was added dimethylcarbamoyl chloride (115 mg, 1.07 mmol). The resulting mixture was stirred at rt for 16 h before evaporation to dryness. The residue was triturated, and filtered, and crystallized from methanol to give trioxolane **OZ133** (260 mg, 77%) as a colorless solid. mp 106–108 °C (methanol); ¹H NMR (500 MHz, CDCl₃) δ 1.60–2.11 (m, 18H), 2.82 (s, 6H), 3.21–3.47 (m, 4H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.61, 27.01, 34.52, 34.84, 34.94, 36.59, 36.87, 38.53, 44.69, 107.28, 111.95, 164.66. Anal. Calcd for C₁₈H₂₈N₂O₄: C, 64.26; H, 8.39; N, 8.33. Found: C, 64.49; H, 8.36; N, 8.42.

Adamantane-2-spiro-3'-1',2',4'-trioxolane-5'-spiro-4''-2'',3''-dihydro-4''H-1''-benzopyran (OZ134). A solution of *O*-methyl 2-adamantanone oxime (895 mg, 5 mmol) and 4-chromanone (740 mg, 5 mmol) in cyclohexane (80 ml) and CH₂Cl₂ (20 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 2% ether in hexanes) to afford trioxolane **OZ134** (590 mg, 38%) as a colorless solid. mp 136–138 °C (methanol); ¹H NMR (500 MHz, CDCl₃) δ

1.61–2.38 (m, 14H), 2.39–2.61 (m, 2H), 4.23–4.51 (m, 2H), 6.83 (d, J = 8.3 Hz, 1H), 6.96 (dd, J = 8.3, 8.3 Hz, 1H), 7.27 (ddd, J = 8.6, 8.6, 1.6 Hz, 1H), 7.53 (dd, J = 7.8, 1.6 Hz, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.61, 27.03, 33.46, 33.97, 34.89, 34.94, 35.78, 36.43, 36.91, 37.08, 64.65, 103.93, 112.95, 117.04, 120.68, 128.26, 131.42, 157.71. Anal.
5 Calcd for $\text{C}_{19}\text{H}_{22}\text{O}_4$: C, 72.59; H, 7.05. Found: C, 72.48; H, 6.87.

Adamantane-2-spiro-3'-5',5'-bis(4'-carboxyphenyl)-1',2',4'-trioxolane

(OZ135). A mixture of **OZ125** (0.44 g, 0.89 mmol), THF (7 ml), and 40% aq. KOH (4.5 ml) was heated at 50°C for 5 days. The reaction mixture was cooled to rt and extracted with ether (5 x 20 ml). The aqueous layer was acidified to pH = 3 with conc. HCl. The resulting precipitate was filtered and recrystallized from ethanol/water (2:1) to afford trioxolane **OZ135** (0.35 g, 90%) as a colorless solid. mp 170 °C (EtOAc) dec; ^1H NMR (500 MHz, CDCl_3) δ 1.60–2.05 (m, 12H), 2.13 (app d, J = 11.7 Hz, 2H), 7.60 (d, J = 8.8 Hz, 4H), 7.98 (d, J = 8.8 Hz, 4H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 25.79, 26.19, 34.25, 34.42, 35.56, 35.99, 108.40, 113.95, 126.42, 129.46, 131.47, 143.44, 166.69. Anal. Calcd for $\text{C}_{25}\text{H}_{24}\text{O}_7$:

15 C, 68.80; H, 5.54. Found: C, 68.64; H, 5.34.

cis-Adamantane-2-spiro-3'-8'-phthalimido-1',2',4'-trioxaspiro[4.5]decane

(OZ136). A solution of *O*-methyl 2-adamantanone oxime (1.79 g, 10 mmol) and 4-phthalimidocyclohexanone (2.43 g, 10 mmol) in pentane (60 ml) and CH_2Cl_2 (80 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 80% ether in hexanes) to afford trioxolane **OZ136** (1.20 g, 29%) as a colorless solid. mp 156–158 °C (ether); ^1H NMR NMR (500 MHz, CDCl_3) δ 1.60–2.19 (m, 20H), 2.45–2.63 (m, 2H), 4.18 (tt, J = 12.4, 3.9 Hz, 1H), 7.64–7.76 (m, 2H), 7.77–7.89 (m, 2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.60, 26.89, 27.00, 33.81, 34.85, 36.45, 36.89, 49.35, 107.43, 111.50, 123.06, 132.13, 133.75, 168.01. Anal. Calcd for $\text{C}_{24}\text{H}_{27}\text{NO}_5$: C, 70.40; H, 6.65; N, 3.42. Found: C, 70.16; H, 6.43; N, 3.43.

cis-Adamantane-2-spiro-3'-8'-amino-1',2',4'-trioxaspiro[4.5]decane

hydrochloride (OZ137). A solution of **OZ136** (0.81 g, 1.98 mmol) and hydrazine monohydrate (198 mg, 3.96 mmol) in chloroform (16 ml) and methanol (2 ml) was heated under nitrogen at 50°C for 24 h. The reaction mixture was cooled to rt, filtered to remove solid by-products, and concentrated. The solid residue was dissolved in CHCl_3 , washed with water and brine, dried over MgSO_4 , filtered, and concentrated. The oily amine was

dissolved in ether (2 ml), treated with 1 M ethereal HCl (7 ml), and filtered to give trioxolane **OZ137** (0.31 g, 50%) as a colorless solid. mp 132 °C dec (ether); ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.41–1.59 (m, 2H), 1.60–2.15 (m, 20H), 3.10 (br s, 1H), 8.12 (br s, 3H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 25.83, 26.23, 27.46, 31.33, 34.27, 34.30, 35.73, 5 36.10, 47.31, 107.24, 110.96. Anal. Calcd for C₁₆H₂₆ClNO₃: C, 60.85; H, 8.30; N, 4.43. Found: C, 60.64; H, 8.16; N, 4.70.

Adamantane-2-spiro-3'-5'-[4'-(methoxycarbonyl)phenyl]-5'-phenyl-1',2',4'-trioxolane (OZ138). A solution of *O*-methyl 2-adamantanone oxime (1.79 g, 10 mmol) and 4-(methoxycarbonyl)benzophenone (2.40 g, 10 mmol) in pentane (40 ml) and CH₂Cl₂ 10 (90 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 10% ether in hexanes) to afford trioxolane **OZ138** (1.00 g, 25%) as a colorless solid. mp 144–146 °C (ether); ¹H NMR (500 MHz, CDCl₃) δ 1.60–2.29 (m, 14H), 3.91 (s, 3H), 7.31–7.39 (m, 3H), 7.43–7.52 (m, 2H), 7.63 (d, J = 8.3 Hz, 2H), 8.03 (d, J = 8.5 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.58, 26.99, 15 33.32, 34.86, 34.88, 35.31, 36.13, 36.31, 36.86, 51.99, 109.28, 114.26, 126.76, 126.96, 128.22, 128.97, 129.42, 130.37, 138.83, 145.73, 166.69. Anal. Calcd for C₂₅H₂₆O₅: C, 73.87; H, 6.45. Found: C, 74.07; H, 6.55.

cis-Adamantane-2-spiro-3'-8'-(4'-phenyl-1'-piperazinyl)carbonyl]-1',2',4'-trioxaspiro[4.5]decane hydrochloride (OZ140). A solution of **OZ72** (0.31 g, 1.0 mmol), 20 DCC (0.27 g, 1.3 mmol), and HOBT (0.16 g, 1.3 mmol) in CHCl₃ (15 ml) was stirred at 0 °C for 15 min before 1-phenylpiperazine (0.21 g, 1.3 mmol) was added. The mixture was then warmed to rt, stirred overnight, and concentrated. The residue was purified by flash chromatography (silica gel, 1% methanol in chloroform) to afford a solid, which was dissolved in chloroform (20 ml) and filtered. The filtrate was concentrated, redissolved in 25 chloroform (15 ml) and ether (30 ml), and filtered. The filtrate was treated with 1 M ethereal HCl (1.5 ml) to afford trioxolane **OZ140** (0.36 g, 74%) as a colorless solid. mp. 155–158 °C (chloroform/ether, 1:2); ¹H NMR (500 MHz, CDCl₃) δ 1.42–2.23 (m, 22H), 2.44–2.62 (m, 1H), 3.51 (br s, 4H), 4.28 (br s, 4H), 7.42–7.60 (m, 3H), 7.79–7.95 (m, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.59, 26.80, 27.01, 33.54, 34.84, 34.89, 36.54, 36.87, 30 38.53, 39.32, 55.25, 107.61, 111.61, 121.22, 130.05, 130.57, 142.36, 173.49. Anal. Calcd for C₂₇H₃₇ClN₂O₄: C, 66.31; H, 7.63; N, 5.73. Found: C, 66.26; H, 7.45; N, 5.83.

cis-Adamantane-2-spiro-3'-1',2',4'-trioxaspiro[4.5]decane-8'-methyl imidazole-1-carboxylate (OZ141). To a solution of **OZ119** (0.29 g, 1 mmol) in CH₃CN(10 ml) and THF (3 ml) was added 1,1'-carbonyldiimidazole (0.21 g, 1.3 mmol). The mixture was stirred at rt for 2 h before being quenched with cold water (50 ml). The resulting precipitate was collected by filtration, washed with water, and dried to afford trioxolane **OZ141** (0.34 g, 91%) as a colorless solid. mp 110–112°C (water); ¹H NMR (500 MHz, CDCl₃) δ 1.25–1.50 (m, 2H), 1.51–2.21 (m, 21H), 4.25 (d, J = 6.3 Hz, 2H), 7.07 (s, 1H), 7.42 (s, 1H), 8.13 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.61, 27.02, 33.54, 34.86, 34.88, 35.66, 36.57, 36.90, 72.07, 108.17, 111.59, 117.03, 130.76, 137.07, 148.71. Anal. Calcd for C₂₁H₂₈N₂O₅: C, 64.93; H, 7.27; N, 7.21. Found: C, 65.12; H, 7.12; N, 7.25.

Adamantane-2-spiro-3'-8'-(*p*-tolylaminocarbonyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ142). To a solution of **OZ80** (301 mg, 1 mmol) and triethylamine (101 mg, 1 mmol) in CH₂Cl₂ (10 ml) at 0 °C was added *p*-tolyl isocyanate (133 mg, 1 mmol). The mixture was stirred at rt for 3 h before removal of solvents. The residue was triturated with water (10 ml) and filtered. Recrystallization of the solid from 95% ethanol gave trioxolane **OZ142** (280 mg, 70%) as a colorless solid. mp 150–152°C (95% ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.61–2.19 (m, 18H), 2.29 (s, 3H), 3.43–3.71 (m, 4H), 6.44 (s, 1H), 7.08 (d, J = 8.0 Hz, 2H), 7.21 (d, J = 8.3 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 20.65, 26.60, 26.99, 34.46, 34.84, 34.94, 36.58, 36.84, 42.46, 106.90, 112.25, 120.44, 129.40, 132.85, 136.53, 155.13. Anal. Calcd for C₂₃H₃₀N₂O₄: C, 69.32; H, 7.59; N, 7.03. Found: C, 69.10; H, 7.50; N, 7.08.

Adamantane-2-spiro-3'-8'-(*t*-butylaminocarbonyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ143). To a solution of **OZ80** (301 mg, 1 mmol) and triethylamine (101 mg, 1 mmol) in CH₂Cl₂ (10 ml) at 0°C was added *tert*-butyl isocyanate (100 mg, 1 mmol). The mixture was stirred at rt for 6 h before removal of solvents. The residue was triturated with water (10 ml) and filtered. Recrystallization of the solid from 95% ethanol gave trioxolane **OZ143** (185 mg, 51%) as a colorless solid. mp 142–144°C (95% ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.35 (s, 9H), 1.62–2.09 (m, 18H), 3.35–3.59 (m, 4H), 4.34 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.60, 27.00, 29.51, 34.38, 34.84, 34.93, 36.57, 36.86, 42.22, 50.82, 107.13, 112.08, 156.72. Anal. Calcd for C₂₀H₃₂N₂O₄: C, 65.91; H, 8.85; N, 7.69. Found: C, 66.19; H, 8.50; N, 7.62.

Adamantane-2-spiro-3'-8'-(phenylaminothiocarbonyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ144). To a solution of **OZ80** (301 mg, 1 mmol) and triethylamine (101 mg, 1 mmol) in CH₂Cl₂ (10 ml) at 0°C was added phenyl isothiocyanate (135 mg, 1 mmol). The mixture was stirred at rt for 6 h before removal of solvents. The residue was 5 triturated with water (10 ml) and filtered. Recrystallization of the solid from 95% ethanol gave trioxolane **OZ144** (224 mg, 56%) as a colorless solid. mp 136–138°C (95% ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.60–2.19 (m, 18H), 3.78–4.05 (m, 4H), 7.07–7.18 (m, 3H), 7.32 (s, 1H), 7.28–7.37 (m, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.56, 26.96, 34.09, 34.82, 34.92, 36.52, 36.81, 47.59, 106.54, 112.45, 122.59, 125.13, 129.27, 140.42, 184.18. 10 Anal. Calcd for C₂₂H₂₈N₂O₃S: C, 65.97; H, 7.05; N, 6.99. Found: C, 65.93; H, 7.15; N, 7.13.

cis-Adamantane-2-spiro-3'-8'-(1'H-imidazol-1'-ylmethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ145). **Step 1.** To a solution of **OZ119** (0.29 g, 1 mmol) and triethylamine (0.15 g, 1.5 mmol) in CH₂Cl₂ (5 ml) at 0°C was added dropwise a solution of 15 methanesulfonyl chloride (0.14 g, 1.2 mmol) in CH₂Cl₂ (1 ml). The mixture was stirred at rt for 1 h before being quenched with water (5 ml). After separation of the aqueous layer, the organic layer was washed with water (5 ml) and brine (5 ml), dried over MgSO₄, filtered, and concentrated to afford the methanesulfonate (0.34 g, 92%) as a colorless solid. mp 82–84°C (75% ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.25–1.34 (m, 2H), 1.66–2.02 (m, 21H), 3.00 (s, 3H), 4.04 (d, J = 6.3 Hz, 2H). **Step 2.** To a suspension of 60% NaH (0.08 g, 2 mmol) in DMF (4 ml) under nitrogen at 0°C was added a solution of imidazole (0.14 g, 2 mmol) in DMF (4 ml). The mixture was stirred for 30 min before a solution of the above 20 methanesulfonate (0.34 g, 0.9 mmol) in DMF (4 ml) was added dropwise. The mixture was heated at 50 °C for 2 h before being quenched with water (40 ml) and then extracted with ethyl acetate (3 x 30 ml). The combined extracts were washed with brine (3 x 30 ml), dried over MgSO₄, filtered, and concentrated. Crystallization of the residue from 25 hexanes/CH₂Cl₂ (4:1) gave trioxolane **OZ145** (0.17 g, 55%) as a colorless solid. mp 125–128 °C (hexanes/CH₂Cl₂, 4:1); ¹H NMR NMR (500 MHz, CDCl₃) δ 1.17–1.39 (m, 2H), 1.55–2.18 (m, 21H), 3.77 (d, J = 7.3 Hz, 2H), 6.86 (s, 1H), 7.05 (s, 1H), 7.42 (s, 1H); ¹³C 30 NMR (125.7 MHz, CDCl₃) δ 26.59, 26.99, 27.70, 33.58, 34.85, 34.87, 36.53, 36.88, 37.97,

52.49, 108.25, 111.60, 119.16, 129.55, 137.43. Anal. Calcd for $C_{20}H_{28}N_2O_3 \cdot 0.2H_2O$: C, 69.02; H, 8.22; N, 8.05. Found: C, 68.81; H, 8.11; N, 7.96.

cis-Adamantane-2-spiro-3'-8'-phthalimidomethyl-1',2',4'-trioxaspiro[4.5]decane (OZ146).

A solution of *O*-methyl 2-adamantanone oxime (2.23 g, 12.4 mmol) and 4-phthalimidomethylcyclohexanone (3.20 g, 12.4 mmol) in pentane (100 ml) and CH_2Cl_2 (50 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 25% ether in hexanes) to afford trioxolane **OZ146** (1.66 g, 32%) as a colorless solid. mp 147–150°C (ethanol); 1H NMR (500 MHz, $CDCl_3$) δ 1.23–1.44 (m, 2H), 1.45–2.08 (m, 21H), 3.56 (d, J = 7.0 Hz, 2H), 7.69–7.74 (m, 2H), 7.81–7.89 (m, 2H); ^{13}C NMR (125.7 MHz, $CDCl_3$) δ 26.61, 27.01, 27.88, 33.66, 34.85, 34.87, 35.70, 36.51, 36.92, 43.12, 108.52, 111.35, 123.22, 132.20, 133.86, 168.47. Anal. Calcd for $C_{25}H_{29}NO_5$: C, 70.90; H, 6.90; N, 3.31. Found: C, 71.16; H, 6.75; N, 3.21.

Adamantane-2-spiro-3'-1',2',4'-trioxaspiro[4.5]decane-8'-yl imidazole-1-carboxylate (OZ147).

To a solution of **OZ32** (0.28 g, 1 mmol) in CH_3CN (10 ml) and THF (3 ml) was added 1,1'-carbonyldiimidazole (0.21 g, 1.3 mmol). The mixture was stirred at 60–70°C for 2 h before being cooled to rt and diluted with cold water (50 ml). The resulting precipitate was collected by filtration, washed with water, and dried to afford trioxolane **OZ147** (0.32 g, 90%, 1:1 mixture of two diastereomers) as a colorless solid. mp 116–118°C (water); 1H NMR (500 MHz, $CDCl_3$) δ 1.62–2.21 (m, 22H), 5.05–5.22 (m, 1H), 7.07 (s, 0.5H), 7.08 (s, 0.5H), 7.41 (s, 0.5H), 7.43 (s, 0.5H), 8.13 (s, 0.5H), 8.15 (s, 0.5H); ^{13}C NMR (125.7 MHz, $CDCl_3$) δ 26.58, 27.00, 28.05, 28.32, 30.53, 30.88, 34.83, 34.94, 36.48, 36.56, 36.85, 74.61, 75.01, 107.24, 107.30, 112.01, 112.11, 117.01, 117.04, 130.74, 137.08, 148.09, 148.14. Anal. Calcd for $C_{20}H_{26}N_2O_5$: C, 64.15; H, 7.00; N, 7.48. Found: C, 64.22; H, 7.00; N, 7.30.

cis-Adamantane-2-spiro-3'-1',2',4'-trioxaspiro[4.5]decane-8'-methyl 4-phenylpiperazine-1-carboxylate (OZ148).

To a solution of **OZ141** (310 mg, 0.86 mmol) in THF (10 ml) at 0°C was added methyl triflate (142 mg, 0.86 mmol). The mixture was stirred at 0 °C for 30 min before 1-phenylpiperazine (140 mg, 0.86 mmol) was added. The reaction was stirred at rt for 18 h before removal of solvents. Crystallization of the residue from ethanol/water (3:1) gave trioxolane **OZ148** (323 mg, 83%) as a colorless solid. mp

145–146°C (ethanol/water, 3:1); ^1H NMR (500 MHz, CDCl_3) δ 1.21–1.42 (m, 2H), 1.58–2.10 (m, 21H), 3.15 (br s, 4H), 3.63 (br s, 4H), 3.96 (d, J = 6.2 Hz, 2H), 6.90 (dd, J = 7.5, 7.5 Hz, 1H), 6.93 (d, J = 7.8 Hz, 2H), 7.28 (dd, J = 8.6, 7.4 Hz, 2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.61, 26.79, 27.01, 33.77, 34.87, 34.88, 36.03, 36.55, 36.91, 43.81, 49.46, 69.57, 108.61, 111.39, 116.71, 120.40, 129.20, 151.27, 155.45. Anal. Calcd for $\text{C}_{28}\text{H}_{38}\text{N}_2\text{O}_5$: C, 69.68; H, 7.94; N, 5.80. Found: C, 69.83; H, 7.98; N, 5.86.

Adamantane-2-spiro-3'-1',2',4'-trioxaspiro[4.5]decane-8'-spiro-1''-3''-oxo-3''H-isobenzofuran (OZ149). A solution of *O*-methyl 2-adamantanone oxime (0.54 g, 3 mmol) and spiro[cyclohexane-1,1'(*3'H*)-isobenzofuran]-3',4-dione (0.65 g, 3 mmol) in pentane (50 ml) and CH_2Cl_2 (50 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 25% ether in hexanes) to afford trioxolane **OZ149** (0.50 g, 44%) as a colorless solid. mp 160–162°C (ethanol/water, 3:1); ^1H NMR NMR (500 MHz, CDCl_3) δ 1.65–2.12 (m, 18H), 2.21 (ddd, J = 13.8, 13.8, 3.9 Hz, 2H), 2.31 (ddd, J = 13.7, 13.7, 4.0 Hz, 2H), 7.38 (d, J = 7.5 Hz, 1H), 7.52 (dd, J = 7.5, 7.5 Hz, 1H), 7.67 (dd, J = 7.5, 7.5 Hz, 1H), 7.88 (d, J = 7.5 Hz, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.61, 26.97, 30.73, 34.27, 34.85, 34.88, 36.60, 36.86, 84.97, 107.56, 112.05, 120.85, 124.64, 125.96, 129.25, 134.08, 153.70, 169.43. Anal. Calcd for $\text{C}_{23}\text{H}_{26}\text{O}_5$: C, 72.23; H, 6.85. Found: C, 72.12; H, 6.65.

Adamantane-2-spiro-3'-8'-(4'-nitrophenyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ151). To a solution of **OZ80** (301 mg, 1 mmol) and triethylamine (101 mg, 1 mmol) in CH_3CN (10 ml) was added 4-nitrophenyl triflate (271 mg, 1 mmol). The mixture was stirred at 65°C for 64 h before removal of solvents. The crude product was purified by flash chromatography (silica gel, 5% ether in hexanes) and by subsequent crystallization from methanol to afford trioxolane **OZ151** (120 mg, 31%) as a yellowish solid. mp 140–142°C (methanol); ^1H NMR (500 MHz, CDCl_3) δ 1.61–2.19 (m, 18H), 3.48–3.75 (m, 4H), 6.83 (d, J = 9.3 Hz, 2H), 8.11 (d, J = 9.3 Hz, 2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.54, 26.94, 33.84, 34.82, 34.92, 36.55, 36.79, 45.57, 106.63, 112.40, 112.93, 126.05, 138.63, 154.14. Anal. Calcd for $\text{C}_{21}\text{H}_{26}\text{N}_2\text{O}_5$: C, 65.27; H, 6.78; N, 7.25. Found: C, 65.40; H, 6.66; N, 7.29.

5-Hydroxyadamantane-2-spiro-3'-1',2',4',9',12'-pentaoxadispiro[4.2.4.2]tetradecane (OZ152). Step 1. A solution of *O*-methyl 5-acetoxy-

2-adamantanone oxime (1.18 g, 5.0 mmol) and 1,4-dioxaspiro[4.5]decan-8-one (790 mg, 5.0 mmol) in pentane (20 ml) and CH₂Cl₂ (100 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 30% ether in petroleum ether) to afford **5-acetoxyadamantane-2-spiro-3'-1',2',4',9',12'-petaoxadispiro[4.2.4.2]tetradecane** (0.61 g, 32%) as a colorless oil. ¹H NMR (500 MHz, CDCl₃) δ 1.78–2.28 (m, 24H), 3.95 (s, 4H). **Step 2.** A mixture of the above acetate trioxolane (1.30 g, 3.42 mmol), EtOH (7 ml), and 30% aq. KOH (6 ml) was heated at 50°C for 2 h. After removal of the solvent, the residue was diluted with water and extracted with ether. The organic layer was washed with water and brine, dried over MgSO₄, and concentrated. The crude product was purified by flash chromatography (silica gel, 80% ether in hexanes) to afford trioxolane **OZ152** (100 mg, 9%, minor isomer, eluted first) as a colorless solid and trioxolane **OZ153** (414 mg, 36%, major isomer, eluted second) as a colorless solid. For **OZ152**: mp 132–134°C (ether); ¹H NMR (500 MHz, CDCl₃) δ 1.56–2.19 (m, 21H), 3.95 (s, 4H); ¹³C NMR (125.7 MHz, CDCl₃) δ 29.27, 31.65, 32.11, 33.52, 38.10, 42.13, 44.59, 64.39, 67.01, 107.84, 108.47, 110.40. Anal. Calcd for C₁₈H₂₆O₆: C, 63.89; H, 7.74. Found: C, 64.02; H, 7.81.

5-Hydroxyadamantane-2-spiro-3'-1',2',4',9',12'-petaoxadispiro[4.2.4.2]tetradecane (OZ153). For preparation, see **OZ152**. mp 112–114°C (ether); ¹H NMR (500 MHz, CDCl₃) δ 1.54–2.22 (m, 21H), 3.98 (s, 4H); ¹³C NMR (125.7 MHz, CDCl₃) δ 28.85, 31.72, 32.09, 33.40, 38.31, 42.11, 44.54, 64.36, 67.37, 107.80, 108.50, 110.36. Anal. Calcd for C₁₈H₂₆O₆: C, 63.89; H, 7.74. Found: C, 64.03; H, 7.66.

cis-Adamantane-2-spiro-3'-8'-(4'-(4',5'-dihydro-4',4'-dimethyl-2'-oxazolyl)phenyl)-1',2',4'-trioxaspiro[4.5]decane (OZ154). A solution of *O*-methyl 2-adamantanone oxime (1.32 g, 7.4 mmol) and 4-[4-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)phenyl]cyclohexanone (2.00 g, 7.4 mmol) in pentane (100 ml) and CH₂Cl₂ (50 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 10 to 30% ether in hexanes) to afford trioxolane **OZ154** (0.80 g, 25%) as a colorless solid. mp 138–140°C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.37 (s, 6H), 1.59–2.16 (m, 22H), 2.51–2.68 (m, 1H), 4.08 (s, 2H), 7.24 (d, J = 8.0 Hz, 2H), 7.85 (d, J = 8.0 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.63,

27.03, 28.38, 31.29, 34.70, 34.88, 34.90, 36.56, 36.93, 42.98, 67.52, 79.15, 108.26, 111.46, 126.22, 126.70, 128.44, 149.58, 162.01. Anal. Calcd for C₂₇H₃₅NO₄: C, 74.11; H, 8.06; N, 3.20. Found: C, 74.35; H, 8.08; N, 3.18.

cis-Adamantane-2-spiro-3'-8'-[(2'-hydroxyethyl)amino]carbonyl]-1',2',4'-trioxaspiro[4.5]decane (OZ155). A solution of **OZ72** (0.31 g, 1.0 mmol), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.29 g, 1.5 mmol), HOBT (0.20 g, 1.5 mmol), and 2-aminoethanol (0.09 g, 1.5 mmol) in DMF (10 ml) was stirred at rt for 18h before being quenched with 2 M aq. HCl (30 ml). The mixture was extracted with ethyl acetate (4 x 30 ml), and the combined extracts were washed with water (2 x 30 ml) and brine (30 ml), dried over MgSO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 5% methanol in CH₂Cl₂) to afford trioxolane **OZ155** (0.16 g, 46%) as a colorless solid. mp 114–116°C (ether/CH₂Cl₂ 2:1); ¹H NMR (500 MHz, CDCl₃) δ 1.59–2.08 (m, 22H), 2.17 (br s, 1H), 3.38–3.45 (m, 2H), 3.71 (t, J = 4.8 Hz, 2H), 6.13 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.44, 26.84, 26.99, 33.58, 34.75, 34.78, 36.35, 36.75, 42.27, 43.58, 62.31, 107.77, 111.53, 176.04. Anal. Calcd for C₁₉H₂₉NO₅: C, 64.93; H, 8.32; N, 3.99. Found: C, 64.68; H, 8.11; N, 3.93.

cis-Adamantane-2-spiro-3'-8'-benzyl-1',2',4'-trioxaspiro[4.5]decane (OZ156). A solution of *O*-methyl 2-adamantanone oxime (895 mg, 5 mmol) and 4-benzylcyclohexanone (940 mg, 5 mmol) in cyclohexane (80 ml) and CH₂Cl₂ (20 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 5% ether in hexanes) and by subsequent recrystallization from ethanol/CH₂Cl₂ (19:1) to afford trioxolane **OZ156** (825 mg, 47%) as a colorless solid. mp 87–89°C (ethanol/CH₂Cl₂, 19:1); ¹H NMR (500 MHz, CDCl₃) δ 1.18–1.37 (m, 2H), 1.49–2.20 (m, 21H), 2.50 (d, J = 7.2 Hz, 2H), 7.09–7.40 (m, 5H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.49, 26.88, 29.93, 34.15, 34.78, 34.79, 36.39, 36.81, 38.16, 42.89, 108.94, 111.19, 125.78, 128.16, 129.07, 140.86. Anal. Calcd for C₂₃H₃₀O₅: C, 77.93; H, 8.53. Found: C, 78.17; H, 8.45.

Adamantane-2-spiro-3'-8'-[(4'-methyl-1'-piperazinyl)carbonyl]-1',2',4'-trioxo-8'-azaspiro[4.5]decane (OZ157). To a solution of **OZ80** (301 mg, 1 mmol) and triethylamine (404 mg, 4 mmol) in CH₂Cl₂ (7 ml) at 0°C was added 4-methyl-1-piperazinecarbonyl chloride hydrochloride (220 mg, 1.1 mmol). The mixture was stirred at

rt for 16 h, diluted with CH₂Cl₂ (10 ml), washed with water (2 x 10 ml) and brine (10 ml), dried over MgSO₄, and concentrated. Crystallization of the residue from ethanol gave trioxolane **OZ157** (105 mg, 27%) as a colorless solid. mp 146–148 °C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.61–2.09 (m, 18H), 2.30 (s, 3H), 2.31–2.48 (m, 4H), 3.21–3.47 (m, 8H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.61, 27.01, 34.52, 34.85, 34.95, 36.59, 36.87, 44.77, 46.14, 46.87, 54.91, 107.24, 112.04, 163.68. Anal. Calcd for C₂₁H₃₃N₃O₄: C, 64.42; H, 8.50; N, 10.73. Found: C, 64.34; H, 8.37; N, 10.61.

Adamantane-2-spiro-3'-8'-(1'-piperidinyl)-1',2',4'-trioxaspiro[4.5]decane hydrochloride (OZ159). To a solution of **OZ05** (555 mg, 2 mmol) in 1,2-dichloroethane (10 ml) were added piperidine (187 mg, 2.2 mmol) and acetic acid (10 drops). The reaction mixture was stirred at rt for 15 min before sodium triacetoxyborohydride (677 mg, 3.2 mmol) was added. The mixture was stirred for 5 h before being quenched with 1 M aq. NaOH (2 ml). The resulting mixture was extracted with CH₂Cl₂ (40 ml), washed with water (2 x 10 ml) and brine (2 x 10 ml), dried over MgSO₄, and concentrated. The residue 15 was dissolved in ether (2 ml), treated with excess 2 M ethereal HCl, and filtered to give trioxolane **OZ159** (460 mg, 60%, 1:1 mixture of two diastereomers) as a colorless solid. mp 12 °C dec (ether); ¹H NMR (500 MHz, CDCl₃) δ 1.39 (br s, 1H), 1.58–2.20 (m, 23H), 2.21–2.60 (m, 4H), 2.78 (br s, 2H), 3.11 (br s, 1H), 3.28–3.59 (m, 2H), 11.94 (br s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 22.53, 22.69, 22.73, 23.33, 23.43, 26.37, 26.40, 26.78, 20 32.65, 32.81, 34.66, 34.69, 34.72, 34.91, 36.28, 36.64, 49.77, 49.98, 63.81, 64.20, 106.50, 106.56, 112.20, 112.37. Anal. Calcd for C₂₁H₃₄ClNO₃•0.25H₂O: C, 64.93; H, 8.95; N, 3.61. Found: C, 64.48; H, 8.59; N, 3.63.

Adamantane-2-spiro-3'-8'-(benzylamino)-1',2',4'-trioxaspiro[4.5]decane hydrochloride (OZ160). To a solution of **OZ05** (555 mg, 2 mmol) in 1,2-dichloroethane (10 ml) were added benzylamine (236 mg, 2.2 mmol) and acetic acid (10 drops). The reaction mixture was stirred at rt for 15 min before sodium triacetoxyborohydride (677 mg, 3.2 mmol) was added. The mixture was stirred for 5 h before being quenched with 1 M aq. NaOH (2 ml). The resulting mixture was extracted with CH₂Cl₂ (40 ml), washed with water (2 x 10 ml) and brine (2 x 10 ml), dried over MgSO₄, and concentrated. The residue 25 was dissolved in ether (2 ml), treated with excess 2 M ethereal HCl, and filtered to give trioxolane **OZ160** (567 mg, 70%, 2:1 mixture of two diastereomers) as a colorless solid.

mp 160°C dec (ether); ^1H NMR (500 MHz, CDCl_3) δ 1.42–2.31 (m, 22H), 2.78–2.89 (m, 1H), 3.91–4.19 (m, 2H), 7.31–7.46 (m, 3H), 7.59–7.71 (m, 2H), 10.00 (br s, 2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 25.95, 26.53, 26.89, 32.21, 34.78, 34.92, 36.38, 36.45, 36.81, 47.82, 53.65, 106.71, 106.79, 111.72, 112.33, 129.07, 129.12, 129.30, 129.35, 130.25, 130.51, 130.57. Anal. Calcd for $\text{C}_{23}\text{H}_{32}\text{ClNO}_3$: C, 68.05; H, 7.95; N, 3.45. Found: C, 67.89; H, 7.71; N, 3.35.

5 **Adamantane-2-spiro-3'-8'-[3'-(4'-morpholinyl)propyl]amino]-1',2',4'-trioxaspiro[4.5]decane (OZ161).** To a solution of **OZ05** (555 mg, 2 mmol) in 1,2-dichloroethane (10 ml) were added 4-(3-aminopropyl)morpholine (317 mg, 2.2 mmol) and 10 acetic acid (10 drops). The reaction mixture was stirred at rt for 15 min before sodium triacetoxyborohydride (677 mg, 3.2 mmol) was added. The mixture was stirred for 5 h before being quenched with 1 M aq. NaOH (2 ml). The resulting mixture was extracted with CH_2Cl_2 (40 ml), washed with water (2 x 10 ml) and brine (2 x 10 ml), dried over MgSO_4 , and concentrated. The residue was dissolved in ether (2 ml), treated with excess 2 15 M ethereal HCl, and filtered to give trioxolane **OZ161** (552 mg, 68%, 1:1 mixture of two diastereomers) as a colorless solid. mp 70–72°C (ether); ^1H NMR (500 MHz, CDCl_3) δ 1.31–2.20 (m, 24H), 2.32–2.60 (m, 7H), 2.61–2.78 (m, 2H), 3.62–3.83 (m, 4H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.29, 26.70, 26.77, 26.81, 29.61, 30.02, 31.97, 32.42, 34.55, 34.59, 34.63, 34.70, 36.16, 36.20, 36.61, 43.27, 45.76, 46.00, 53.62, 53.64, 54.62, 54.86, 57.31, 57.42, 66.80, 108.35, 108.39, 111.05, 111.34. Anal. Calcd for $\text{C}_{23}\text{H}_{38}\text{N}_2\text{O}_4$: C, 67.95; H, 9.42; N, 6.89. Found: C, 67.84; H, 9.30; N, 6.68.

20 **Adamantane-2-spiro-3'-8'-(cyclohexylamino)-1',2',4'-trioxaspiro[4.5]decane hydrochloride (OZ162).** To a solution of **OZ05** (555 mg, 2 mmol) in 1,2-dichloroethane (10 ml) were added cyclohexylamine (218 mg, 2.2 mmol) and acetic acid (10 drops). The 25 reaction mixture was stirred at rt for 15 min before sodium triacetoxyborohydride (677 mg, 3.2 mmol) was added. The mixture was stirred for 5 h before being quenched with 1 M aq. NaOH (2 ml). The resulting mixture was extracted with CH_2Cl_2 (40 ml), washed with water (2 x 10 ml) and brine (2 x 10 ml), dried over MgSO_4 , and concentrated. The residue was dissolved in ether (2 ml), treated with excess 2 M ethereal HCl, and filtered to give 30 **OZ162** (516 mg, 65%, 1:1 mixture of two diastereomers) as a colorless solid. mp 240°C dec (ether); ^1H NMR (500 MHz, CDCl_3) δ 1.26 (br s, 2H), 1.55–2.42 (m, 30H), 2.97–3.21

(m, 2H), 9.33 (br s, 1H), 9.37 (br s, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 24.83, 24.87, 26.56, 26.90, 26.97, 29.45, 32.58, 34.80, 34.82, 34.94, 36.39, 36.51, 36.85, 52.70, 54.89, 55.12, 106.82, 106.91, 111.67, 112.32. Anal. Calcd for $\text{C}_{22}\text{H}_{36}\text{ClNO}_3$: C, 66.39; H, 9.12; N, 3.52. Found: C, 66.28; H, 8.97; N, 3.54.

5 **cis-Adamantane-2-spiro-3'-8'-(aminomethyl)-1',2',4'-trioxaspiro[4.5]decane hydrochloride (OZ163).** A solution of **OZ146** (423 mg, 1 mmol) and hydrazine monohydrate (150 mg, 3 mmol) in chloroform (9 ml) and methanol (1 ml) was heated at 55°C for 48 h. The reaction mixture was cooled to rt and filtered to remove solid by-products. The filtrate was washed with water (10 ml) and brine (10 ml), dried over MgSO_4 ,
10 filtered, and concentrated. The solid was dissolved in ether (10 ml), treated with 1 M ethereal HCl (1.2 ml), and filtered. Recrystallization from ether gave trioxolane **OZ163** (80 mg, 24%) as a yellowish solid. mp 146 °C dec (ether); ^1H NMR (500 MHz, CDCl_3) δ 1.23–1.42 (m, 2H), 1.59–2.20 (m, 21H), 2.86 (br s, 2H), 8.35 (br s, 3H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.45, 26.86, 27.61, 33.27, 34.45, 34.76, 36.37, 36.77, 39.25, 44.88, 107.92, 111.52. Anal. Calcd for $\text{C}_{17}\text{H}_{28}\text{ClNO}_3$: C, 61.90; H, 8.56; N, 4.25. Found: C, 59.83; H, 8.21; N, 5.07.

15 **cis-Adamantane-2-spiro-3'-8'-[4'-(ethoxycarbonyl)phenyl]-1',2',4'-trioxaspiro[4.5]decane (OZ164).** A solution of *O*-methyl 2-adamantanone oxime (1.10 g, 6.2 mmol) and 4-[4-(ethoxycarbonyl)phenyl]cyclohexanone (1.70 g, 6.2 mmol) in pentane (100 ml) and CH_2Cl_2 (50 ml) was treated with ozone according to the general procedure.
20 The crude product was purified by flash chromatography (silica gel, 10% ether in hexanes) to afford trioxolane **OZ164** (1.60 g, 63%) as a colorless solid. mp 129–132°C (hexanes/ether 9:1); ^1H NMR (500 MHz, CDCl_3) δ 1.38 (t, J = 7.2 Hz, 3H), 1.63–2.22 (m, 22H), 2.56–2.71 (m, 1H), 4.36 (q, J = 7.2 Hz, 2H), 7.27 (d, J = 7.8 Hz, 2H), 7.96 (d, J = 8.0 Hz, 2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 14.34, 26.49, 26.89, 31.18, 34.59, 34.80, 36.42, 36.80, 42.99, 60.76, 108.18, 111.51, 126.77, 128.54, 129.74, 151.39, 166.57. Anal. Calcd for $\text{C}_{25}\text{H}_{32}\text{O}_5$: C, 72.79; H, 7.82. Found: C, 72.83; H, 7.90.

25 **cis-Adamantane-2-spiro-3'-8'-(4'-carboxyphenyl)-1',2',4'-trioxaspiro[4.5]decane (OZ165).** A mixture of **OZ164** (1.38 g, 3.35 mmol), KOH (1.13 g), THF (30 ml), methanol (30 ml), and water (6 ml) was heated at 50°C for 2 h. The mixture was concentrated to 10 ml, diluted with water (50 ml), and extracted with ethyl

acetate. The aqueous layer was acidified with 1 M aq. HCl to pH = 2, and the resulting solid was collected by filtration to give trioxolane **OZ165** (1.08 g, 84%) as a colorless solid. mp 157°C dec; ¹H NMR (500 MHz, CDCl₃) δ 1.63–2.22 (m, 22H), 2.57–2.72 (m, 1H), 7.31 (d, J = 8.3 Hz, 2H), 8.03 (d, J = 8.1 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 5
26.49, 26.90, 31.14, 34.58, 34.81, 36.43, 36.80, 43.10, 108.14, 111.54, 126.99, 127.23,
130.46, 152.54, 171.45. Anal. Calcd for C₂₃H₂₈O₅: C, 71.85; H, 7.34. Found: C, 71.68; H,
7.33.

cis-Adamantane-2-spiro-3'-8'-[[4'-(ethoxycarbonyl)phenoxy]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ166). To a solution of **OZ119** (0.59 g, 2.0 mmol),
10 triphenylphosphine (0.63 g, 2.4 mmol), and ethyl 4-hydroxybenzoate (0.50 g, 3.0 mmol) in THF (12 ml) at 0°C was added dropwise a solution of diisopropyl azodicarboxylate (0.65 g, 3.2 mmol) in THF (0.5 ml). The mixture was then warmed to rt and stirred at rt for 2 h before removal of solvents. The crude product was purified by flash chromatography (silica gel, 20% ether in hexanes) to afford trioxolane **OZ166** (0.65 g, 73%) as a colorless solid.
15 mp 142–143°C (hexanes/ether 9:1); ¹H NMR (500 MHz, CDCl₃) δ 1.38 (t, J = 7.2 Hz, 3H), 1.30–1.58 (m, 2H), 1.60–2.21 (m, 21H), 3.82 (d, J = 5.9 Hz, 2H), 4.34 (q, J = 7.2 Hz, 2H), 6.88 (d, J = 9.0 Hz, 2H), 7.97 (d, J = 8.8 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 14.35, 26.48, 26.85, 26.87, 33.72, 34.78, 34.80, 36.14, 36.40, 36.79, 60.58, 72.43, 108.64, 111.41, 113.97, 122.84, 131.50, 162.75, 166.38. Anal. Calcd for C₂₆H₃₄O₆: C, 70.56; H, 7.74.
20 Found: C, 70.72; H, 7.76.

trans-Adamantane-2-spiro-3'-8'-phthalimidomethyl-1',2',4'-trioxaspiro[4.5]decane (OZ167). For the major isomer (*cis*), see **OZ146**. A solution of *O*-methyl 2-adamantanone oxime (2.23 g, 12.4 mmol) and 4-phthalimidomethylcyclohexanone (3.20 g, 12.4 mmol) in pentane (100 ml) and CH₂Cl₂ (50 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 25% ether in hexanes and 40% CH₂Cl₂ in hexanes) to afford trioxolane **OZ167** (0.16 g, 3%) as a colorless solid. mp 140–142°C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.40–2.17 (m, 23H), 3.60 (d, J = 7.5 Hz, 2H), 7.68–7.75 (m, 2H), 7.82–7.88 (m, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.63, 27.03, 30 27.69, 33.46, 34.83, 34.99, 35.71, 36.51, 36.93, 42.98, 108.58, 111.74, 123.25, 132.19,

133.91, 168.52. Anal. Calcd for C₂₅H₂₉NO₅: C, 70.90; H, 6.90; N, 3.31. Found: C, 70.75; H, 7.03; N, 3.25.

Adamantane-2-spiro-3'-1',2',4',9',10',12'-hexaoxadispiro[4.2.4.2]tetradecane-11'-spiro-2''-adamantane (OZ169). A solution of *O*-methyl 2-adamantanone oxime (1.80 g, 10 mmol) and 1,4-cyclohexanedione (2.24 g, 20 mmol) in pentane (60 ml) and CH₂Cl₂ (40 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 10% ether in hexanes) to afford trioxolane **OZ169** (346 mg, 16%, 2:1 mixture of two diastereomers) as a colorless solid. mp 156–158°C (hexanes); ¹H NMR (500 MHz, CDCl₃) δ 1.92 (s, 8H), 1.60–2.25 (m, 28H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.45, 26.83, 26.86, 31.57, 34.72, 34.75, 34.80, 34.84, 36.29, 36.31, 36.74, 107.65, 107.71, 111.72. Anal. Calcd for C₂₆H₃₆O₆: C, 70.24; H, 8.16. Found: C, 70.18; H, 8.28.

Adamantane-2-spiro-3'-8'-(2',2',6',6'-tetramethyl-4'-piperidinyl)amino]-1',2',4'-trioxaspiro[4.5]decane dihydrochloride (OZ171). To a solution of **OZ05** (555 mg, 2 mmol) in 1,2-dichloroethane (10 ml) were added 4-amino-2,2,6,6-tetramethylpiperidine (344 mg, 2.2 mmol) and acetic acid (10 drops). The reaction mixture was stirred at rt for 15 min before sodium triacetoxyborohydride (677 mg, 3.2 mmol) was added. The mixture was stirred for 5 h before being quenched with 1 M aq. NaOH (2 ml). The resulting mixture was extracted with CH₂Cl₂ (40 ml), washed with water (2 x 10 ml) and brine (2 x 10 ml), dried over MgSO₄, and concentrated. The residue was dissolved in ether (2 ml), treated with excess 2 M ethereal HCl, and filtered to give trioxolane **OZ171** (650 mg, 66%, 1:1 mixture of two diastereomers) as a colorless solid. mp 165°C dec (ether); ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.43 (s, 6H), 1.45 (s, 6H), 1.46–2.37 (m, 26H), 3.14–3.40 (m, 1H), 3.55–3.79 (m, 1H), 8.28–8.45 (m, 1H), 9.25–9.47 (m, 2H), 9.55–9.72 (m, 1H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 24.03, 24.07, 25.96, 26.38, 29.78, 31.70, 34.38, 34.43, 34.55, 35.81, 35.88, 36.22, 37.00, 45.66, 45.71, 50.74, 50.93, 56.22, 56.26, 107.42, 107.46, 111.13, 111.41. Anal. Calcd for C₂₅H₄₄Cl₂N₂O₃•1.5 H₂O: C, 57.90; H, 9.14; N, 5.40. Found: C, 57.65; H, 8.74; N, 5.36.

Adamantane-2-spiro-3'-8'-oxo-1',2',4'-trioxaspiro[4.5]decane amidinohydrazone hydrochloride (OZ172). To a solution of **OZ05** (555 mg, 2 mmol) in THF (11 ml), water (3 ml), and ethanol (3.5 ml) were added 2 M aq. HCl (1.5 ml) and

aminoguanidine bicarbonate (299 mg, 2.2 mmol). The mixture was stirred at rt for 30 h before removal of solvents. The residue was triturated with ethanol (10 ml) and the resulting precipitate was collected by filtration and washed with THF to give trioxolane **OZ172** (476 mg, 64%) as a colorless solid. mp 150°C dec (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.46–2.27 (m, 18H), 2.42–2.61 (m, 2H), 2.62–2.83 (m, 2H), 6.34 (s, 1H), 7.63 (br s, 2H), 7.91 (s, 1H), 10.95 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 24.83, 26.37, 26.77, 31.72, 32.49, 33.62, 34.70, 34.74, 34.84, 36.23, 36.26, 36.65, 107.26, 112.27, 156.57, 157.93. Anal. Calcd for C₁₇H₂₇ClN₄O₃: C, 55.05; H, 7.34; N, 15.11. Found: C, 55.14; H, 7.51; N, 15.30.

Adamantane-2-spiro-3'-8'-(methoxyacetyl)benzylamino]-1',2',4'-trioxaspiro[4.5]decane (OZ173). To a solution of **OZ160** (342 mg, 0.84 mmol) in CH₂Cl₂ (10 ml) at 0°C were added triethylamine (255 mg, 2.53 mmol) and methoxyacetyl chloride (137 mg, 1.26 mmol). The resulting mixture was stirred at rt for 16 h, diluted with CH₂Cl₂ (10 ml), and washed with water (10 ml) and brine (10 ml). The organic layer was separated, dried over MgSO₄, and concentrated. The residue was triturated with ether to give trioxolane **OZ173** (110 mg, 30%, 3:2 mixture of two diastereomers) as a colorless solid. mp 132–134°C (ether); ¹H NMR (500 MHz, CDCl₃) δ 1.47–2.20 (m, 22H), 3.38 (s, 1.8H), 3.48 (s, 1.2H), 3.99 (s, 1.2H), 4.23 (s, 0.8H), 4.46 (s, 1.2H), 4.55 (s, 0.8H), 4.42–4.58 (m, 1H), 7.09–7.46 (m, 5H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.41, 26.80, 26.87, 27.11, 28.74, 33.31, 33.54, 34.67, 34.74, 34.93, 36.29, 36.72, 44.76, 45.52, 51.71, 55.36, 59.20, 71.54, 72.30, 107.56, 111.65, 125.61, 126.74, 127.10, 127.30, 128.33, 128.78, 137.93, 139.04, 169.30, 169.82. Anal. Calcd for C₂₆H₃₅NO₅: C, 70.72; H, 7.99; N, 3.17. Found: C, 70.76; H, 8.02; N, 3.08.

Adamantane-2-spiro-3'-8'-(methoxyacetyl)cyclohexylamino]-1',2',4'-trioxaspiro[4.5]decane (OZ174). To a solution of **OZ162** (330 mg, 0.83 mmol) in CH₂Cl₂ (10 ml) at 0°C were added triethylamine (251 mg, 2.49 mmol) and methoxyacetyl chloride (135 mg, 1.24 mmol). The resulting mixture was stirred at rt for 16 h, diluted with CH₂Cl₂ (10 ml), and washed with water (10 ml) and brine (10 ml). The organic layer was separated, dried over MgSO₄, and concentrated. The residue was triturated with ether to give trioxolane **OZ174** (109 mg, 30%, 4:1 mixture of two diastereomers) as a colorless solid. mp 140–142°C (ether); ¹H NMR (500 MHz, CDCl₃) δ 1.02–2.20 (m, 30H), 2.32–2.72 (m,

2H), 2.81–3.05 (m, 1H), 3.40 (s, 2.4H), 3.42 (s, 0.6H), 3.48–3.69 (m, 1H), 4.02 (s, 1.6H), 4.03 (m, 0.4H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 25.25, 26.00, 26.44, 26.84, 27.89, 29.77, 33.50, 34.21, 34.77, 36.32, 36.73, 55.51, 56.10, 58.84, 73.12, 73.71, 107.39, 107.52, 111.83, 168.17. Anal. Calcd for $\text{C}_{25}\text{H}_{39}\text{NO}_5$: C, 69.25; H, 9.07; N, 3.23. Found: C, 69.12; H, 9.06; N, 3.23.

5 *cis*-Adamantane-2-spiro-3'-8'-(2'-hydroxyamino-2'-oxoethyl)-1',2',4'-trioxaspiro[4.5]decane (**OZ175**). To a solution of **OZ78** (322 mg, 1.0 mmol) in ether (10 ml) at 0°C were added triethylamine (202 mg, 2 mmol) and ethyl chloroformate (217 mg, 2 mmol). The mixture was stirred at 0°C for 15 min before a freshly prepared solution of 10 hydroxylamine was added. [A suspension of hydroxylamine hydrochloride (170 mg, 2.48 mmol) and sodium bicarbonate (203 mg, 2.48 mmol) in methanol (5 ml) was stirred at rt for 15 min. The supernatant was used as such.] The resulting mixture was stirred at rt for 12 h, diluted with ether (10 ml), washed with water (10 ml), dried over MgSO_4 , and concentrated. The crude product was purified by flash chromatography (silica gel, 5% 15 methanol in CH_2Cl_2) and by subsequent recrystallization from ethanol to afford trioxolane **OZ175** (95 mg, 28%) as a colorless solid. mp 138–140°C (ethanol); ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 0.81–1.27 (m, 3H), 1.40–2.19 (m, 22H), 8.65 (s, 1H), 10.33 (s, 1H); ^{13}C NMR (125.7 MHz, $\text{DMSO}-d_6$) δ 25.84, 26.25, 29.40, 32.60, 33.35, 34.26, 35.81, 36.13, 38.68, 108.33, 110.44, 167.91. Anal. Calcd for $\text{C}_{18}\text{H}_{27}\text{NO}_5$: C, 64.07; H, 8.07; N, 4.15. Found: C, 20 H, 64.11; H, 8.10; N, 3.97.

20 *cis*-Adamantane-2-spiro-3'-8'-(4'-carboxyphenoxy)methyl]-1',2',4'-trioxaspiro[4.5]decane (**OZ176**). A mixture of **OZ166** (0.30 g, 0.68 mmol), KOH (0.38 g), THF (10 ml), methanol (10 ml), and water (2 ml) was heated at 50°C for 3 h. The mixture was concentrated to 5 ml, diluted with water (15 ml), and acidified with 1 M aq. 25 HCl (1 ml). The resulting solid was collected by filtration to give trioxolane **OZ176** (0.21 g, 75%) as a colorless solid. mp 165–168°C; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 1.15–1.27 (m, 2H), 1.50–2.17 (m, 21H), 3.88 (d, J = 6.2 Hz, 2H), 7.00 (d, J = 8.8 Hz, 2H), 7.87 (d, J = 8.3 Hz, 2H); ^{13}C NMR (125.7 MHz, $\text{DMSO}-d_6$) δ 25.99, 26.40, 26.53, 33.27, 34.45, 35.35, 35.95, 36.26, 72.09, 108.70, 110.71, 114.41, 123.04, 131.50, 162.47, 167.15. Anal. Calcd 30 for $\text{C}_{24}\text{H}_{30}\text{O}_6$: C, 69.54; H, 7.30. Found: C, 69.67; H, 7.21.

cis-Adamantane-2-spiro-3'-8'-(1'H-1',2',4'-triazol-1'-ylmethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ177). To a suspension of 60% NaH (0.08 g, 2 mmol) in DMF (4 ml) under nitrogen at 0°C was added a solution of 1,2,4-triazole (0.14 g, 2 mmol) in DMF (4 ml). The mixture was stirred for 30 min before a solution of the methanesulfonate of **OZ119** (0.37 g, 1.0 mmol) in DMF (4 ml) was added dropwise. The mixture was heated at 50°C for 2 h before being quenched with water (40 ml) and then extracted with ethyl acetate (3 x 30 ml). The combined extracts were washed with brine (3 x 30 ml), dried over MgSO₄, filtered, and concentrated. Crystallization of the residue from hexanes/ether (4:1) gave trioxolane **OZ177** (0.21 g, 61%) as a colorless solid. mp 123–124°C (hexanes/ether 4:1); ¹H NMR (500 MHz, CDCl₃) δ 1.17–1.42 (m, 2H), 1.50–2.19 (m, 21H), 4.02 (d, J = 7.0 Hz, 2H), 7.95 (s, 1H), 8.02 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.43, 26.82, 27.48, 33.43, 34.75, 36.35, 36.47, 36.73, 54.84, 108.19, 111.57, 143.35, 152.10. Anal. Calcd for C₁₉H₂₇N₃O₃: C, 66.06; H, 7.88; N, 12.16. Found: C, 65.86; H, 8.06; N, 11.89.

cis-Adamantane-2-spiro-3'-8'-(4'-methylsulfonyl)phenyl]-1',2',4'-trioxaspiro[4.5]decane (OZ178). A solution of O-methyl 2-adamantanone oxime (0.54 g, 3 mmol) and 4-[4-(methylsulfonyl)phenyl]cyclohexanone (0.75 g, 3 mmol) in pentane (50 ml) and CH₂Cl₂ (50 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 30% ethyl acetate in hexanes) to afford trioxolane **OZ178** (0.22 g, 18%) as a colorless solid. mp 132–135°C (hexanes/CH₂Cl₂ 4:1); ¹H NMR (500 MHz, CDCl₃) δ 1.62–2.19 (m, 22H), 2.60–2.74 (m, 1H), 3.04 (s, 3H), 7.40 (d, J = 8.3 Hz, 2H), 7.86 (d, J = 8.0 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.48, 26.88, 31.14, 34.48, 34.80, 36.43, 36.78, 42.94, 44.53, 107.95, 111.64, 127.59, 127.80, 138.45, 152.59. Anal. Calcd for C₂₃H₃₀O₅S: C, 66.00; H, 7.22. Found: C, 66.08; H, 7.16.

cis-Adamantane-2-spiro-3'-8'-(1'H-imidazol-1'-ylmethyl)-1',2',4'-trioxaspiro[4.5]decane hydrochloride (OZ179). To a solution of **OZ145** (1.08 g, 3.1 mmol) in ether (80 ml) was added 1 M ethereal HCl (3.5 ml). The resulting precipitate was collected by filtration to afford trioxolane **OZ179** (1.14 g, 97%) as a colorless solid. mp 153–156°C; ¹H NMR (500 MHz, CDCl₃) δ 1.19–1.46 (m, 2H), 1.50–2.19 (m, 21H), 4.24 (br s, 2H), 7.15 (s, 1H), 7.42 (s, 1H), 9.70 (s, 1H), 15.94 (br s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.38, 26.77, 27.26, 33.20, 34.71, 36.29, 36.68, 37.17, 54.75, 107.85, 111.62,

119.72, 121.22, 135.82. Anal. Calcd for $C_{20}H_{29}ClN_2O_3$: C, 63.06; H, 7.67; N, 7.35. Found: C, 63.21; H, 7.63; N, 7.30.

cis-Adamantane-2-spiro-3'-8'-(4'-(4',5'-dihydro-4',4'-dimethyl-2'-oxazolyl)phenyl)-1',2',4'-trioxaspiro[4.5]decane hydrochloride (OZ180). To a solution of **OZ154** (0.21 g, 0.48 mmol) in ether (9 ml) and CH_2Cl_2 (1 ml) was added 1 M ethereal HCl (0.5 ml). The resulting precipitate was collected by filtration to afford trioxolane **OZ180** (0.20 g, 88%) as a colorless solid. mp 143–145°C; 1H NMR (500 MHz, $CDCl_3$) δ 1.58–2.25 (m, 28H), 2.58–2.80 (m, 1H), 4.69 (br s, 2H), 7.44 (br s, 2H), 8.40 (br s, 2H); ^{13}C NMR (125.7 MHz, $CDCl_3$) δ 26.44, 26.84, 27.19, 30.87, 34.37, 34.76, 36.39, 36.74, 43.21, 63.92, 83.36, 107.83, 111.59, 117.60, 128.16, 131.38, 156.27, 168.98. Anal. Calcd for $C_{27}H_{36}ClNO_4$: C, 68.41; H, 7.65; N, 2.95. Found: C, 68.26; H, 7.80; N, 2.90.

cis-Adamantane-2-spiro-3'-8'-(aminomethyl)-1',2',4'-trioxaspiro[4.5]decane citrate (OZ181). **Step 1.** A solution of **OZ146** (1.00 g, 2.36 mmol) and hydrazine monohydrate (0.50 g, 10 mmol) in chloroform (22.5 ml) and methanol (2.5 ml) was heated under nitrogen at 55 °C for 25 h. The reaction mixture was cooled to rt and filtered to remove solid by-products. The filtrate was washed with water (10 ml) and brine (10 ml), dried over $MgSO_4$, filtered, and concentrated. The crude product was purified by flash chromatography (silica gel, $CHCl_3/MeOH/Et_3N$, 90:10:1) to afford **cis-Adamantane-2-spiro-3'-8'-(aminomethyl)-1',2',4'-trioxaspiro[4.5]decane** (0.63 g, 91%) as a colorless solid. 1H NMR (500 MHz, $DMSO-d_6$) δ 1.14–1.22 (m, 2H), 1.30–1.40 (m, 2H), 1.60–2.10 (m, 21H), 2.55 (d, $J = 6.6$ Hz, 2H). **Step 2.** To a solution of the above amine (0.40 g, 1.36 mmol) in acetone (10 ml) was added a solution of citric acid (0.25 g, 1.30 mmol) in acetone (10 ml). The mixture was stirred at rt for 30 min and filtered. The filtrate was concentrated and treated with ether (25 ml). The resulting precipitate was collected by filtration, re-dissolved in methanol (5 ml), and concentrated to afford trioxolane **OZ181** (0.30 g, 45%) as a colorless solid. mp 76–77 °C; 1H NMR (500 MHz, $DMSO-d_6$) δ 1.04–1.21 (m, 2H), 1.56–2.04 (m, 21H), 2.53 (AB system, 4H), 2.69 (d, $J = 7.3$ Hz, 2H), 7.78 (br s, 3H), 11.50 (br s, 2H); ^{13}C NMR (125.7 MHz, $DMSO-d_6$) δ 25.95, 26.37, 27.10, 33.01, 33.88, 34.40, 34.42, 35.90, 36.23, 43.61, 44.43, 71.35, 108.29, 110.81, 171.39. Anal. Calcd for $C_{23}H_{35}NO_{10}\bullet0.4H_2O$: C, 55.52; H, 7.36; N, 2.82. Found: C, 55.25; H, 7.25; N, 2.66.

Adamantane-2-spiro-3'-8'-[[2'-(1'H-imidazol-1'-yl)ethoxy]carbonyl]-1',2',4'-trioxaspiro[4.5]decane (OZ182). To a solution of **OZ72** (0.31 g, 1.0 mmol), triphenylphosphine (0.26 g, 1.0 mmol), and 1-(2-hydroxyethyl)imidazole (0.11 g, 1.0 mmol) in THF (10 ml) at 0 °C was added dropwise a solution of diisopropyl azodicarboxylate (0.20 g, 1.0 mmol) in THF (2 ml). The mixture was then warmed to rt and stirred at rt for 16 h before removal of solvents. The crude product was purified by flash chromatography (silica gel, 1% methanol in methylene chloride) to afford trioxolane **OZ182** (0.21 g, 52%, 3:1 mixture of two diastereomers) as a colorless solid. mp 75–76°C (ether/hexanes 1:1); ¹H NMR (500 MHz, CDCl₃) δ 1.60–2.18 (m, 22H), 2.25–2.48 (m, 1H), 4.20 (t, J = 5.3 Hz, 2H), 4.33 (t, J = 5.1 Hz, 2H), 6.94 (s, 1H), 7.09 (s, 1H), 7.57 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.11, 26.27, 26.44, 26.47, 26.84, 26.87, 33.21, 33.40, 34.75, 34.76, 34.78, 34.81, 36.35, 36.37, 36.75, 36.78, 41.15, 45.87, 63.06, 107.65, 108.11, 111.38, 111.61, 119.02, 129.31, 137.33, 174.34. Anal. Calcd for C₂₂H₃₀N₂O₅: C, 65.65; H, 7.51; N, 6.96. Found: C, 65.86; H, 7.58; N, 6.78.

cis-Adamantane-2-spiro-3'-8'-[4'-(hydroxyamino)carbonyl]phenyl]-1',2',4'-trioxaspiro[4.5]decane (OZ183). A mixture of ethyl chloroformate (0.13 g, 1.2 mmol), **OZ165** (0.41 g, 1.0 mmol), and triethylamine (0.13 g, 1.3 mmol), ether (5 ml), THF (5 ml), and DMF (5 ml) was stirred at 0°C for 1 h. The solid was removed by filtration, and the filtrate was added to a freshly prepared solution of hydroxylamine. [To a suspension of KOH (84 mg, 1.5 mmol) in methanol (1 ml) at 0 °C was added a solution of hydroxylamine hydrochloride (0.10 g, 1.5 mmol) in methanol (2 ml). The reaction mixture was stirred at 0°C for 15 min and filtered to remove solid by-products. The filtrate was used as such.] The resulting mixture was stirred at rt for 1 h and concentrated. The crude product was triturated with chloroform (6 ml) at 45°C for 10 min and cooled to rt. The precipitate was collected by filtration and recrystallized from chloroform/methanol (2:1) to afford trioxolane **OZ183** (0.13 g, 33%) as a colorless solid. mp 167–168°C (chloroform/methanol 2:1); ¹H NMR (500 MHz, DMSO-d₆) δ 1.40–2.17 (m, 22H), 2.57–2.80 (m, 1H), 7.29 (d, J = 7.8 Hz, 2H), 7.67 (d, J = 7.8 Hz, 2H), 8.95 (s, 1H), 11.14 (s, 1H); ¹³C NMR (125.7 MHz, DMSO-d₆) δ 26.03, 26.44, 31.06, 34.21, 34.48, 36.01, 36.30, 41.61, 108.26, 110.83, 126.82, 127.25, 130.92, 149.41, 164.47. Anal. Calcd for C₂₃H₂₉NO₅: C, 69.15; H, 7.32; N, 3.51. Found: C, 68.89; H, 7.30; N, 3.70.

Adamantane-2-spiro-3'-8'-(cyclopropylmethyl)amino]-1',2',4'-trioxaspiro[4.5]decane hydrochloride (OZ184). To a solution of **OZ05** (555 mg, 2 mmol) in 1,2-dichloroethane (10 ml) were added cyclopropanemethylamine (156 mg, 2.2 mmol) and acetic acid (10 drops). The reaction mixture was stirred at rt for 15 min before sodium triacetoxyborohydride (677 mg, 3.2 mmol) was added. The mixture was stirred for 5 h before being quenched with 1 M aq. NaOH (2 ml). The resulting mixture was extracted with CH₂Cl₂ (40 ml), washed with water (2 x 10 ml) and brine (2 x 10 ml), dried over MgSO₄, and concentrated. The residue was dissolved in ether (2 ml), treated with excess 2 M ethereal HCl, and filtered to give trioxolane **OZ184** (401 mg, 54%, 1:1 mixture of two diastereomers) as a colorless solid. mp 110 °C dec (ether); ¹H NMR (500 MHz, CDCl₃) δ 0.39–0.60 (m, 2H), 0.61–0.85 (m, 2H), 1.22–1.43 (m, 1H), 1.59–2.45 (m, 22H), 2.76–3.02 (m, 2H), 3.08–3.35 (m, 1H), 9.65 (br s, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 4.83, 4.87, 7.06, 7.13, 25.87, 25.94, 26.37, 26.73, 26.77, 32.29, 34.67, 34.70, 34.79, 36.20, 36.28, 36.66, 48.93, 49.25, 54.42, 54.60, 106.74, 106.75, 111.77, 112.28. Anal. Calcd for C₂₀H₃₂ClNO₃: C, 64.94; H, 8.72; N, 3.79. Found: C, 65.18; H, 8.56; N, 3.83.

Adamantane-2-spiro-3'-8'-(cyclopropylamino)-1',2',4'-trioxaspiro[4.5]decane hydrochloride (OZ185). To a solution of **OZ05** (555 mg, 2 mmol) in 1,2-dichloroethane (10 ml) were added cyclopropylamine (125 mg, 2.2 mmol) and acetic acid (10 drops). The reaction mixture was stirred at rt for 15 min before sodium triacetoxyborohydride (677 mg, 3.2 mmol) was added. The mixture was stirred for 5 h before being quenched with 1 M aq. NaOH (2 ml). The resulting mixture was extracted with CH₂Cl₂ (40 ml), washed with water (2 x 10 ml) and brine (2 x 10 ml), dried over MgSO₄, and concentrated. The residue was dissolved in ether (2 ml), treated with excess 2 M ethereal HCl, and filtered to give trioxolane **OZ185** (348 mg, 49%, 1:1 mixture of two diastereomers) as a colorless solid. mp 102–103°C dec (ether); ¹H NMR (500 MHz, CDCl₃) δ 0.69–1.05 (m, 2H), 1.20–1.45 (m, 2H), 1.59–2.21 (m, 20H), 2.22–2.45 (m, 2H), 2.46–2.69 (m, 1H), 3.01–3.39 (m, 1H), 9.62 (br s, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 3.85, 26.21, 26.24, 26.40, 26.76, 26.80, 27.49, 27.94, 32.35, 34.70, 34.73, 34.86, 36.24, 36.32, 36.70, 56.85, 57.19, 106.76, 106.78, 111.84, 112.34. Anal. Calcd for C₁₉H₃₀ClNO₃: C, 64.12; H, 8.50; N, 3.94. Found: C, 64.00; H, 8.38; N, 3.84.

cis-Adamantane-2-spiro-3'-8'-(methoxyacetyl)amino]-1',2',4'-trioxaspiro[4.5]decane (OZ186). To a solution of **OZ137** (550 mg, 1.74 mmol) in CH₂Cl₂ (10 ml) at 0°C were added triethylamine (350 mg, 3.48 mmol) and methoxyacetyl chloride (198 mg, 1.82 mmol). The resulting mixture was stirred at rt for 16 h, diluted with CH₂Cl₂ (10 ml), and washed with water (10 ml) and brine (10 ml). The organic layer was separated, dried over MgSO₄, and concentrated. The crude product was purified by flash chromatography (silica gel, 85% ether in hexanes) to give trioxolane **OZ186** (379 mg, 62%) as a colorless solid. mp 105–106°C (ether); ¹H NMR (500 MHz, CDCl₃) δ 1.40–1.61 (m, 2H), 1.62–2.21 (m, 20H), 3.41 (s, 3H), 3.86 (s, 2H), 3.80–3.96 (m, 1H), 6.35–6.49 (m, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.34, 26.72, 29.67, 32.56, 34.64, 36.20, 36.63, 45.84, 58.94, 71.83, 107.53, 111.47, 168.65. Anal. Calcd for C₁₉H₂₉NO₅: C, 64.93; H, 8.32; N, 3.99. Found: C, 64.81; H, 8.31; N, 3.91.

cis-Adamantane-2-spiro-3'-8'-(dimethylamino)carbonyl]amino]-1',2',4'-trioxaspiro[4.5]decane (OZ187). To a solution of **OZ137** (550 mg, 1.74 mmol) in CH₂Cl₂ (10 ml) at 0 °C were added triethylamine (352 mg, 3.48 mmol) and dimethylcarbamoyl chloride (197 mg, 1.82 mmol). The resulting mixture was stirred at rt for 16 h, diluted with CH₂Cl₂ (10 ml), and washed with water (10 ml) and brine (10 ml). The organic layer was separated, dried over MgSO₄, and concentrated. The crude product was purified by flash chromatography (silica gel, 90% ether in hexanes) to give trioxolane **OZ187** (346 mg, 57%) as a colorless solid. mp 142–144 °C (ether); ¹H NMR (500 MHz, CDCl₃) δ 1.32–1.55 (m, 2H), 1.62–2.21 (m, 20H), 2.88 (s, 6H), 3.62–3.85 (m, 1H), 4.15–4.29 (m, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.42, 26.79, 30.67, 32.86, 34.72, 36.07, 36.28, 36.72, 47.91, 107.94, 111.45, 157.69. Anal. Calcd for C₁₉H₃₀N₂O₄: C, 65.12; H, 8.63; N, 7.99. Found: C, 65.30; H, 8.68; N, 8.06.

Adamantane-2-spiro-3'-8'-(4'-morpholinylcarbonyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ188). To a solution of **OZ80** (301 mg, 1 mmol) and triethylamine (202 mg, 2 mmol) in CH₂Cl₂ (7 ml) at 0 °C was added 4-morpholinecarbonyl chloride (170 mg, 1.1 mmol). The mixture was stirred at rt for 16 h, diluted with CH₂Cl₂ (10 ml), washed with water (2 x 10 ml) and brine (10 ml), dried over MgSO₄, and concentrated. Crystallization of the residue from ethanol gave trioxolane **OZ188** (310 mg, 82%) as a colorless solid. mp 132–134 °C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.60–2.21 (m,

18H), 3.18–3.28 (m, 4H), 3.29–3.58 (m, 4H), 3.60–3.82 (m, 4H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.42, 26.82, 34.37, 34.73, 34.82, 36.39, 36.70, 44.59, 47.41, 66.62, 107.03, 112.04, 163.66. Anal. Calcd for $\text{C}_{20}\text{H}_{30}\text{N}_2\text{O}_5$: C, 63.47; H, 7.99; N, 7.40. Found: C, 63.24; H, 7.84; N, 7.44.

5 **cis-Adamantane-2-spiro-3'-8'-[2'-(4'-morpholinyl)-2'-oxoethyl]-1',2',4'-trioxaspiro[4.5]decane (OZ189).** To a solution of **OZ78** (322 mg, 1.0 mmol) in ether (10 ml) at 0 °C were added triethylamine (202 mg, 2 mmol) and ethyl chloroformate (217 mg, 2 mmol). The mixture was stirred at 0 °C for 15 min before morpholine (175 mg, 2 mmol) was added. The resulting mixture was stirred at rt for 12 h, diluted with ether (10 ml), washed with water (10 ml), dried over MgSO_4 , and concentrated. The crude product was purified by crystallization from ethanol to afford trioxolane **OZ189** (290 mg, 74%) as a colorless solid. mp 118–120 °C (ethanol); ^1H NMR (500 MHz, CDCl_3) δ 1.16–1.35 (m, 2H), 1.60–2.16 (m, 21H), 2.21 (d, J = 6.9 Hz, 2H), 3.38–3.54 (m, 2H), 3.55–3.82 (m, 6H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.48, 26.86, 30.28, 33.26, 34.05, 34.79, 36.39, 36.79, 39.01, 41.93, 46.18, 66.66, 66.97, 108.58, 111.35, 170.67. Anal. Calcd for $\text{C}_{22}\text{H}_{33}\text{NO}_5$: C, 67.49; H, 8.50; N, 3.58. Found: C, 67.46; H, 8.39; N, 3.34.

10

15

20 **Adamantane-2-spiro-3'-8'-(dimethylaminosulfonyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ190).** To a stirred solution of **OZ80** (301 mg, 1 mmol) in CH_2Cl_2 (10 ml) at rt were added triethylamine (0.4 ml, 3 mmol) and dimethylaminosulfonyl chloride (0.13 ml, 1.2 mmol). The mixture was stirred at rt for 3 h before removal of the solvent. The residue was diluted with ether (15 ml), washed with water (2 x 10 ml), dried over MgSO_4 , and concentrated. Crystallization of the residue from ether/hexanes (1:1) gave trioxolane **OZ190** (301 mg, 81%) as a colorless solid. mp 104–106 °C (ether/hexanes 1:1); ^1H NMR (500 MHz, CDCl_3) δ 1.62–2.17 (m, 18H), 2.82 (s, 6H), 3.29–3.53 (m, 4H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.40, 26.79, 34.24, 34.71, 34.80, 36.36, 36.67, 38.18, 44.51, 106.23, 112.25. Anal. Calcd for $\text{C}_{17}\text{H}_{28}\text{N}_2\text{O}_5\text{S}$: C, 54.82; H, 7.58; N, 7.52. Found: C, 54.70; H, 7.38; N, 7.50.

25

30 **Adamantane-2-spiro-3'-8'-amidino-1',2',4'-trioxa-8'-azaspiro[4.5]decane hydrochloride (OZ191).** To a stirred solution of **OZ80** (301 mg, 1 mmol) and triethylamine (202 mg, 2 mmol) in DMF (2 ml) and CH_2Cl_2 (2 ml) at rt was added *N,N*-diisopropylethylamine (130 mg, 2 mmol). After 1*H*-pyrazole-1-carboxamidine

hydrochloride (147 mg, 1 mmol) was added, the reaction mixture became a cloudy suspension. The stirring was continued for 3 h during which period the reaction mixture turned into a clear solution. Addition of dry ether (15 ml) to the above solution produced a colorless precipitate, which was then filtered and washed with ether (3 x 5 ml). The
5 collected solid was recrystallized from ether/CH₂Cl₂ (3:1) to give trioxolane **OZ191** (302 mg, 88%) as a colorless solid. mp 144–148 °C (ether/CH₂Cl₂, 3:1); ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.57–2.17 (m, 18H), 3.41–3.69 (m, 4H), 7.72 (s, 4H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 25.93, 26.31, 33.61, 34.38, 34.43, 35.76, 36.15, 43.39, 106.29, 111.74, 156.36. Anal. Calcd for C₁₆H₂₆ClN₃O₃: C, 55.89; H, 7.62; N, 12.22. Found: C, 55.73; H,
10 7.54; N, 12.23.

Adamantane-2-spiro-3'-8'-(4'-chlorophenylamino)carbonyl]-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ192). To a solution of **OZ80** (301 mg, 1 mmol) and triethylamine (202 mg, 2 mmol) in CH₂Cl₂ (7 ml) at 0–5 °C was added 4-chlorophenyl isocyanate (154 mg, 1 mmol). The reaction mixture was stirred at rt for 16 h, diluted with CH₂Cl₂ (10 ml),
15 and washed with water (2 x 10 ml) and brine (10 ml). The organic layer was dried over MgSO₄ and concentrated. The residue was purified by crystallization from methanol to afford trioxolane **OZ192** (346 mg, 83%) as a colorless solid. mp 132–134 °C (methanol); ¹H NMR (500 MHz, CDCl₃) δ 1.61–2.17 (m, 18H), 3.42–3.77 (m, 4H), 6.43 (s, 1H), 7.17–7.37 (m, 4H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.41, 26.81, 34.34, 34.73, 34.82, 36.38,
20 36.67, 42.34, 106.65, 112.32, 121.19, 128.20, 128.86, 137.53, 154.46. Anal. Calcd for C₂₂H₂₇ClN₂O₄: C, 63.08; H, 6.50; N, 6.69. Found: C, 62.95; H, 6.36; N, 6.65.

Adamantane-2-spiro-3'-8'-(4'-fluorophenoxy)-1',2',4'-trioxaspiro[4.5]decane (OZ193). A solution of *O*-methyl 2-adamantanone oxime (895 mg, 5 mmol) and 4-(4-fluorophenoxy)cyclohexanone (950 mg, 5.1 mmol) in cyclohexane (80 ml) and CH₂Cl₂ (20 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 5% ether in hexanes) and by subsequent recrystallization from ethanol/CH₂Cl₂ (19:1) to afford trioxolane **OZ193** (250 mg, 13%) as a colorless solid. mp 102–104 °C (ethanol/CH₂Cl₂ 19:1); ¹H NMR (500 MHz, CDCl₃) δ 1.57–2.21 (m, 22H), 4.29–4.41 (m, 1H), 6.79–6.89 (m, 2H), 6.91–7.05 (m, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.48, 26.88, 27.82, 30.06, 34.79, 34.85, 36.43, 36.79, 72.54,
30

108.22, 111.71, 115.87 (d, J = 23.3 Hz), 117.44 (d, J = 8.2 Hz), 153.44, 157.34 (d, J = 239.0 Hz). Anal. Calcd for $C_{22}H_{27}FO_4$: C, 70.57; H, 7.27. Found: C, 70.71; H, 7.33.

Adamantane-2-spiro-3'-8'-(diisopropylamino)carbonyl]-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ194). To a solution of **OZ80** (301 mg, 1 mmol) and triethylamine (303 mg, 3 mmol) in CH_2Cl_2 (10 ml) at 0–5 °C was added diisopropylcarbamoyl chloride (164 mg, 1 mmol). The resulting mixture was stirred at rt for 16 h, diluted with CH_2Cl_2 (10 ml), and washed with water (2 x 10 ml) and brine (10 ml). The organic layer was dried over $MgSO_4$ and concentrated. The residue was purified by crystallization from methanol to afford trioxolane **OZ194** (290 mg, 74%) as a colorless solid. mp 114–116 °C (methanol); 1H NMR (500 MHz, $CDCl_3$) δ 1.27 (d, J = 6.8 Hz, 12H), 1.60–2.21 (m, 18H), 3.11–3.39 (m, 4H), 3.60 (sep, J = 6.6 Hz, 2H); ^{13}C NMR (125.7 MHz, $CDCl_3$) δ 21.57, 26.44, 26.84, 34.39, 34.72, 34.81, 36.40, 36.73, 45.26, 47.52, 107.29, 111.79, 163.59. Anal. Calcd for $C_{22}H_{36}N_2O_4$: C, 67.32; H, 9.24; N, 7.14. Found: C, 67.14; H, 9.13; N, 7.11.

cis-Adamantane-2-spiro-3'-8'-(tert-butylacetyl)amino]-1',2',4'-trioxaspiro[4.5]decane (OZ195). To a solution of **OZ137** (550 mg, 1.74 mmol) in CH_2Cl_2 (10 ml) at 0 °C were added triethylamine (529 mg, 5.22 mmol) and *tert*-butylacetyl chloride (304 mg, 2.26 mmol). The resulting mixture was stirred at rt for 16 h, diluted with CH_2Cl_2 (10 ml), and washed with water (10 ml) and brine (10 ml). The organic layer was separated, dried over $MgSO_4$, and concentrated. The crude product was purified by flash chromatography (silica gel, 75% ether in hexanes) to give trioxolane **OZ195** (335 mg, 51%) as a colorless solid. mp 142–144 °C (ether); 1H NMR (500 MHz, $CDCl_3$) δ 1.02 (s, 9H), 1.30–1.51 (m, 2H), 1.52–1.99 (m, 20H), 1.96 (s, 2H), 3.79–3.95 (m, 1H), 5.23–5.28 (m, 1H); ^{13}C NMR (125.7 MHz, $CDCl_3$) δ 26.44, 26.82, 29.77, 30.00, 30.79, 32.76, 34.76, 36.31, 36.74, 46.45, 50.69, 107.76, 111.63, 170.97. Anal. Calcd for $C_{22}H_{35}NO_4$: C, 69.99; H, 9.34; N, 3.71. Found: C, 70.15; H, 9.38; N, 3.65.

cis-Adamantane-2-spiro-3'-8'-(3'-carboxy-1'-oxopropyl)amino]-1',2',4'-trioxaspiro[4.5]decane (OZ196). To a solution of **OZ137** (550 mg, 1.74 mmol) in CH_2Cl_2 (10 ml) at 0 °C were added triethylamine (350 mg, 3.48 mmol) and succinic anhydride (176 mg, 1.74 mmol). The resulting mixture was stirred at rt for 24 h, concentrated, and triturated with water (3 x 10 ml), hexanes (2 x 10 ml), and THF (5 ml) to give trioxolane **OZ196** (350 mg, 53%) as a colorless solid. mp 122–124 °C (THF); 1H NMR (500 MHz,

DMSO-*d*₆) δ 1.33–1.57 (m, 2H), 1.62–2.19 (m, 20H), 2.31–2.41 (m, 2H), 2.42–2.57 (m, 2H), 3.65–3.82 (m, 1H), 7.83–7.87 (m, 1H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 26.00, 26.39, 29.34, 29.43, 32.20, 34.43, 35.88, 36.26, 45.65, 108.07, 110.81, 170.41, 173.99. Anal. Calcd for C₂₀H₂₉NO₆: C, 63.31; H, 7.70; N, 3.69. Found: C, 63.46; H, 7.68; N, 3.84.

5 **cis-Adamantane-2-spiro-3'-8'-(2',5'-dioxo-1'-pyrrolidinyl)methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ197).** To a solution of OZ119 (0.29 g, 1 mmol), triphenylphosphine (0.42 g, 1.6 mmol), and succinimide (0.11 g, 1.1 mmol) in THF (6 ml) at 0 °C was added a solution of DIPAD (0.32 g, 1.6 mmol) in THF (1 ml). The mixture was warmed to rt and stirred overnight. After removal of the solvent, the crude product was purified by flash chromatography (silica gel, 25% ether in hexanes) and by subsequent recrystallization from hexanes/CH₂Cl₂ (3:1) to give trioxolane OZ197 (0.30 g, 80%) as a colorless solid. mp 147–148 °C (hexanes/CH₂Cl₂ 3:1); ¹H NMR (500 MHz, CDCl₃) δ 1.37–1.59 (m, 2H), 1.61–2.35 (m, 21H), 2.92 (s, 4H), 3.59 (d, J = 7.1 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.39, 26.79, 27.70, 28.02, 33.46, 34.69, 34.71, 34.74, 36.28, 36.71, 43.75, 108.32, 111.25, 177.26. Anal. Calcd for C₂₁H₂₉NO₅: C, 67.18; H, 7.79; N, 3.73. Found: C, 67.12; H, 7.81; N, 3.63.

10 **cis-Adamantane-2-spiro-3'-8'-(3'-carboxyphenyl)-1',2',4'-trioxaspiro[4.5]decane (OZ198).** A mixture of OZ208 (0.38 g, 0.92 mmol), KOH (0.36 g), THF (10 ml), methanol (10 ml), and water (2 ml) was heated at 50 °C for 2 h. The mixture was concentrated, diluted with water (10 ml), and acidified with 1 M aq. HCl to pH = 2. The resulting solid was collected by filtration and washed with hexanes/ether (10 ml, 2:1) to give trioxolane OZ198 (0.28 g, 79%) as a colorless solid. mp 150–152 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.63–2.22 (m, 22H), 2.58–2.73 (m, 1H), 7.40 (dd, J = 7.7, 7.7 Hz, 1H), 7.46 (d, J = 7.4 Hz, 1H), 7.95 (d, J = 7.7 Hz, 1H), 7.97 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.51, 26.91, 31.31, 34.63, 34.82, 36.43, 36.82, 42.72, 108.21, 111.49, 128.13, 128.60, 128.75, 129.46, 132.06, 146.59, 171.58. Anal. Calcd for C₂₃H₂₈O₅: C, 71.85; H, 7.34. Found: C, 71.74; H, 7.30.

15 **Adamantane-2-spiro-3'-8'-carbamoyl-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ199).** To a solution of OZ80 (450 mg, 1.49 mmol) in CH₂Cl₂ (12 ml) at rt were added pyridine (1.2 ml, 14.9 mmol), HOAc (0.82 ml, 14.9 mmol), triethylamine (0.4 ml, 2.98 mmol), and potassium cyanate (243 mg, 2.98 mmol). After being stirred for 35 h the

reaction mixture was poured into a mixture of ether (50 ml) and water (50 ml). The organic layer was separated, washed with brine (15 ml), dried over MgSO₄, and concentrated.

Crystallization of the residue from ether/CH₂Cl₂ (3:1) afforded trioxolane **OZ199** (449 mg, 98%) as a colorless solid. mp 140–142 °C (ether/CH₂Cl₂ 3:1); ¹H NMR (500 MHz, CDCl₃) δ 1.57–2.21 (m, 18H), 3.31–3.69 (m, 4H), 4.55 (s, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.41, 26.81, 34.27, 34.73, 34.81, 36.37, 36.69, 42.25, 106.72, 112.21, 157.65. Anal. Calcd for C₁₆H₂₄N₂O₄•0.4H₂O: C, 60.89; H, 7.92; N, 8.88. Found: C, 60.86; H, 7.60; N, 8.84.

Adamantane-2-spiro-3'-8'-[2'-(ethylsulfonyl)ethyl]-1',2',4'-trioxa-8'-

azaspiro[4.5]decane (OZ200). To a stirred solution of **OZ80** (450 mg, 1.49 mmol) in CH₂Cl₂ (10 ml) and methanol (10 ml) at rt was added triethylamine (0.4 ml, 2.98 mmol) followed by ethyl vinyl sulfone (0.15 ml, 1.49 mmol). The resulting mixture was stirred at rt for 3 h before removal of the solvents. The residue was diluted with ether (15 ml), washed with water (2 x 10 ml), dried (MgSO₄), and concentrated. Crystallization of the crude product from ether/hexanes (1:1) afforded trioxolane **OZ200** (415 mg, 72%) as a colorless solid. mp 105–107 °C (ether/hexanes 1:1); ¹H NMR (500 MHz, CDCl₃) δ 1.39 (t, J = 7.6 Hz, 3H), 1.57–2.21 (m, 18H), 2.41–2.59 (m, 2H), 2.60–2.78 (m, 2H), 2.89 (t, J = 6.5 Hz, 2H), 3.09 (t, J = 6.5 Hz, 2H), 3.14 (q, J = 7.4 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 6.59, 26.40, 26.80, 34.33, 34.71, 34.79, 36.34, 36.69, 48.56, 49.74, 50.94, 51.10, 106.54, 111.85. Anal. Calcd for C₁₉H₃₁NO₅S: C, 59.19; H, 8.10; N, 3.63. Found: C, 58.98; H, 7.95; N, 3.65.

cis-Adamantane-2-spiro-3'-8'-(4'-fluorophenyl)amino]-1',2',4'-

trioxaspiro[4.5]decane (OZ201). To a solution of **OZ05** (555 mg, 2 mmol) in 1,2-dichloroethane (10 ml) were added 4-fluoroaniline (236 mg, 2.12 mmol) and acetic acid (10 drops). The reaction mixture was stirred at rt for 15 min before sodium triacetoxyborohydride (677 mg, 3.2 mmol) was added. The mixture was stirred for 5 h before being quenched with 1 M aq. NaOH (2 ml). The resulting mixture was extracted with CH₂Cl₂ (40 ml), washed with water (2 x 10 ml) and brine (2 x 10 ml), dried over MgSO₄, and concentrated to give an oil (517 mg, 69%, 2:1 mixture of two diastereomers). Trituration with ether and hexanes gave trioxolane **OZ201** (280 mg, 37%) as a colorless solid. mp 118–120 °C (hexanes); ¹H NMR (500 MHz, CDCl₃) δ 1.37–1.52 (m, 2H), 1.53–2.21 (m, 20H), 3.19–3.27 (m, 1H), 3.28–3.49 (m, 1H), 6.41–6.63 (m, 2H), 6.77–6.99 (m,

2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.46, 26.87, 30.10, 32.75, 34.77, 34.81, 36.34, 36.76, 50.92, 108.08, 111.58, 114.14 (d, J = 7.3 Hz), 115.71 (d, J = 22.4 Hz), 143.44, 155.70 (d, J = 234.9 Hz). Anal. Calcd for $\text{C}_{22}\text{H}_{28}\text{FNO}_3$: C, 70.75; H, 7.56; N, 3.75. Found: C, 70.85; H, 7.42; N, 3.76.

5 **cis-Adamantane-2-spiro-3'-8'-(2'-acetoxy-2'-methylpropionyl)amino]-1',2',4'-trioxaspiro[4.5]decane (OZ202).** To a solution of **OZ137** (550 mg, 1.74 mmol) in CH_2Cl_2 (10 ml) at 0 °C were added triethylamine (529 mg, 5.22 mmol) and 2-acetoxy-2-methylpropionyl chloride (430 mg, 2.61 mmol). The resulting mixture was stirred at rt for 16 h, diluted with CH_2Cl_2 (10 ml), and washed with water (10 ml) and brine (10 ml). The 10 organic layer was separated, dried over MgSO_4 , and concentrated. The crude product was purified by trituration with hexanes to give trioxolane **OZ202** (350 mg, 49%) as a colorless solid. mp 130–132 °C (hexanes); ^1H NMR (500 MHz, CDCl_3) δ 1.35–1.52 (m, 2H), 1.61 (s, 6H), 1.62–2.06 (m, 20H), 2.07 (s, 3H), 3.75–3.95 (m, 1H), 5.77–5.93 (m, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 21.87, 24.29, 26.43, 26.81, 29.73, 32.68, 34.75, 36.30, 36.73, 46.51, 81.35, 107.66, 111.65, 169.15, 172.35. Anal. Calcd for $\text{C}_{22}\text{H}_{33}\text{NO}_6$: C, 64.84; H, 8.16; N, 3.44. Found: C, 64.80; H, 7.93; N, 3.52.

15 **Adamantane-2-spiro-3'-8'-(1'-pyrrolidinylcarbonyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ203).** To a solution of **OZ80** (301 mg, 1 mmol) and triethylamine (303 mg, 3 mmol) in CH_2Cl_2 (10 ml) at 0 °C was added 1-pyrrolidinecarbonyl chloride (118 mg, 1 mmol). The mixture was stirred at rt for 16 h, diluted with CH_2Cl_2 (10 ml), and washed with water (2 x 10 ml) and brine (10 ml). The organic layer was separated, dried over MgSO_4 , and concentrated. Crystallization of the residue from methanol gave trioxolane **OZ203** (152 mg, 42%) as a colorless solid. mp 130–132 °C (methanol); ^1H NMR (500 MHz, CDCl_3) δ 1.61–2.15 (m, 22H), 3.23–3.57 (m, 8H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 25.53, 26.44, 26.83, 34.51, 34.73, 34.82, 36.40, 36.72, 43.94, 48.38, 107.26, 111.90, 162.56. Anal. Calcd for $\text{C}_{20}\text{H}_{30}\text{N}_2\text{O}_4$: C, 66.27; H, 8.34; N, 7.73. Found: C, 66.33; H, 8.30; N, 7.60.

20 **cis-Adamantane-2-spiro-3'-8'-(4'-methoxycarbonylphenyl)methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ204).** A solution of *O*-methyl 2-adamantanone oxime (895 mg, 5 mmol) and 4-[(4-methoxycarbonylphenyl)methyl]cyclohexanone (1.27 g, 5 mmol) in cyclohexane (80 ml) and CH_2Cl_2 (20 ml) was treated with ozone according to the general

procedure. The crude product was purified by flash chromatography (silica gel, 5% ether in hexanes) and subsequent recrystallization from ethanol/CH₂Cl₂ (19:1) to afford trioxolane **OZ204** (950 mg, 46%) as a colorless solid. mp 104–106 °C (ethanol/CH₂Cl₂ 19:1); ¹H NMR (500 MHz, CDCl₃) δ 1.19–1.37 (m, 2H), 1.49–2.07 (m, 21H), 2.56 (d, J = 6.9 Hz, 2H), 3.90 (s, 3H), 7.20 (d, J = 7.9 Hz, 2H), 7.95 (d, J = 7.9 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.48, 26.87, 29.90, 34.08, 34.78, 36.38, 36.80, 38.00, 42.86, 51.95, 108.76, 111.28, 127.91, 129.08, 129.57, 146.42, 167.12. Anal. Calcd for C₂₅H₃₂O₅: C, 72.79; H, 7.82. Found: C, 72.72; H, 7.85.

cis-Adamantane-2-spiro-3'-8'-(2'-hydroxy-2'-methylpropyl)-1',2',4'-trioxaspiro[4.5]decane (OZ205). To a solution of **OZ61** (350 mg, 1 mmol) in CH₂Cl₂ at –78 °C was added methyllithium (3 ml, 1.6 M in ether, 4.8 mmol). The reaction was stirred at –78 °C for 2 h before being quenched with water. The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂ (2 x 10 ml). The combined organic layers were washed with water (10 ml) and brine (10 ml), dried over MgSO₄, filtered, and concentrated. The crude product was purified by crystallization from ethanol to afford trioxolane **OZ205** (262 mg, 78%) as a colorless solid. mp 96–98 °C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.23 (s, 6H), 1.21–1.37 (m, 2H), 1.40 (d, J = 5.5 Hz, 2H), 1.43–1.61 (m, 1H), 1.62–2.09 (m, 20H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.49, 26.89, 30.03, 31.99, 32.47, 34.31, 34.78, 34.80, 36.40, 36.82, 49.76, 71.39, 108.62, 111.17. Anal. Calcd for C₂₀H₃₂O₄: C, 71.39; H, 9.59. Found: C, 71.44; H, 9.39.

cis-Adamantane-2-spiro-3'-8'-(2',4'-dioxo-3'-imidazolidinyl)methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ206). To a solution of **OZ119** (0.29 g, 1 mmol), triphenylphosphine (0.42 g, 1.6 mmol), and hydantoin (0.11 g, 1.1 mmol) in DMF (6 ml) and THF (6 ml) at 0 °C was added a solution of DIPAD (0.32 g, 1.6 mmol) in THF (1 ml). The mixture was warmed to rt and stirred overnight. After removal of the solvents, the crude product was purified by flash chromatography (silica gel, 25% acetone in hexanes) and subsequent recrystallization from hexanes/CH₂Cl₂ (5:1) to give trioxolane **OZ206** (0.21 g, 56%) as a colorless solid. mp 158–160 °C (hexanes/CH₂Cl₂ 5:1); ¹H NMR (500 MHz, CDCl₃) δ 1.21–1.41 (m, 2H), 1.58–2.19 (m, 21H), 3.40 (d, J = 6.9 Hz, 2H), 3.99 (s, 2H), 5.81 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.47, 26.87, 27.69, 33.54, 34.77,

34.79, 35.10, 36.36, 36.79, 43.76, 46.27, 108.43, 111.36, 158.35, 171.31. Anal. Calcd for C₂₀H₂₈N₂O₅: C, 63.81; H, 7.50; N, 7.44. Found: C, 63.68; H, 7.31; N, 7.39.

cis-Adamantane-2-spiro-3'-8'-(aminomethyl)-1',2',4'-trioxaspiro[4.5]decane p-tosylate (OZ207). To a solution of *cis*-Adamantane-2-spiro-3'-8'-(aminomethyl)-

5 1',2',4'-trioxaspiro[4.5]decane (1.465 g, 5 mmol) in ether (60 ml) and CH₂Cl₂ (20 ml) was added a solution of *p*-TsOH (0.96 g, 5 mmol) in ether (80 ml). The resulting mixture was placed at -20 °C overnight. The solid was collected by filtration to afford trioxolane 10 OZ207 (2.24 g, 96%) as a colorless solid. mp 162–164 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.01–1.23 (m, 2H), 1.51–2.07 (m, 21H), 2.29 (s, 3H), 2.68 (app t, J = 5.7 Hz, 2H), 7.12 (d, J = 7.8 Hz, 2H), 7.48 (d, J = 8.3 Hz, 2H), 7.68 (br s, 3H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 20.93, 25.95, 26.36, 27.08, 32.99, 33.86, 34.40, 34.41, 35.89, 36.22, 43.63, 108.28, 110.80, 125.65, 128.21, 137.77, 145.87. Anal. Calcd for C₂₄H₃₅NO₆S: C, 61.91; H, 7.58; N, 3.01. Found: C, 61.78; H, 7.38; N, 2.97.

cis-Adamantane-2-spiro-3'-8'-(3'-ethoxycarbonyl)phenyl]-1',2',4'-trioxaspiro[4.5]decane (OZ208). A solution of *O*-methyl 2-adamantanone oxime (0.65 g,

15 2.6 mmol) and 4-[3-(ethoxycarbonyl)phenyl]cyclohexanone (0.47 g, 2.6 mmol) in pentane (50 ml) and CH₂Cl₂ (25 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 10% ether in hexanes) to afford trioxolane 20 OZ208 (0.50 g, 47%) as a colorless solid. mp 72–73 °C (95% ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.39 (t, J = 7.1 Hz, 3H), 1.61–2.21 (m, 22H), 2.55–2.69 (m, 1H), 4.37 (q, J = 7.1 Hz, 2H), 7.35 (dd, J = 7.6, 7.6 Hz, 1H), 7.39 (d, J = 7.7 Hz, 1H), 7.88 (d, J = 7.7 Hz, 1H), 7.89 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 14.35, 26.50, 26.90, 31.33, 34.64, 34.81, 36.43, 36.81, 42.78, 60.90, 108.24, 111.47, 127.48, 127.98, 128.41, 130.62, 131.21, 146.38, 166.70. Anal. Calcd for C₂₅H₃₂O₅: C, 72.79; H, 7.82. Found: C, 25 72.61; H, 7.60.

cis-Adamantane-2-spiro-3'-8'-(aminomethyl)-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ209). To a solution of *cis*-Adamantane-2-spiro-3'-8'-(aminomethyl)-

1',2',4'-trioxaspiro[4.5]decane (0.30 g, 1.02 mmol) in ether (10 ml) and CH₂Cl₂ (5 ml) was added a solution of methanesulfonic acid (0.10 g, 1.04 mmol) in ether (30 ml). The 30 resulting mixture was concentrated to 10 ml and placed at -20 °C overnight. The solid was collected by filtration to afford trioxolane OZ209 (0.34 g, 86%) as a colorless solid. mp

146–148 °C; ^1H NMR (500 MHz, DMSO-*d*₆) δ 1.01–1.23 (m, 2H), 1.51–2.07 (m, 21H), 2.34 (s, 3H), 2.69 (app t, *J* = 6.0 Hz, 2H), 7.70 (br s, 3H); ^{13}C NMR (125.7 MHz, DMSO-*d*₆) δ 25.95, 26.36, 27.09, 33.01, 33.85, 34.39, 34.41, 35.89, 36.22, 43.61, 108.28, 110.79. Anal. Calcd for C₁₈H₃₁NO₆S: C, 55.50; H, 8.02; N, 3.60. Found: C, 55.41; H, 7.94; N, 3.58.

cis-Adamantane-2-spiro-3'-8'-(phenylsulfonylmethyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ210). A solution of *O*-methyl 2-adamantanone oxime (1.79 g, 10 mmol) and 4-[(phenylsulfonylmethyl)cyclohexanone (1.20 g, 4.76 mmol) in pentane (50 ml) and CH₂Cl₂ (25 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 33% ether in hexanes) to afford trioxolane **OZ210** (0.78 g, 39%) as a colorless solid. mp 120–122 °C (ether/hexanes 1:1); ^1H NMR (500 MHz, CDCl₃) δ 1.25–1.46 (m, 2H), 1.60–2.21 (m, 21H), 2.99 (d, *J* = 6.3 Hz, 2H), 7.54–7.62 (m, 2H), 7.63–7.70 (m, 1H), 7.88–7.96 (m, 2H); ^{13}C NMR (125.7 MHz, CDCl₃) δ 26.44, 26.83, 30.11, 31.19, 33.69, 34.75, 34.76, 36.35, 36.75, 61.79, 107.77, 111.53, 127.73, 129.32, 133.63, 140.21. Anal. Calcd for C₂₃H₃₀O₅S: C, 66.00; H, 7.22. Found: C, 66.15; H, 7.10.

cis-Adamantane-2-spiro-3'-8'-(1'H-pyrazol-1'-ylmethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ211). To a suspension of 60% NaH (0.08 g, 2 mmol) in DMF (4 ml) under nitrogen at 0°C was added a solution of pyrazole (0.14 g, 2 mmol) in DMF (4 ml). The mixture was stirred for 30 min before a solution of the methanesulfonate of **OZ119** (0.37 g, 1.0 mmol) in DMF (4 ml) was added dropwise. The reaction mixture was heated at 50°C for 2 h, quenched with water (40 ml), and then extracted with ethyl acetate (3 x 30 ml). The combined extracts were washed with brine (3 x 30 ml), dried over MgSO₄, filtered, and concentrated. The crude product was purified by flash chromatography (silica gel, 33% ether in hexanes) to afford trioxolane **OZ211** (0.28 g, 81%) as a colorless solid. mp 103–106 °C (hexanes/CH₂Cl₂, 4:1); ^1H NMR (500 MHz, CDCl₃) δ 1.19–1.37 (m, 2H), 1.53–2.18 (m, 21H), 3.77 (d, *J* = 7.1 Hz, 2H), 6.22 (s, 1H), 7.33 (s, 1H), 7.51 (s, 1H); ^{13}C NMR (125.7 MHz, CDCl₃) δ 26.47, 26.85, 27.63, 33.60, 34.77, 36.37, 36.78, 37.16, 57.46, 105.02, 108.52, 111.43, 129.63, 139.41. Anal. Calcd for C₂₀H₂₈N₂O₃: C, 69.74; H, 8.19; N, 8.13. Found: C, 69.88; H, 8.18; N, 8.17.

cis-Adamantane-2-spiro-3'-8'-[¹,¹'-dioxido-3'-oxo-1',2'-benzisothiazol-2'(³H-yl)methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ212). To a solution of **OZ119** (0.29 g, 1 mmol), triphenylphosphine (0.42 g, 1.6 mmol), and saccharin (0.20 g, 1.1 mmol) in THF (10 ml) at 0 °C was added a solution of DIPAD (0.32 g, 1.6 mmol) in THF (1 ml).
5 The mixture was warmed to rt and stirred overnight. After removal of the solvent, the crude product was purified by flash chromatography (silica gel, 25% ether in hexanes) and by subsequent recrystallization from hexanes/CH₂Cl₂ (4:1) to give trioxolane **OZ212** (0.17 g, 37%) as a colorless solid. mp 152–155 °C (hexanes/CH₂Cl₂, 4:1); ¹H NMR (500 MHz, CDCl₃) δ 1.23–1.45 (m, 2H), 1.59–2.18 (m, 21H), 3.63 (d, J = 7.4 Hz, 2H), 7.80–7.90 (m, 2H), 7.93 (d, J = 7.1 Hz, 1H), 8.06 (d, J = 7.4 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.49, 26.88, 27.79, 33.50, 34.79, 34.80, 35.14, 36.39, 36.81, 44.49, 108.43, 111.39, 120.93, 125.22, 127.33, 134.31, 134.73, 137.64, 159.26. Anal. Calcd for C₂₄H₂₉NO₆S: C, 62.73; H, 6.36; N, 3.05. Found: C, 62.74; H, 6.18; N, 3.02.

cis-Adamantane-2-spiro-3'-8'-[[(methoxyamino)carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ213). To a solution of **OZ78** (322 mg, 1 mmol) in CH₂Cl₂ (10 ml) at 0°C were added triethylamine (202 mg, 2 mmol) and ethyl chloroformate (217 mg, 2 mmol). After the mixture was stirred at 0 °C for 15 min, methoxylamine was added. [To a suspension of methoxylamine hydrochloride (167 mg, 2 mmol) in methanol (5 ml) was added NaHCO₃ (164 mg, 2 mmol). The mixture was stirred at rt for 15 min]. The resulting mixture was stirred at rt for 12 h, diluted with CH₂Cl₂ (10 ml), washed with water (10 ml), dried over MgSO₄, and concentrated. The crude product was purified by crystallization from methanol to afford trioxolane **OZ213** (0.17 g, 48%) as a colorless solid. mp 72–74 °C (methanol); ¹H NMR (500 MHz, DMSO-d₆) δ 0.99–1.21 (m, 2H), 1.45–2.11 (m, 23H), 3.56 (s, 3H), 10.93 (s, 1H); ¹³C NMR (125.7 MHz, DMSO-d₆) δ 25.96, 26.37, 29.54, 32.64, 33.50, 34.40, 35.91, 36.25, 38.86, 63.34, 108.49, 110.64, 168.09. Anal. Calcd for C₁₉H₂₉NO₅: C, 64.93; H, 8.32; N, 3.99. Found: C, 64.79; H, 8.13; N, 3.76.

cis-Adamantane-2-spiro-3'-8'-(4'-carboxyphenyl)methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ214). A mixture of **OZ204** (412 mg, 1 mmol), NaOH (120 mg, 3 mmol), methanol (10 ml), and water (10 ml) was stirred at rt for 16 h. After removal of the solvents, the residue was acidified with 6 M aq. HCl (4 ml) to pH = 2, and the resulting precipitate was collected by filtration and further crystallized from 95% ethanol to

give trioxolane **OZ214** (182 mg, 46%) as a colorless solid. mp 160–162 °C (95% ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.09–1.39 (m, 2H), 1.43–2.22 (m, 21H), 2.59 (d, J = 7.1 Hz, 2H), 7.25 (d, J = 7.9 Hz, 2H), 8.04 (d, J = 7.9 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.49, 26.88, 29.92, 34.08, 34.79, 36.39, 36.80, 38.00, 42.95, 108.74, 111.31, 126.98, 129.23, 130.24, 147.48, 171.61. Anal. Calcd for C₂₄H₃₀O₅: C, 72.34; H, 7.59. Found: C, 72.16; H, 7.37.

cis-Adamantane-2-spiro-3'-8'-phthalimidoethyl-1',2',4'-trioxaspiro[4.5]decane (OZ215). A solution of *O*-methyl 2-adamantanone oxime (895 mg, 5 mmol) and 4-phthalimidoethylcyclohexanone (1.35 g, 5 mmol) in cyclohexane (85 ml) and CH₂Cl₂ (15 ml) was treated with ozone according to the general procedure. The crude product was purified by flash chromatography (silica gel, 15% ether in hexanes) and by subsequent crystallization from ethanol to afford trioxolane **OZ215** (1.33 g, 61%) as a colorless solid. mp 136–138 °C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.15–1.43 (m, 3H), 1.49–2.21 (m, 22H), 3.70 (d, J = 7.5 Hz, 2H), 7.62–7.78 (m, 2H), 7.79–7.97 (m, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.48, 26.87, 29.81, 33.78, 34.04, 34.76, 34.79, 36.05, 36.38, 36.80, 108.73, 111.18, 123.14, 132.16, 133.84, 168.33. Anal. Calcd for C₂₆H₃₁NO₅: C, 71.37; H, 7.14; N, 3.20. Found: C, 71.50; H, 6.93; N, 3.16.

Adamantane-2-spiro-3'-8'-(4'-pyridinylmethyl)-1',2',4'-trioxa-8'-azaspiro[4.5]decane (OZ216). To a stirred solution of **OZ80** (200 mg, 0.66 mmol) in 1,2-dichloroethane (5 ml) at rt was added triethylamine (0.2 ml, 1.2 mmol) followed by 4-pyridinecarboxaldehyde (71 mg, 0.66 mmol) and sodium triacetoxyborohydride (197 mg, 0.924 mmol). The resulting mixture was stirred at rt for 2 h, quenched with saturated aqueous NaHCO₃ (5 ml), and extracted with EtOAc (3 x 10 ml). The combined organic extracts were dried over MgSO₄, filtered, and concentrated. Crystallization of the crude product from ether/methanol (3:1) gave trioxolane **OZ216** (167 mg, 71%) as a colorless solid. mp 124–126 °C (ether/methanol 3:1); ¹H NMR (500 MHz, CDCl₃) δ 1.59–2.19 (m, 18H), 2.37–2.51 (m, 4H), 3.52 (s, 2H), 7.27 (d, J = 4.9 Hz, 2H), 8.54 (d, J = 5.0 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.45, 26.87, 34.45, 34.74, 34.83, 36.40, 36.75, 51.24, 61.20, 106.94, 111.70, 123.63, 148.00, 149.81. Anal. Calcd for C₂₁H₂₈N₂O₃: C, 70.76; H, 7.92; N, 7.86. Found: C, 70.80; H, 7.77; N, 7.65.

cis-Adamantane-2-spiro-3'-8'-[[[(2'-thiazolyl)amino]carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ217). To a solution of **OZ78** (322 mg, 1 mmol) in CH₂Cl₂ (10 ml) at 0 °C were added triethylamine (303 mg, 3 mmol) and ethyl chloroformate (217 mg, 2 mmol). The mixture was stirred at 0 °C for 15 min before 2-aminothiazole (100 mg, 1 mmol) was added. The resulting mixture was stirred at rt for 12 h, concentrated, and triturated with water. The crude product was purified by crystallization from ethanol to afford trioxolane **OZ217** (0.29 g, 72%) as a colorless solid. mp 160–162 °C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.19–1.47 (m, 2H), 1.51–2.18 (m, 21H), 2.46 (d, J = 6.9 Hz, 2H), 7.02 (d, J = 3.6 Hz, 1H), 7.42 (d, J = 3.6 Hz, 1H), 12.51 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.46, 26.84, 30.10, 33.23, 33.91, 34.77, 36.37, 36.77, 42.81, 108.35, 111.45, 113.68, 136.10, 159.96, 170.18. Anal. Calcd for C₂₁H₂₈N₂O₄S: C, 62.35; H, 6.98; N, 6.93. Found: C, 62.28; H, 6.92; N, 6.87.

cis-Adamantane-2-spiro-3'-8'-[(1'-piperidinylcarbonyl)methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ218). To a solution of **OZ78** (322 mg, 1.0 mmol) in CH₂Cl₂ (10 ml) at 0 °C were added triethylamine (202 mg, 2 mmol) and ethyl chloroformate (217 mg, 2 mmol). The mixture was stirred at 0°C for 15 min before piperidine (100 mg, 1.2 mmol) was added. The resulting mixture was stirred at rt for 12 h, concentrated, and triturated with water. The crude product was purified by crystallization from ethanol to afford trioxolane **OZ218** (0.24 g, 62%) as a colorless solid. mp 98–100 °C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.15–1.39 (m, 2H), 1.43–2.17 (m, 27H), 2.21 (d, J = 6.8 Hz, 2H), 3.30–3.49 (m, 2H), 3.50–3.65 (m, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 24.57, 25.66, 26.49, 26.60, 26.87, 30.31, 33.43, 34.11, 34.79, 36.39, 36.81, 39.26, 42.69, 46.87, 108.72, 111.29, 170.28. Anal. Calcd for C₂₃H₃₅NO₄: C, 70.92; H, 9.06; N, 3.60. Found: C, 70.83; H, 8.99; N, 3.60.

cis-Adamantane-2-spiro-3'-8'-(1'H-imidazol-1'-ylethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ219). **Step 1.** To a solution of **OZ89** (924 mg, 3 mmol) and triethylamine (606 mg, 6 mmol) in CH₂Cl₂ (30 ml) at 0°C was added methanesulfonyl chloride (516 mg, 4.5 mmol). The mixture was stirred at rt for 1 h, diluted with CH₂Cl₂ (20 ml), and washed with with water (2 x 10 ml) and brine (10 ml). The organic layer was dried over MgSO₄, filtered, and concentrated to afford the methanesulfonate (1.16 g, 100%) as a colorless solid. **Step 2.** To a solution of imidazole (100 mg, 1.5 mmol) in DMF (5 ml) was

added 60% NaH (75 mg, 1.9 mmol). The mixture was stirred for 15 min before a solution of the above methanesulfonate (0.40 g, 1 mmol) in DMF (2 ml) was added dropwise. The mixture was heated at 50 °C for 3 h, quenched with water (15 ml), and then extracted with ether (3 x 20 ml). The combined extracts were dried over MgSO₄, filtered, and
5 concentrated. Crystallization of the residue from hexanes/ether (19:1) gave trioxolane **OZ219** (0.22 g, 61%) as a colorless solid. mp 116–118 °C (hexanes/ether, 19:1); ¹H NMR (500 MHz, CDCl₃) δ 1.11–1.39 (m, 3H), 1.51–2.18 (m, 22H), 3.95 (t, J = 8.0 Hz, 2H), 6.89 (s, 1H), 7.06 (s, 1H), 7.46 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.46, 26.85, 29.80, 33.26, 33.93, 34.77, 36.38, 36.77, 37.35, 44.81, 108.48, 111.40, 118.65, 129.52, 136.95.
10 Anal. Calcd for C₂₁H₃₀N₂O₃: C, 70.36; H, 8.44; N, 7.81. Found: C, 70.14; H, 8.27; N, 7.81.

Adamantane-2-spiro-3'-8'-benzyl-1',2',4'-trioxa-8'-azaspiro[4.5]decane

(**OZ220**). To a stirred solution of **OZ80** (200 mg, 0.66 mmol) in 1,2-dichloroethane (5 ml) at rt was added triethylamine (0.2 ml, 1.2 mmol) followed by benzaldehyde (70 mg, 0.66 mmol) and sodium triacetoxyborohydride (197 mg, 0.924 mmol). The resulting mixture
15 was stirred at rt for 2 h, quenched with saturated aqueous NaHCO₃ (5 ml), and extracted with EtOAc (3 x 10 ml). The combined organic extracts were dried over MgSO₄, filtered, and concentrated. Crystallization of the crude product from ether/methanol (3:1) gave trioxolane **OZ220** (177 mg, 75%) as a colorless solid. mp 108–110 °C (ether/methanol 3:1); ¹H NMR (500 MHz, CDCl₃) δ 1.58–2.21 (m, 18H), 2.38–2.52 (m, 2H), 2.53–2.69 (m, 2H), 3.51 (s, 2H), 7.18–7.45 (m, 5H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.47, 26.88, 34.46, 34.75, 34.83, 36.40, 36.78, 51.09, 62.50, 107.26, 111.56, 126.99, 128.21, 128.96,
20 138.63. Anal. Calcd for C₂₂H₂₉NO₃: C, 74.33; H, 8.22; N, 3.94. Found: C, 74.52; H, 8.17; N, 4.03.

cis-Adamantane-2-spiro-3'-8'-[(aminocarbonyl)amino]-1',2',4'-trioxaspiro[4.5]decane (**OZ221**).

To a solution of **OZ137** (550 mg, 1.74 mmol) in CH₂Cl₂ (10 ml) at rt were added pyridine (1.38 g, 17.4 mmol), acetic acid (1.01 g, 16.8 mmol), triethylamine (349 mg, 3.45 mmol), and KOCN (278 mg, 3.45 mmol). The resulting mixture was stirred at rt for 48 h, diluted with ether (100 ml), and washed with water (100 ml) and brine (25 ml). The organic layer was separated, dried over MgSO₄, and
30 concentrated to give trioxolane **OZ221** (166 mg, 30%) as a colorless solid. mp 140–142 °C (ether); ¹H NMR (500 MHz, CDCl₃) δ 1.35–1.52 (m, 2H), 1.62–2.21 (m, 20H), 3.51–3.54

(m, 1H), 4.70 (s, 2H), 4.58–5.03 (m, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.43, 26.80, 30.34, 32.61, 34.76, 36.30, 36.73, 47.41, 107.88, 111.66, 158.32. Anal. Calcd for $\text{C}_{17}\text{H}_{26}\text{N}_2\text{O}_4$: C, 63.33; H, 8.13; N, 8.69. Found: C, 63.06; H, 8.29; N, 8.49.

cis-Adamantane-2-spiro-3'-8'-[[[*tert*-butylamino)carbonyl]amino]-1',2',4'-trioxaspiro[4.5]decane (OZ222).

To a solution of **OZ137** (315 mg, 1 mmol) in CH_2Cl_2 (10 ml) at 0 °C were added triethylamine (350 mg, 3.48 mmol) and *tert*-butyl isocyanate (100 mg, 1 mmol). The resulting mixture was stirred at rt for 7 h before removal of solvents. The residue was triturated with water (10 ml) and further purified by crystallization from 95% ethanol to give trioxolane **OZ222** (300 mg, 79%) as a colorless solid. mp 130 °C dec (ethanol); ^1H NMR (500 MHz, CDCl_3) δ 1.32 (s, 9H), 1.22–2.21 (m, 22H), 3.64 (s, 1H), 4.28 (s, 1H), 4.37 (s, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.44, 26.81, 29.54, 30.64, 32.83, 34.75, 36.30, 36.74, 47.05, 50.29, 108.01, 111.53. Anal. Calcd for $\text{C}_{21}\text{H}_{34}\text{N}_2\text{O}_4$: C, 66.64; H, 9.05; N, 7.40. Found: C, 66.65; H, 9.01; N, 7.22.

cis-Adamantane-2-spiro-3'-8'-(5'-methoxycarbonyl-1'H-imidazol-1'-ylmethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ223).

To a suspension of 60% NaH (0.24 g, 6 mmol) in DMF (5 ml) under nitrogen at 0°C was added a solution of methyl 4-imidazolecarboxylate (0.76 g, 6 mmol) in DMF (18 ml). The mixture was stirred for 30 min before a solution of the methanesulfonate of **OZ119** (0.96 g, 2.6 mmol) in DMF (6 ml) was added dropwise. The reaction mixture was heated at 55 °C overnight, quenched with water (100 ml), and then extracted with CH_2Cl_2 (3 x 50 ml). The combined extracts were washed with water and brine, dried over MgSO_4 , filtered, and concentrated. The crude product was purified by flash chromatography (silica gel, 40% ethyl acetate in hexanes, then 5% methanol in CH_2Cl_2) to afford trioxolane **OZ223** (0.21 g, 20%, eluted first) as a colorless solid and trioxolane **OZ224** (0.36 g, 47%, eluted second) as a colorless solid. For **OZ223**: mp 148–150 °C (hexanes/ CH_2Cl_2 , 4:1); ^1H NMR (500 MHz, CDCl_3) δ 1.17–1.41 (m, 2H), 1.55–2.18 (m, 21H), 3.85 (s, 3H), 4.13 (d, J = 7.0 Hz, 2H), 7.52 (s, 1H), 7.75 (s, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.43, 26.83, 27.43, 33.45, 34.74, 36.34, 36.74, 36.96, 51.43, 52.08, 108.33, 111.48, 122.20, 138.15, 142.54, 160.70. Anal. Calcd for $\text{C}_{22}\text{H}_{30}\text{N}_2\text{O}_5$: C, 65.65; H, 7.51; N, 6.96. Found: C, 65.78; H, 7.41; N, 6.97.

cis-Adamantane-2-spiro-3'-8'-(4'-methoxycarbonyl-1'H-imidazol-1'-ylmethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ224).

For the preparation of **OZ224**, see **OZ223**. mp

150–152 °C (ethanol); ^1H NMR (500 MHz, CDCl_3) δ 1.15–1.39 (m, 2H), 1.49–2.15 (m, 21H), 3.81 (d, J = 7.4 Hz, 2H), 3.89 (s, 3H), 7.44 (s, 1H), 7.57 (s, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.42, 26.81, 27.53, 33.39, 34.75, 36.34, 36.72, 37.73, 51.66, 52.95, 108.01, 111.68, 125.29, 133.99, 138.15, 163.25. Anal. Calcd for $\text{C}_{22}\text{H}_{30}\text{N}_2\text{O}_5$: C, 65.65; H, 5 7.51; N, 6.96. Found: C, 65.79; H, 7.34; N, 6.85.

cis-Adamantane-2-spiro-3'-8'-(4'-carboxy-1'H-imidazol-1'-ylmethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ225). A mixture of **OZ224** (0.16 g, 0.4 mmol), 15% KOH (1.5 ml), and methanol (15 ml) was heated at 55 °C for 4 h. After being cooled to rt, the mixture was concentrated to 3 ml, diluted with water (15 ml), and acidified with acetic acid to pH = 10 5. The solid was collected by filtration to afford trioxolane **OZ225** (0.10 g, 64%) as a colorless solid. mp 162 °C dec; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 1.01–1.23 (m, 2H), 1.40–2.05 (m, 21H), 3.87 (d, J = 7.3 Hz, 2H), 7.64 (s, 1H), 7.71 (s, 1H); ^{13}C NMR (125.7 MHz, $\text{DMSO}-d_6$) δ 25.96, 26.37, 27.05, 33.03, 34.42, 35.90, 36.25, 36.66, 51.32, 108.54, 110.75, 125.80, 134.59, 138.63, 164.23. Anal. Calcd for $\text{C}_{21}\text{H}_{28}\text{N}_2\text{O}_5 \cdot \text{H}_2\text{O}$: C, 62.05; H, 15 7.44; N, 6.89. Found: C, 62.36; H, 7.16; N, 6.50.

Adamantane-2-spiro-3'-8'-phenyl-1',2',4'-trioxaspiro[4.5]dec-7'-ene (OZ226).

Step 1. Addition of phenyllithium to OZ05. To a stirred solution of **OZ05** (1.10 g, 4.0 mmol) in ether (50 ml) at –78 °C was added phenyllithium (2.6 ml, 1.8 M, 4.40 mmol). The reaction mixture was allowed to reach rt during 3 h and quenched with saturated aq. 20 NH_4Cl solution (30 ml). After the ether layer was separated, the aqueous layer was extracted with ether (3 x 40 ml). The combined organic extracts were washed with brine (50 ml), dried over MgSO_4 , and concentrated. The crude product was purified by flash chromatography (silica gel, 5% EtOAc in hexanes) to afford the trioxolane carbinol intermediate (923 mg, 65 %, 1:1 mixture of two diastereomers) as a colorless oil. ^1H NMR (500 MHz, CDCl_3) δ 1.58–2.39 (m, 22H), 7.19–7.28 (m, 1H), 7.29–7.40 (m, 2H), 7.42–25 7.55 (m, 2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.64, 26.66, 27.06, 27.08, 30.36, 30.46, 34.84, 34.90, 34.91, 35.10, 36.45, 36.51, 36.57, 36.63, 36.92, 36.95, 72.08, 72.38, 108.39, 108.41, 111.52, 111.64, 124.41, 124.57, 126.98, 127.07, 128.32, 128.35, 148.11, 148.30.

Step 2. Dehydration of the carbinol intermediate. To a stirred solution of the above 30 carbinol (550 mg, 1.54 mmol) in CH_2Cl_2 (10 ml) at –10 °C was added triethylamine (1.0 ml, 7.75 mmol) followed by a solution of methanesulfonyl chloride (0.25 ml, 3.10 mmol)

in CH_2Cl_2 (5 ml). The resulting mixture was stirred at 0°C for 8 h and poured into water (10 ml). After separation of the organic layer, the aqueous layer was extracted with CH_2Cl_2 (3 x 15 ml). The combined organic extracts were dried over MgSO_4 , filtered, and concentrated. The crude product was purified by flash chromatography (silica gel, 1% ether in hexanes) and by subsequent recrystallization from ether/hexanes (1:1) to afford trioxolane **OZ226** (435 mg, 83 %) as a colorless solid. mp 62–64 °C (ether/hexanes, 1:1); ^1H NMR (500 MHz, CDCl_3) δ 1.42–2.21 (m, 16H), 2.40–2.73 (m, 4H), 5.73–5.99 (m, 1H), 7.02–7.45 (m, 5H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.54, 26.71, 27.10, 31.36, 34.81, 34.88, 34.95, 35.12, 35.23, 36.64, 36.70, 36.98, 107.80, 111.81, 120.95, 125.27, 126.96, 128.25, 136.69, 141.52. Anal. Calcd for $\text{C}_{22}\text{H}_{26}\text{O}_3$: C, 78.07; H, 7.74. Found: C, 78.28; H, 7.81.

cis-Adamantane-2-spiro-3'-8'-[[(4'-methyl-1'-piperazinyl)carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ227). To a solution of **OZ78** (322 mg, 1 mmol) in CH_2Cl_2 (10 ml) at 0°C were added triethylamine (303 mg, 3 mmol) and ethyl chloroformate (217 mg, 2 mmol). The mixture was stirred at 0 °C for 15 min before 1-methylpiperazine (110 mg, 1.1 mmol) was added. The resulting mixture was stirred at rt for 12 h, diluted with CH_2Cl_2 (10 ml), washed with water (10 ml), dried over MgSO_4 , and concentrated. The crude product was purified by crystallization from ethanol to afford trioxolane **OZ227** (0.19 g, 47%) as a colorless solid. mp 96–98 °C (ethanol); ^1H NMR (500 MHz, CDCl_3) δ 1.15–1.37 (m, 2H), 1.59–2.18 (m, 21H), 2.21 (d, J = 6.9 Hz, 2H), 2.29 (s, 3H), 2.30–2.58 (m, 4H), 3.40–3.57 (m, 2H), 3.58–3.78 (m, 2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.64, 27.02, 30.34, 33.41, 34.13, 34.87, 36.56, 36.93, 39.18, 41.62, 45.75, 45.94, 54.89, 55.31, 108.66, 111.32, 170.46. Anal. Calcd for $\text{C}_{23}\text{H}_{36}\text{N}_2\text{O}_4$: C, 68.29; H, 8.97; N, 6.92. Found: C, 68.07; H, 8.69; N, 6.81.

cis-Adamantane-2-spiro-3'-8'-(azidoethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ228). For the preparation of the mesylate of **OZ89**, see **OZ219**. To a solution of NaN_3 (375 mg, 5 mmol) in DMF (5 ml) was added the mesylate (760 mg, 2 mmol) in DMF (2 ml). The mixture was stirred at 50–55 °C for 16 h before being quenched with water (15 ml). After separation of the organic layer, the aqueous layer was extracted with ether (3 x 20 ml). The combined organic layers were dried over MgSO_4 , filtered, and concentrated. The residue was purified by crystallization from ethanol to give trioxolane **OZ228** (618

mg, 93%) as a colorless solid. mp 58–60 °C (ethanol); ^1H NMR (500 MHz, CDCl_3) δ 1.11–1.37 (m, 2H), 1.38–1.48 (m, 1H), 1.49–1.61 (m, 2H), 1.62–2.18 (m, 20H), 3.29 (t, J = 7.0 Hz, 2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.69, 27.10, 29.91, 33.63, 34.13, 34.92, 34.94, 35.02, 36.62, 36.99, 49.44, 108.69, 111.37. Anal. Calcd for $\text{C}_{18}\text{H}_{27}\text{N}_3\text{O}_3$: C, 64.84; H, 8.16; N, 12.60. Found: C, 64.68; H, 7.94; N, 12.47.

5 **cis-Adamantane-2-spiro-3'-8'-(aminoethyl)-1',2',4'-trioxaspiro[4.5]decane hydrochloride (OZ229).** To a solution of **OZ228** (333 mg, 1 mmol) in THF (7 ml) were added triphenylphosphine (262 mg, 1 mol) and water (1 ml). The mixture was stirred at rt for 16 h and diluted with 2 M aq. HCl (5 ml). The precipitate was filtered, and washed with 10 CH_2Cl_2 (10 ml), and dried to give trioxolane **OZ229** (194 mg, 56%) as a colorless solid. mp 150–152 °C; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 1.00–1.19 (m, 2H), 1.25–2.08 (m, 23H), 2.67–2.89 (m, 2H), 8.04 (s, 3H); ^{13}C NMR (125.7 MHz, $\text{DMSO}-d_6$) δ 25.83, 26.23, 29.33, 32.40, 33.02, 33.37, 34.24, 34.26, 35.81, 36.11, 36.81, 108.36, 110.45. Anal. Calcd for $\text{C}_{18}\text{H}_{30}\text{ClNO}_3$: C, 62.87; H, 8.79; N, 4.07. Found: C, 63.00; H, 8.58; N, 4.34.

15 **N,N'-Bis[cis-[adamantane-2-spiro-3'-1',2',4'-trioxaspiro[4.5]dec-8'-yl]methyl]-1,2-benzenedicarboxamide (OZ230).** A solution of **OZ146** (10.40 g, 24.60 mmol) and hydrazine monohydrate (5.00 g, 50 mmol) in chloroform (180 ml) and methanol (20 ml) was heated under nitrogen at 55°C for 24 h. The reaction mixture was cooled to rt and filtered to remove solid by-products. The filtrate was washed with water (100 ml) and brine (100 ml), dried over MgSO_4 , filtered, and concentrated. The crude product was purified by flash chromatography (silica gel, $\text{CHCl}_3/\text{MeOH/Et}_3\text{N}$, 90:10:1) to afford trioxolane **OZ230** (1.60 g, 20%, eluted first) and **cis-Adamantane-2-spiro-3'-8'-(aminomethyl)-1',2',4'-trioxaspiro[4.5]decane** (5.10 g, 71%, eluted second). **OZ230** was obtained as a colorless solid. mp 164–166 °C ($\text{CHCl}_3/\text{ethanol}$ 9:1); ^1H NMR (500 MHz, CDCl_3) δ 1.19–1.39 (m, 4H), 1.59–2.11 (m, 42H), 3.19–3.35 (m, 4H), 6.75–6.88 (m, 2H), 7.41–7.52 (m, 2H), 7.53–7.65 (m, 2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.48, 26.88, 27.81, 33.77, 34.79, 36.29, 36.39, 36.80, 45.39, 108.54, 111.38, 128.51, 130.27, 134.51, 169.27. Anal. Calcd for $\text{C}_{42}\text{H}_{56}\text{N}_2\text{O}_8$: C, 70.37; H, 7.87; N, 3.91. Found: C, 70.50; H, 7.81; N, 3.99.

25 **cis-Adamantane-2-spiro-3'-8'-(5'-carboxy-1'H-imidazol-1'-ylmethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ231).** A mixture of **OZ223** (0.10 g, 0.25 mmol), 15% KOH (1.0 ml), methanol (10 ml), and THF (2 ml) was heated at 55 °C for 4 h. After being cooled

to room temperature, the mixture was concentrated to 3 ml, diluted with water (15 ml), and acidified with acetic acid to pH = 5. The solid was collected by filtration to afford trioxolane **OZ231** (77 mg, 79%) as a colorless solid. mp 164–166 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.03–1.37 (m, 2H), 1.38–2.18 (m, 21H), 4.16 (d, J = 6.7 Hz, 2H), 7.58 (s, 1H), 7.89 (s, 1H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 25.86, 26.26, 26.88, 32.92, 34.29, 35.81, 36.14, 36.44, 50.38, 108.39, 110.62, 122.87 (br s), 137.04 (br s), 143.25 (br s), 161.10. Anal. Calcd for C₂₁H₂₈N₂O₅•0.5H₂O: C, 63.46; H, 7.35; N, 7.05. Found: C, 63.41; H, 7.11; N, 6.71.

cis-Adamantane-2-spiro-3'-8'-(dimethylamino)methyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ232).

A solution of **cis-Adamantane-2-spiro-3'-8'-(aminomethyl)-1',2',4'-trioxaspiro[4.5]decane** (293 mg, 1 mmol), formaldehyde (162 mg, 37% aq. solution, 2 mmol), sodium triacetoxyborohydride (612 mg, 2.8 mmol) in 1,2-dichloroethane (15 ml) was stirred at rt for 4 h before being quenched with saturated aq. NaHCO₃ (10 ml). After separation of the organic layer, the aqueous layer was extracted with CH₂Cl₂ (2 x 20 ml). The combined organic layers were washed with water and brine, dried over MgSO₄, and concentrated. The resulting crude product was dissolved in CH₂Cl₂/ether (1:5, 10 ml) and treated with a solution of methanesulfonic acid (96 mg, 1 mmol) in ether (2 ml). The precipitate was collected by filtration to afford trioxolane **OZ232** (230 mg, 55%) as a colorless solid. mp 130 °C dec; ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.25–1.45 (m, 2H), 1.59–2.16 (m, 21H), 2.82 (s, 3H), 2.87 (app t, J = 6.2 Hz, 2H), 2.91 (app d, J = 4.6 Hz, 6H), 10.61 (s, 1H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 26.57, 26.96, 28.20, 32.46, 33.37, 34.84, 36.50, 36.85, 39.25, 44.35, 64.04, 107.55, 111.77. Anal. Calcd for C₂₀H₃₅NO₆S•0.6H₂O: C, 55.92; H, 8.53; N, 3.26. Found: C, 55.71; H, 8.08; N, 3.12.

cis-Adamantane-2-spiro-3'-8'-(5'-methoxycarbonyl-1'H-1',2',4'-triazol-1'-ylmethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ233).

To a suspension of 60% NaH (0.20 g, 5 mmol) in DMF (5 ml) under nitrogen at 0 °C was added a solution of methyl 1*H*-1,2,4-triazole-3-carboxylate (0.64 g, 5 mmol) in DMF (5 ml). The mixture was stirred for 1 h before a solution of the methanesulfonate of **OZ119** (0.93 g, 2.5 mmol) in DMF (5 ml) was added dropwise. The reaction mixture was heated at 55 °C overnight, quenched with water (60 ml), and then extracted with CH₂Cl₂ (3 x 40 ml). The combined extracts were washed

with water and brine, dried over MgSO₄, filtered, and concentrated. The crude product was purified by flash chromatography (silica gel, 33% to 66% ethyl acetate in hexanes) to afford trioxolane **OZ233** (0.27 g, 27%, eluted first) as a colorless solid and trioxolane **OZ234** (0.21 g, 21%, eluted second) as a colorless solid. For **OZ233**: mp 120–122 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.29–1.49 (m, 2H), 1.52–2.16 (m, 21H), 3.99 (s, 3H), 4.50 (d, J = 7.1 Hz, 2H), 7.96 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.64, 27.04, 27.46, 33.59, 34.89, 36.57, 36.94, 37.15, 52.90, 55.75, 108.32, 111.53, 150.78, 158.49, 181.90. Anal. Calcd for C₂₁H₂₉N₃O₅: C, 62.51; H, 7.24; N, 10.41. Found: C, 62.40; H, 7.11; N, 10.51.

5 **cis-Adamantane-2-spiro-3'-8'-(3'-methoxycarbonyl-1'H-1',2',4'-triazol-1'-ylmethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ234).** For the preparation of **OZ234**, see **OZ233**. mp 144–146 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.23–1.41 (m, 2H), 1.52–2.16 (m, 21H), 3.99 (s, 3H), 4.07 (d, J = 7.2 Hz, 2H), 8.08 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.61, 27.00, 27.55, 33.45, 34.87, 36.50, 36.55, 36.89, 52.55, 55.73, 108.07, 111.70, 144.75, 155.30, 160.13. Anal. Calcd for C₂₁H₂₉N₃O₅: C, 62.51; H, 7.24; N, 10.41. Found:

10 15 C, 62.62; H, 7.17; N, 10.52.

10 **cis-Adamantane-2-spiro-3'-8'-(1'H-1',2',4'-triazol-1'-ylmethyl)-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ235).** To a solution of **OZ177** (1.20 g, 3.5 mmol) in ether (10 ml) was added a solution of methanesulfonic acid (0.40 g, 4.2 mmol) in ether (10 ml). The resulting mixture was placed at –20 °C overnight. The solid was collected by filtration and dried in vaccuo to afford trioxolane **OZ235** (1.48 g, 96%) as a colorless solid. mp 139–142 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.26–1.44 (m, 2H), 1.58–2.19 (m, 21H), 2.86 (s, 3H), 4.33 (d, J = 7.1 Hz, 2H), 8.54 (s, 1H), 10.04 (s, 1H), 12.85 (br s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.58, 26.97, 27.29, 33.34, 34.85, 36.21, 36.51, 36.86, 39.65, 56.71, 107.92, 111.69, 142.30, 144.05. Anal. Calcd for C₂₀H₃₁N₃O₆S: C, 54.40; H, 7.08; N, 9.52. Found: C, 54.28; H, 6.92; N, 9.33.

20 25

20 **cis-Adamantane-2-spiro-3'-8'-[bis(2'-amino-2'-oxoethyl)amino]methyl-1',2',4'-trioxaspiro[4.5]decane (OZ236).** A mixture of **cis-adamantane-2-spiro-3'-8'-aminomethyl-1',2',4'-trioxaspiro[4.5]decane** (293 mg, 1 mmol), 2-bromoacetamide (138 mg, 1 mmol), and potassium carbonate (276 mg, 2 mmol) in acetonitrile (18 ml) was heated at 50 °C for 16 h before being diluted with water (25 ml). The resulting mixture was extracted with chloroform (3 x 18 ml). The combined extracts were washed with water and

brine, dried over MgSO₄, and concentrated. The crude product was purified by flash chromatography (silica gel, 18% methanol in CH₂Cl₂) and by recrystallization from CHCl₃ to afford trioxolane **OZ236** (180 mg, 44%) as a colorless solid. mp 157–159°C (CHCl₃); ¹H NMR (500 MHz, DMSO-*d*₆) δ 0.89–1.16 (m, 2H), 1.38–2.09 (m, 21H), 2.25 (d, J = 7.1 Hz, 2H), 2.97 (s, 4H), 7.13 (s, 2H), 7.50 (s, 2H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 25.96, 26.36, 28.13, 33.51, 33.54, 34.40, 34.42, 35.92, 36.25, 59.21, 61.26, 108.90, 110.57, 172.79. Anal. Calcd for C₂₁H₃₃N₃O₅: C, 61.90; H, 8.16; N, 10.31. Found: C, 62.04; H, 7.91; N, 10.12.

cis-Adamantane-2-spiro-3'-8'-[[(aminoiminomethyl)amino]methyl]-1',2',4'-trioxaspiro[4.5]decane hydrochloride (OZ237). A mixture of *cis*-adamantane-2-spiro-3'-8'-aminomethyl-1',2',4'-trioxaspiro[4.5]decane (293 mg, 1 mmol), 1*H*-pyrazole-1-carboxamidine hydrochloride (147 mg, 1 mmol), *N,N*-diisopropylethylamine (129 mg, 1 mmol) in DMF (5 ml) was stirred at rt for 16 h before being diluted with ether (50 ml). The solid was collected by filtration and recrystallized from 30% aq. ethanol to afford

trioxolane **OZ237** (210 mg, 56%) as a colorless solid. mp 146–149°C (30% aq. ethanol); ¹H NMR (500 MHz, DMSO-*d*₆) δ 0.99–1.21 (m, 2H), 1.39–2.05 (m, 21H), 2.98 (app t, J = 6.0 Hz, 2H), 6.50–7.89 (m, 5H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 25.86, 26.27, 27.00, 33.05, 34.31, 35.28, 35.83, 36.14, 45.59, 108.41, 110.61, 157.17. Anal. Calcd for C₁₈H₃₀ClN₃O₃: C, 58.13; H, 8.13; N, 11.30. Found: C, 58.31; H, 8.27; N, 10.96.

cis-Adamantane-2-spiro-3'-8'-(2'-amino-2'-oxoethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ243). To a solution of **OZ78** (322 mg, 1 mmol) in CH₂Cl₂ (10 ml) at 0°C was added TEA (202 mg, 2 mmol) followed by ethyl chloroformate (217 mg, 2 mmol). After 15 min, ammonia (7 N in methanol, 3 ml) was added, and the stirring was continued for 12 h. The precipitate was filtered and dried to afford trioxolane **OZ243** (210 mg, 65%) as a colorless solid. mp 140–142°C; ¹H NMR (500 MHz, CDCl₃) δ 1.09–1.43 (m, 3H), 1.45–2.15 (m, 20H), 2.11 (d, J = 7.1 Hz, 2H), 5.48 (s, 1H), 5.66 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.47, 26.85, 29.97, 33.32, 33.95, 34.77, 36.38, 36.78, 42.55, 108.50, 111.35, 174.39. Anal. Calcd for C₁₈H₂₇NO₄: C, 67.26; H, 8.47; N, 4.36. Found: C, 67.40; H, 8.47; N, 4.39.

cis-Adamantane-2-spiro-3'-8'-[[(4'-phenyl-1'-piperazinyl)carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ244). To a solution of **OZ78** (322 mg, 1 mmol) in

CH_2Cl_2 (10 ml) at 0 °C was added TEA (202mg, 2mmol) followed by ethyl chloroformate (217 mg, 2 mmol). After 15 min, 1-phenylpiperazine (162 mg, 1 mmol) was added, and the stirring was continued for 12 h. The reaction mixture was concentrated, diluted with water, and filtered. The crude product was purified by recrystallization from ethanol to give 5 trioxolane **OZ244** (280 mg, 60%) as a colorless solid. mp 140–142°C (ethanol); ^1H NMR (500 MHz, CDCl_3) δ 1.18–1.38 (m, 2H), 1.55–2.18 (m, 21H), 2.26 (d, J = 6.9 Hz, 2H), 3.02–3.29 (m, 4H), 3.55–3.70 (m, 2H), 3.71–3.89 (m, 2H), 6.81–7.02 (m, 3H), 7.20–7.38 (m, 2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.48, 26.86, 30.30, 33.34, 34.06, 34.78, 36.39, 36.79, 39.18, 41.51, 45.69, 49.47, 49.77, 108.59, 111.33, 116.58, 120.51, 129.22, 150.91, 10 170.50. Anal. Calcd for $\text{C}_{28}\text{H}_{38}\text{N}_2\text{O}_4$: C, 72.07; H, 8.21; N, 6.00. Found: C, 72.22; H, 8.16; N, 5.99.

Adamantane-2-spiro-3'-8'-hydroxy-8'-(2'-thiazolyl)-1',2',4'-trioxaspiro[4.5]decane (OZ247). To a stirred solution of 2-bromothiazole (246 mg, 1.5 mmol) in dry THF (4 ml) under N_2 at –78 °C was added *n*-BuLi (1.6 M in hexanes, 1 ml, 1.5 mmol). The resulting bright yellow solution was stirred for 1 h at the same temperature, and then a solution of **OZ05** (415 mg, 1.5 mmol) in dry THF (10 ml) was added. The 15 mixture was allowed to reach 0°C, poured into ice-water mixture (15 ml), and extracted with ether (3 x 25 ml). The combined organic extracts were washed with brine (25 ml), dried over MgSO_4 , and concentrated. The crude product was purified by flash chromatography (silica gel, 10% EtOAc in hexanes) followed by recrystallization from hexanes/ether (9:1) to afford trioxolane **OZ247** (202 mg, 37%, 1:1 mixture of 2 diastereomers) as a colorless solid. mp 64–66°C (hexanes/ether 9:1); ^1H NMR (500 MHz, CDCl_3) δ 1.60–2.42 (m, 22H), 3.18 (s, 0.5H), 3.40 (s, 0.5H), 7.28 (d, J = 3.0 Hz, 0.5H), 7.30 (d, J = 3.0 Hz, 0.5H), 7.69 (d, J = 3.3 Hz, 0.5H), 7.72 (d, J = 3.0 Hz, 0.5H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.45, 26.46, 26.85, 29.98, 30.09, 34.73, 34.77, 34.79, 34.86, 36.34, 25 36.40, 36.48, 36.75, 36.77, 72.44, 73.00, 107.91, 107.97, 111.61, 111.84, 119.02, 141.95, 142.16, 177.99, 178.23. Anal. Calcd for $\text{C}_{19}\text{H}_{25}\text{NO}_4\text{S}$: C, 62.78; H, 6.93; N, 3.85. Found: C, 62.94; H, 7.01; N, 3.89.

cis-Adamantane-2-spiro-3'-8'-(1'H-imidazol-2'-yl)-1',2',4'-trioxaspiro[4.5]decane (OZ251). Step 1. To a solution of oxalyl chloride (0.99 g, 7.8 mmol) in CH_2Cl_2 (50 ml) at –78°C was added methyl sulfoxide (1.41 g, 18 mmol)

dropwise. The mixture was stirred at -78°C for 30 min before **OZ119** (1.76 g, 6 mmol) in CH₂Cl₂ (5 ml) was added. After the resulting mixture was stirred for 45 min, triethylamine (3.03 g, 30 mmol) was added. The mixture was warmed to rt for 2 h and quenched with water (50 ml). The organic layer was washed with water (2 x 30 ml) and brine, dried over MgSO₄, and concentrated. The crude product (1.80 g) was crystallized from 50% ethanol to afford the desired aldehyde, **cis-Adamantane-2-spiro-3'-8'-formyl-1',2',4'-trioxaspiro[4.5]decane**, (0.82 g, 47%) as a colorless solid. mp 74–76 °C (50% ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.64–2.02 (m, 22 H), 2.20–2.30 (m, 1 H), 9.63 (d, J = 1.1 Hz, 1H). **Step 2.** To a solution of the above aldehyde (292 mg, 1mmol) and 40 % glyoxal (145 mg, 1 mmol) in methanol (12 ml) at 0°C was added ammonia (0.45 ml, 7 N in methanol). The resulting mixture was stirred at rt overnight and concentrated. The crude product was crystallized from hexanes/CH₂Cl₂ (3:2) to afford trioxolane **OZ251** (240 mg, 73%) as a colorless solid. mp 138–140°C (hexanes/CH₂Cl₂, 3:2); ¹H NMR (500 MHz, CDCl₃) δ 1.58–2.23 (m, 22H), 2.75–2.98 (m, 1H), 6.96 (s, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.54, 26.94, 29.11, 33.92, 34.82, 34.86, 36.23, 36.47, 36.84, 108.00, 111.54, 121.10 (br s), 151.00. Anal. Calcd for C₁₉H₂₆N₂O₃: C, 69.06; H, 7.93; N, 8.48. Found: C, 69.04; H, 7.93; N, 8.60.

cis-Adamantane-2-spiro-3'-8'-(2'-thiazolylamino)methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ252). A mixture of **cis-Adamantane-2-spiro-3'-8'-formyl-1',2',4'-trioxaspiro[4.5]decane** (292 mg, 1.0 mmol), 2-aminothiazole (150 mg, 1.5 mmol), and acetic acid (240 mg, 4.0 mmol) in CH₂Cl₂ (10 ml) and ClCH₂CH₂Cl (10 ml) was stirred at rt for 2.5 h before sodium triacetoxyborohydride (422 mg, 2.0 mmol) was added. The resulting mixture was stirred at rt overnight and then quenched with saturated aq. NaHCO₃ (50 ml). The organic layer was separated and washed with water and brine, dried over MgSO₄, and concentrated. The crude prude was purified by flash chromatography (silica gel, 2% CH₃OH in CH₂Cl₂). The enriched product was dissolved in ether/CH₂Cl₂ (4:1, 20 ml), treated with methanesulfonic acid (40 mg, 0.4 mmol), and placed at -20°C overnight. After the solvent was decanted, the residue was washed with ether and dried in vacuo to afford trioxolane **OZ252** (110 mg, 23%) as a colorless solid. mp 136–138°C; ¹H NMR (500 MHz, CDCl₃) δ 1.20–1.41 (m, 2H), 1.50–2.21 (m, 21H), 2.88 (s, 3H), 3.11 (app t, J = 6.1 Hz, 2H), 6.54 (d, J = 4.1 Hz, 1H), 7.05 (d, J = 4.1 Hz, 1H), 10.51 (s, 1H), 14.17

(s, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.46, 26.84, 27.88, 33.44, 34.77, 35.66, 36.38, 36.76, 39.45, 54.26, 104.97, 108.18, 111.57, 127.14, 170.79. Anal. Calcd for $\text{C}_{21}\text{H}_{32}\text{N}_2\text{O}_6\text{S}_2$: C, 53.37; H, 6.82; N, 5.93. Found: C, 53.16; H, 6.76; N, 5.91.

cis-Adamantane-2-spiro-3'-8'-(cyclopropylamino)methyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ253).

To a solution **cis-adamantane-2-spiro-3'-8'-formyl-1',2',4'-trioxaspiro[4.5]decane** (292 mg, 1.0 mmol), cyclopropylamine (57 mg, 1.0 mmol), and acetic acid (90 mg, 1.5 mmol) in 1,2-dichloroethane (10 ml) was added sodium triacetoxyborohydride (295 mg, 1.4 mmol). The mixture was stirred for 2 h and then quenched with saturated aq. NaHCO_3 (20 ml). The organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 (2 x 20 ml). The combined organic extracts were washed with water and brine, dried over MgSO_4 , and concentrated. The crude product was purified by flash chromatography (silica gel, 20% ether in hexanes, 400 ml; then 10% methanol in CH_2Cl_2 , 300 ml) to give two fractions. The first fraction (130 mg) was crystallized from $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$ (6:1) to afford trioxolane **OZ254** (96 mg, 31%) as a colorless solid. The second fraction (160 mg) was dissolved in ether (3 ml) and treated with a solution of methanesulfonic acid (46 mg) in ether (3 ml). The precipitate was collected by filtration and dried in vacuo to afford trioxolane **OZ253** (160 mg, 37%) as a colorless solid. For **OZ253**: mp 144–147°C (ether); ^1H NMR (500 MHz, CDCl_3) δ 0.77–0.95 (m, 2H), 1.10–1.22 (m, 2H), 1.23–1.41 (m, 2H), 1.50–2.19 (m, 21H), 2.50–2.69 (m, 1H), 2.73 (s, 3H), 2.82–3.02 (m, 2H), 8.63 (s, 2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 3.70, 26.46, 26.86, 27.89, 31.23, 33.10, 33.43, 34.77, 36.38, 36.77, 39.51, 54.07, 107.97, 111.50. Anal. Calcd for $\text{C}_{21}\text{H}_{35}\text{NO}_6\text{S}$: C, 58.72; H, 8.21; N, 3.26. Found: C, 58.65; H, 8.15; N, 3.35.

N,N-Bis(cis-adamantane-2-spiro-3'-1',2',4'-trioxaspiro[4.5]decane-8'-methyl)cyclopropylamine (OZ254). For the preparation of trioxolane **OZ254**, see **OZ253**.

mp 138–140°C ($\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$ 6:1); ^1H NMR (500 MHz, CDCl_3) δ 0.22–0.35 (m, 2H), 0.36–0.48 (m, 2H), 0.97–1.15 (m, 4H), 1.45–2.15 (m, 43H), 2.28 (d, J = 7.1 Hz, 4H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 6.80, 26.52, 26.92, 28.68, 34.09, 34.43, 34.80, 34.82, 36.42, 36.85, 38.74, 63.12, 109.31, 111.15. Anal. Calcd for $\text{C}_{37}\text{H}_{55}\text{NO}_6$: C, 72.87; H, 9.09; N, 2.30. Found: C, 72.83; H, 8.95; N, 2.33.

cis-Adamantane-2-spiro-3'-8'-([(4'-pyridinylcarbonyl)amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ255). To a solution of **OZ209** (389 mg, 1.0 mmol) and

triethylamine (0.6 g, 6 mmol) in CH₂Cl₂ (10 ml) at 0 °C was added a solution of isonicotinoyl chloride hydrochloride (267 mg, 1.5 mmol) in CH₂Cl₂ (10 ml). The resulting mixture was stirred at rt overnight before being quenched with water (20 ml). After separation of the organic phase, the aqueous layer was extracted with CH₂Cl₂ (20 ml). The combined organic extracts were washed with water and brine, dried over MgSO₄, and concentrated. The crude product was crystallized from 40% aq. ethanol to afford trioxolane OZ255 (410 mg, 103%) as a colorless solid. mp 145–146°C (40% aq. ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.19–1.41 (m, 2H), 1.55–2.19 (m, 21H), 3.34 (app t, J = 6.3 Hz, 2H), 6.36 (br s, 1H), 7.61 (d, J = 4.4 Hz, 2H), 8.75 (br s, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 10 26.46, 26.85, 27.82, 33.71, 34.78, 36.21, 36.38, 36.76, 45.41, 108.46, 111.49, 120.87, 141.70, 150.57, 165.63. Anal. Calcd for C₂₃H₃₀N₂O₄: C, 69.32; H, 7.59; N, 7.03. Found: C, 69.18; H, 7.43; N, 7.04.

cis-Adamantane-2-spiro-3'-8'-[[2'-amino-2'-oxoethyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ256). A mixture of OZ209 (389 mg, 1 mmol) and 15 triethylamine (101 mg, 1 mmol) in acetonitrile (40 ml) was stirred for 15 min before 2-bromoacetamide (138 mg, 1 mmol) and potassium carbonate (276 mg, 2 mmol) were added. The mixture was heated at 50°C for 16 h, then diluted with water (25 ml), and extracted with CH₂Cl₂ (3 x 20 ml). The combined organic extracts were washed with water and brine, dried over MgSO₄, and concentrated. The crude product was purified by flash chromatography (silica gel, 6% CH₃OH in CH₂Cl₂) to afford trioxolane OZ256 (90 mg, 20 26%) as a colorless solid. mp 136–138°C; ¹H NMR (500 MHz, CDCl₃) δ 1.05–1.31 (m, 2H), 1.37–2.19 (m, 22H), 2.49 (d, J = 6.4 Hz, 2H), 3.25 (s, 2H), 5.95 (s, 1H), 7.04 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.43, 26.83, 28.07, 33.86, 34.74, 34.76, 36.35, 36.52, 36.75, 52.52, 55.72, 108.73, 111.31, 174.84. Anal. Calcd for C₁₉H₃₀N₂O₄•0.25H₂O: C, 63.80; H, 8.68; N, 7.83. Found: C, 63.68; H, 8.25; N, 7.82.

cis-Adamantane-2-spiro-3'-8'-[[methanesulfonyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ257). To a solution of OZ209 (389 mg, 1 mmol) and triethylamine (404 mg, 4 mmol) in CH₂Cl₂ (10 ml) at 0°C was added a solution of methanesulfonyl chloride (171 mg, 1.5 mmol) in CH₂Cl₂ (1.5 ml). The mixture was stirred 30 at rt for 16 h, washed with water and brine, dried over MgSO₄, and concentrated. The crude product was purified by flash chromatography (silica gel, 5% CH₃OH in CH₂Cl₂) to afford

trioxolane **OZ257** (290 mg, 78%) as a colorless solid. mp 124–126 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.15–1.33 (m, 2H), 1.45–2.17 (m, 21H), 2.95 (s, 3H), 2.99 (app t, J = 6.7 Hz, 2H), 4.31 (br s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.47, 26.86, 27.55, 33.60, 34.78, 34.79, 36.38, 36.77, 40.36, 48.54, 108.40, 111.50. Anal. Calcd for C₁₈H₂₉NO₅S: C, 58.20; H, 7.87; N, 3.77. Found: C, 58.32; H, 7.74; N, 3.83.

Adamantane-2-spiro-3'-8'-[2'-(7'-chloro-4'-quinolinyl)amino]ethyl]amino]-1',2',4'-trioxaspiro[4.5]decane (OZ258**).** To a stirred solution of **OZ05** (75 mg, 0.27 mmol) in CH₂Cl₂ (5 ml) at rt under N₂ was added *N*²-(7-chloro-4-quinolinyl)-1,2-diaminoethane (176 mg, 0.34 mmol) followed by sodium triacetoxyborohydride (72 mg, 0.34 mmol). The resulting mixture was stirred at rt for 24 h before being poured into water (10 ml). The organic layer was separated, dried, and concentrated. Recrystallization of the crude product from ethanol afforded trioxolane **OZ258** (86 mg, 66%) as a colorless solid. mp 146–148°C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.42–2.21 (m, 23H), 2.55–2.77 (m, 1H), 3.05 (t, J = 5.6 Hz, 2H), 3.34 (br s, 2H), 5.90 (br s, 1H), 6.39 (d, J = 5.2 Hz, 1H), 7.37 (dd, J = 8.8, 1.9 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.96 (d, J = 1.9 Hz, 1H), 8.53 (d, J = 5.2 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.65, 27.08, 30.17, 32.23, 34.86, 35.06, 36.60, 36.94, 42.89, 45.17, 54.43, 99.36, 108.36, 111.80, 121.09, 125.40, 125.46, 128.93, 134.98, 149.20, 150.00, 152.06. Anal. Calcd for C₂₇H₃₄ClN₃O₃: C, 67.00; H, 7.08; N, 8.68. Found: C, 67.18; H, 7.12; N, 8.49.

Adamantane-2-spiro-3'-8'-(3'-pyridinylamino)-1',2',4'-trioxaspiro[4.5]decane (OZ259**).** To afford trioxolane **OZ259** (? mg, 83 %, 1:1 mixture of 2 diastereomers) as a colorless solid. mp 132–134 °C (?); ¹H NMR (500 MHz, CDCl₃) δ 1.42–2.23 (m, 22H), 3.25–3.49 (m, 1H), 3.59–3.83 (m, 1H), 6.82–6.90 (m, 1H), 7.02–7.12 (m, 1H), 7.90–7.96 (m, 1H), 7.98–8.04 (m, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.40, 26.81, 26.83, 29.40, 29.86, 32.16, 32.60, 34.69, 34.72, 34.76, 34.87, 36.29, 36.32, 36.71, 49.54, 49.87, 107.86, 111.60, 111.81, 118.78, 118.85, 123.67, 136.22, 136.45, 138.57, 138.61, 143.06. Anal. Calcd for C₂₁H₂₈N₂O₃: C, 70.76; H, 7.92; N, 7.86. Found: C, 70.88; H, 7.91; N, 7.84.

cis-Adamantane-2-spiro-3'-8'-[3'-(ethoxycarbonyl)propyl]-1',2',4'-trioxaspiro[4.5]decane (OZ260**).** A solution of *O*-methyl 2-adamantanone oxime (895 mg, 5 mmol) and 4-[3-(ethoxycarbonyl)propyl]cyclohexanone (710 mg, 3.35 mmol) in cyclohexane (85 ml) and CH₂Cl₂ (15 ml) was treated with ozone according to the general

procedure. The crude product was purified by flash chromatography (silica gel, 5% ether in petroleum ether) and by subsequent crystallization from ethanol to afford trioxolane **OZ260** (660 mg, 52%) as a colorless solid. mp 52–54°C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.01–1.37 (m, 5H), 1.25 (t, J = 7.1 Hz, 3H), 1.47–2.21 (m, 22H), 2.27 (t, J = 7.6 Hz, 2H), 4.12 (q, J = 7.1 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 14.24, 22.63, 26.51, 26.90, 30.01, 34.19, 34.55, 34.79, 34.81, 35.66, 35.90, 36.41, 36.83, 60.18, 108.99, 111.17, 173.68. Anal. Calcd for C₂₂H₃₄O₅: C, 69.81; H, 9.05. Found: C, 69.82; H, 8.96.

cis-Adamantane-2-spiro-3'-8'-(3'-carboxypropyl)-1',2',4'-trioxaspiro[4.5]decane (OZ261).

To a solution of **OZ260** (250 mg, 0.66 mmol) in 95%

10 ethanol (5 ml) was added 15% NaOH solution (1 ml). The mixture was stirred at 25 °C for 24 h before being concentrated and acidified with 6 M aq. HCl (3 ml). The precipitate was filtered, washed with water, and crystallized from ethanol to give trioxolane **OZ261** (186 mg, 81%) as a colorless solid. mp 156–158°C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.03–1.39 (m, 5H), 1.45–2.20 (m, 22H), 2.27 (t, J = 7.4 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 22.33, 26.50, 26.90, 29.98, 34.06, 34.17, 34.81, 35.55, 35.87, 36.40, 36.83, 108.96, 111.19, 179.14. Anal. Calcd for C₂₀H₃₀O₅: C, 68.54; H, 8.63. Found: C, 68.41; H, 8.49.

cis-Adamantane-2-spiro-3'-8'-(acetylamino)methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ262).

To a solution of **OZ209** (389 mg, 1 mmol) and

20 triethylamine (505 mg, 5 mmol) in CH₂Cl₂ (10 ml) at 0°C was added dropwise a solution of acetyl chloride (140 mg, 1.9 mmol) in CH₂Cl₂ (5 ml). The mixture was stirred at rt for 16 h, washed with water and brine, dried over MgSO₄, and concentrated. The crude product was purified by flash chromatography (silica gel, 5% CH₃OH in CH₂Cl₂) and by crystallization from hexanes/CH₂Cl₂ (3:1) to afford trioxolane **OZ262** (150 mg, 45%) as a colorless solid. mp 102°C dec (hexanes/CH₂Cl₂, 3:1); ¹H NMR (500 MHz, CDCl₃) δ 1.15–1.37 (m, 2H), 1.41–2.09 (m, 21H), 1.98 (s, 3H), 3.11 (app t, J = 6.3 Hz, 2H), 5.52 (br s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 23.34, 26.46, 26.85, 27.72, 33.73, 34.76, 34.77, 36.16, 36.37, 36.77, 44.87, 108.60, 111.38, 170.03. Anal. Calcd for C₁₉H₂₉NO₄: C, 68.03; H, 8.71; N, 4.18. Found: C, 68.26; H, 8.70; N, 4.18.

cis-Adamantane-2-spiro-3'-8'-[[(1'H-imidazol-4'-yl)carbonyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ263).

To a solution of 4-imidazolecarboxylic

acid (134 mg, 1.2 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (290 mg, 1.5 mmol), and 1-hydroxybenzotriazole (200 mg, 1.5 mmol) in DMF (40 ml) under N₂ was added a solution of **OZ209** (389 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in DMF (5 ml). The resulting mixture was stirred at r.t. for 48 h before being
5 quenched with water (120 ml). The mixture was extracted with CH₂Cl₂ (3 x 40 ml). The combined organic extracts were washed with water and brine, dried over MgSO₄, and concentrated. The crude product was dissolved in CH₂Cl₂ (10 ml) and treated with
10 methanesulfonic acid (90 mg). The solid was collected by filtration and recrystallized from ether/CH₂Cl₂/CH₃OH (3:1:1) to afford trioxolane **OZ 263** (72 mg, 15%) as a colorless solid. mp 161–162°C (ether/CH₂Cl₂/CH₃OH 3:1:1); ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.02–1.23 (m, 2H), 1.45–2.09 (m, 21H), 2.32 (s, 3H), 3.13 (app t, J = 6.3 Hz, 2H), 8.12 (s, 1H), 8.73 (br s, 1H), 9.03 (s, 1H), 14.47 (br s, 2H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 25.96, 26.36, 27.64, 33.34, 34.41, 35.77, 35.90, 36.23, 44.06, 108.68, 110.66, 119.91, 120.22, 128.13, 128.22, 135.92, 136.09, 157.40. Anal. Calcd for C₂₂H₃₃N₃O₇S: C, 54.64; H, 6.88; N, 8.69. Found: C, 54.72; H, 6.76; N, 8.90.

cis-Adamantane-2-spiro-3'-8'-[[[(1'-oxido-4'-pyridinyl)carbonyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ264). To a solution of isonicotinic acid *N*-oxide (167 mg, 1.2 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (290 mg, 1.5 mmol), and 1-hydroxybenzotriazole (200 mg, 1.5 mmol) in DMF (10 ml) under N₂ was added a solution of **OZ209** (389 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in DMF (5 ml). The resulting mixture was stirred at rt for 16 h before being quenched with water (50 ml). The precipitate was collected by filtration to afford trioxolane **OZ264** (340 mg, 82 %) as a colorless solid. mp 152–154°C; ¹H NMR (500 MHz, CDCl₃) δ 1.21–1.43 (m, 2H), 1.49–2.11 (m, 21H), 3.33 (app t, J = 6.2 Hz, 2H), 6.54 (br s, 1H), 7.69 (d, J = 6.3 Hz, 2H), 8.20 (d, J = 6.0 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.44, 26.84, 27.82, 33.69, 34.77, 36.18, 36.37, 36.75, 45.56, 108.43, 111.52, 124.32, 131.08, 139.29, 163.52. Anal. Calcd for C₂₃H₃₀N₂O₅: C, 66.65; H, 7.30; N, 6.76. Found: C, 66.81; H, 7.18; N, 6.55.

cis-Adamantane-2-spiro-3'-8'-[[[(aminocarbonyl)amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ265). A mixture of **OZ209** (389 mg, 1 mmol), pyridine (790 mg, 10 mmol), acetic acid (600 mg, 10 mmol), triethylamine (303 mg, 3 mmol), and

potassium cyanate (164 mg, 2 mmol) in CH₂Cl₂ (10 ml) was stirred at r.t. for 38 h. The mixture was then washed with water and brine, dried over MgSO₄, and concentrated. The crude product was recrystallized from 40% aq. ethanol to afford trioxolane **OZ265** (250 mg, 74%) as a colorless solid. mp 138–140 °C (40% aq. ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.11–1.33 (m, 2H), 1.41–2.18 (m, 21H), 3.02 (app t, J = 5.5 Hz, 2H), 4.64 (br s, 2H), 5.09 (br s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.45, 26.84, 27.66, 33.75, 34.76, 36.36, 36.65, 36.76, 45.85 (br s), 108.69, 111.35, 158.96. Anal. Calcd for C₁₈H₂₈N₂O₄: C, 64.26; H, 8.39; N, 8.33. Found: C, 64.40; H, 8.15; N, 8.46.

cis-Adamantane-2-spiro-3'-8'-[[[(dimethylamino)carbonyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ266). To a solution of **OZ209** (389 mg, 1.0 mmol) and triethylamine (202 mg, 2.0 mmol) in CH₂Cl₂ (10 ml) at 0°C was added dimethylcarbamoyl chloride (120 mg, 1.1 mmol). The mixture was stirred at rt for 16 h before being washed with water and brine, dried over MgSO₄, and concentrated. The crude product was crystallized from 50% aq. ethanol to afford trioxolane **OZ266** (270 mg, 74%) as a colorless solid. mp 153–155°C (50% aq. ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.14–1.33 (m, 2H), 1.44–2.17 (m, 21H), 2.91 (s, 6H), 3.09 (app t, J = 6.2 Hz, 2H), 4.46 (br s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.49, 26.88, 27.77, 33.84, 34.79, 36.19, 36.39, 36.61, 36.80, 46.25, 108.85, 111.30, 158.43. Anal. Calcd for C₂₀H₃₂N₂O₄: C, 65.91; H, 8.85; N, 7.69. Found: C, 66.16; H, 8.80; N, 7.90.

cis-Adamantane-2-spiro-3'-8'-[[[(4'-methyl-1'-piperazinyl)carbonyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ267). To a solution of **OZ209** (389 mg, 1.0 mmol) and triethylamine (404 mg, 4.0 mmol) in CH₂Cl₂ (10 ml) at 0°C was added 4-methyl-1-piperazinecarbonyl chloride hydrochloride (240 mg, 1.2 mmol). The mixture was stirred at rt for 16 h before being washed with water and brine, dried over MgSO₄, and concentrated. The crude product was crystallized from 60% aq. ethanol to afford trioxolane **OZ267** (280 mg, 67%) as a colorless solid. mp 82°C dec (60% aq. ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.11–1.30 (m, 2H), 1.43–2.15 (m, 21H), 2.31 (s, 3H), 2.39 (t, J = 5.1 Hz, 4H), 3.09 (app t, J = 6.2 Hz, 2H), 3.38 (t, J = 5.1 Hz, 4H), 4.59 (app t, J = 5.5 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.45, 26.84, 27.77, 33.78, 34.76, 36.35, 36.48, 36.76, 43.71, 46.08, 46.18, 54.64, 108.77, 111.29, 157.69. Anal. Calcd for C₂₃H₃₇N₃O₄: C, 65.84; H, 8.89; N, 10.02. Found: C, 65.91; H, 8.64; N, 10.07.

N-(cis-Adamantane-2-spiro-3'-1',2',4'-trioxaspiro[4.5]decane-8'-methyl)oxamide (OZ268). To a solution of oxamic acid (107 mg, 1.2 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (290 mg, 1.5 mmol), and 1-hydroxybenzotriazole (200 mg, 1.5 mmol) in DMF (15 ml) under N₂ was added a solution of **OZ209** (389 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in DMF (5 ml). The resulting mixture was stirred at rt for 16 h before being quenched with water (80 ml). The precipitate was collected by filtration to afford trioxolane **OZ268** (320 mg, 88%) as a colorless solid. mp 152–155 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 0.95–1.23 (m, 2H), 1.39–2.13 (m, 21H), 2.97 (app t, J = 6.5 Hz, 2H), 7.74 (s, 1H), 7.80 (s, 1H), 8.67 (app t, J = 6.2 Hz, 1H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 25.97, 26.38, 27.55, 33.30, 34.41, 35.47, 35.91, 36.25, 44.03, 108.70, 110.62, 160.50, 162.38. Anal. Calcd for C₁₉H₂₈N₂O₅: C, 62.62; H, 7.74; N, 7.69. Found: C, 62.80; H, 7.55; N, 7.89.

trans-Adamantane-2-spiro-3'-8'-(aminomethyl)-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ269). A mixture of **OZ167** (2.54 g, 6.0 mmol) and hydrazine monohydrate (1.80 g, 36.0 mmol) in chloroform/ethanol (7:3, 60 ml) was heated at 55–65°C for 24 h. After being cooled to rt, the solid byproduct was filtered off and the filtrate was washed with water (2 x 40 ml) and brine (20 ml). The combined aqueous layers were extracted with CH₂Cl₂ (3 x 30 ml). The CH₂Cl₂ extracts were washed with water (50 ml) and brine (50 ml). The combined organic solutions were dried over MgSO₄ and concentrated. The residue was dissolved in CH₂Cl₂ (10 ml) and treated with a solution of methanesulfonic acid (0.6 g) in CH₂Cl₂ (2 ml). The product was precipitated by addition of ether (40 ml) and collected by filtration to afford trioxolane **OZ269** (1.80 g, 77%) as a colorless solid. mp 140–141°C; ¹H NMR (500 MHz, CDCl₃) δ 1.32–1.52 (m, 2H), 1.54–2.15 (m, 21H), 2.76 (s, 3H), 2.87 (app t, J = 6.3 Hz, 2H), 7.60 (s, 3H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.44, 26.86, 27.24, 33.23, 34.56, 34.71, 34.90, 36.33, 36.74, 39.29, 44.63, 108.06, 111.81. Anal. Calcd for C₁₈H₃₁NO₆S•0.4H₂O: C, 53.84; H, 8.12; N, 3.49. Found: C, 53.51; H, 7.64; N, 3.66.

cis-Adamantane-2-spiro-3'-8'-[[(aminoacetyl)amino]methyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ271). To a solution of *N*-phthaloylglycine (226 mg, 1.1 mmol), EDCI (290 mg, 1.5 mmol), and HOBr (200 mg, 1.5 mmol) in DMF (30 ml) under N₂ was added a solution of **OZ209** (*cis*-Adamantane-2-spiro-3'-8'-(aminomethyl)-

1',2',4'-trioxaspiro[4.5]decane mesylate) (389 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in DMF (5 ml). The resulting mixture was stirred at rt for 16 h before being quenched with water (80 ml). The precipitate was collected by filtration to afford **cis-adamantane-2-spiro-3'-8'-[(2-phthalimidoacetyl)amino]methyl]-1',2',4'-trioxaspiro[4.5]decane** (426 mg, 89%) as a colorless solid. mp 139–142°C; ¹H NMR (500 MHz, CDCl₃) δ 1.15–1.30 (m, 2H), 1.50–2.00 (m, 21H), 3.14 (t, J = 6.6 Hz, 2H), 4.33 (s, 2H), 7.72–7.77 (m, 2H), 7.85–7.90 (m, 2H). **Step 2.** A mixture of **cis-adamantane-2-spiro-3'-8'-[(2-phthalimidoacetyl)amino]methyl]-1',2',4'-trioxaspiro[4.5]decane** (420 mg, 0.88 mmol) and hydrazine monohydrate (300 mg, 5.36 mmol) in chloroform/ethanol (7:3, 10 ml) was heated at 55–60°C for 24 h. After the mixture was cooled to rt, the solid byproduct was filtered off. The filtrate was washed with water (2 x 10 ml) and brine (10 ml), dried over MgSO₄, and concentrated. The residue was dissolved in CH₂Cl₂/ether (1:4, 10 ml) and treated with methanesulfonic acid (77 mg, 0.8 mmol). The precipitate was collected by filtration to afford trioxolane **OZ271** (260 mg, 66%) as a colorless solid. mp 153°C dec; ¹H NMR (500 MHz, DMSO-d₆) δ 1.01–1.19 (m, 2H), 1.38–2.11 (m, 21H), 2.32 (s, 3H), 3.00 (app t, J = 5.8 Hz, 2H), 3.54 (d, J = 4.9 Hz, 2H), 7.94 (s, 3H), 8.31 (t, J = 5.2 Hz, 1H); ¹³C NMR (125.7 MHz, DMSO-d₆) δ 25.96, 26.37, 27.52, 33.35, 34.42, 35.71, 35.91, 36.24, 40.28, 43.96, 108.65, 110.68, 165.95. Anal. Calcd for C₂₀H₃₄N₂O₇S: C, 53.79; H, 7.67; N, 6.27. Found: C, 53.60; H, 7.46; N, 6.10.

cis-Adamantane-2-spiro-3'-8'-[(4'-morpholinylcarbonyl)amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ272). To a solution of **OZ209** (*cis*-Adamantane-2-spiro-3'-8'-(aminomethyl)-1',2',4'-trioxaspiro[4.5]decane mesylate) (389 mg, 1.0 mmol) and triethylamine (404 mg, 4.0 mmol) in CH₂Cl₂ (10 ml) at 0°C was added 4-morpholinecarbonyl chloride (225 mg, 1.5 mmol). The mixture was stirred at rt for 16 h, washed with water and brine, dried over MgSO₄, and concentrated. The crude product was crystallized from hexanes/ether (4:1) to afford trioxolane **OZ272** (290 mg, 71%) as a colorless solid. mp 141–142°C (hexanes/ether, 4:1); ¹H NMR (500 MHz, CDCl₃) δ 1.06–1.35 (m, 2H), 1.42–2.18 (m, 21H), 3.11 (app t, J = 5.9 Hz, 2H), 3.33 (t, J = 4.8 Hz, 4H), 3.69 (t, J = 4.9 Hz, 4H), 4.54 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.48, 26.87, 27.78, 33.80, 34.79, 36.38, 36.51, 36.79, 44.02, 46.17, 66.46, 108.75, 111.36, 157.83. Anal. Calcd for C₂₂H₃₄N₂O₅: C, 65.00; H, 8.43; N, 6.89. Found: C, 64.84; H, 8.42; N, 6.91.

cis-Adamantane-2-spiro-3'-8'-[[[3'-pyridinylcarbonyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ273). To a solution of **cis-adamantane-2-spiro-3'-8'-aminomethyl-1',2',4'-trioxaspiro[4.5]decane** (360 mg, 1.2 mmol) and triethylamine (370 mg, 3.6 mmol) in CH₂Cl₂ (12 ml) at 0°C was added nicotinoyl chloride (278 mg, 1.56 mmol). The mixture was stirred at rt for 16 h, washed with water and brine, dried over MgSO₄, and concentrated. The crude product was purified by flash chromatography (silica gel, 2% MeOH in CH₂Cl₂) to afford trioxolane **OZ273** (240 mg, 60%) as a colorless solid. mp 70–72 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.18–1.42 (m, 2H), 1.49–2.21 (m, 21H), 3.35 (app t, J = 6.3 Hz, 2H), 6.39 (s, 1H), 7.37–7.48 (m, 1H), 8.11 (d, J = 8.0 Hz, 1H), 8.73 (s, 1H), 8.96 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.45, 26.85, 27.84, 33.72, 34.77, 36.26, 36.37, 36.76, 45.38, 108.51, 111.44, 123.52, 130.35, 135.09, 147.71, 152.20, 165.68. Anal. Calcd for C₂₃H₃₀N₂O₄: C, 69.32; H, 7.59; N, 7.03. Found: C, 69.29; H, 7.56; N, 7.01.

Adamantane-2-spiro-3'-8'-fluoro-8'-phenyl-1',2',4'-trioxaspiro[4.5]decane (OZ274). To a stirred solution of phenyl carbinol (178 mg, 0.5 mmol), obtained by addition of phenyllithium to **OZ05** (Adamantane-2-spiro-3'-8'-oxo-1',2',4'-trioxaspiro[4.5]decane), in dry CH₂Cl₂ (5 ml) under N₂ at –78 °C was added DAST (88 mg, 0.55 mmol). The reaction mixture was stirred at –78 °C for 1.5 h and poured into ice water (5 ml). The organic layer was separated, and the aqueous layer was then extracted with CH₂Cl₂ (3 x 5 ml). The combined organic extracts were washed with water (10 ml), dried over MgSO₄, and concentrated. The purification of the crude product by flash chromatography (silica gel, 1% ether in hexanes) followed by recrystallization from 5% ether in hexanes afforded trioxolane **OZ274** (97 mg, 54%) as a colorless solid. mp 94–96°C; ¹H NMR (500 MHz, CDCl₃) δ 1.58–2.43 (m, 22H), 7.21–7.58 (m, 5H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.47, 26.92, 30.14 (d, J = 2.3 Hz), 34.74, 34.95 (d, J = 23.4 Hz), 35.03, 36.39, 36.77, 95.09 (d, J = 174.9 Hz), 107.82, 111.82, 123.92 (d, 9.6 Hz), 127.55 (d, J = 1.4 Hz), 128.31 (d, J = 1.4 Hz), 144.29 (d, J = 21.5 Hz). Anal. Calcd for C₂₂H₂₇FO₃: C, 73.72; H, 7.59. Found: C, 73.90; H, 7.47.

Adamantane-2-spiro-3'-8'-hydroxy-8'-(2'-pyridinylmethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ275). To a stirred solution of 2-picoline (279 mg, 3.0 mmol) in dry THF (10 ml) under N₂ at –78 °C was added *n*-BuLi (1.6 M in hexanes, 1.9 ml, 3.0

mmol). The resulting bright yellow solution was stirred at the same temperature for 1 h before a solution of **OZ05** (690 mg, 2.5 mmol) in dry THF (15 ml) was added slowly. The mixture was allowed to reach 0°C, and then poured into ice water (50 ml), and extracted with ether (3 x 50 ml). The combined organic extracts were washed with brine (50 ml), dried over MgSO₄, and concentrated. The purification of the crude product by flash chromatography (silica gel, 70% EtOAc in hexanes) followed by recrystallization from ethanol afforded trioxolane **OZ275** (385 mg, 41%) as a colorless solid. mp 128–130°C; ¹H NMR (500 MHz, CDCl₃) δ 1.41–2.25 (m, 22H), 2.88 (s, 2H), 5.82 (s, 1H), 7.11 (d, J = 7.7 Hz, 1H), 7.17 (dd, J = 7.3, 4.6 Hz, 1H), 7.63 (ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 8.49 (d, J = 4.1 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.51, 26.89, 29.93, 34.80, 35.03, 36.43, 36.83, 47.30, 70.09, 109.01, 111.30, 121.53, 124.42, 136.89, 148.40, 159.55. Anal. Calcd for C₂₂H₂₉NO₄: C, 71.13; H, 7.87; N, 3.77. Found: C, 71.31; H, 7.94; N, 3.93.

Adamantane-2-spiro-3'-8'-hydroxy-8'-(2'-benzothiazolylmethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ276). To a stirred solution of 2-methylbenzothiazole (244 mg, 1.6 mmol) in dry THF (4 ml) under N₂ at –78 °C was added *n*-BuLi (1.6 M in hexanes, 1.1 ml, 1.8 mmol). The resulting bright yellow solution was stirred at the same temperature for 1 h before a solution of **OZ05** (500 mg, 1.8 mmol) in dry THF (10 ml) was added slowly. The mixture was allowed to reach 0°C, and then poured into ice water (15 ml), and extracted with ether (3 x 25 ml). The combined organic extracts were washed with brine (25 ml), dried over MgSO₄, and concentrated. The purification of the crude product by flash chromatography (silica gel, 30% EtOAc in hexanes) followed by recrystallization (ether/hexane 1:1) afforded trioxolane **OZ276** (353 mg, 52%) as a colorless solid. mp 130–132°C; ¹H NMR (500 MHz, CDCl₃) δ 1.58–2.29 (m, 22H), 3.19 (s, 2H), 4.28 (br s, 1H), 7.31–7.43 (m, 1H), 7.44–7.53 (m, 1H), 7.86 (d, J = 7.7 Hz, 1H), 7.99 (d, J = 8.2 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.49, 26.88, 29.87, 34.71, 34.79, 34.80, 36.41, 36.80, 44.92, 70.19, 108.63, 111.47, 121.44, 122.70, 125.06, 126.17, 134.35, 152.98, 168.22. Anal. Calcd for C₂₄H₂₉NO₄S: C, 67.42; H, 6.84; N, 3.28. Found: C, 67.70; H, 6.76; N, 3.23.

cis-Adamantane-2-spiro-3'-8'-[[[(2'-amino-2'-methylpropyl)amino]carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane p-tosylate (OZ277). Step 1. A solution of **OZ78** (*cis*-Adamantane-2-spiro-3'-8'-carboxymethyl-

1',2',4'-trioxaspiro[4.5]decane) (12.92 g, 40 mmol), HOEt (6.49 g, 48 mmol), and EDCI (9.20 g, 48 mmol) in DMF (300 ml) under N₂ was stirred at rt for 24 h. Under ice cooling, the reaction was quenched with water (150 ml). The precipitate was collected by filtration, washed with 95% ethanol (150 ml), and dried to afford the **OZ78** active ester (16.61 g, 95%) as a colorless solid. mp 154–156 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.37–1.51 (m, 2H), 1.63–2.17 (m, 21H), 2.72 (d, J = 7.1 Hz, 2H), 7.39 (d, J = 78.5 Hz, 1H), 7.43 (dd, J = 8.2, 7.2 Hz, 1H), 7.56 (dd, J = 8.0, 7.4 Hz, 1H), 8.07 (d, J = 8.5 Hz, 1H). **Step 2.** To a solution of the **OZ78** active ester (13.19 g, 30 mmol) in CHCl₃ (300 ml) was added rapidly a solution of 1,2-diamino-2-methylpropane (5.29 g, 60 mmol) in CHCl₃ (50 ml). The resulting mixture was stirred at rt for 1 h before being quenched with water (500 ml). After separation of the organic layer, the aqueous layer was extracted with CHCl₃ (2 × 100 ml). The combined extracts were washed with water (3 × 500 ml) and brine (300 ml), dried over MgSO₄, and filtered. To the filtrate was added a solution of *p*-toluenesulfonic acid monohydrate (5.71 g, 30 mmol) in ethanol (30 ml). After evaporation of the solvents, the residue was treated with ethanol (100 ml), filtered, and washed with hexanes (200 ml) to afford trioxolane **OZ277** (14.25 g, 84%) as a colorless solid. mp 160–162°C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.01–1.17 (m, 2H), 1.16 (s, 6H), 1.58–1.99 (m, 21H), 2.05 (d, J = 7.1 Hz, 2H), 2.28 (s, 3H), 3.19 (d, J = 6.3 Hz, 2H), 7.11 (d, J = 8.0 Hz, 2H), 7.48 (d, J = 8.0 Hz, 2H), 7.70 (s, 3H), 8.02 (t, J = 6.2 Hz, 1H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 20.92, 23.47, 25.96, 26.36, 29.68, 32.71, 33.56, 34.40, 35.91, 36.23, 41.97, 46.02, 54.52, 108.52, 110.63, 125.64, 128.20, 137.80, 145.82, 172.49. Anal. Calcd for C₂₉H₄₄N₂O₇S: C, 61.68; H, 7.85; N, 4.96. Found: C, 61.46; H, 7.67; N, 4.76.

cis-Adamantane-2-spiro-3'-8'-[[[1'H-tetrazol-5'-ylamino)carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ278). To a solution of **OZ78** (322 mg, 1.0 mmol), 5-aminotetrazole (103 mg, 1.0 mmol), and 4-methylmorpholine (304 mg, 3 mmol) in DMF (10 ml) at 0°C was added benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (531 mg, 1.2 mmol). The resulting mixture was stirred at rt for 3 days and filtered. After the filtrate was concentrated, the residue was crystallized from 40% aq. ethanol followed by recrystallization from CH₂Cl₂ to afford trioxolane **OZ278** (68 mg, 17%) as a colorless solid. mp 150–152°C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.01–1.23 (m, 2H), 1.41–2.07 (m, 21H), 2.35 (d, J = 6.9 Hz, 2H), 11.94 (s, 1H), 15.82 (s, 1H); ¹³C NMR

(125.7 MHz, DMSO-*d*₆) δ 25.95, 26.36, 29.53, 32.80, 33.50, 34.40, 35.90, 36.23, 41.51, 108.40, 110.68, 149.95, 171.13. Anal. Calcd for C₁₉H₂₇N₅O₄: C, 58.60; H, 6.99; N, 17.98. Found: C, 58.76; H, 7.05; N, 18.14.

***cis*-Adamantane-2-spiro-3'-8'-(1'-piperazinylcarbonyl)methyl]-1',2',4'-trioxaspiro[4.5]decane *p*-tosylate (OZ279).**

To a solution of the **OZ78** active ester (13.19 g, 30 mmol) in CHCl₃ (300 ml) was added rapidly a solution of piperazine (12.92 g, 150 mmol) in CHCl₃ (50 ml). The resulting mixture was stirred at rt for 1.5 h before being quenched with water (500 ml). After separation of the organic layer, the aqueous layer was extracted with CHCl₃ (2 x 100 ml). The combined extracts were washed with water (3 x 500 ml) and brine (300 ml), dried over MgSO₄, and filtered. To the filtrate was added a solution of *p*-toluenesulfonic acid monohydrate (5.71 g, 30 mmol) in ethanol (30 ml). After evaporation of the solvents, the residue was dissolved in CHCl₃ (70 ml), and the product was precipitated by adding isopropanol (420 ml), filtered, and washed with isopropanol/CHCl₃ (6:1, 210 ml) and hexanes (300 ml). The solid was redissolved in CHCl₃ (60 ml), precipitated by adding hexanes (600 ml), filtered, and washed with hexanes (200 ml) to afford trioxolane **OZ279** (12.58 g, 75%) as a colorless solid. mp 148–150°C; ¹H NMR (500 MHz, CDCl₃) δ 1.03–1.29 (m, 2H), 1.49–2.05 (m, 21H), 2.15 (d, J = 6.3 Hz, 2H), 2.39 (s, 3H), 3.18 (s, 2H), 3.25 (s, 2H), 3.71 (s, 2H), 3.83 (s, 2H), 7.22 (d, J = 7.7 Hz, 2H), 7.71 (d, J = 7.4 Hz, 2H), 9.25 (s, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 21.35, 26.47, 26.85, 30.19, 33.00, 33.96, 34.77, 36.38, 36.78, 38.19, 38.90, 42.36, 43.68, 43.78, 108.41, 111.37, 125.66, 129.22, 140.94, 141.11, 170.45. Anal. Calcd for C₂₉H₄₂N₂O₇S: C, 61.90; H, 7.52; N, 4.98. Found: C, 62.18; H, 7.68; N, 4.95.

***cis*-Adamantane-2-spiro-3'-8'-(2'-hydroxybenzoyl)amino]-1',2',4'-trioxaspiro[4.5]decane (OZ280).**

To a mixture of salicylic acid (166 mg, 1.2 mmol), EDCI (290 mg, 1.5 mmol), and HOEt (200 mg, 1.5 mmol) in DMF (10 ml) under N₂ was added a solution of **OZ209** (*cis*-Adamantane-2-spiro-3'-8'-(aminomethyl)-1',2',4'-trioxaspiro[4.5]decane mesylate) (389 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in DMF (5 ml). The resulting mixture was stirred at rt for 16 h before being quenched with water (70 ml). The precipitate was collected by filtration and recrystallized from ethanol to afford trioxolane **OZ280** (175 mg, 42%) as a colorless solid. mp 149–150°C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.21–1.41 (m, 2H), 1.47–2.07 (m, 21H),

3.32 (app t, J = 6.3 Hz, 2H), 6.40 (s, 1H), 6.85 (ddd, J = 7.4, 7.4, 1.1 Hz, 1H), 6.99 (dd, J = 8.2, 0.8 Hz, 1H), 7.35 (dd, J = 8.0, 1.4 Hz, 1H), 7.40 (ddd, J = 7.8, 7.8, 1.5 Hz, 1H), 12.31 (s, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.43, 26.82, 27.82, 33.69, 34.76, 36.21, 36.34, 36.74, 44.86, 108.49, 111.47, 114.19, 118.60, 118.68, 125.13, 134.23, 161.55, 170.01.

5 Anal. Calcd for $\text{C}_{24}\text{H}_{31}\text{NO}_5$: C, 69.71; H, 7.56; N, 3.39. Found: C, 69.57; H, 7.66; N, 3.48.

cis-Adamantane-2-spiro-3'-8'-[[2'-amino-2'-methylpropionyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ281). To a mixture of 2-aminoisobutyric acid (618 mg, 6.0 mmol), EDCI (1.16 g, 6.0 mmol), and HOBr (800 mg, 6.0 mmol) in DMF (150 ml) under N_2 was added a solution of **OZ209** (1.47 g, 3.0 mmol) and triethylamine (404 mg, 4.0 mmol) in DMF (15 ml). The resulting mixture was stirred at rt for 48 h and concentrated. The residue was treated with saturated aq. NaHCO_3 (40 ml), diluted with water (40 ml), then basified with 1M aq. NaOH to $\text{pH} = 8$, and extracted with CHCl_3 (3 x 60 ml). The combined extracts were washed with water and brine, dried over MgSO_4 , and concentrated. The crude product was crystallized from 50% aq. ethanol to afford trioxolane **OZ281** (0.92 g, 81%) as a colorless solid. mp 153–155°C (ether/ CH_2Cl_2 , 1:1); ^1H NMR (500 MHz, CDCl_3) δ 1.19–1.35 (m, 2H), 1.36 (s, 6H), 1.43–2.09 (m, 23H), 3.09 (app t, J = 6.5 Hz, 2H), 7.73 (s, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.48, 26.88, 27.75, 29.36, 33.82, 34.79, 36.39, 36.80, 44.36, 54.92, 108.69, 111.32, 177.45. Anal. Calcd for $\text{C}_{21}\text{H}_{34}\text{N}_2\text{O}_4$: C, 66.64; H, 9.05; N, 7.40. Found: C, 66.48; H, 9.05; N, 7.52.

20 **cis-Adamantane-2-spiro-3'-8'-[[[(4'-hydroxy-3'-pyridinyl)carbonyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ282).** To a mixture of 6-hydroxynicotinic acid (167 mg, 1.2 mmol), EDCI (290 mg, 1.5 mmol), and HOBr (200 mg, 1.5 mmol) in DMF (10 ml) under N_2 was added a solution of **OZ209** (389 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in DMF (5 ml). The resulting mixture was stirred at rt for 16 h before being quenched with water (70 ml). The precipitate was collected by filtration to afford trioxolane **OZ282** (390 mg, 94%) as a colorless solid. mp 150–152°C; ^1H NMR (500 MHz, CDCl_3) δ 1.17–1.39 (m, 2H), 1.47–2.09 (m, 21H), 3.26 (app t, J = 6.2 Hz, 2H), 6.54 (d, J = 9.3 Hz, 1H), 6.62 (t, J = 5.7 Hz, 1H), 7.83 (dd, J = 9.5, 2.3 Hz, 1H), 8.06 (d, 1.9 Hz, 1H), 12.62 (br s, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.44, 26.83, 27.85, 33.71, 34.77, 36.24, 36.35, 36.75, 45.28, 108.57, 111.44, 114.94,

119.53, 136.62, 139.61, 164.25, 164.76. Anal. Calcd for $C_{23}H_{30}N_2O_5 \cdot 0.67H_2O$: C, 64.77; H, 7.40; N, 6.57. Found: C, 64.30; H, 7.18; N, 6.78.

5 *cis*-Adamantane-2-spiro-3'-8'-[[[(3'-amino-1'H-triazol-5'-yl)carbonyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (**OZ283**). To a mixture of 3-amino-1*H*-1,2,4-triazole-5-carboxylic acid hemihydrate (164 mg, 1.2 mmol), EDCI (290 mg, 1.5 mmol), and HOBr (200 mg, 1.5 mmol) in DMF (10 ml) under N_2 was added a solution of **OZ209** (389 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in DMF (5 ml). The resulting mixture was stirred at rt for 48 h before being quenched with water (70 ml). The precipitate was collected by filtration to afford trioxolane **OZ283** (325 mg, 81%) as a colorless solid. mp 146°C dec; 1H NMR (500 MHz, DMSO- d_6) δ 1.01–1.19 (m, 2H), 1.41–2.05 (m, 21H), 3.04 (app t, J = 6.6 Hz, 2H), 6.05 (br s, 2H), 7.98 (br s, 1H), 12.37 (br s, 1H); ^{13}C NMR (125.7 MHz, DMSO- d_6) δ 25.98, 26.39, 27.59, 33.37, 34.42, 35.76, 35.92, 36.26, 43.58, 108.79, 110.62, 155.04 (br s), 157.07 (br s), 159.77 (br s). Anal. Calcd for $C_{20}H_{29}N_5O_4$: C, 59.54; H, 7.24; N, 17.36. Found: C, 59.38; H, 7.33; N, 17.57.

10 *cis*-Adamantane-2-spiro-3'-8'-[[[(2'-amino-3'-pyridinyl)carbonyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (**OZ284**). To a mixture of 2-aminonicotinic acid (168 mg, 1.2 mmol), EDCI (290 mg, 1.5 mmol), and HOBr (200 mg, 1.5 mmol) in DMF (10 ml) under N_2 was added a solution of **OZ209** (389 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in DMF (5 ml). The resulting mixture was stirred at rt for 16 h before being quenched with water (70 ml). The precipitate was collected by filtration, re-dissolved in CH_2Cl_2 (3 ml), and treated with a solution of methanesulfonic acid (96 mg, 1.0 mmol) in CH_2Cl_2 (21 ml). The solid was collected by filtration to afford trioxolane **OZ284** (280 mg, 55%) as a colorless solid. mp 164–165°C (CH_2Cl_2); 1H NMR (500 MHz, DMSO- d_6) δ 1.03–1.23 (m, 2H), 1.46–1.98 (m, 21H), 2.40 (s, 3H), 3.13 (app t, J = 6.1 Hz, 2H), 6.99 (dd, J = 7.8, 6.4 Hz, 1H), 8.15 (dd, J = 6.3, 1.4 Hz, 1H), 8.42 (dd, J = 7.8, 1.5 Hz, 1H), 8.46 (br s, 2H), 8.94 (t, J = 5.9 Hz, 1H), 13.48 (br s, 1H); ^{13}C NMR (125.7 MHz, DMSO- d_6) δ 25.98, 26.39, 27.74, 33.40, 34.42, 35.59, 35.92, 36.25, 44.48, 108.70, 110.68, 111.70, 115.29, 140.11, 143.26, 153.34, 164.69. Anal. Calcd for $C_{24}H_{35}N_3O_7S$: C, 56.56; H, 6.92; N, 8.25. Found: C, 56.35; H, 6.96; N, 8.40.

15 *cis*-Adamantane-2-spiro-3'-8'-(3'-oxo-1'-piperazinyl)methyl]-1',2',4'-trioxaspiro[4.5]decane (**OZ285**). A mixture of *cis*-adamantane-2-spiro-3'-8'-formyl-

1',2',4'-trioxaspiro[4.5]decane (292 mg, 1.0 mmol), piperazine-2-one (114 mg, 1.0 mmol), and acetic acid (60 mg, 1.0 mmol) in 1,2-dichloroethane (15 ml) under N₂ was stirred at rt for 10 min before sodium triacetoxyborohydride (322 mg, 1.5 mmol) was added. The resulting mixture was stirred at rt for 4 h and then quenched with saturated aq. 5 NaHCO₃ (15 ml). The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂ (2 x 15 ml). The combined organic extracts were washed with water and brine, dried over MgSO₄, and concentrated. The crude product was crystallized from hexanes/CH₂Cl₂ (4:1) to afford trioxolane **OZ285** (210 mg, 56%) as a colorless solid. mp 157°C dec; ¹H NMR (500 MHz, CDCl₃) δ 1.07–1.25 (m, 2H), 1.41–2.05 (m, 21H), 2.17–10 2.27 (m, 2H), 2.61 (br s, 2H), 3.03–3.15 (m, 2H), 3.35 (br s, 2H), 6.55 (br s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.45, 26.85, 28.35, 33.57, 33.91, 34.76, 34.77, 36.35, 36.77, 41.33, 49.67, 57.21, 63.41, 108.91, 111.28, 169.75. Anal. Calcd for C₂₁H₃₂N₂O₄: C, 66.99; H, 8.57; N, 7.44. Found: C, 66.78; H, 8.51; N, 7.46.

cis-Adamantane-2-spiro-3'-8'-[[[4'-(aminocarbonyl)phenyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ286). A mixture of *cis*-adamantane-2-spiro-3'-8'-formyl-1',2',4'-trioxaspiro[4.5]decane (292 mg, 1.0 mmol), 4-aminobenzamide (136 mg, 1.0 mmol), and acetic acid (60 mg, 1.0 mmol) in 1,2-dichloroethane (15 ml) under N₂ was stirred at rt for 10 min before sodium triacetoxyborohydride (322 mg, 1.5 mmol) was added. The resulting mixture was stirred at rt for 4 h and then quenched with saturated aq. 15 NaHCO₃ (20 ml). The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂ (2 x 15 ml). The combined organic extracts were washed with water and brine, dried over MgSO₄, and concentrated. The crude product was crystallized from 95% aq. ethanol to afford trioxolane **OZ286** (120 mg, 29%) as a colorless solid. mp 153–156°C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.03–1.25 (m, 2H) 1.46–2.08 (m, 21H), 2.91 (br s, 2H), 20 6.21 (s, 1H), 6.52 (d, J = 8.2 Hz, 2H), 6.80 (br s, 1H), 7.50 (br s, 1H), 7.61 (d, J = 8.2 Hz, 2H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 26.00, 26.40, 27.96, 33.54, 34.45, 35.25, 35.94, 25 36.28, 48.05, 108.89, 110.67, 120.70, 129.26, 151.68, 168.17. Anal. Calcd for C₂₄H₃₂N₂O₄•1.5H₂O: C, 65.58; H, 8.03; N, 6.37. Found: C, 65.86; H, 7.82; N, 6.77.

cis-Adamantane-2-spiro-3'-8'-[[[(2'-amino-2'-methylpropyl)amino]methyl]-1',2',4'-trioxaspiro[4.5]decane dimesylate (OZ287). A mixture of *cis*-adamantane-2-spiro-3'-8'-formyl-1',2',4'-trioxaspiro[4.5]decane (292 mg, 1.0 mmol), 1,2-diamino-2-

methylpropane (88 mg, 1.0 mmol), and acetic acid (60 mg, 1.0 mmol) in 1,2-dichloroethane (10 ml) under N₂ was stirred at rt for 10 min before sodium triacetoxyborohydride (322 mg, 1.5 mmol) was added. The resulting mixture was stirred at rt for 4.5 h and then quenched with saturated aq. NaHCO₃ (20 ml). The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (2 x 15 ml). The combined organic extracts were washed with water and brine, dried over MgSO₄, and concentrated. The crude product was re-dissolved in CH₂Cl₂ (3 ml), treated with a solution of methanesulfonic acid (192 mg, 2.0 mmol) in CH₂Cl₂ (2 ml), and diluted with ether (20 ml). The solid was obtained by filtration to afford trioxolane **OZ287** (236 mg, 42%) as a colorless solid. mp 158°C dec; ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.08–1.25 (m, 2H), 1.36 (s, 6H), 1.58–1.99 (m, 21H), 2.40 (s, 6H), 2.89 (br s, 2H), 3.16 (br s, 2H), 8.14 (s, 3H), 8.28 (s, 2H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 23.76, 25.97, 26.38, 27.42, 32.53, 33.06, 34.42, 34.43, 35.91, 36.24, 52.24, 53.79, 54.60, 108.22, 110.85. Anal. Calcd for C₂₃H₄₄N₂O₉S₂•0.2CH₂Cl₂: C, 48.57; H, 7.80; N, 4.88. Found: C, 48.36; H, 7.43; N, 4.91.

cis-Adamantane-2-spiro-3'-8'-(4'-hydroxyphenyl)-1',2',4'-trioxaspiro[4.5]decane (OZ288). **Step 1.** To a mixture of 4-(4-hydroxyphenyl)cyclohexanone (19.0 g, 0.1 mol) and triethylamine (40.4 g, 0.4 mol) in CH₂Cl₂ (700 ml) at 0°C was added dropwise acetyl chloride (15.7 g, 0.2 mol). After the addition was finished, the reaction mixture was warmed to rt and stirred overnight. The reaction mixture was washed with water and brine, dried over MgSO₄, and concentrated. The crude product was crystallized from 95% aq. ethanol to afford 4-(4-acetoxyphenyl)-cyclohexanone (17.6 g, 76%) as a colorless solid. mp 104–106°C (95% aq. ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.88–1.98 (m, 2H), 2.20–2.26 (m, 2H), 2.48–2.54 (m, 4H), 2.30 (s, 3H), 3.00–3.07 (m, 1H), 7.03 (d, J = 8.7 Hz, 2H), 7.25 (d, J = 8.7 Hz, 2H). **Step 2.** A solution of *O*-methyl 2-adamantanone oxime (16.0 g, 89 mmol) and 4-(4-acetoxyphenyl)cyclohexanone (13.8 g, 59 mmol) in cyclohexane (400 ml) and CH₂Cl₂ (100 ml) was treated with ozone according to the general procedure. The crude product was triturated with ethanol (200 ml) to afford **adamantane-2-spiro-3'-8'-(4'-acetoxyphenyl)-1',2',4'-trioxaspiro[4.5]decane** (16.4 g, 70%) as a colorless solid. mp 149–151 °C (ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.64–2.08 (m, 22H), 2.29 (s, 3H), 2.50–2.60 (m, 1H), 7.00 (d, J = 8.2 Hz, 2H), 7.20 (d, J = 8.2 Hz, 2H). **Step 3.** A mixture of **adamantane-**

2-spiro-3'-8'-(4'-acetoxyphenyl)-1',2',4'-trioxaspiro[4.5]decane (16.4 g, 41 mmol) and 15% aq. KOH (65 ml) in THF/MeOH (1:2, 500 ml) was heated at 50°C for 4 h. After being cooled to rt, the reaction mixture was concentrated to 70 ml, diluted with water (70 ml), and acidified with acetic acid (30 ml). The precipitate was collected by filtration to afford trioxolane **OZ288** (14.36 g, 98%) as a colorless solid. mp 136–138°C; ¹H NMR (500 MHz, CDCl₃) δ 1.56–2.18 (m, 22H), 2.41–2.58 (m, 1H), 5.90 (br s, 1H), 6.76 (d, J = 8.5 Hz, 2H), 7.05 (d, J = 8.5 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.49, 26.89, 31.65, 34.75, 34.80, 36.41, 36.81, 42.05, 108.46, 111.35, 115.22, 127.71, 138.03, 154.26. Anal. Calcd for C₂₂H₂₈O₄: C, 74.13; H, 7.92. Found: C, 73.90; H, 7.85.

cis-Adamantane-2-spiro-3'-8'-[(ethoxycarbonyl)amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ289). To a solution of **OZ209** (272 mg, 0.7 mmol) and triethylamine (271 mg, 2.7 mmol) in CH₂Cl₂ (15 ml) at 0 °C was added a solution of ethyl chloroformate (109 mg, 1 mmol) in CH₂Cl₂ (2 ml). After being stirred at rt for 5 h, the reaction mixture was washed with water and brine, dried over MgSO₄, and concentrated.

The crude product was crystallized from hexanes/ether (9:1) to afford trioxolane **OZ289** (160 mg, 63%) as a colorless solid. mp 69–71 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.12–1.39 (m, 5H), 1.42–2.09 (m, 21H), 3.04 (app t, J = 6.3 Hz, 2H), 4.10 (q, J = 7.4 Hz, 2H), 4.69 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 14.62, 26.47, 26.87, 27.60, 33.76, 34.79, 36.38, 36.61, 36.79, 46.22, 60.73, 108.68, 111.35, 156.70. Anal. Calcd for C₂₀H₃₁NO₅: C, 65.73; H, 8.55; N, 3.83. Found: C, 66.00; H, 8.69; N, 4.00.

cis-Adamantane-2-spiro-3'-8'-[(2'-ethoxy-2'-oxoethyl)amino]methyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ290). A mixture of *cis*-adamantane-2-spiro-3'-8'-formyl-1',2',4'-trioxaspiro[4.5]decane (584 mg, 2.0 mmol), glycine ethyl ester hydrochloride (280 mg, 2.0 mmol), and triethylamine (202 mg, 2.0 mmol) in 1,2-dichloroethane (16 ml) under N₂ was stirred at rt for 10 min before sodium triacetoxyborohydride (644 mg, 3.0 mmol) was added. The resulting mixture was stirred at rt for 5 h, quenched with saturated aq. NaHCO₃ (20 ml), and basified with 1 M aq. NaOH to pH = 8. The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂ (2 x 15 ml). The combined organic extracts were washed with water and brine, dried over MgSO₄, and concentrated. The crude product was re-dissolved in CH₂Cl₂/ether (1:3, 10 ml) and treated with a solution of methanesulfonic acid (198 mg, 2.0 mmol) in

ether (2 ml). The precipitate was obtained by filtration to afford trioxolane **OZ290** (346 mg, 36%) as a colorless solid. mp 109–112 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.03–1.21 (m, 2H), 1.23 (t, J = 7.0 Hz, 3H), 1.57–1.99 (m, 21H), 2.34 (s, 3H), 2.84 (br s, 2H), 3.97 (s, 2H), 4.21 (q, J = 7.1 Hz, 2H), 8.97 (s, 2H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 5 14.11, 25.98, 26.39, 27.36, 32.56, 32.97, 34.42, 34.43, 35.92, 36.25, 47.35, 51.94, 61.90, 108.21, 110.83, 166.76. Anal. Calcd for C₂₂H₃₇NO₈S: C, 55.56; H, 7.84; N, 2.95. Found: C, 55.73; H, 7.71; N, 2.96.

cis-Adamantane-2-spiro-3'-8'-[[[(ethylamino)carbonyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ291). To a solution of **OZ209** (272 mg, 0.7 mmol) and 10 triethylamine (71 mg, 0.7 mmol) in CH₂Cl₂ (10 ml) at 0°C was added a solution of ethyl isocyanate (60 mg, 0.84 mmol). After being stirred at rt for 2 h, the reaction mixture was washed with water and brine, dried over MgSO₄, and concentrated. The crude product was crystallized from 35% aq. ethanol to afford trioxolane **OZ291** (155 mg, 61%) as a colorless solid. mp 112–116°C; ¹H NMR (500 MHz, CDCl₃) δ 1.13 (t, J = 7.3 Hz, 3H), 1.15–1.29 15 (m, 2H), 1.42–2.09 (m, 21H), 3.04 (d, J = 5.4 Hz, 2H), 3.20 (q, J = 7.3 Hz, 2H), 4.39 (br s, 1H), 4.52 (br s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 15.45, 26.46, 26.85, 27.74, 33.79, 34.77, 35.37, 36.37, 36.78, 45.81, 108.74, 111.33, 158.19. Anal. Calcd for C₂₀H₃₂N₂O₄: C, 65.91; H, 8.85; N, 7.69. Found: C, 65.73; H, 8.65; N, 7.53.

cis-Adamantane-2-spiro-3'-8'-[[[(2'-pyridinylmethyl)amino]methyl]-1',2',4'-trioxaspiro[4.5]decane dimesylate (OZ292). A mixture of **cis-adamantane-2-spiro-3'-8'-formyl-1',2',4'-trioxaspiro[4.5]decane** (292 mg, 1.0 mmol), 2-(aminomethyl)pyridine (108 mg, 1.0 mmol), and acetic acid (60 mg, 1 mmol) in 1,2-dichloroethane (10 ml) under N₂ was stirred at rt for 10 min before sodium triacetoxyborohydride (322 mg, 1.5 mmol) 20 was added. The resulting mixture was stirred at rt for 4 h and then quenched with saturated aq. NaHCO₃ (20 ml). The organic layer was separated, and the aqueous layer was extracted with CHCl₃ (2 x 15 ml). The combined organic extracts were washed with water and brine, dried over MgSO₄, and concentrated. The crude product was purified by flash chromatography (silica gel, 2–10% MeOH in CH₂Cl₂) to give the desired amine (250 mg). The free amine was dissolved in ether (5 ml) and treated with a solution of methanesulfonic acid (130 mg) in ether (5 ml). The precipitate was triturated with CH₂Cl₂ to afford 25 trioxolane **OZ292** (145 mg, 25%) as a colorless solid. mp 142–145°C; ¹H NMR (500 MHz, 30

DMSO-*d*₆) δ 1.05–1.25 (m, 2H), 1.54–1.99 (m, 21H), 2.40 (s, 6H), 2.88 (d, *J* = 5.2 Hz, 2H), 4.33 (s, 2H), 7.50 (dd, *J* = 6.2, 6.2 Hz, 1H), 7.58 (d, *J* = 8.0 Hz, 1H), 7.97 (dd, *J* = 7.3, 7.3 Hz, 1H), 8.35 (br s, 1H), 8.67 (d, *J* = 4.6 Hz, 1H), 8.99 (s, 2H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 25.97, 26.38, 27.40, 32.73, 33.02, 34.42, 34.44, 35.92, 36.25, 50.51, 51.93, 108.24, 110.83, 123.97, 124.16, 138.42, 148.58, 151.47. Anal. Calcd for C₂₅H₄₀N₂O₉S₂•0.33CH₂Cl₂: C, 50.29; H, 6.77; N, 4.63. Found: C, 49.86; H, 6.66; N, 4.56.

cis-Adamantane-2-spiro-3'-8'-(3'-pyridinylamino)methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ293). A mixture of **cis-adamantane-2-spiro-3'-8'-formyl-1',2',4'-trioxaspiro[4.5]decane** (292 mg, 1.0 mmol), 3-aminopyridine (84 mg, 1.0 mmol), and acetic acid (60 mg, 1 mmol) in 1,2-dichloroethane (10 ml) under N₂ was stirred at rt for 10 min before sodium triacetoxyborohydride (322 mg, 1.5 mmol) was added. The resulting mixture was stirred at rt for 4 h, quenched with saturated aq. NaHCO₃ (15 ml), and basified with 1 M aq. NaOH to pH = 8. The organic layer was separated, and the aqueous layer was extracted with CHCl₃ (2 x 10 ml). The combined organic extracts were washed with water and brine, dried over MgSO₄, and concentrated. The crude product was crystallized from CH₂Cl₂/ether (1:5) to afford trioxolane **OZ293** (100 mg, 27%) as a colorless solid. mp 134–138°C; ¹H NMR (500 MHz, CDCl₃) δ 1.19–1.37 (m, 2H), 1.45–2.09 (m, 21H), 3.01 (d, J = 6.6 Hz, 2H), 3.77 (br s, 1H), 6.85 (d, J = 8.2 Hz, 1H), 7.08 (dd, J = 8.0, 4.7 Hz, 1H), 7.94 (s, 1H), 8.01 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.46, 26.86, 28.08, 33.83, 34.78, 34.79, 35.97, 36.38, 36.77, 49.08, 108.66, 111.44, 118.34, 123.74, 135.81, 138.41, 144.27. Anal. Calcd for C₂₂H₃₀N₂O₃: C, 71.32; H, 8.16; N, 7.56. Found: C, 71.54; H, 7.87; N, 7.49.

cis-Adamantane-2-spiro-3'-8'-[[[4'-formyl-1'-piperazinyl)carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ294). To a solution of the OZ78 active ester (440 mg, 1.0 mmol) in CHCl₃ (20 ml) was added a solution of 1-piperazinecarboxaldehyde (137 mg, 1.2 mmol) in CHCl₃ (1 ml). The resulting mixture was stirred at rt for 2 h before removal of the solvent. The residue was crystallized from ethanol/water (1:2) to afford trioxolane OZ294 (242 mg, 58%, 2:1 mixture of rotamers) as a colorless solid. mp 142–144°C; ¹H NMR (500 MHz, CDCl₃) δ 1.15–1.32 (m, 2H), 1.45–2.09 (m, 21H), 2.20–2.28 (m, 2H), 3.32–3.78 (m, 8H), 8.10 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.46, 26.84, 30.27, 33.18, 34.01, 34.77, 36.38, 36.77, 39.26, 39.99, 40.22, 41.02, 42.15, 45.15, 45.33, 45.70,

46.25, 108.49, 111.39, 160.74, 160.92, 170.55, 170.72. Anal. Calcd for C₂₃H₃₄N₂O₅: C, 66.00; H, 8.19; N, 6.69. Found: C, 66.16; H, 7.95; N, 6.46.

cis-Adamantane-2-spiro-3'-8'-[[[(2'-pyridinylmethyl)amino]carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ295). To a solution of the **OZ78** active ester (440 mg, 1.0 mmol) in CHCl₃ (20 ml) was added a solution of 2-(aminomethyl)pyridine (130 mg, 1.2 mmol) in CHCl₃ (2 ml). The resulting mixture was stirred at rt for 2 h before being quenched with water (20 ml). After separation of the organic layer, the aqueous layer was extracted with CHCl₃ (2 x 20 ml). The combined extracts were washed with water (2 x 30 ml) and brine (20 ml), dried over MgSO₄, filtered, and concentrated. The residue was dissolved in ether (10 ml) and CH₂Cl₂ (10 ml) and treated with a solution of methanesulfonic acid (96 mg, 1.0 mmol) in CH₂Cl₂ (1 ml). After evaporation of the solvents, the residue was crystallized from ether/ethanol (10:1) to afford trioxolane **OZ295** (450 mg, 88%) as a colorless solid. mp 152–154 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.15–1.34 (m, 2H), 1.55–2.09 (m, 21H), 2.19 (d, J = 7.1 Hz, 2H), 2.91 (s, 3H), 4.74 (d, J = 6.0 Hz, 2H), 7.81 (dd, J = 6.7, 6.7 Hz, 1H), 8.03 (d, J = 8.0 Hz, 1H), 8.37 (dd, J = 7.8, 7.8 Hz, 1H), 8.55 (t, J = 5.9 Hz, 1H), 8.67 (d, J = 5.5 Hz, 1H), 16.98 (br s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.42, 26.81, 29.85, 33.24, 33.93, 34.74, 36.30, 36.75, 39.36, 40.87, 42.10, 108.46, 111.20, 125.19, 127.81, 141.32, 145.72, 154.52, 173.54. Anal. Calcd for C₂₅H₃₆N₂O₇S: C, 59.03; H, 7.13; N, 5.51. Found: C, 59.11; H, 7.15; N, 5.36.

cis-Adamantane-2-spiro-3'-8'-[[[(3'-oxo-1'-piperazinyl)carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ296). To a solution of the **OZ78** active ester (440 mg, 1.0 mmol) in CHCl₃ (20 ml) was added piperazin-2-one (120 mg, 1.2 mmol). The resulting mixture was stirred at rt for 3 h before removal of the solvent. The residue was crystallized from ethanol/water (1:1) to afford trioxolane **OZ296** (207 mg, 51%, 3:2 mixture of rotamers) as a colorless solid. mp 150–152°C; ¹H NMR (500 MHz, CDCl₃) δ 1.17–1.34 (m, 2H), 1.57–2.09 (m, 21H), 2.21 (d, J = 6.8 Hz, 1.2H), 2.24 (d, J = 6.8 Hz, 0.8H), 3.39 (s, 1.2H), 3.42 (s, 0.8H), 3.67 (t, J = 5.0 Hz, 0.8H), 3.82 (t, J = 5.4 Hz, 1.2H), 4.12 (s, 1.2H), 4.25 (s, 0.8H), 6.42 (s, 0.6H), 6.58 (s, 0.4H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.47, 26.85, 30.20, 30.26, 32.98, 34.00, 34.78, 36.38, 36.78, 38.31, 39.34, 39.48, 40.83, 41.34, 42.40, 46.06, 49.01, 108.46, 108.50, 111.35, 111.43, 166.60, 167.91, 170.37, 170.62. Anal. Calcd for C₂₂H₃₂N₂O₅: C, 65.32; H, 7.97; N, 6.93. Found: C, 65.17; H, 7.78; N, 6.79.

cis-Adamantane-2-spiro-3'-8'-[[[4'-hydroxy-1'-piperidinyl]carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ297). To a solution of the **OZ78** active ester (440 mg, 1.0 mmol) in CHCl₃ (20 ml) was added 4-hydroxypiperidine (121 mg, 1.2 mmol). The resulting mixture was stirred at rt for 1 h before being quenched with water (20 ml). After separation of the organic layer, the aqueous layer was extracted with CHCl₃ (2 x 20 ml). The combined extracts were washed with water (3 x 30 ml) and brine (20 ml), dried over MgSO₄, filtered, and concentrated. The residue was crystallized from ether/CHCl₃ (10:1) to afford trioxolane **OZ297** (152 mg, 37%) as a colorless solid. mp 154–156°C; ¹H NMR (500 MHz, CDCl₃) δ 1.15–1.35 (m, 2H), 1.41–1.59 (m, 2H), 1.60–2.09 (m, 23H), 2.23 (d, J = 7.1 Hz, 2H), 3.09–3.31 (m, 2H), 3.68–3.82 (m, 1H), 3.87–4.03 (m, 1H), 4.05–4.21 (m, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.49, 26.86, 30.28, 33.39, 34.01, 34.07, 34.66, 34.78, 36.39, 36.80, 38.92, 39.22, 42.97, 67.20, 108.64, 111.32, 170.39. Anal. Calcd for C₂₃H₃₅NO₅: C, 68.12; H, 8.70; N, 3.45. Found: C, 68.19; H, 8.56; N, 3.26.

cis-Adamantane-2-spiro-3'-8'-[[[4'-(aminosulfonyl)phenyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ298). A mixture of *cis*-adamantane-2-spiro-3'-8'-formyl-1',2',4'-trioxaspiro[4.5]decane (292 mg, 1.0 mmol), sulfanilamide (172 mg, 1.0 mmol), and acetic acid (60 mg, 1 mmol) in 1,2-dichloroethane (10 ml) under N₂ was stirred at rt for 10 min before sodium triacetoxyborohydride (322 mg, 1.5 mmol) was added. The resulting mixture was stirred at rt for 4 h, quenched with saturated aq. NaHCO₃ (15 ml), and concentrated to 16 ml. The precipitate was collected by filtration and recrystallized from hexanes/ether (5:1) to afford trioxolane **OZ298** (220 mg, 49%) as a colorless solid. mp 153–155°C; ¹H NMR (500 MHz, CDCl₃) δ 1.19–1.41 (m, 2H), 1.55–2.09 (m, 21H), 3.05 (app t, J = 6.2 Hz, 2H), 4.28 (s, 1H), 4.69 (s, 2H), 6.57 (d, J = 8.5 Hz, 2H), 7.69 (d, J = 8.8 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.45, 26.85, 28.04, 33.78, 34.77, 34.78, 35.91, 36.38, 36.76, 48.84, 108.55, 111.51, 111.56, 128.45, 128.61, 151.72. Anal. Calcd for C₂₃H₃₂N₂O₅S: C, 61.58; H, 7.19; N, 6.24. Found: C, 61.61; H, 7.35; N, 6.30.

cis-Adamantane-2-spiro-3'-8'-[(2'-pyrimidinylsulfonyl)methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ299). Step 1. To a mixture of **OZ119** (*cis*-Adamantane-2-spiro-3'-8'-hydroxymethyl-1',2',4'-trioxaspiro[4.5]decane) (588 mg, 2 mmol) and triphenylphosphine (628 mg, 2.4 mmol) in benzene (10 ml) at rt under N₂ was added dropwise a solution of DIPAD (486 mg, 2.4 mmol) in benzene (2 ml). After 5 min, 2-

pyrimidinethiol (224 mg, 2 mmol) in benzene (5 ml) was added slowly over a period of 20 min. The stirring was continued for 24 h before removal of the solvent. The crude product was purified by flash chromatography (silica gel, 15% ethyl acetate in hexanes) to give **cis-adamantane-2-spiro-3'-8'-(2'-pyrimidinylthio)methyl]-1',2',4'- trioxaspiro[4.5]decane** (420 mg, 54%) as a colorless solid. mp 140–142°C; ¹H NMR (500 MHz, CDCl₃) δ 1.21–1.42 (m, 2H), 1.60–2.11 (m, 21H), 3.09 (d, J = 6.9 Hz, 2H), 6.95 (t, J = 4.8 Hz, 1H), 8.50 (d, J = 4.7 Hz, 2H). **Step 2.** To a solution of the above thioether (396 mg, 1.0 mmol) in CH₂Cl₂ (5 ml) at 0°C was added dropwise a solution of 3-chloroperoxybenzoic acid (70 % reagent, 790 mg, 3.2 mmol) in CHCl₃/CH₂Cl₂ (1:1, 16 ml). After 2 h, the mixture was allowed to warm up to rt and stirred overnight before being quenched with saturated aq. NaHCO₃ (40 ml). The organic layer was separated, and the aqueous layer was extracted with CHCl₃ (2 x 20 ml). The combined organic extracts were washed with water and brine, dried over MgSO₄, and concentrated. The crude product was purified by flash chromatography (silica gel, 20% to 50% ethyl acetate in hexanes) to afford trioxolane **OZ299** (315 mg, 73%) as a colorless solid. mp 152–154°C; ¹H NMR (500 MHz, CDCl₃) δ 1.32–1.49 (m, 2H), 1.61–2.07 (m, 20H), 2.12–2.29 (m, 1H), 3.47 (d, J = 6.8 Hz, 2H), 7.57 (dd, J = 4.9, 4.9 Hz, 1H), 8.96 (d, J = 4.9 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.44, 26.82, 30.04, 30.87, 33.66, 34.76, 36.35, 36.75, 56.34, 107.78, 111.59, 123.71, 158.66, 166.30. Anal. Calcd for C₂₁H₂₈N₂O₅S: C, 59.98; H, 6.71; N, 6.66. Found: C, 60.16; H, 6.78; N, 6.77.

cis-Adamantane-2-spiro-3'-8'-[[(3'-carboxy-1'-oxopropyl)amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ300). To a solution of **OZ299** (389 mg, 1 mmol) and triethylamine (101 mg, 1 mmol) in CH₂Cl₂ (10 ml) at 0°C was added succinic anhydride (100 mg, 1 mmol). After being stirred at rt overnight, the reaction mixture was washed with water and brine, dried over MgSO₄, and concentrated to afford trioxolane **OZ300** (160 mg, 41%) as a colorless solid. mp 152–154°C; ¹H NMR (500 MHz, DMSO-d₆) δ 0.92–1.11 (m, 2H) 1.34–2.07 (m, 21H), 2.29 (t, J = 7.0 Hz, 2H), 2.39 (t, J = 6.8 Hz, 2H), 2.88 (app t, J = 6.2 Hz, 2H), 7.82 (t, J = 5.6 Hz, 1H), 12.02 (s, 1H); ¹³C NMR (125.7 MHz, DMSO-d₆) δ 25.97, 26.38, 27.61, 29.37, 30.14, 33.41, 34.41, 35.85, 35.91, 36.25, 43.86, 108.74, 110.59, 171.01, 173.98. Anal. Calcd for C₂₁H₃₁NO₆: C, 64.10; H, 7.94; N, 3.56. Found: C, 63.85; H, 7.86; N, 3.54.

cis-Adamantane-2-spiro-3'-8'-(4'-pyridinyloxy)methyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ301). A mixture of diisopropyl azodicarboxylate (243 mg, 1.2 mmol) and triphenylphosphine (315 mg, 1.2 mmol) in THF (5 ml) under argon was stirred at 0°C for 30 min before **OZ119** (294 mg, 1 mmol) and 4-hydroxypyridine (114 mg, 1.2 mmol) were added. The resulting mixture was stirred at rt for 5 h. After concentration, the crude product was purified by flash chromatography (silica gel, 40% ethyl acetate in hexanes, then 2% to 6% MeOH in CH₂Cl₂) to give crude **cis-adamantane-2-spiro-3'-8'-(4'-pyridinyloxy)methyl]-1',2',4'-trioxaspiro[4.5]decane** (eluted first) and pure trioxolane **OZ302** (85 mg, 23%, eluted second) as a colorless solid.

10 The crude **cis-adamantane-2-spiro-3'-8'-(4'-pyridinyloxy)methyl]-1',2',4'-trioxaspiro[4.5]decane** was dissolved in CH₂Cl₂/ether (1:3, 8 ml) and treated with a solution of methanesulfonic acid (77 mg, 0.8 mmol) in ether (2 ml). The precipitate was collected by filtration to afford trioxolane **OZ301** (172 mg, 37%) as a colorless solid. For **OZ301**: mp 153–155°C; ¹H NMR (500 MHz, CDCl₃) δ 1.34–1.49 (m, 2H), 1.61–2.09 (m, 21H), 2.88 (s, 3H), 4.08 (d, J = 6.3 Hz, 2H), 7.29 (d, J = 7.3 Hz, 2H), 8.72 (d, J = 6.8 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.41, 26.48, 26.81, 33.46, 34.76, 35.60, 36.36, 36.71, 39.34, 74.77, 108.08, 111.66, 112.64, 143.28, 171.01. Anal. Calcd for C₂₃H₃₃NO₇S: C, 59.08; H, 7.11; N, 3.00. Found: C, 58.89; H, 7.15; N, 3.09.

cis-Adamantane-2-spiro-3'-8'-(4'-oxo-1'(4'H)-pyridinyl)methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ302). For the preparation of **OZ302**, see **OZ301**. mp 138–140°C; ¹H NMR (500 MHz, CDCl₃) δ 1.17–1.35 (m, 2H), 1.59–2.03 (m, 21H), 3.60 (d, J = 7.3 Hz, 2H), 6.39 (d, J = 7.8 Hz, 2H), 7.22 (d, J = 7.3 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.40, 26.79, 27.33, 33.34, 34.74, 36.33, 36.69, 37.66, 62.30, 107.90, 111.77, 118.67, 139.88, 178.82. Anal. Calcd for C₂₂H₂₉NO₄•0.25CH₂Cl₂: C, 68.05; H, 7.57; N, 3.57. Found: C, 67.74; H, 7.37; N, 3.69.

cis-Adamantane-2-spiro-3'-8'-(4'-formyl-1'-piperazinyl)methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ303). A mixture of **cis-adamantane-2-spiro-3'-8'-formyl-1',2',4'-trioxaspiro[4.5]decane** (292 mg, 1.0 mmol), 1-piperazinecarboxaldehyde (114 mg, 1.0 mmol), and acetic acid (60 mg, 1.0 mmol) in 1,2-dichloroethane (10 ml) under N₂ was stirred at rt for 10 min before sodium triacetoxyborohydride (322 mg, 1.5 mmol) was added. The resulting mixture was stirred at rt for 4 h and then quenched with saturated aq.

NaHCO₃ (15 ml). The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (2 x 10 ml). The combined organic extracts were washed with water and brine, dried over MgSO₄, and concentrated. The crude product was triturated in hexanes/ether (2:1) to afford trioxolane **OZ303** (240 mg, 61%) as a colorless solid. mp 140–142°C; ¹H NMR (500 MHz, CDCl₃) δ 1.08–1.25 (m, 2H), 1.42–2.07 (m, 21H), 2.16 (d, J = 7.3 Hz, 2H), 2.35 (t, J = 5.7 Hz, 2H), 2.39 (t, J = 5.2 Hz, 2H), 3.36 (t, J = 4.9 Hz, 2H), 3.54 (t, J = 4.9 Hz, 2H), 8.01 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.48, 26.87, 28.50, 33.58, 33.99, 34.78, 34.80, 36.38, 36.79, 40.02, 45.69, 52.79, 54.19, 64.25, 108.98, 111.28, 160.67. Anal. Calcd for C₂₂H₃₄N₂O₄: C, 67.66; H, 8.78; N, 7.17. Found: C, 67.85; H, 8.62; N, 7.35.

10 **cis-Adamantane-2-spiro-3'-8'-[[[(2'-pyridinylcarbonyl)amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ304).** To a mixture of picolinic acid (148 mg, 1.2 mmol), EDCI (290 mg, 1.5 mmol), and HOEt (200 mg, 1.5 mmol) in DMF (10 ml) under N₂ was added a solution of **OZ209** (389 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in 15 DMF (5 ml). The reaction mixture was stirred at rt for 16 h before removal of the solvents. The crude product was dissolved in CH₂Cl₂ (100 ml), washed with water and brine, dried over MgSO₄, and concentrated. Crystallization of the residue from acetone/water (1:4) gave trioxolane **OZ304** (90 mg, 23%) as a colorless solid. mp 130–133°C; ¹H NMR (500 MHz, CDCl₃) δ 1.19–1.45 (m, 2H), 1.57–2.09 (m, 21H), 3.35 (app t, J = 6.6 Hz, 2H), 7.42 (ddd, J = 8.1, 4.4, 1.0 Hz, 1H), 7.85 (ddd, J = 7.8, 7.8, 1.7 Hz, 1H), 8.15 (br s, 1H), 8.20 (d, J = 7.8 Hz, 1H), 8.55 (d, J = 4.9 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.47, 26.86, 27.87, 33.80, 34.78, 36.37, 36.51, 36.79, 44.68, 108.69, 111.34, 122.22, 126.09, 137.35, 148.02, 149.94, 164.32. Anal. Calcd for C₂₃H₃₀N₂O₄: C, 69.32; H, 7.59; N, 7.03. Found: C, 69.33; H, 7.45; N, 6.86.

25 **cis-Adamantane-2-spiro-3'-8'-[[[(2'-aminoethyl)amino]carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane p-tosylate (OZ305).** To a solution of the **OZ78** active ester (440 mg, 1.0 mmol) in CHCl₃ (15 ml) was added rapidly a solution of ethylenediamine (601 mg, 10 mmol) in ethanol (5 ml). The resulting mixture was stirred at rt for 2 h before being quenched with water (20 ml). After separation of the organic layer, 30 the aqueous layer was extracted with CHCl₃ (2 x 20 ml). The combined extracts were washed with water (3 x 20 ml) and brine (20 ml), dried over MgSO₄, filtered, and

concentrated. The residue was dissolved in CH₂Cl₂ (20 ml) and treated with a solution of *p*-toluenesulfonic acid monohydrate (191 mg, 1.0 mmol) in ethanol (2 ml). After evaporation of the solvents, the residue was treated with ether (20 ml), filtered, and washed with ether (20 ml) to afford trioxolane **OZ305** (448 mg, 83%) as a colorless solid. mp 140–142°C; ¹H NMR (500 MHz, CDCl₃) δ 0.91–1.11 (m, 2H), 1.59–2.07 (m, 23H), 2.37 (s, 3H), 2.99–3.05 (m, 2H), 3.39–3.44 (m, 2H), 7.16 (d, J = 7.8 Hz, 2H), 7.47 (s, 1H), 7.69 (d, J = 7.8 Hz, 2H), 7.73 (s, 3H); ¹³C NMR (125.7 MHz, CDCl₃) δ 21.33, 26.48, 26.86, 29.73, 33.08, 33.84, 34.77, 36.37, 36.80, 36.98, 40.16, 42.46, 108.44, 111.15, 111.31, 125.73, 129.32, 140.71, 141.33, 173.94. Anal. Calcd for C₂₇H₄₀N₂O₇S: C, 60.42; H, 7.51; N, 5.22. Found: C, 60.47; H, 7.47; N, 4.83.

cis-Adamantane-2-spiro-3'-8'-[[[(2'-amino-2'-oxoethyl)amino]carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ306). To a solution of glycinamide hydrochloride (221 mg, 2.0 mmol), triethylamine (304 mg, 3 mmol), ethanol (5 ml), and water (1 ml) in CHCl₃ (10 ml) was added the **OZ78** active ester (440 mg, 1.0 mmol). The resulting mixture was stirred at rt for 17 h before being diluted with CHCl₃ (20 ml) and water (40 ml). After separation of the organic layer, the aqueous layer was extracted with CHCl₃ (3 x 10 ml). The combined extracts were washed with water (2 x 20 ml) and brine (2 x 20 ml), dried over MgSO₄, filtered, and concentrated. The residue was crystallized from 30% aq. ethanol to afford trioxolane **OZ306** (284 mg, 75%) as a colorless solid. mp 130–132°C; ¹H NMR (500 MHz, CDCl₃) δ 1.11–1.38 (m, 2H), 1.42–2.07 (m, 21H), 2.15 (d, J = 5.4 Hz, 2H), 3.95 (s, 2H), 5.84 (br s, 1H), 6.52 (br s, 1H), 6.73 (br s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.45, 26.84, 29.94, 33.47, 33.88, 34.75, 36.34, 36.77, 42.77, 42.88, 108.50, 111.33, 171.40, 172.88. Anal. Calcd for C₂₀H₃₀N₂O₅: C, 63.47; H, 7.99; N, 7.40. Found: C, 63.60; H, 8.10; N, 7.53.

cis-Adamantane-2-spiro-3'-8'-[(methylsulfonyl)methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ307). **Step 1.** To a solution of sodium thiomethoxide (0.42 g, 6 mmol) in DMF (30 ml) was added dropwise a solution of the methanesulfonate of **OZ119** (1.11 g, 3 mmol) in DMF (10 ml). The mixture was heated at 55 °C for 6 h before removal of the solvent. The residue was dissolved in CH₂Cl₂ (30 ml) and washed with water and brine, dried over MgSO₄, filtered, and concentrated. The crude product was purified by flash chromatography (silica gel, 90% ethyl acetate in hexanes) to afford *cis*-

adamantane-2-spiro-3'-8'-(methylthio)methyl]-1',2',4'-trioxaspiro[4.5]decane (0.35 g, 36%) as a colorless oil. ^1H NMR (200 MHz, CDCl_3) δ 1.15–1.37 (m, 2H), 1.50–2.02 (m, 21H), 2.10 (s, 3H), 2.40 (d, J = 7.0 Hz, 2H). **Step 2.** To a solution of the above thioether (350 mg, 1.08 mmol) in CH_2Cl_2 (5 ml) at 0°C was added dropwise a solution of 3-chloroperoxybenzoic acid (70 % reagent, 790 mg, 3.2 mmol) in $\text{CHCl}_3/\text{CH}_2\text{Cl}_2$ (1:1, 16 ml). After 2 h, the mixture was allowed to warm up to rt and stirred overnight before being quenched with saturated aq. NaHCO_3 (50 ml). The resulting mixture was concentrated to 50 ml and filtered. The collected precipitate was purified by flash chromatography (silica gel, 25% ethyl acetate in hexanes; then 5% MeOH in CH_2Cl_2) to afford trioxolane **OZ307** (245 mg, 64%) as a colorless solid. mp 118–121°C; ^1H NMR (500 MHz, CDCl_3) δ 1.33–1.52 (m, 2H), 1.59–2.03 (m, 20H), 2.04–2.25 (m, 1H), 2.92 (s, 3H), 2.94 (d, J = 6.4 Hz, 2H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.43, 26.81, 30.15, 30.78, 33.66, 34.75, 36.35, 36.73, 42.16, 60.13, 107.72, 111.61. Anal. Calcd for $\text{C}_{18}\text{H}_{28}\text{O}_5\text{S}$: C, 60.65; H, 7.92. Found: C, 60.70; H, 7.75.

cis-Adamantane-2-spiro-3'-8'-(2'-amino-2'-oxoethyl)(methylsulfonyl)amino)methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ308). To a solution of **OZ256** (220 mg, 0.62 mmol) and triethylamine (202 mg, 2 mmol) in CH_2Cl_2 (10 ml) at 0°C was added a solution of methanesulfonyl chloride (137 mg, 1.2 mmol) in CH_2Cl_2 (2 ml). The reaction mixture was stirred at rt for 4 h, diluted with CH_2Cl_2 (10 ml), washed with water and brine, dried over MgSO_4 , filtered, and concentrated. The crude product was crystallized from CH_2Cl_2 /hexanes (1:4) to afford trioxolane **OZ308** (250 mg, 94%) as a colorless solid. mp 132–136°C; ^1H NMR (500 MHz, CDCl_3) δ 1.17–1.35 (m, 2H), 1.59–2.05 (m, 21H), 2.96 (s, 3H), 3.12 (d, J = 7.3 Hz, 2H), 3.89 (s, 2H), 5.60 (s, 1H), 6.17 (s, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.44, 26.84, 27.71, 33.55, 34.76, 36.36, 36.75, 37.97, 51.56, 54.89, 108.43, 111.44, 170.70. Anal. Calcd for $\text{C}_{20}\text{H}_{32}\text{N}_2\text{O}_6\text{S}$: C, 56.05; H, 7.53; N, 6.54. Found: C, 56.22; H, 7.63; N, 6.71.

cis-Adamantane-2-spiro-3'-8'-(carboxymethyl)amino)methyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ309). A mixture of *cis*-adamantane-2-spiro-3'-8'-formyl-1',2',4'-trioxaspiro[4.5]decane (588 mg, 2.0 mmol), glycine (2.20 g, 20 mmol), acetic acid (180 mg, 3 mmol), and sodium cyanoborohydride (190 mg, 3 mmol) in methanol (100 ml) under Ar was stirred at rt for 16 h. The reaction mixture was

concentrated, and the residue was triturated with water (50 ml). The solid was collected by filtration and washed with water and ether. The solid free base was suspended in methanol (10 ml), treated with a solution of methanesulfonic acid (91 mg, 0.95 mmol) in methanol (2 ml), and concentrated. The residue was crystallized from MeOH/ether (1:9) to afford

5 trioxolane **OZ309** (350 mg, 39%) as a colorless solid. mp 144–146°C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 0.97–1.21 (m, 2H), 1.54–2.02 (m, 21H), 2.30 (s, 3H), 2.82 (d, *J* = 5.9 Hz, 2H), 3.86 (s, 2H), 8.80 (s, 2H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 25.97, 26.37, 27.36, 32.59, 32.96, 34.41, 34.43, 35.91, 36.23, 47.46, 51.83, 108.21, 110.84, 168.26. Anal. Calcd for C₂₀H₃₃NO₈S•0.5H₂O: C, 52.61; H, 7.51; N, 3.07. Found: C, 52.27; H, 7.49; N, 3.15.

10 **cis-Adamantane-2-spiro-3'-8'-[[[1'-methyl-1'H-imidazol-2'-yl)sulfonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ310).** Step 1. To a suspension of 60% NaH (160 mg, 4 mmol) in DMF (5 ml) under N₂ at 0°C was added dropwise a solution of 2-mercaptop-1-methylimidazole (456 mg, 4.0 mmol) in DMF (10 ml). The mixture was stirred for 1 h before a solution of the methanesulfonate of **OZ119** (744 mg, 2 mmol) in DMF (4 ml) was
15 added dropwise. The mixture was stirred at rt overnight and concentrated. The residue was dissolved in CH₂Cl₂ (30 ml), washed with water and brine, dried over MgSO₄, filtered, and concentrated. The crude product was purified by flash chromatography (silica gel, 25% ethyl acetate in hexanes) to afford **cis-adamantane-2-spiro-3'-8'-[[[1'-methyl-1'H-imidazol-2'-yl)thio]methyl]-1',2',4'-trioxaspiro[4.5]decane** (0.24 g, 30%) as a colorless solid. mp 140–142°C. ¹H NMR (200 MHz, CDCl₃) δ 1.20–1.35 (m, 2H), 1.60–2.00 (m, 21H), 3.00 (*d*, *J* = 6.8 Hz, 2H), 3.60 (s, 3H), 6.90 (s, 1H), 7.03 (s, 1H). Step 2. To a solution of the above thioether (250 mg, 0.6 mmol) in CH₂Cl₂ (5 ml) at 0°C was added dropwise a solution of 3-chloroperoxybenzoic acid (70 % reagent, 400 mg, 1.6 mmol) in CHCl₃/CH₂Cl₂ (1:1, 8 ml). After 2 h, the mixture was allowed to warm up to rt, stirred
20 overnight, and concentrated to 3 ml. The residue was diluted with saturated aq. NaHCO₃ (20 ml) and extracted with CH₂Cl₂ (2 x 20 ml). The combined extracts were washed with water and brine, dried over MgSO₄, filtered, and concentrated. The crude product was purified by flash chromatography (silica gel, 10% to 50% ethyl acetate in hexanes) to afford trioxolane **OZ310** (130 mg, 51%) as a colorless solid. mp 151–152°C; ¹H NMR
25 (500 MHz, CDCl₃) δ 1.31–1.51 (m, 2H), 1.59–2.04 (m, 20H), 2.06–2.25 (m, 1H), 3.41 (*d*, *J* = 6.3 Hz, 2H), 3.99 (s, 3H), 6.98 (s, 1H), 7.12 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ

26.44, 26.84, 29.96, 30.89, 33.68, 34.76, 35.08, 36.35, 36.75, 59.99, 107.77, 111.55, 125.39, 128.96, 142.61. Anal. Calcd for C₂₁H₃₀N₂O₅S: C, 59.69; H, 7.16; N, 6.63. Found: C, 59.56; H, 7.10; N, 6.47.

cis-Adamantane-2-spiro-3'-8'-[[[4'-(aminocarbonyl)-1'-

5 **piperidinyl]carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ311).** To a solution of the **OZ78** active ester (220 mg, 0.5 mmol) in CHCl₃ (10 ml) and ethanol (10 ml) was added isonipecotamide (128 mg, 1.0 mmol). The resulting mixture was stirred at rt for 4 h before removal of the solvents. The residue was crystallized from ethanol/water (2:1) to afford trioxolane **OZ311** (164 mg, 76%) as a colorless solid. mp 149–151°C; ¹H NMR (500 MHz, CDCl₃) δ 1.16–1.32 (m, 2H), 1.58–2.06 (m, 25H), 2.22 (d, J = 6.8 Hz, 2H), 2.39 (tt, J = 11.2, 3.9 Hz, 1H), 2.69 (t, J = 11.5 Hz, 1H), 3.06 (t, J = 11.7 Hz, 1H), 3.92 (d, J = 13.7 Hz, 1H), 4.60 (d, J = 13.2 Hz, 1H), 5.54 (s, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.46, 26.84, 28.60, 29.02, 30.25, 30.30, 33.31, 34.05, 34.77, 36.37, 36.78, 39.24, 41.04, 42.37, 45.15, 108.61, 111.31, 170.39, 176.16. Anal. Calcd for C₂₄H₃₆N₂O₅: C, 66.64; H, 8.39; N, 6.48.

10 Found: C, 66.39; H, 8.46; N, 6.30.

cis-Adamantane-2-spiro-3'-8'-[(4'-carboxy-1'-piperidinyl)carbonyl]methyl]-

1'2',4'-trioxaspiro[4.5]decane (OZ312). To a solution of the **OZ78** active ester (220 mg, 0.5 mmol), water (5 ml), and ethanol (10 ml) in CHCl₃ (10 ml) was added isonipecotic acid (129 mg, 1.0 mmol). The resulting mixture was stirred at rt for 16.5 h before removal of the solvents. The residue was crystallized from ethanol/water (1:1) to afford trioxolane **OZ312** (179 mg, 82%) as a colorless solid. mp 159–161°C; ¹H NMR (500 MHz, CDCl₃) δ 1.18–1.35 (m, 2H), 1.58–2.06 (m, 25H), 2.24 (d, J = 6.8 Hz, 2H), 2.60 (tt, J = 10.7, 3.9 Hz, 1H), 2.86 (t, J = 11.2 Hz, 1H), 3.14 (t, J = 11.2 Hz, 1H), 3.85 (d, J = 13.7 Hz, 1H), 4.44 (d, J = 13.6 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.48, 26.86, 27.72, 28.33, 30.27, 33.37, 34.06, 34.79, 36.39, 36.80, 39.23, 40.46, 40.93, 44.96, 108.62, 111.34, 170.53, 178.19.

25 Anal. Calcd for C₂₄H₃₅NO₆: C, 66.49; H, 8.14; N, 3.23. Found: C, 66.28; H, 8.26; N, 3.13.

cis-Adamantane-2-spiro-3'-8'-[[[[2'-(4'-

morpholinyl)ethyl]amino]carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane p-tosylate (OZ313). To a solution of the **OZ78** active ester (220 mg, 0.5 mmol) in CHCl₃ (10 ml) was added a solution of 4-(2-aminoethyl)morpholine (130 mg, 1.0 mmol) in CHCl₃ (1 ml). The resulting mixture was stirred at rt for 2 h before being quenched with water (20 ml). After

separation of the organic layer, the aqueous layer was extracted with CHCl₃ (2 x 20 ml). The combined extracts were washed with water (3 x 20 ml) and brine (20 ml), dried over MgSO₄, and filtered. To the filtrate was added a solution of *p*-toluenesulfonic acid monohydrate (76 mg, 0.4 mmol) in ethanol (1 ml). After evaporation of the solvents, the residue was treated with ether (20 ml), filtered, and washed with ether (20 ml) to afford trioxolane **OZ313** (191 mg, 62%) as a colorless solid. mp 130–132°C; ¹H NMR (500 MHz, CDCl₃) δ 1.07–1.29 (m, 2H), 1.55–2.04 (m, 21H), 2.08 (d, J = 7.3 Hz, 2H), 2.39 (s, 3H), 2.81–3.05 (m, 2H), 3.27–3.42 (m, 2H), 3.61–3.82 (m, 4H), 3.89–4.09 (m, 4H), 7.23 (d, J = 7.8 Hz, 2H), 7.75 (d, J = 7.8 Hz, 2H), 7.94 (br s, 1H), 10.56 (br s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 21.33, 26.46, 26.85, 29.77, 33.19, 33.53, 33.90, 34.76, 36.35, 36.78, 42.38, 52.73, 57.20, 63.67, 108.48, 111.17, 125.82, 129.14, 140.96, 174.20. Anal. Calcd for C₃₁H₄₆N₂O₈S•0.5H₂O: C, 60.47; H, 7.69; N, 4.55. Found: C, 60.26; H, 8.03; N, 4.36.

cis-Adamantane-2-spiro-3'-8'-[[[4'-(2'-pyrimidinyl)-1'-piperazinyl]carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ314). To a solution of the **OZ78** active ester (220 mg, 0.5 mmol) in CHCl₃ (10 ml) was added a solution of 1-(2-pyrimidinyl)piperazine (164 mg, 1.0 mmol) in CHCl₃ (10 ml). The resulting mixture was stirred at rt for 2 h before removal of the solvent. The residue was crystallized from ethanol to afford trioxolane **OZ314** (199 mg, 85%) as a colorless solid. mp 160–162°C; ¹H NMR (500 MHz, CDCl₃) δ 1.18–1.35 (m, 2H), 1.58–2.08 (m, 21H), 2.27 (d, J = 6.8 Hz, 2H), 3.54 (t, J = 5.2 Hz, 2H), 3.71 (t, J = 5.2 Hz, 2H), 3.73–3.89 (m, 4H), 6.54 (dd, J = 4.9, 4.9 Hz, 1H), 8.33 (d, J = 4.4 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.47, 26.85, 30.30, 33.32, 34.06, 34.77, 36.37, 36.79, 39.31, 41.40, 43.60, 43.81, 45.51, 108.60, 110.46, 111.32, 157.76, 161.51, 170.73. Anal. Calcd for C₂₆H₃₆N₄O₄: C, 66.64; H, 7.74; N, 11.96. Found: C, 67.03; H, 8.25; N, 11.84.

cis-Adamantane-2-spiro-3'-8'-[[[(trans-4'-aminocyclohexyl)amino]carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane p-tosylate (OZ315). To a solution of the **OZ78** active ester (220 mg, 0.5 mmol) in CHCl₃ (10 ml) was added rapidly a solution of *trans*-1,4-diaminocyclohexane (343 mg, 3.0 mmol) in CHCl₃ (10 ml). The resulting mixture was stirred at rt for 1 h and filtered. The filtrate was diluted with water (30 ml). After separation of the organic layer, the aqueous layer was extracted with CHCl₃ (2 x 10 ml). The combined extracts were washed with water (2 x 20 ml) and

brine (20 ml), dried over MgSO₄, and filtered. To the filtrate was added a solution of *p*-toluenesulfonic acid monohydrate (50 mg, 0.26 mmol) in ethanol (1 ml). After evaporation of the solvents, the residue was treated with ether (20 ml), filtered, and washed with ether (20 ml) to afford trioxolane **OZ315** (139 mg, 47%) as a colorless solid. mp 140°C dec; ¹H NMR (500 MHz, DMSO-*d*₆) δ 0.97–1.43 (m, 6H), 1.54–2.02 (m, 27H), 2.29 (s, 3H), 2.84–3.06 (m, 1H), 3.38–3.52 (m, 1H), 7.12 (d, J = 7.8 Hz, 2H), 7.48 (d, J = 7.8 Hz, 2H), 7.71 (s, 1H), 7.73 (s, 3H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 20.95, 25.97, 26.37, 29.26, 29.57, 30.16, 33.03, 33.58, 34.42, 35.92, 36.25, 42.10, 46.60, 48.75, 108.57, 110.63, 125.65, 128.25, 137.87, 145.76, 170.48. Anal. Calcd for C₃₁H₄₆N₂O₇S: C, 63.02; H, 7.85; N, 4.74.
10 Found: C, 62.88; H, 7.68; N, 4.57.

cis-Adamantane-2-spiro-3'-8'-[[2'-[(3'-pyridinylcarbonyl)amino]acetyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ316). To a solution of nicotinoylglycine (216 mg, 1.2 mmol), EDCI (290 mg, 1.5 mmol), and HOBr (200 mg, 1.5 mmol) in DMF (10 ml) under N₂ was added a solution 15 of **OZ209** (389 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in DMF (5 ml). The resulting mixture was stirred at rt for 16 h before being quenched with water (70 ml) and 1 M aq. NaOH (3 ml). The precipitate was collected by filtration, re-dissolved in CH₂Cl₂ (4 ml), and treated with a solution of methanesulfonic acid (94 mg, 0.98 mmol) in ether (12 ml). The precipitate was obtained by filtration to afford trioxolane **OZ316** (420 mg, 76%) 20 as a colorless solid. mp 142–145°C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 0.95–1.23 (m, 2H), 1.41–1.97 (m, 21H), 2.38 (s, 3H), 2.94 (app t, J = 6.3 Hz, 2H), 3.91 (d, J = 5.3 Hz, 2H), 7.96 (br s, 1H), 8.02 (dd, J = 5.9, 5.9 Hz, 1H), 8.69 (d, J = 7.3 Hz, 1H), 8.94 (d, J = 5.3 Hz, 1H), 9.19 (s, 1H), 9.22 (t, J = 5.6 Hz, 1H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 26.00, 26.40, 27.63, 33.43, 34.44, 35.84, 35.94, 36.27, 42.82, 43.94, 108.76, 110.66, 125.99, 131.79, 141.26, 144.34, 147.12, 163.32, 168.40. Anal. Calcd for C₂₆H₃₇N₃O₈S: C, 56.61; H, 6.76; N, 7.62. Found: C, 56.51; H, 6.60; N, 7.56.

cis-Adamantane-2-spiro-3'-8'-[[[(1'-aminocyclopentyl)carbonyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ317). To a solution of 1-amino-1-cyclopentanecarboxylic acid (155 mg, 1.2 mmol), EDCI (290 mg, 1.5 mmol), and HOBr (200 mg, 1.5 mmol) in DMF (10 ml) under N₂ was added a 30 solution of **OZ209** (389 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in DMF (5

ml). The resulting mixture was stirred at rt for 16 h before being quenched with water (70 ml) and 3 M aq. NaOH (2 ml). The precipitate was collected by filtration and triturated with 50% aq. ethanol to afford trioxolane **OZ317** (250 mg, 62%) as a colorless solid. mp 160–162°C (50% aq. ethanol); ¹H NMR (500 MHz, CDCl₃) δ 1.15–1.33 (m, 2H), 1.38–5 2.07 (m, 27H), 2.19–2.29 (m, 2H), 3.12 (app t, J = 6.6 Hz, 2H), 7.90 (br s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.47, 26.86, 27.55, 33.60, 34.78, 34.79, 36.38, 36.77, 40.36, 48.54, 108.40, 111.50. Anal. Calcd for C₂₃H₃₆N₂O₄: C, 68.29; H, 8.97; N, 6.92. Found: C, 68.47; H, 8.70; N, 6.72.

cis-Adamantane-2-spiro-3'-8'-[(3'-ethoxy-3'-oxopropyl)amino]methyl]-1',2',4'-trioxaspiro[4.5]decane p-tosylate (OZ318). To a mixture of **cis-adamantane-2-spiro-3'-8'-formyl-1',2',4'-trioxaspiro[4.5]decane** (292 mg, 1.0 mmol), β-alanine ethyl ester hydrochloride (154 mg, 1.0 mmol), and triethylamine (101 mg, 1.0 mmol) in 1,2-dichloroethane (15 ml) at rt under N₂ was added sodium triacetoxyborohydride (322 mg, 1.5 mmol). The resulting mixture was stirred at rt for 4 h, and then quenched with saturated 10 aq. NaHCO₃ (20 ml) and 1 M. aq. NaOH (3 ml). The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂ (2 x 20 ml). The combined organic extracts were washed with water and brine, dried over MgSO₄, and concentrated. The crude product was dissolved in CH₂Cl₂ (2 ml) and added to a solution of *p*-toluenesulfonic acid monohydrate (170 mg, 0.89 mmol) in ether/CH₂Cl₂ (4:1, 5 ml). Hexanes (10 ml) was added, and the 15 resulting solid was collected by filtration to afford trioxolane **OZ318** (220 mg, 39%) as a colorless solid. mp 128–131°C; ¹H NMR (500 MHz, CDCl₃) δ 1.10–1.23 (m, 2H), 1.24 (t, J = 7.1 Hz, 3H), 1.45–2.07 (m, 21H), 2.37 (s, 3H), 2.76–2.85 (m, 2H), 2.96 (app t, J = 7.1 Hz, 2H), 3.25–3.34 (m, 2H), 4.13 (q, J = 7.0 Hz, 2H), 7.20 (d, J = 8.3 Hz, 2H), 7.71 (d, J = 7.8 Hz, 2H), 8.60 (s, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 14.05, 21.28, 26.43, 26.84, 27.66, 30.22, 33.04, 33.11, 34.73, 36.34, 36.74, 44.08, 53.62, 61.28, 107.91, 111.33, 25 125.78, 128.98, 140.61, 141.54, 170.62. Anal. Calcd for C₂₉H₄₃NO₈S: C, 61.57; H, 7.66; N, 2.48. Found: C, 61.79; H, 7.53; N, 2.50.

cis-Adamantane-2-spiro-3'-8'-[(3'-amino-3'-oxopropyl)amino]methyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ319). A mixture of β-alaninamide hydrochloride 30 (375 mg, 3 mmol), **cis-adamantane-2-spiro-3'-8'-formyl-1',2',4'-trioxaspiro[4.5]decane** (292 mg, 1 mmol), and NaBH₃CN (100 mg, 1.5 mmol) in methanol (15 ml) was stirred at rt

for 2 days and then concentrated. The crude product was triturated with 0.5 M aq. NaOH, and the resulting solid was crystallized from ether/CH₂Cl₂ (9:1) to afford the trioxolane free amine (200 mg, 55%). To a solution of methanesulfonic acid (50 mg, 0.51 mmol) in ether (5 ml) was added a solution of the above free amine (179 mg, 0.49 mmol) in CH₂Cl₂ (2 ml). The solid was collected by filtration, washed with ether, and dried to afford trioxolane **OZ319** (190 mg, 84%) as a colorless solid. mp 133–136°C; ¹H NMR (500 MHz, CDCl₃) δ 1.22–1.38 (m, 2H), 1.61–2.05 (m, 21H), 2.75 (s, 3H), 2.81–2.96 (m, 4H), 3.25 (br s, 2H), 6.76 (s, 1H), 7.58 (s, 1H), 8.59 (br s, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.43, 26.83, 27.57, 30.54, 33.28, 33.34, 34.76, 36.36, 36.74, 39.49, 44.94, 53.42, 107.89, 111.59, 173.76. Anal. Calcd for C₂₁H₃₆N₂O₇S: C, 54.76; H, 7.88; N, 6.08. Found: C, 54.60; H, 7.61; N, 6.06.

cis-Adamantane-2-spiro-3'-8'-(4'-aminocarbonyl-1'H-imidazol-1'-ylmethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ320). To a mixture of **OZ225** (*cis*-Adamantane-2-spiro-3'-8'-(4'-carboxy-1'H-imidazol-1'-ylmethyl)-1',2',4'-trioxaspiro[4.5]decane) (600 mg, 1.54 mmol), Boc₂O (375 mg, 2.02 mmol), ammonium bicarbonate (156 mg, 1.92 mmol) in acetonitrile (60 ml) under N₂ was slowly added pyridine (75 mg, 0.95 mmol). After completion of the addition, the reaction mixture was stirred at rt for 16 h before concentration. The crude product was dissolved in CH₂Cl₂ (50 ml), washed with water and brine, dried over MgSO₄, and concentrated to afford the corresponding anhydride of **OZ225** (560 mg). A mixture of the above anhydride and ammonia (7 N in methanol, 3 ml) in CH₂Cl₂ (10 ml) was stirred at rt overnight and then filtered. The filtrate was concentrated and triturated with CH₂Cl₂/ether (1:2). The resulting solid was collected by filtration and dried to afford trioxolane **OZ320** (250 mg, 42%) as a colorless solid. mp 152–155°C; ¹H NMR (500 MHz, CDCl₃) δ 1.19–1.34 (m, 2H), 1.54–2.07 (m, 21H), 3.81 (d, J = 7.3 Hz, 2H), 5.46 (br s, 1H), 6.96 (s, 1H), 7.36 (s, 1H), 7.56 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.43, 26.82, 27.52, 33.40, 34.76, 36.34, 36.73, 37.66, 52.98, 108.06, 111.68, 122.65, 136.80, 137.06, 164.62. Anal. Calcd for C₂₁H₂₉N₃O₄•0.1CH₂Cl₂: C, 64.00; H, 7.43; N, 10.61. Found: C, 64.26; H, 7.13; N, 10.34.

cis-Adamantane-2-spiro-3'-8'-(5'-aminocarbonyl-1'H-imidazol-1'-ylmethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ321). To a mixture of **OZ231** (*cis*-Adamantane-2-spiro-3'-8'-(5'-carboxy-1'H-imidazol-1'-ylmethyl)-1',2',4'-trioxaspiro[4.5]decane) (350 mg,

0.9 mmol), Boc₂O (275 mg, 1.26 mmol), and ammonium bicarbonate (92 mg, 1.17 mmol) in DMF (2 ml) under N₂ was slowly added pyridine (50 mg, 0.6 mmol). After completion of the addition, the reaction mixture was stirred at rt for 16 h before ammonia (7 N in methanol, 1 ml) was added. The resulting mixture was stirred for 3 h and concentrated. The 5 crude product was dissolved in CH₂Cl₂ (30 ml), washed with water and brine, dried over MgSO₄, and concentrated. Crystallization from 40% aq. ethanol/NEt₃ (9:1) afforded trioxolane **OZ321** (50 mg, 14%) as a colorless solid. mp 148–150 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.18–1.32 (m, 2H), 1.54–2.07 (m, 21H), 4.18 (d, J = 8.3 Hz, 2H), 5.68 (br s, 2H), 7.50 (s, 1H), 7.51 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.44, 26.83, 27.46, 33.49, 10 34.75, 36.35, 36.75, 37.03, 52.10, 108.39, 111.47, 124.40, 133.22, 142.17, 161.66. Anal. Calcd for C₂₁H₂₉N₃O₄•0.5H₂O: C, 63.62; H, 7.63; N, 10.60. Found: C, 63.58; H, 7.68; N, 10.28.

cis-Adamantane-2-spiro-3'-8'-[[[2'-(formylamino)acetyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ322). To a solution of *N*-formylglycine (124 mg, 1.2 mmol), EDCI (290 mg, 1.5 mmol), and HOBr (200 mg, 1.5 mmol) in DMF (10 ml) under N₂ was added a solution of **OZ209** (389 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in DMF (5 ml). The resulting mixture was stirred at rt for 16 h before being quenched with water (70 ml). The precipitate was collected by filtration and recrystallized from hexane/CH₂Cl₂ (4:1) to afford trioxolane **OZ322** (270 mg, 71%) as a colorless solid. 20 mp 125–129 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.15–1.33 (m, 2H), 1.45–2.07 (m, 21H), 3.14 (app t, J = 6.4 Hz, 2H), 3.98 (d, J = 4.9 Hz, 2H), 6.52 (s, 1H), 6.77 (s, 1H), 8.23 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.44, 26.84, 27.68, 33.68, 34.76, 36.19, 36.35, 36.75, 41.85, 44.86, 108.51, 111.40, 161.50, 168.26. Anal. Calcd for C₂₀H₃₀N₂O₅: C, 63.47; H, 7.99; N, 7.40. Found: C, 63.55; H, 8.02; N, 7.27.

cis-Adamantane-2-spiro-3'-8'-[4'-(2'-aminoethoxy)phenyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ323). Step 1. To a solution of **OZ288** (1.07 g, 3 mmol), triphenylphosphine (1.26 g, 4.8 mmol), *N*-(2-hydroxyethyl)phthalimide (0.86 g, 4.5 mmol) in THF (20 ml) at 0°C was added dropwise diisopropyl azodicarboxylate (0.98 g, 4.8 mmol). The mixture was stirred at rt for 36 h and concentrated. The residue was 30 purified by flash chromatography (silica gel, 10% ethyl acetate in hexanes) followed by crystallization from ethanol/triethylamine (4:1) to afford the desired phthalimide derivative

(180 mg, 12%) as a colorless solid. mp 142–144 °C; ^1H NMR (500 MHz, CDCl_3) δ 1.62–2.02 (m, 22H), 2.43–2.48 (m, 1H), 4.09 (t, J = 5.9 Hz, 2H), 4.20 (t, J = 5.9 Hz, 2H), 6.80 (d, J = 8.3 Hz, 2H), 7.07 (d, J = 8.3 Hz, 2H), 7.71–7.73 (m, 2H), 7.84–7.86 (m, 2H). **Step 2.** A mixture of above phthalimide derivative (180 mg, 0.34 mmol) and hydrazine 5 monohydrate (140 mg, 2.5 mmol) in chloroform/ethanol (7:3, 10 ml) was heated at 55–60°C for 24 h. After being cooled to rt, the solid by-product was filtered off. The filtrate was diluted with CHCl_3 (10 ml), washed with water (2 x 20 ml) and brine (20 ml), dried over MgSO_4 , and concentrated. The residue was dissolved in ether (4 ml) and then a solution of methanesulfonic acid (34 mg, 0.35 mmol) in ether (4 ml) was added. The solid 10 was collected by filtration to afford trioxolane **OZ323** (118 mg, 70%) as a colorless solid. mp 152–155°C; ^1H NMR (500 MHz, CDCl_3) δ 1.55–2.07 (m, 22H), 2.47 (t, J = 12.0 Hz, 1H), 2.67 (s, 3H), 3.28–3.33 (m, 2H), 4.11 (s, 2H), 6.83 (d, J = 8.3 Hz, 2H), 7.07 (d, J = 8.8 Hz, 2H), 7.73 (s, 3H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.50, 26.90, 31.62, 34.69, 34.81, 36.42, 36.82, 39.18, 39.43, 41.99, 63.92, 108.34, 111.35, 114.71, 127.74, 139.44, 156.18. 15 Anal. Calcd for $\text{C}_{25}\text{H}_{37}\text{NO}_7\text{S} \bullet 0.17\text{CH}_2\text{Cl}_2$: C, 59.29; H, 7.38; N, 2.75. Found: C, 59.49; H, 7.06; N, 2.81.

cis-Adamantane-2-spiro-3'-8'-[[[1'-oxido-2'-pyridinyl)sulfonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ324). To a solution of **OZ328** (280 mg, 0.69 mmol) in CH_2Cl_2 (5 ml) at 0°C was added dropwise a solution of 3-chloroperoxybenzoic acid (70% reagent, 400 mg, 1.6 mmol) in $\text{CHCl}_3/\text{CH}_2\text{Cl}_2$ (1:1, 8 ml). After 2 h of stirring, the mixture 20 was allowed to warm up to rt and stirred overnight before being diluted with saturated aq. NaHCO_3 (50 ml). The mixture was stirred for additional 1.5 h. The aqueous layer was extracted with CHCl_3 (3 x 15 ml). The combined organic solutions were washed with water and brine, dried over MgSO_4 , filtered, and concentrated. The crude product was triturated 25 with ether/hexanes (1:1, 10 ml) to afford trioxolane **OZ324** (150 mg, 50%) as a colorless solid. mp 148–151°C; ^1H NMR (500 MHz, CDCl_3) δ 1.35–1.52 (m, 2H), 1.53–2.22 (m, 21H), 3.65 (d, J = 6.8 Hz, 2H), 7.44 (ddd, J = 7.8, 7.8, 1.0 Hz, 1H), 7.51 (ddd, J = 6.8, 6.8, 2.0 Hz, 1H), 8.10 (dd, J = 8.1, 1.8 Hz, 1H), 8.27 (d, J = 6.3 Hz, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.43, 26.83, 29.91, 30.95, 33.64, 34.75, 34.76, 36.34, 36.74, 58.48, 107.73, 111.54, 125.39, 127.57, 129.67, 141.15, 147.35. Anal. Calcd for $\text{C}_{22}\text{H}_{29}\text{NO}_6\text{S}$: C, 60.67; H, 6.71; N, 3.22. Found: C, 60.51; H, 6.63; N, 3.11.

cis-Adamantane-2-spiro-3'-8'-(2'-pyrimidinyloxy)methyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ325). To a suspension of 60% NaH (80 mg, 2 mmol) in DMF (10 ml) under N₂ at 0°C was added dropwise a solution of **OZ119** (588 mg, 2 mmol) in DMF (20 ml). The mixture was stirred at rt for 1 h and cooled down to 0°C.

5 After 2-chloropyrimidine (241 mg, 2 mmol) was added, the resulting mixture was stirred at rt overnight. Water (70 ml) was added, and the precipitate was collected by filtration. The crude product was dissolved in ether (20 ml) and added to a solution of methanesulfonic acid (170 mg, 1.77 mmol) in ether/CH₂Cl₂ (1:1, 4 ml). The solid was collected by filtration and dried to afford trioxolane **OZ325** (530 mg, 57%) as a colorless solid. mp 133–135°C;

10 ¹H NMR (500 MHz, CDCl₃) δ 1.27–1.41 (m, 2H), 1.62–2.04 (m, 21H), 2.93 (s, 3H), 4.42 (d, J = 7.4 Hz, 2H), 7.31–7.36 (m, 1H), 8.94 (d, J = 5.4 Hz, 2H), 11.28 (br s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.45, 26.51, 26.84, 33.40, 34.77, 35.29, 36.37, 36.75, 39.28, 74.65, 108.31, 111.55, 115.16, 159.43, 160.34. Anal. Calcd for C₂₂H₃₂N₂O₇S: C, 56.39; H, 6.88; N, 5.98. Found: C, 56.16; H, 6.72; N, 5.89.

15 **cis-Adamantane-2-spiro-3'-8'-(2'-pyrimidinylamino)methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ326).** A mixture of **OZ209** (389 mg, 1 mmol), triethylamine (101 mg, 1 mmol), K₂CO₃ (276 mg, 2 mmol), and 2-chloropyrimidine (170 mg, 1.5 mmol) in DMF (15 ml) was heated at 50 °C for 20 h. The mixture was cooled to rt and diluted with water (70 ml). The precipitate was collected and triturated with ether/hexanes (1:1, 10 ml). The filtrate was concentrated, and the residue was purified by flash chromatography (silica gel, 1%–5% methanol in CH₂Cl₂) to afford trioxolane **OZ326** (75 mg, 20%) as a colorless solid. mp 112–115°C; ¹H NMR (500 MHz, CDCl₃) δ 1.15–1.35 (m, 2H), 1.55–2.07 (m, 21H), 3.29 (app t, J = 6.6 Hz, 2H), 5.23 (s, 1H), 6.51 (t, J = 4.9 Hz, 1H), 8.26 (d, J = 4.4 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.47, 26.87, 27.86, 33.82, 34.78, 34.80, 36.26, 36.38, 36.80, 46.71, 108.81, 110.46, 111.31, 158.00, 162.48. Anal. Calcd for C₂₁H₂₉N₃O₃: C, 67.90; H, 7.87; N, 11.31. Found: C, 67.82; H, 7.82; N, 11.26.

20 **cis-Adamantane-2-spiro-3'-8'-(2'-S)-2'-aminocarbonyl-1'-pyrrolidinyl)methyl]-1',2',4'-trioxaspiro[4.5]decane p-tosylate (OZ327).** A mixture of **cis-adamantane-2-spiro-3'-8'-formyl-1',2',4'-trioxaspiro[4.5]decane** (292 mg, 1.0 mmol), L-prolinamide (342 mg, 3.0 mmol), and NaBH₃CN (100 mg, 1.5 mmol) in methanol (20 ml) was stirred at rt overnight before removal of the solvent. The residue was

diluted with saturated aq. NaHCO₃ (30 ml) and extracted with CHCl₃ (3 x 25 ml). The combined organic extracts were washed with water and brine, dried over MgSO₄, and concentrated. The crude product was dissolved in ethanol (10 ml) and added to a solution of *p*-toluenesulfonic acid monohydrate (570 mg, 3 mmol) in 50% aq. ethanol (20 ml).

5 Water (10 ml) was added, and the resulting precipitate was collected by filtration to afford trioxolane **OZ327** (235 mg, 42%) as a colorless solid. mp 171–173°C; ¹H NMR (500 MHz, CDCl₃) δ 1.03–1.22 (m, 2H), 1.51–1.94 (m, 23H), 1.95–2.06 (m, 1H), 2.28 (s, 3H), 2.32–2.44 (m, 1H), 3.01 (app t, J = 5.9 Hz, 2H), 3.05–3.19 (m, 1H), 3.60–3.75 (m, 1H), 4.04 (app q, J = 8.1 Hz, 1H), 7.10 (d, J = 8.3 Hz, 2H), 7.46 (d, J = 7.8 Hz, 2H), 7.81 (s, 1H), 8.05 (s, 1H), 8.96 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 20.94, 22.58, 25.96, 26.36, 26.59, 27.34, 27.67, 28.93, 32.39, 32.80, 33.00, 34.40, 35.89, 36.22, 54.77, 59.92, 67.78, 108.10, 110.85, 125.65, 128.20, 137.72, 145.98, 169.15. Anal. Calcd for C₂₉H₄₂N₂O₇S: C, 61.90; H, 7.52; N, 4.98. Found: C, 62.07; H, 7.42; N, 4.70.

15 **cis-Adamantane-2-spiro-3'-8'-[[(1'-oxido-2'-pyridinyl)thio]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ328).** To a solution of 2-mercaptopypyridine-*N*-oxide sodium salt hydrate (0.68 g, 4.0 mmol) in DMF (20 ml) was added dropwise a solution of the methanesulfonate of **OZ119** (0.8 g, 1.8 mmol) in DMF (5 ml). The mixture was stirred at 50–60 °C overnight and then concentrated. The residue was triturated sequentially with water, ether, and then 80% aq. ethanol. The solid was collected by filtration and dried to afford trioxolane **OZ328** (0.25 g, 34%) as a colorless solid. mp 151–153°C; ¹H NMR (500 MHz, CDCl₃) δ 1.31–1.47 (m, 2H), 1.59–2.07 (m, 21H), 2.78 (d, J = 6.8 Hz, 2H), 7.04 (dd, J = 6.3, 6.3 Hz, 1H), 7.10 (d, J = 8.3 Hz, 1H), 7.24 (dd, J = 7.8, 7.8 Hz, 1H), 8.26 (d, J = 6.4 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.45, 26.84, 30.01, 33.81, 34.76, 35.46, 36.37, 36.55, 36.75, 108.29, 111.51, 120.15, 121.25, 125.58, 138.80, 152.58. Anal. Calcd for C₂₂H₂₉NO₄S: C, 65.48; H, 7.24; N, 3.47. Found: C, 65.40; H, 7.07; N, 3.56.

25 **cis-Adamantane-2-spiro-3'-8'-[[(1'-piperazinylcarbonyl)amino]methyl]-1',2',4'-trioxaspiro[4.5]decane p-tosylate (OZ329).** Step 1. A mixture of **OZ209** (2.0 g, 5.0 mmol), pyridine (0.8 g, 10 mmol), 4-nitrophenyl chloroformate (2.02 g, 10 mmol) in CH₂Cl₂ (60 ml) was refluxed for 4.5 h, cooled to rt, and then diluted with CH₂Cl₂ (80 ml).

30 The solution was washed with water and brine, dried over MgSO₄, filtered, and concentrated. The crude product was purified by flash chromatography (silica gel, 0–1%

methanol in CH_2Cl_2) to afford the desired carbamate (1.36 g, 59%) as a colorless solid. mp 135–138 °C; ^1H NMR (500 MHz, CDCl_3) δ 1.23–1.33 (m, 2H), 1.58–2.00 (m, 21H), 3.17 (t, J = 6.3 Hz, 2H), 5.17 (br s, 1H), 7.31 (d, J = 9.3 Hz, 2H), 8.24 (d, J = 9.3 Hz, 2H). **Step 2.** A mixture of above carbamate (0.61 g, 1.3 mmol) and piperazine (1.15 g, 13 mmol) in 5 CHCl_3 (10 ml) was stirred at rt for 2 h. The reaction mixture was diluted with CHCl_3 (25 ml), washed with water, 0.25 M aq. NaOH, water, and brine, dried over MgSO_4 , filtered, and concentrated. The crude product was dissolved in ether (10 ml) and added to a solution of *p*-toluenesulfonic acid monohydrate (380 mg, 2 mmol) in methanol/ CH_2Cl_2 (1:10, 11 ml). Ether (30 ml) was added. The precipitate was collected and dried to afford trioxolane 10 **OZ329** (530 mg, 71%) as a colorless solid. mp 165–167°C; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 0.91–1.09 (m, 2H), 1.32–1.97 (m, 21H), 2.28 (s, 3H), 2.87 (app t, J = 6.1 Hz, 2H), 3.04 (br s, 4H), 3.46 (t, J = 5.2 Hz, 4H), 6.71 (t, J = 5.4 Hz, 1H), 7.11 (d, J = 7.8 Hz, 2H), 7.47 (d, J = 7.8 Hz, 2H), 8.64 (s, 2H); ^{13}C NMR (125.7 MHz, $\text{DMSO}-d_6$) δ 20.96, 25.99, 26.40, 27.70, 33.48, 34.43, 35.94, 36.07, 36.27, 40.75, 42.84, 45.57, 108.87, 110.64, 125.67, 128.28, 137.91, 145.73, 157.19. Anal. Calcd for $\text{C}_{29}\text{H}_{43}\text{N}_3\text{O}_7\text{S}$: C, 60.29; H, 7.50; N, 7.27. Found: C, 60.37; H, 7.34; N, 7.19.

cis-Adamantane-2-spiro-3'-8'-[[[(3'-amino-2'-pyrazinyl)carbonyl]amino)methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ330). To a 20 solution of 3-amino-pyrazine-2-carboxylic acid (167 mg, 1.2 mmol), EDCI (290 mg, 1.5 mmol), and HOEt (200 mg, 1.5 mmol) in DMF (10 ml) under N_2 was added a solution of **OZ209** (389 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in DMF (5 ml). The resulting mixture was stirred at rt for 16 h before being quenched with water (70 ml). The precipitate was collected by filtration, triturated with ether/hexanes (1:1), and crystallized 25 from 95% aq. ethanol to afford trioxolane **OZ330** (86 mg, 21%) as a colorless solid. mp 128–131°C; ^1H NMR (500 MHz, CDCl_3) δ 1.21–1.39 (m, 2H), 1.51–2.07 (m, 21H), 3.29 (app t, J = 6.4 Hz, 2H), 7.78 (d, J = 2.5 Hz, 1H), 7.99 (br s, 1H), 8.14 (d, J = 2.5 Hz, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.47, 26.87, 27.86, 33.78, 34.79, 36.38, 36.50, 36.79, 44.44, 108.63, 111.39, 126.61, 131.58, 146.58, 155.04, 166.04. Anal Calcd for 30 $\text{C}_{22}\text{H}_{30}\text{N}_4\text{O}_4 \cdot 0.17\text{CH}_2\text{Cl}_2$: C, 62.11; H, 7.13; N, 13.07. Found: C, 61.86; H, 6.98; N, 13.40.

cis-Adamantane-2-spiro-3'-8'-[[[(1'-methyl-1'H-tetrazol-5'-yl)thio]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ331). To a solution of 1-methyl-5-mercaptotetrazole, sodium salt dihydrate (0.70 g, 4.0 mmol) in DMF (20 ml) was added a solution of the methanesulfonate of **OZ119** (0.90 g, 2.0 mmol) in DMF (5 ml). The mixture was stirred at 5 50–60°C overnight and then concentrated. The residue was triturated with water, and the resulting solid was purified by repeated flash chromatography (silica gel, hexanes/ethyl acetate, 6:1; then silica gel, CH₂Cl₂/MeOH, 50:1) to afford trioxolane **OZ331** (0.48 g, 61%) as a colorless solid. mp 146–149 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.26–1.41 (m, 2H), 1.59–2.07 (m, 21H), 3.28 (d, J = 6.3 Hz, 2H), 3.91 (s, 3H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.43, 26.82, 29.18, 33.29, 33.67, 34.75, 35.81, 36.34, 36.74, 39.10, 108.27, 10 111.47, 154.42. Anal Calcd for C₁₉H₂₈N₄O₃S: C, 58.14; H, 7.19; N, 14.27. Found: C, 58.15; H, 7.04; N, 14.50.

cis-Adamantane-2-spiro-3'-8'-[[[(1'-methyl-1'H-tetrazol-5'-yl)sulfonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ332). To a solution of **OZ331** (320 mg, 0.815 mmol) in CH₂Cl₂ (5 ml) at 0°C was added dropwise a solution of 3-chloroperoxybenzoic acid (70 % reagent, 630 mg, 2.8 mmol) in CHCl₃/CH₂Cl₂ (1:1, 12 ml). After 2 h, the mixture was allowed to warm up to rt, stirred at rt overnight, and diluted with saturated aq. NaHCO₃ (25 ml). The mixture was stirred for an additional 1.5 h. The aqueous layer was extracted with CH₂Cl₂ (2 x 15 ml). The combined organic solutions were washed with water and brine, 15 dried over MgSO₄, filtered, and concentrated. The crude product was triturated with 60% aq. ethanol and recrystallized from CH₂Cl₂/95% aq. ethanol (1:4) to afford trioxolane **OZ332** (260 mg, 75%) as a colorless solid. mp 140–141°C; ¹H NMR (500 MHz, CDCl₃) δ 1.42–1.56 (m, 2H), 1.64–2.09 (m, 20H), 2.16–2.28 (m, 1H), 3.63 (d, J = 6.4 Hz, 2H), 4.36 (s, 3H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.42, 26.81, 29.86, 30.94, 33.55, 34.75, 36.05, 20 36.34, 36.72, 60.88, 107.42, 111.70, 153.70. Anal Calcd for C₁₉H₂₈N₄O₅S: C, 53.76; H, 6.65; N, 13.20. Found: C, 53.61; H, 6.46; N, 13.31.

cis-Adamantane-2-spiro-3'-8'-[[[(1'-aminocyclohexyl)carbonyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ333). To a solution of 1-amino-1-cyclohexanecarboxylic acid (172 mg, 1.2 mmol), EDCI (290 mg, 1.5 mmol), and HOBT 30 (200 mg, 1.5 mmol) in DMF (10 ml) under N₂ was added a solution of **OZ209** (389 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in DMF (5 ml). The resulting mixture

was stirred at rt for 16 h, quenched with water (70 ml), and basified with 1 M aq. NaOH (4 ml). The precipitate was collected by filtration and recrystallized from 40% aq. ethanol to afford trioxolane **OZ333** (330 mg, 79%) as a colorless solid. mp 147–150°C; ¹H NMR (500 MHz, CDCl₃) δ 1.15–2.08 (m, 33H), 3.10 (app t, J = 6.4 Hz, 2H), 7.93 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 21.24, 25.19, 26.46, 26.85, 27.73, 33.81, 34.67, 34.77, 36.37, 36.40, 36.78, 44.24, 57.32, 108.70, 111.28, 177.94. Anal Calcd for C₂₄H₃₈N₂O₄: C, 68.87; H, 9.15; N, 6.69. Found: C, 68.94; H, 9.07; N, 6.82.

cis-Adamantane-2-spiro-3'-8'-(aminoxy)methyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ334). **Step 1.** To a solution of **OZ119** (294 mg, 1 mmol), triphenylphosphine (393 mg, 1.5 mmol), *N*-hydroxyphthalimide (245 mg, 1.5 mmol) in THF (15 ml) at 0°C was added dropwise diisopropyl azodicarboxylate (364 mg, 1.8 mmol). After the stirring was continued at rt for 16 h, the mixture was concentrated. The residue was purified by flash chromatography (silica gel, 14% ethyl acetate in hexanes) to afford the desired phthalimide derivative (440 mg, 100%) as a colorless solid. mp 155–157°C; ¹H NMR (500 MHz, CDCl₃) δ 1.31–1.39 (m, 2H), 1.68–2.00 (m, 21H), 4.02 (d, J = 6.8 Hz, 2 H), 7.73–7.76 (m, 2H), 7.82–7.84 (m, 2H). **Step 2.** A mixture of above phthalimide derivative (400 mg, 0.91 mmol) and hydrazine monohydrate (275 mg, 5.5 mmol) in chloroform/ethanol (7:3, 10 ml) was heated at 55–60°C for 24 h. After being cooled to rt, the solid by-product was filtered off. The filtrate was diluted with CHCl₃ (10 ml), washed with water (2 x 20 ml) and brine (20 ml), dried over MgSO₄, and concentrated. The residue was dissolved in ether (8 ml), and then a solution of methanesulfonic acid (88 mg, 0.91 mmol) in CH₂Cl₂ (2 ml) was added. The resulting mixture was diluted with ether (8 ml), and the precipitate was collected by filtration to afford trioxolane **OZ334** (250 mg, 69%) as a colorless solid. mp 125–126°C; ¹H NMR (500 MHz, CDCl₃) δ 1.19–1.36 (m, 2H), 1.58–2.07 (m, 21H), 2.82 (s, 3H), 3.91 (d, J = 5.8 Hz, 2H), 10.21 (s, 3H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.43, 26.47, 26.86, 33.44, 34.68, 34.77, 36.37, 36.79, 39.44, 79.49, 108.33, 111.42. Anal Calcd for C₁₈H₃₁NO₇S•0.13CH₂Cl₂: C, 52.31; H, 7.57; N, 3.37. Found: C, 52.57; H, 7.06; N, 3.42.

cis-Adamantane-2-spiro-3'-8'-([(2'S)-2'-aminopropionyl]amino)methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ335). To a solution of Fmoc-Ala-OH (375 mg, 1.2 mmol), EDCI (290 mg, 1.5 mmol), and HOEt (200 mg, 1.5 mmol) in DMF (10 ml) under

N₂ was added a solution of **OZ209** (389 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in DMF (5 ml). The resulting mixture was stirred at rt for 16 h before being quenched with water (70 ml). The precipitate was collected by filtration and dissolved in 10% piperidine in DMF (20 ml). The resulting mixture was stirred at rt overnight, diluted 5 with water (70 ml), and extracted with CHCl₃ (3 x 30 ml). The combined extracts were washed with water and brine, dried over MgSO₄, and concentrated. The residue was triturated with hexanes to afford trioxolane **OZ335** (100 mg, 27%) as a colorless solid. mp 115–117 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.15–1.31 (m, 2H), 1.34 (d, J = 6.8 Hz, 3H), 1.41–2.05 (m, 23H), 3.12 (app t, J = 6.4 Hz, 2H), 3.49 (q, J = 7.0 Hz, 1H), 7.39 (s, 1H); ¹³C 10 NMR (125.7 MHz, CDCl₃) δ 21.91, 26.47, 26.86, 27.75, 33.79, 34.78, 36.33, 36.38, 36.79, 44.16, 50.81, 108.66, 111.33, 175.60. Anal Calcd for C₂₀H₃₂N₂O₄: C, 65.91; H, 8.85; N, 7.69. Found: C, 66.08; H, 8.68; N, 7.59.

cis-Adamantane-2-spiro-3'-8'-[[[3'-aminopropionyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane p-tosylate (OZ336). To a solution of Fmoc-β-Ala-OH (375 mg, 1.2 mmol), EDCI (290 mg, 1.5 mmol), and HOBr (200 mg, 1.5 mmol) in DMF (10 ml) under N₂ was added a solution of **OZ209** (389 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in DMF (5 ml). The mixture was stirred at rt for 16 h before being quenched with water (70 ml). The precipitate was collected by filtration and dissolved in 10% piperidine in DMF (20 ml). The resulting mixture was stirred at rt overnight, diluted with 20 water (70 ml), and extracted with CHCl₃ (3 x 30 ml). The combined extracts were washed with water and brine, dried over MgSO₄, and concentrated. The residue was triturated with CH₂Cl₂/hexanes (1:10, 11 ml), and the solid was dissolved in CH₂Cl₂ (5 ml). After a 25 solution of *p*-toluenesulfonic acid monohydrate (127 mg, 0.67 mmol) in methanol (2 ml) was added, the mixture was concentrated and triturated with CH₂Cl₂/ether (1:2, 15 ml) to afford trioxolane **OZ336** (220 mg, 41%) as a colorless solid. mp 166°C dec; ¹H NMR (500 MHz, DMSO-*d*₆) δ 0.98–1.13 (m, 2H), 1.33–1.95 (m, 21H), 2.28 (s, 3H), 2.43 (t, J = 6.8 Hz, 2H), 2.93 (app t, J = 6.1 Hz, 2H), 2.94–3.02 (m, 2H), 7.11 (d, J = 7.8 Hz, 2H), 7.47 (d, J = 8.3 Hz, 2H), 7.64 (s, 3H), 8.08 (t, J = 5.7 Hz, 1H); ¹³C NMR (125.7 MHz, DMSO-*d*₆) δ 20.95, 25.97, 26.38, 27.67, 32.00, 33.41, 34.42, 35.56, 35.79, 35.92, 36.25, 43.90, 108.71, 30 110.66, 125.68, 128.23, 137.79, 145.89, 169.53. Anal Calcd for C₂₇H₄₀N₂O₇S: C, 60.42; H, 7.51; N, 5.22. Found: C, 60.37; H, 7.31; N, 5.22.

cis-Adamantane-2-spiro-3'-8'-[[[(2'S)-2'-pyrrolidinylcarbonyl]amino]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ337). To a solution of Fmoc-Pro-OH (410 mg, 1.2 mmol), EDCI (290 mg, 1.5 mmol), and HOBr (200 mg, 1.5 mmol) in DMF (10 ml) under N₂ was added a solution of **OZ209** (389 mg, 1.0 mmol) and triethylamine (101 mg, 1.0 mmol) in DMF (5 ml). The mixture was stirred at rt for 16 h before being quenched with water (70 ml). The precipitate was collected by filtration and dissolved in 10% piperidine in DMF (20 ml). The resulting mixture was stirred at rt overnight before being diluted with water (70 ml). The precipitate was collected by filtration and triturated twice with hexanes to afford trioxolane **OZ337** (180 mg, 46%) as a colorless solid. mp 132–134°C; ¹H NMR (500 MHz, CDCl₃) δ 1.15–1.34 (m, 2H), 1.44–2.25 (m, 25H), 2.81–2.96 (m, 1H), 2.97–3.06 (m, 1H), 3.10 (app t, J = 6.3 Hz, 2H), 3.66–3.80 (m, 1H), 7.72 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.20, 26.46, 26.85, 27.73, 30.78, 33.78, 33.79, 34.77, 36.36, 36.78, 44.03, 47.28, 60.64, 108.66, 111.29, 175.11. Anal Calcd for C₂₂H₃₄N₂O₄: C, 67.66; H, 8.78; N, 7.17. Found: C, 67.71; H, 8.65; N, 7.19.

cis-Adamantane-2-spiro-3'-8'-[[[(3'S)-3'-amino-1'-pyrrolidinyl]carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ338). Step 1. To a solution of the **OZ78** active ester (880 mg, 2 mmol) in CHCl₃ (40 ml) was added (3S)-3-(*tert*-butoxycarbonylamino)pyrrolidine (447 mg, 2.4 mmol). The resulting mixture was stirred at rt for 1 h before being evaporated. The residue was crystallized from 50% aq. ethanol (40 ml) to give the amide intermediate (577 mg, 59%, 2:1 mixture of rotamers). mp 97–100°C; ¹H NMR (500 MHz, CDCl₃) δ 1.16–1.32 (m, 2H), 1.45 (s, 9H), 1.60–2.06 (m, 22H), 2.09–2.27 (m, 3H), 3.21–3.41 (m, 1H), 3.43–3.62 (m, 2H), 3.64–3.79 (m, 1H), 4.09–4.28 (m, 1H), 4.49–4.73 (m, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.48, 26.85, 28.34, 30.18, 30.23, 30.26, 32.38, 32.95, 33.00, 34.04, 34.05, 34.78, 36.38, 36.79, 40.65, 41.05, 43.56, 44.74, 52.71, 108.63, 108.65, 111.28, 111.32, 155.15, 170.97. **Step 2.** To a solution of the above amide (491 mg, 1.0 mmol) in ether (30 ml) was added a solution of methanesulfonic acid (481 mg, 5.0 mmol) in ether (20 ml). The resulting mixture was stirred at rt for 48 h. After the solvent was decanted off, the residue was washed with ether (20 ml) and crystallized from EtOAc/EtOH (3:1, 20 ml) to give trioxolane **OZ338** (231 mg, 47%, 2:1 mixture of rotamers) as a colorless solid. mp 146°C dec; ¹H NMR (500 MHz, CDCl₃) δ 1.11–1.34 (m, 2H), 1.45–2.05 (m, 21H), 2.06–2.27 (m, 3H), 2.28–2.41 (m, 1H),

2.74 (s, 3H), 3.43–4.01 (m, 5H), 7.96 (s, 2H), 8.02 (s, 1H); ^{13}C NMR (125.7 MHz, CDCl_3) δ 26.48, 26.87, 28.55, 30.11, 30.14, 30.18, 30.24, 30.31, 32.81, 32.86, 34.02, 34.08, 34.79, 36.39, 36.79, 39.39, 40.74, 40.99, 43.32, 44.32, 49.34, 49.38, 50.20, 50.94, 108.49, 108.60, 111.30, 111.35, 171.20, 171.83. Anal Calcd for $\text{C}_{23}\text{H}_{38}\text{N}_2\text{O}_7\text{S}$: C, 56.77; H, 7.87; N, 5.76.

5 Found: C, 56.91; H, 7.66; N, 5.67.

cis-Adamantane-2-spiro-3'-8'-[[(4'-amino-1'-piperidinyl)carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane p-tosylate (OZ339). Step 1. To a solution of the OZ78 active ester (880 mg, 2 mmol) in CHCl_3 (40 ml) was added 4-(*tert*-butoxycarbonylamino)piperidine (481 mg, 2.4 mmol). The resulting mixture was stirred at 10 rt for 1 h before being evaporated. The residue was crystallized from 50% aq. ethanol (80 ml) to give the amide intermediate (995 mg, 99%). mp 146–148°C; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 1.02–1.29 (m, 4H), 1.38 (s, 9H), 1.59–1.94 (m, 23H), 2.19 (d, J = 6.8 Hz, 2H), 2.63 (dd, J = 11.8, 11.8 Hz, 1H), 3.02 (dd, J = 12.2, 12.2 Hz, 1H), 3.39–3.51 (m, 1H), 3.80 (d, J = 13.7 Hz, 1H), 4.23 (d, J = 13.2 Hz, 1H), 6.84 (d, J = 7.8 Hz, 1H). Step 2. A 15 mixture of the above amide (505 mg, 1 mmol) and *p*-toluenesulfonic acid monohydrate (951 mg, 5 mmol) in EtOAc/isopropanol (9:1, 50 ml) was stirred at rt for 48 h. The precipitate was filtered, washed with EtOAc (20 ml), dissolved in 20 % aq. ethanol (90 ml), and basified with 14% aq. KOH (10 ml). The solid was filtered, dissolved in CHCl_3 , dried over MgSO_4 , and concentrated. To a solution of the above free base (170 mg) in EtOAc (10 ml) was added a solution of *p*-toluenesulfonic acid monohydrate (80 mg, 0.42 mmol) in EtOAc (10 ml). The precipitate was collected by filtration, washed with EtOAc (10 ml), and dried to give trioxolane OZ339 (180 mg, 31%) as a colorless solid. mp 154–156°C; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 1.05–1.18 (m, 2H), 1.20–1.29 (m, 1H), 1.30–1.42 (m, 1H), 1.59–1.97 (m, 23H), 2.22 (d, J = 5.4 Hz, 2H), 2.29 (s, 3H), 2.57 (dd, J = 11.8, 11.8 Hz, 1H), 3.02 (dd, J = 12.2, 12.2 Hz, 1H), 3.24 (br s, 1H), 3.92 (d, J = 13.7 Hz, 1H), 4.39 (d, J = 13.2 Hz, 1H), 7.12 (d, J = 7.8 Hz, 2H), 7.48 (d, J = 7.8 Hz, 2H), 7.82 (s, 3H); ^{13}C NMR (125.7 MHz, $\text{DMSO}-d_6$) δ 20.94, 25.97, 26.37, 29.61, 29.77, 30.48, 32.73, 33.67, 34.41, 35.93, 36.25, 38.37, 43.32, 47.66, 47.75, 108.58, 110.62, 125.64, 128.23, 137.81, 145.84, 169.78. Anal Calcd for $\text{C}_{30}\text{H}_{44}\text{N}_2\text{O}_7\text{S}$: C, 62.47; H, 7.69; N, 4.86. Found: C, 62.57; H, 7.54; 20 N, 4.76.

cis-Adamantane-2-spiro-3'-8'-(2'-oxo-2'-hydrazinoethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ340). To a stirred solution of the methyl ester of **OZ78** (0.68 g, 2 mmol) in methanol (10 ml) and THF (5 ml) was added hydrazine monohydrate (3 ml, 60 mmol). The resulting mixture was heated at 50–60°C for 24 h, then cooled to rt, and concentrated. The residue was dissolved in EtOAc (100 ml), washed with water (50 ml) and brine (50 ml), dried over MgSO₄, and filtered. After removal of the solvent, the crude product was purified by crystallization from CH₂Cl₂/EtOH to afford trioxolane **OZ340** (0.56 g, 83%) as a colorless solid. mp 124–126 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.15–1.35 (m, 2H), 1.61–2.02 (m, 21H), 2.03 (d, J = 6.8 Hz, 2H), 3.55–4.09 (m, 2H), 6.76 (s, 1H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.46, 26.85, 29.99, 33.36, 33.91, 34.77, 36.37, 36.77, 41.23, 108.43, 111.40, 172.77. Anal Calcd for C₁₈H₂₈N₂O₄: C, 64.26; H, 8.39; N, 8.33. Found: C, 64.12; H, 8.42; N, 8.12.

cis-Adamantane-2-spiro-3'-8'-(2'-oxo-2'-guanidinoethyl)-1',2',4'-trioxaspiro[4.5]decane (OZ341). A solution of potassium *tert*-butoxide (0.56 g, 5.0 mmol) and guanidine hydrochloride (0.48 g, 5.0 mmol) in dioxane (20 ml) was heated under N₂ at 50°C for 20 min. After the mixture was cooled to rt, a solution of the **OZ78** active ester (0.46 g, 1.05 mmol) in CHCl₃ (20 ml) was added dropwise. The mixture was stirred at rt for 4 h and then concentrated. After addition of water (30 ml), the resulting precipitate was collected, washed with water, and dried to give trioxolane **OZ341** (0.36 g, 94%) as a colorless solid. mp 146–147 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.19–1.35 (m, 2H), 1.61–2.07 (m, 21H), 2.21 (d, J = 7.3 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.49, 26.89, 30.13, 33.71, 34.16, 34.80, 36.39, 36.82, 47.35, 108.87, 111.21, 161.10. Anal Calcd for C₁₉H₂₉N₃O₄: C, 62.79; H, 8.04; N, 11.56. Found: C, 63.00; H, 7.88; N, 11.42.

cis-Adamantane-2-spiro-3'-8'-[[1',1'-dioxido-4'-thiomorpholinyl]carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane (OZ342). Step 1. To a solution of the **OZ78** active ester (0.5 g, 1.14 mmol) in CHCl₃ (15 ml) was added dropwise a solution of thiomorpholine (0.15 g, 1.45 mmol) in CHCl₃ (10 ml). The resulting mixture was stirred at rt for 1.5 h and then quenched with water (30 ml). After separation of the organic layer, the aqueous layer was extracted with CHCl₃ (2 x 20 ml). The combined extracts were washed with water (2 x 20 ml) and brine (20 ml), dried over MgSO₄, and filtered. After removal of the solvent, the crude product was purified by

crystallization from ether to afford the thioether intermediate (0.45 g, 97%) as a colorless solid. mp 126–127 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.15–1.31 (m, 2H), 1.59–2.05 (m, 21H), 2.20 (d, J = 6.8 Hz, 2H), 2.57–2.63 (m, 4H), 3.69–3.78 (m, 2H), 3.85–3.92 (m, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.48, 26.86, 27.46, 27.94, 30.31, 33.21, 34.05, 34.79, 36.39, 36.79, 39.36, 44.29, 48.41, 108.59, 111.35, 170.40. **Step 2.** To a solution of the above thioether intermediate (0.39 g, 0.96 mmol) in CH₂Cl₂ (10 ml) at 0°C was added dropwise a solution of *m*-CPBA (0.52 g, 2.1 mmol) in CH₂Cl₂ (15 ml). The resulting mixture was stirred at rt for 24 h and then partitioned between CH₂Cl₂ (20 ml) and saturated aq. NaHCO₃ (20 ml). The organic layer was washed with water (20 ml) and brine (20 ml), dried over MgSO₄, and filtered. After removal of the solvent, the crude product was purified by crystallization from CH₂Cl₂/EtOH to afford trioxolane **OZ342** (0.34 g, 81%) as a colorless solid. mp 159–160°C; ¹H NMR (500 MHz, CDCl₃) δ 1.15–1.33 (m, 2H), 1.59–2.03 (m, 21H), 2.26 (d, J = 6.8 Hz, 2H), 3.02 (s, 4H), 3.96 (s, 2H), 4.11 (s, 2H); ¹³C NMR (125.7 MHz, CDCl₃) δ 26.46, 26.85, 30.25, 33.07, 33.96, 34.78, 36.38, 36.77, 39.04, 40.22, 43.90, 52.14, 52.28, 108.35, 111.48, 170.54. Anal Calcd for C₂₂H₃₃NO₆S: C, 60.11; H, 7.57; N, 3.19. Found: C, 60.30; H, 7.43; N, 3.23.

EXAMPLE 2

Antimalarial Activity of OZ01-OZ342

Each trioxolane was screened against the chloroquine-resistant K1 and chloroquine-sensitive NF54 strains of *P. falciparum* *in vitro*. In the single dose STI *in vivo* screen, Moro SPF or NMRI mice infected with the ANKA strain of *P. berghei* (groups of three mice) were treated on day one post-infection with trioxolanes dissolved or suspended in 3% ethanol and 7% Tween 80. Trioxolanes were administered as single 10 mg/kg doses sc and po. Trioxolanes were also administered as single 10 mg/kg doses in standard suspending vehicle (SSV). SSV consists of 0.5% w/v CMC, 0.5% v/v benzyl alcohol, 0.4% v/v Tween 80, and 0.9% w/v sodium chloride in water. Antimalarial activity was measured by percent reduction in parasitemia on day three post-infection and survival times compared to an untreated control group. Survival to day 30 post-infection is considered to be a cure. In U.S. Patent No. 6,486,199, Table 1 presented data for trioxolanes OZ01–OZ90 along with the controls, fenozan, artemisinin, arteether, artemether, and artesunate.

The data showed that antimalarial activity falls off both when the trioxolane peroxide bond is too exposed or is sterically inaccessible to iron(II) species. Other factors influencing antimalarial activity include the stability of carbon radicals formed by β -scission subsequent to the initial electron transfer to the peroxide bond and the influence of steric effects remote from the peroxide bond on the interactions between carbon radicals and potential drug targets. The data also demonstrated that trioxolane carboxylic acids are usually less active than their hydrocarbon, ester, and hydroxamic acid counterparts.

Below is the activity data for OZ91-OZ342:

10

Table 1

Compd	IC ₅₀ (ng/ml) K1/NF54	Activity (%)		Survival (days) 10 mg/kg po/SSV po/sc
		10 mg/kg po/SSV	po/sc	
NONE	---	0		6-7
OZ91	1.4/0.42	20/0/85		5.7/6.0/7.3
OZ92	1.6/0.40	81/35/99.98		6.7/6.3/10.0
OZ93	3.3/0.92	57/3/100		6.7/6.0/13.3
OZ94	57/28	21/0/11		6.0/5.7/5.3
OZ95	2.8/1.3	31/0/49		6.0/6.0/6.0
OZ96	8.4/>10	12/14/19		5.7/5.7/5.3
OZ97	2.2/1.8	59/2/66		6.7/5.3/7.0
OZ98	2.3/0.9	72/11/77		6.3/5.3/7.3
OZ99	77/27	30/40/36		6.3/5.7/6.3
OZ100	1.4/0.34	61/36/80		6.7/6.3/7.0
OZ101	3.0/1.6	44/0/99.97		6.3/5.3/13

OZ102	1.6/0.45	92/73/99.97	7.0/6.7/19.7
OZ103	0.64/0.17	86/63/87	7.3/6.7/7.3
OZ104	1.4/0.50	56/0/99.98	6.3/5.7/12.0
OZ105	5.4/5.0	16/0/28	5.7/5.7/6.3
OZ106	2.2/1.7	0/0/0	5.3/5.05.3
OZ107	1.0/0.30	70/32/99.74	6.3/6.3/8.0
OZ108	68/29	0/0/0	5.0/5.0/5.7
OZ109	21/24	2/0/24	5.7/5.7/6.3
OZ110	5.3/2.1	50/0/97.97	6.7/5.3/7.7
OZ111	0.92/0.35	98/79/99.94	7.7/6.3/8.3
OZ112	>10/>10	6/0/36	5.7/5.7/6.3
OZ113	0.95/0.20	92/96/89	7.3/8.0/7.3
OZ114	3.7/2.2	0/0/99.64	5.7/6.0/8.7
OZ115	11/6.9	33/0/97	6.3/5.7/7.3
OZ116	4.2/3.3	97/96/96	7.7/8.3/8.0
OZ117	2.1/1.2	95/96/99.94	7.0/7.7/8.7
OZ118	1.0/0.24	99.0/98/99.57	7.0/8.0/8.3
OZ119	0.83/0.20	99.29/99.15/99.66	7.7/8.0/8.3
OZ120	1.2/0.59	33/8/96	6.0/5.7/8.0
OZ121	0.96/0.41	91/98/99.61	7.3/8.0/7.3
OZ122	>100/>100	10/3/0	5.7/5.3/5.0
OZ123	1.6/1.9	99.66/94/99.96	8.0/7.0/16
OZ124	2.1/1.7	72/17/86	6.3/5.3/7.0

OZ125	68/>100	8/0/0	5.3/5.7/6.0
OZ126	0.20/0.50	55/72/99.44	7.0/6.7/8.5
OZ127	0.61/1.3	95/98/97	7.0/7.7/7.7
OZ128	0.59/1.1	99.93/99.95/99.98	8.3/8.7/11.7
OZ129	10/>10	0/4/0	5.3/5.7/5.7
OZ130	0.62/0.94	98.8/98.9/98.6	9.0/8.0/7.3
OZ131	1.7/4.1	21/41/90	5.7/6.0/8.0
OZ132	9.8/>10	38/0/40	6.3/5.7/6.3
OZ133	0.70/1.1	94/97/72	7.0/7.3/7.0
OZ134	0.88/1.1	72/27/99.95	6.3/6.0/15.3
OZ135	>100/>100	1/0/0	5.3/5.3/5.3
OZ136	23/21	0/0/0	6.0/6.0/6.0
OZ137	11/18	0/6/61	5.7/6.3/7.0
OZ138	10/19	0/5/7	5.7/6.3/6.3
OZ140	5.9/8.2	0/8/60	6.0/6.3/7.0
OZ141	1.7/1.9	98/97/99.89	8.0/8.0/8.7
OZ142	2.3/2.3	0/2/99.98	6.0/6.3/14.3
OZ143	0.98/1.8	48/44/99.85	6.7/6.7/9.7
OZ144	1.4/2.1	99.45/92/99.94	7.3/7.3/16.7
OZ145	0.50/0.76	99.82/99.21/99.87	8.3/10.7/10.7
OZ146	2.2/2.7	62/40/91	7.0/6.3/9.0
OZ147	1.1/1.8	85/71/99.89	8.0/8.0/19.7
OZ148	17/16	38/58/21	7.3/7.7/6.3

OZ149	8.0/8.8	64/3/87	7.7/6.0/14.3
OZ151	3.8/4.0	71/71/99.63	7.3/7.3/11.0
OZ152	3.2/7.2	0/12/22	6.3/6.7/6.7
OZ153	7.7/19	15/23/20	6.3/7.0/6.3
OZ154	5.0/6.1	99.74/81/59	14.7/8.7/7.7
OZ155	12/>10	53/53/73	6.3/7.0/8.3
OZ156	2.1/2.1	99.98/98.8/99.98	17.0/10.3/19.7
OZ157	0.20/0.22	90/80/97	7.3/8.3/8.3
OZ159	0.70/0.94	34/31/98	6.7/6.7/9.0
OZ160	0.70/0.87	45/43/99.94	6.3/6.7/12.0
OZ161	0.40/0.50	59/46/99.96	7.0/6.7/12.7
OZ162	0.50/0.71	41/22/99.55	6.3/6.3/9.3
OZ163	0.2/0.2	99.90/99.94/100	8.0/9.0/9.7
OZ164	59/>10	11/0/7	5.7/5.7/6.3
OZ165	39/>10	18/3/9	6.3/6.0/5.7
OZ166	28/>10	11/0/4	6.7/6.3/5.7
OZ167	6.7/>10	0/6/97	6.0/6.0/7.3
OZ169	15/>10	98/22/99.76	7.7/6.7/9.0
OZ171	1.3/1.4	98/85/99.94	9.0/7.0/9.7
OZ172	3.5/5.0	68/82/100	8.0/10.3/10.3
OZ173	58/32	15/0/80	7.0/6.7/9.7
OZ174	27/34	0/15/90	6.7/7.3/10.3
OZ175	1.4/2.0	99.1/97/92	10.0/12.3/8.7

OZ176	25/35	11/18/24	7.0/7.7/7.0
OZ177	0.9/1.7	99.91/99.88/99.91	12.3/12.7/17.7
OZ178	21/27	32/23/31	7.3/7.3/10.0
OZ179	1.3/1.1	99.91/99.78/99.91	11.3/10.3/11.3
OZ180	3.7/2.8	99.91/97/65	13.7/12.7/10.3
OZ181	0.58/0.35	99.98/99.91/100	9.0/10.0/11.0
OZ182	4.5/5.5	91/96/95	8.0/7.3/7.7
OZ183	0.80/2.1	65/19/81	6.0/6.0/8.3
OZ184	1.0/1.4	54/59/97	6.7/7.0/8.7
OZ185	1.1/1.4	86/56/99.96	7.7/6.7/10.7
OZ186	>10/>10	87/96/67	8.0/9.0/8.0
OZ187	4.0/6.8	77/94/77	7.7/10.0/7.0
OZ188	1.5/3.0	93/98/99.87	8.7/10.0/9.0
OZ189	1.7/3.0	95/99.79/98	9.3/9.0/10.7
OZ190	0.16/1.0	98/78/2	8.7/7.7/5.7
OZ191	6.0/>10	7/5/17	5.7/5.7/6.0
OZ192	2.5/4.4	38/45/99.98	6.0/7.0/13.7
OZ193	5.5/8.3	99.75/93/99.92	9.3/8.0/11.0
OZ194	2.0/6.6	87/73/99.95	8.3/8.0/20.3
OZ195	2.2/3.7	98/99.02/99.75	9.3/10.7/9.0
OZ196	>10/>10	10/0/17	6.0/5.3/5.7
OZ197	1.0/2.0	87/90/99.54	7.7/8.7/10.3
OZ198	>10/>10	4/6/6	5.7/6.0/5.7

OZ199	0.69/1.1	99.48/76/99.44	8.3/7.7/8.7
OZ200	1.0/2.9	81/78/92	7.0/7.3/8.0
OZ201	2.0/3.1	100/100/100	13/10.3/25
OZ202	6.0/7.9	79/51/74	7.0/7.3/7.3
OZ203	3.9/6.7	87/99.42/99.72	7.3/8.7/9.7
OZ204	>10/>10	0/0/0	6.0/6.3/6.0
OZ205	1.5/2.0	99.96/99.94/99.96	10.0/8.7/9.7
OZ206	1.0/2.7	93/92/91	8.0/8.7/9.7
OZ207	0.33/0.57	99.96/99.98/99.98	9.3/12.0/11.3
OZ208	6.0/6.5	0/29/10	6.3/6.7/5.7
OZ209	0.21/0.32	99.94/99.96/99.97	9.5/10.0/12.5
OZ210	1.4/1.6	99.23/77/99.94	9.3/8.0/10.3
OZ211	1.0/1.2	82/78/99.90	8.0/7.3/8.7
OZ212	2.7/2.9	66/25/59	6.7/6.7/8.0
OZ213	2.3/2.8	83/74/85	8.0/8.0/8.0
OZ214	>10/>10	44/54/65	6.3/7.3/7.7
OZ215	6.4/7.3	96/25/39	9.76.3/7.0
OZ216	0.40/0.67	62/69/99.02	6.3/7.7/11.0
OZ217	2.0/2.0	67/8/98	7.0/6.0/8.0
OZ218	2.0/3.0	98/99.30/99.68	10.0/14.3/9.0
OZ219	0.85/1.6	99.89/99.82/99.91	8.7/8.0/9.3
OZ220	6.9/4.9	40/0/99.95	6.0/5.3/10.0
OZ221	>10/>10	80/87/97	6.3/7.0/8.0

OZ222	3.9/6.3	87/75/99.76	7.7/7.0/10.0
OZ223	4.0/>10	89/79/99.57	7.3/6.3/12.0
OZ224	2.0/3.0	0/5/20	6.0/5.7/5.7
OZ225	7.3/>10	0/0/17	5.7/5.7/6.3
OZ226	4.0/4.0	0/0/99.92	5.0/5.3/11.0
OZ227	0.20/0.20	99.68/99.90/99.84	8.3/9.3/10.7
OZ228	2.0/2.1	99.94/28/99.94	10.3/6.0/14.0
OZ229	0.24/0.23	99.96/99.08/99.98	10.0/8.3/12.7
OZ230	3.9/3.6	0/0/0	5.3/5.7/5.7
OZ231	>10/>10	0/0/0	5.3/5.7/6.0
OZ232	0.30/0.50	76/74/99.94	8.0/7.3/8.7
OZ233	1.7/1.9	69/76/99.66	7.0/7.7/8.3
OZ234	3.0/3.6	12/0/0	6.0/6.0/6.3
OZ235	1.0/2.0	99.92/99.97/97	8.7/9.0/8.0
OZ236	2.0/2.0	89/86/98.61	6.3/7.7/7.7
OZ237	5.7/7.1	5/9/52	6.0/6.0/6.7
OZ243	0.91/1.1	87/97/70	7.3/8.7/6.3
OZ244	4.0/4.2	6/0/18	5.7/5.3/6.3
OZ247	1.8/2.3	57/27/99.85	6.3/6.0/9.0
OZ251	0.60/0.35	29/6/99.87	6.7/6.0/9.0
OZ252	2.3/2.2	98.91/99.49/99.82	8.3/9.0/9.3
OZ253	0.56/0.45	75/59/99.82	7.0/6.7/9.3
OZ254	>100/57	27/11/2	6.0/5.7/5.7

OZ255	2.2/1.1	99.61/99.54/99.92	9.0/8.7/10.0
OZ256	0.3/0.2	99.70/99.67/99.95	8.7/8.7/9.7
OZ257	42/21	99.00/99.49/99.84	8.3/7.7/9.7
OZ258	5.8/5.2	75/70/99.95	6.0/6.0/10.7
OZ260	5.6/4.3	72/51/81	6.7/7.0/7.7
OZ261	39/18	61/47/92	7.0/7.0/8.0
OZ262	0.63/0.84	96/98/99.39	11.7/12.3/10.0
OZ263	0.84/1.1	99.53/99.45/99.92	13.0/13.3/11.0
OZ264	1.2/1.5	99.61/99.92/99.97	11.0/10.3/13.7
OZ265	0.56/1.6	99/98/99.67	13.0/9.7/11.7
OZ266	1.1/1.5	99/99.39/99.75	13.7/11.7/11.7
OZ267	0.20/0.34	99.92/99.89/99.97	8.3/8.7/9.3
OZ268	0.44/0.71	99.86/99.47/99.92	9.3/13.3/9.7
OZ269	0.32/0.61	98/86/99.92	10.7/11.3/9.0
OZ270	0.85/1.3	99.17/99.47/99.81	13.7/12.3/11.3
<u>Compd</u>	<u>IC₅₀ (ng/ml) K1/NF54</u>	<u>Activity (%) 10/3 mg/kg SSV po</u>	<u>Survival (days) 10/3 mg/kg SSV po</u>
OZ271	0.36/0.29	99.93/99.52	8.7/8.6
OZ272	1.1/1.3	98/49	10.3/6.6
OZ273	0.97/1.0	99.58/64	11.7/7.2
OZ274	5.1/5.7	11/ND	7.0/ND
OZ275	0.66/0.74	68/ND	7.3/ND
OZ276	0.86/0.94	17/ND	7.3/ND
OZ277	0.57/0.58	99.98/99.28	9.3/9.6

OZ278	23/39	56/ND	7.3/ND
OZ279	0.21/0.24	99.98/99.42	9.3/8.4
OZ280	1.2/1.4	0/ND	5.7ND
OZ281	0.50/0.30	99.87/96	8.7/10.2
OZ282	2.0/2.4	98.5/53	8.3/7.2
OZ283	1.7/2.0	99.81/56	8.3/8.2
OZ284	1.0/1.4	97/61	9.0/7.8
OZ285	1.3/1.8	99.81/72	8.7/7.6
OZ286	0.94/1.6	99.73/60	8.7/7.0
OZ287	0.49/0.83	95/68	8.3/7.2
OZ288	1.7/2.7	99.96/82	11.0/8.0
OZ289	0.40/0.56	99.94/92	13.4/7.4
OZ290	0.42/0.45	99.64/95	9.0/7.0
OZ291	0.52/0.72	98/34	8.0/6.8
OZ292	0.19/0.26	74/46	7.0/6.6
OZ293	0.25/0.34	99.58/77	8.8/7.4
OZ294	0.39/0.63	99.79/70	8.6/7.4
OZ295	0.44/0.75	47/35	7.0/6.4
OZ296	0.60/0.89	99.22/90	10.0/9.2
OZ297	0.49/0.76	99.69/83	9.8/7.6
OZ298	2.0/3.0	99.95/98	9.4/9.0
OZ299	6.8/6.3	36/0	6.6/6.4
OZ300	71/97	6/0	6.8/7.0

OZ301	2.1/2.8	100/97	11.8/8.4
OZ302	1.9/2.9	99.60/88	9.0/9.0
OZ303	1.6/2.4	99.01/69	8.6/7.6
OZ304	1.6/2.3	98/61	8.2/8.8
OZ305	1.8/1.9	99.93/96	9.2/9.6
OZ306	3.9/3.6	99.58/87	9.2/8.2
OZ307	0.62/0.88	98/74	9.4/7.8
OZ308	1.2/1.7	86/30	7.8/6.6
OZ309	11/17	99.80/86	8.8/7.8
OZ310	0.82/1.1	81/38	7.8/8.2
OZ311	1.2/1.8	80/40	8.6/7.0
OZ312	19/27	43/13	7.2/6.2
OZ313	0.55/0.76	98.9/58	10.4/7.4
OZ314	11/17	13/11	6.6/6.6
OZ315	2.8/3.0	99.97/92	11.2/9.6
OZ316	1.0/1.7	69/7	10.0/8.0
OZ317	0.33/0.36	99.92/99.20	9.8/10.0
OZ318	0.56/0.82	88/29	12.4/7.6
OZ319	0.41/0.91	99.92/99.14	10.6/10.8
OZ320	0.68/1.30	99.76/92	10.4/11.8
OZ321	0.58/0.97	99.77/64	14.0/9.8
OZ322	0.90/1.5	98/61	10.0/9.4
OZ323	0.85/1.1	99.98/99.92	15.6/9.2
OZ324	2.4/3.4	60/26	9.4/7.4

OZ325	0.62/1.4	99.43/30	8.8/6.2
OZ326	0.65/1.2	80/7	7.4/6.0
OZ327	0.85/1.1	97/72	9.8/7.0
OZ328	1.4/3.0	99.77/75	8.6/7.6
OZ329	0.43/0.68	99.97/99.50	11.2/9.2
OZ330	0.55/1.2	99.96/82	12.2/7.2
OZ331	0.50/1.2	99.47/66	9.0/7.0
OZ332	1.7/2.5	8/0	6.0/6.0
OZ333	0.24/0.44	99.86/96	9.2/8.0
OZ334	28/20	47/13	6.8/6.6
OZ335	0.29/0.28	99.95/97	9.2/10.0
OZ336	1.4/0.91	99.93/98	9.2/9.6
OZ337	0.29/0.25	99.92/97	8.6/11.6
OZ338	0.38/0.45	99.93/99.80	9.8/8.0
OZ339	0.35/0.39	99.95/99.65	10.2/9.2
OZ340	4.9/2.9	93/36	9.2/6.4
OZ341	2.4/2.0	97/32	8.0/7.0
OZ342	1.8/1.2	27/0	6.8/6.4
AM	0.45/0.36	99.75/79	9.4/8.7
AS	1.4/1.5	87/66	7.0/8.0
CQ	76/4.4	99.92/82	9.0/8.0
MFQ	2.2/5.0	99.11/9	17/6.3

As shown in the inventors' earlier studies with OZ01 to OZ90, antimarial activity falls off when the trioxolane peroxide bond is too exposed or is sterically inaccessible to iron(II) species. Other factors influencing 5 antimarial activity include the stability of carbon radicals formed by β -scission subsequent to the initial electron transfer to the peroxide bond and the influence of steric effects remote from the peroxide bond on the interactions between carbon radicals and potential drug targets. The new activity data demonstrates that trioxolane carboxylic acids are usually less active than their 10 hydrocarbon, ester, amide, and hydroxamic acid counterparts. The position of ionizable functional groups such as carboxylic acids and amines is also critical to activity. The best combination of high intrinsic potency and good oral activity is found when a weak base functional group is present.

15

EXAMPLE 3

Onset of Action and Recrudescence of OZ11, OZ27, OZ78, OZ156, OZ175, OZ177, OZ207, OZ209, OZ277, and OZ279

Onset of Action and Recrudescence Experiments

20

The onset of drug action was determined after a single fixed dose of 100 mg/kg (SSV vehicle) po to groups of five animals on day +3 post- infection (day 0). Parasitemias at this point are usually between 25-40%. The infected controls do not survive beyond day +6 post-infection. The reduction of parasitemia is monitored 12, 24, and 48 h after treatment, and the time of recrudescence (> 5% parasitemia) is assessed by daily blood smears for 14 days, followed by intermittent assessment for up to 60 days.

25

The onset part of this experiment reveals how rapidly a compound reduces parasite load; the recrudescence part of the experiment provides information about the efficacy of the compound against the parasite. A long delay in recrudescence can be due to a very good antiparasitic effect of the compound or to a compound with a long half-life.

30

Both the trioxolanes and the artemisinins produced a rapid decline in parasitemia, confirming that they are rapidly acting antimarial agents. In contrast to both chloroquine and these peroxidic antimarials, mefloquine has a slow onset of action. Recrudescence (>

5% parasitemia) occurs quite rapidly for artemisinin and artesunate. The time of recrudescence increased for the more lipophilic artemisinin derivatives artemether and arteether.

In contrast to artemether, recrudescence occurred much more slowly for the 5 lipophilic trioxolanes OZ11 and OZ27; the recrudescence time for OZ27 was especially marked, superior to that of mefloquine. However, recrudescence times for the relatively polar trioxolanes OZ78, OZ175, and OZ277 were very similar to that of artemether. The more lipophilic trioxolane (OZ156) of the OZ156/OZ177 pair produced the longest delay in recrudescence, longer than chloroquine, but less than mefloquine. The recrudescence 10 times for OZ177 and OZ279 were roughly equivalent to that of chloroquine.

Strikingly, there was no recrudescence observed for OZ207 and OZ209, two different salt forms (OZ207 – tosylate, OZ209 – mesylate) of aminomethyl trioxolane 15 OZ163 (hydrochloride). The recrudescence data for these two trioxolanes suggests that they are either more powerful antimalarial agents or have longer half-lives than any of the semisynthetic artemisinins.

Table 2

Compd	Time of Recrudescence (days)
OZ11	22.2
OZ27	22.0 (3/5), > 60 (2/5)
OZ78	11.2
OZ156	19.0 (4/5), > 60 (1/5)
OZ175	13.0
OZ177	18.5
OZ207	> 60
OZ209	> 60
OZ277	13.0
OZ279	15.0
Artemisinin	8.4
Artesunate	8.6
Artemether	12.0
Arteether	11.4
Chloroquine	17.8
Mefloquine	28.0

EXAMPLE 4

Effect of Trioxolanes on *Schistosoma* Species

Effect of Trioxolane OZ207 on *Schistosoma japonicum*

5

Table 3

Comparative effect of OZ207 and artemether in mice infected with *Schistosoma japonicum*

Drug	Age of worm	Dose (mg/kg × 1)	Mice without ♀ worm	MTWB/ x± SD	WRR/ %	MFWB/ x± SD	FWR R/ %
Control	-	-	0/8	26.6 ± 4.2	-	11.6 ± 2.4	-
OZ207	35 days	200	4/7	9.1 ± 3.9	66	0.6 ± 0.7	95
OZ207	35 days	400	4/6	4.3 ± 1.2	84	0.7 ± 1.2	94
Artemether	35 days	400	0/7	10.1 ± 4.4	62	3.4 ± 1.6	71
OZ207	7days	200	0/8	5.4 ± 2.4	81	2.1 ± 1.0	82

MTWB, mean total worm burden; WRR, worm reduction rate MFWB, mean female worm burden; FWRR, female worm reduction rate.

Table 3 illustrates that the mean total worm burden and mean female worm burden in OZ207 400 mg/kg group was significantly lower than those in artemether 400 mg/kg group ($P<0.01$). The mean female worm burden in OZ207 200 mg/kg group was also significantly lower than that in artemether group ($P<0.01$).

Effect of Trioxolanes on 21-day-old schistosomules

Mice were infected with 100 *Schistosoma mansoni* cercariae on day 21 post-treatment. Each group was treated per os with trioxolanes at a single dose of 200 mg/kg. Untreated mice served as the control. All groups were killed 4 weeks after treatment and the liver and intestine were removed and separated. The liver and intestine were compressed and alive male and female worms could be seen and counted. The effect of the compounds was evaluated by mean total and female worm burden. The results are shown in Table 5.

Effect of Trioxolanes on adult schistosomes (49-day-old)

Mice were infected with 100 *Schistosoma mansoni* cercariae on day 49 post-treatment. Each group was treated per os with OZ compounds at single doses of 200, 400, and 600 mg/kg. Untreated mice served as the control. All groups were killed 4 weeks after

treatment and the liver and intestine were removed and separated. The liver and intestine were compressed and alive male and female worms could be seen and counted. The effect of the compounds was evaluated by mean total and female worm burden, and the results are set forth in Table 4.

5

Table 4

IN VIVO ACTIVITY AGAINST SCHISTOSOMA MANSONI (MICE INFECTED)						
TESTED	% reduction of schistosomule growth at day 21 after per os		% reduction of adult worms growth at day 49 after per os			application of mg/kg
	application of 200 mg/kg		200		400	
	TWR (%)	FWR (%)	TWR (%) / DEAD WORM (%)			
OZ 03	liquid	74	74		29 / 8	
OZ 04		7	7		0 / 0	
OZ 05		90	88	46 / 12	23 / 32*	70 / 58
OZ 10		66	73		28 / 13	21 / 23
OZ 11		85	84		16 / 4	
OZ 12		78	79		14 / 0	
OZ 14		7	0		0 / 0	
OZ 15		63	70		0 / 10	
OZ 16		78	77		ND	
OZ 17		23	7		0 / 5	
OZ 18		12	9		0 / 0	
OZ 19		77	74		ND	
OZ 20		0	0		0 / 0	
OZ 21		0	0		0 / 0	
OZ 22	liquid	75	76		ND	
OZ 23		90	84		0 / 4	
OZ 24		65	61		21 / 0	
OZ 25		86	84		46 / 34	
OZ 26		37	40		ND	

OZ 27	63	58		20 / 10	
OZ 28	81	87		ND	
OZ 29	28	20		0 / 0	
OZ 30	16	12		ND	
OZ 31	60	63		4 / 4	
OZ 32	73	70		27 / 28	
OZ 33	28	14		ND	
OZ 35	73	63		ND	
OZ 36	16	12		0 / 0	

IN VIVO ACTIVITY AGAINST SCHISTOSOMA MANSONI (MICE INFECTED)					
OZ COMPOUNDS TESTED	% reduction of schistosomule growth at day 21 after per os application of 200 mg/kg		% reduction of adult worms growth at day 49 after per os application of mg/kg		
			200	400	600
	TWR (%)	FWR (%)	TWR (%) / DEAD WORM (%)		
OZ 37	63	53		ND	
OZ 43	ND	ND		1 / 0	
OZ 49	ND	ND		17 / 10	
OZ 50	ND	ND		12 / 4	
OZ 56	69	66		ND	
OZ 61	ND	ND		8 / 21	
OZ 67	ND	ND		38 / 0	
OZ 68	ND	ND		17 / 0*	
OZ 71	91	85		0 / 16	
OZ 72	ND	ND		0 / 10	
OZ 76	ND	ND		32 / 0	
OZ 78	82	87	24 / 29	0 / 17	0 / 14
OZ 79	ND	ND		4 / 0	
OZ 80	79	75	0 / 3	ND	
OZ 81	ND	ND		28 / 0	

OZ 83	ND	ND	7 / 19	
OZ 89	86	81	0 / 17	
OZ 90	81	79	ND	
OZ 105	ND	ND	8 / 0	
OZ 107	ND	ND	26 / 4	
OZ 108	30	28	28 / 0	
OZ 111	71	68	ND	
OZ 119	88	87	ND	
OZ 126	ND	ND	0 / 9	
OZ 130	ND	ND	0 / 8	
OZ 140	ND	ND	0 / 3	
OZ 145	80	83	ND	
OZ 148	ND	ND	25 / 0	
OZ 151	19	19	ND	
OZ 152	19	11	ND	
OZ 153	ND	ND	no dead worm*	

IN VIVO ACTIVITY AGAINST SCHISTOSOMA MANSONI (MICE INFECTED)					
OZ COMPOUNDS TESTED	% reduction of schistosomule growth at day 21 after per os		% reduction of adult worms growth at day 49 after per os		
	application of 200 mg/kg		200	400	600
	TWR (%)	FWR (%)	TWR (%) / DEAD WORM (%)		
OZ 154	ND	ND		58 / 0*	
OZ 156	ND	ND		0 / 6	
OZ 157	65	68		ND	
OZ 159	19	19		ND	
OZ 160	0	0		ND	
OZ 163	84	80		ND	
OZ 169	0	0		ND	
OZ 170	ND	ND		12 / 0	
OZ 189	ND	ND		0 / 30*	
OZ 205	84	83		0 / 12	

OZ 207	93	100	32 / 17	35 / 21	11 / 24++
OZ 209	ND	ND	39 / 34	16 / 28+	41 / 21++
OZ 226	ND	ND		52 / 0*	
OZ 256	ND	ND		10 / 19	
OZ 271	ND	ND		0 / 6	
OZ 277	ND	ND		0 / 0	
OZ 279	ND	ND		0 / 12	
OZ 281	ND	ND		12 / 15	
ARTEMETHER	(n2) 81	(n2) 78		(n2)	53 / 29
PRAZIQUANTEL	ND	ND			93 / 89
					100 / 100

TWR = Total worm reduction rate.

FWR = Female worm reduction rate.

DEAD WORM = Percentage of dead worm in the liver.

ND = Not determined

OZ 207 (base): S.haematobium : 1x200 mg/kg p.o.= TWR 73 %, DEAD WORM 68 %

S. Japonicum : 1x200 mg/kg p.o.=TWR 66 %, FWR 95 %
1x400 mg / kg p.o.= TWR 84 %,FWR 94 %

EXAMPLE 5

Activity of Trioxolanes Against *P. berghei*

In the single dose ED₅₀/ED₉₀/ED₉₉ determinations, Moro SPF or NMRI mice

5 (group of three) infected with the ANKA strain of *Plasmodium berghei* were treated on day one post-infection. Trioxolanes were dissolved or suspended in the standard suspending vehicle (SSV)* and administered as single 10, 6, 3, 1, 0.3, and 0.1 mg/kg doses po and sc. The SSV consists of 0.5% w/v CMC, 0.5% v/v benzyl alcohol, 0.4% v/v Tween 80, and 0.9% w/v sodium chloride in water. Antimalarial activity was measured by percent reduction in parasitemia on day three post-infection. The ED₅₀/ED₉₀ values were calculated by nonlinear fitting.

10

Table 5

Compd	ED ₅₀ (mg/kg)	ED ₉₀ (mg/kg)	ED ₉₉ (mg/kg)
OZ05	8.7	12	15
OZ11	4.4	6.2	8.2
OZ27	2.9	5.7	9.9
OZ78	4.2	9.1	17
OZ113	3.6	9.0	19
OZ127	2.5	7.6	19
OZ156	1.3	2.6	4.7
OZ175	3.5	6.2	9.9
OZ177	2.1	3.7	5.8
OZ179	1.4	3.3	6.6
OZ181	0.63	1.8	4.0
OZ205	1.6	3.3	6.0
OZ207	0.37	1.2	3.0
OZ209	0.55	1.4	3.0
OZ219	1.6	3.0	5.2
OZ227	2.3	4.0	6.2
OZ235	4.0	7.1	11
OZ277	0.78	2.0	4.4
OZ279	0.63	1.8	3.9
Artesunate	4.7	19	60
Artelinate	4.8	10	18
Artemether	2.2	4.2	7.1
Chloroquine	1.8	3.5	5.9
Mefloquine	4.0	5.4	6.8

5 Table 5 shows ED₅₀/ED₉₀/ED₉₉ data obtained by po administration of trioxolanes
in the SSV formulation. The relatively lipophilic artemether is substantially more active
than the more polar artesunate and artelinate. In contrast, the most active trioxolanes
(OZ181, OZ207, OZ209) - different salt forms of the same amino trioxolane, and amino
and amide trioxolanes OZ277 and OZ279, are relatively polar compounds.

10

EXAMPLE 6

Dosing of OZ279, OZ277, OZ256, and OZ209

Based on results of dosing OZ279, OZ277, OZ256, and OZ209 in rats and dogs, the inventors determined projected optimal dosing of the same compounds in humans. Artesunate is listed as a reference compound.

5

Table 6

Parameter	Ideal	Accept	Artes	OZ 279	OZ 277	OZ 256	OZ 209
Rat Data							
IV t _{1/2} (10 mg/kg)	180 min	60 min	40 (DHA)	100.5	77.2	94.0	150.0
Oral Bioavailability							
10 mg/kg	>30%	>20%	not done	37.2	36.9	18.6	12.4
25 mg/kg	>30%	>20%	21 (DHA)	71.1	44.1	51.9	22.4
Oral t _{1/2} (25 mg/kg)	180 min	60 min	not done	166.8	90.5	73.3	101.5
Dog Data							
IV t _{1/2} (10 mg/kg)	180 min	60 min	not done	177.5	95.0	85.4	182.8
Oral Bioavailability							
10 mg/kg	>30%	>20%	not done	32.8 (V)	87.9	42.0 (V)	24.5 (V)
25 mg/kg	>30%	>20%	not done	55.7 (V)	96.1	38.3 (V)	15.9 (V)
Oral t _{1/2} (10 mg/kg)	180 min	60 min	not done	195.3	148.1	82.8	127.3
Human Data							
Projected daily dose mg/day (% BA)	150 mg	300 mg	150-300 (actual)	105-154 (30%)	28-56 (30%)	91-133 (20%)	35-70 (20%)

EXAMPLE 7

Effectiveness of Selected OZ Compounds in the Treatment and Prophylaxis of Malarial Infections

5 In Vitro Antimalarial Assays

Various OZ compounds were tested by the semiautomated microdilution assay against intraerythrocytic forms of *Plasmodium falciparum* derived from asynchronous stock cultures. The culture medium used was RPMI 1640 supplemented with 10% human type A⁺ serum, 25 mM HEPES, 25 mM NaHCO₃ (pH 7.3). Human type A⁺ erythrocytes served as host cells. The culture was kept at 37°C in an atmosphere of 3% O₂, 4% CO₂, and 93% N₂ in humidified modular chambers.

Compounds were dissolved in DMSO (10 mg/ml), pre-diluted in complete culture medium, and titrated in duplicate in serial twofold dilutions over a 64-fold range in 96-well microtiter plates. After addition of the parasite cultures with an initial parasitemia (expressed as the percentage of erythrocytes infected) of 0.75% in a 2.5% erythrocytes suspension, the test plates were incubated under the conditions described above for 72 h. Growth of the parasites cultures was measured by the incorporation of radiolabelled [³H]-hypoxanthine added 16 h prior to termination of the test. Fifty percent inhibitory concentration (IC₅₀) were estimated by Logit regression analysis. Compounds were tested against reference *P. falciparum* strains, K1 strain (Thailand resistant to chloroquine) and NF54 strain (an airport strain of unknown origin that is sensitive to standard antimalarials).

In Vivo Antimalarial Assays

Moro NMRI male mice (Fü Albino specific pathogen free) weighing 18 ± 2 g were infected intravenously (i.v.) with 2 × 10⁷ *P. berghei* ANKA strain-infected erythrocytes from donor mice on day 0 of the experiment. From donor mice with circa 30% parasitemia, heparinized blood was taken and diluted in physiological saline to 10⁸ parasitized erythrocytes per ml. An aliquot (0.2 ml) of this suspension was injected i.v. into experimental and control groups of mice. In untreated control mice, parasitemia rose regularly to 40 to 50% by day 3 post-infection and 70 to 80% by day 4 post-infection. The mice died between days 5 and 7 post-infection. Throughout the experiments, mice were kept in groups of three or five animals in Makrolon type II cages in an air-conditioned

animal room at 22 to 23°C. A diet with *p*-aminobenzoic acid (PABA) of 45 mg (NAFAG FUTTER[©] food N° 9009 PAB-45) per kg of body weight, and tap water is available *ad libitum*.

OZ compounds were prepared at an appropriate concentration, either as a solution or a suspension containing SSV (0.5% w/v CMC, 0.5% v/v benzyl alcohol, 0.4% v/v Tween 80, and 0.9% w/v sodium chloride in water). They were administered per os (p.o.) in a total volume of 0.01 ml per gram of mouse. The activity of the compound was determined by a variety of methods outlined in subsequent sections. Survival time was also recorded, and survival to day 30 post-infection was considered to be a cure.

10

Determinations of 50, 90, and 99% effective doses (ED₅₀, ED₉₀, and ED₉₉, respectively) were determined after treatment with a single dose only. Mice were treated once on day 1 post-infection (24 h after infection). On day 3 post-infection (72 h after infection) blood smears of all animals were prepared and stained with Giemsa. Parasitemia was determined microscopically, and the difference between the mean value of the control group (taken as 100%) and those of the experimental groups was calculated and expressed as percent reduction. The ED₅₀, ED₉₀, and ED₉₉ values were calculated by non-linear fitting with statistical program and were expressed in mg/kg.

The first experiment conducted consisted of administration of a divided 3 x 10 mg/kg p.o. dose administered on days 1, 2, and 3 post-infection vs. a single 1 x 30 mg/kg po dose administered on day 1 post-infection. On day 4 post-infection, blood smears of all animals were prepared and stained with Giemsa. Parasitemia was determined microscopically, and the difference between the mean value of the control group (taken as 100%) and those of the experimental groups was calculated and expressed as percent reduction. Compounds were administered orally in the SSV vehicle. The results are shown in Table 7 below:

30

Table 7

	1x30 mg/kg			3x10 mg/kg		
	Activity (%)	Survival (days)	Cures	Activity (%)	Survival (days)	Cures
OZ	p.o. SSV			p.o. SSV		
209	100	>30	0/5	100	>30	3/3
271	99.97	14	0/5	100	27.8	4/5
277	99.92	10.4	0/5	100	27.6	4/5
279	99.95	14.8	0/5	100	25.4	3/5
301	NA	NA	NA	100	>30	5/5
315	NA	NA	NA	100	>30	5/5
CQ	99.94	9.5	0/5	99.99	14.3	0/5
MFQ	99.94	20.3	0/5	99.92	23.3	0/5
AS	83.83	9	0/5	98.62	11	0/5

5 As shown by Table 7, a 3 x 10 mg/kg dose of these trioxolanes cured between 3/5 and 5/5 of the infected mice. At this same dose, none of the standard antimalarial drugs cured any of the infected mice. At the 1 x 30 mg/kg dose, all tested trioxolanes showed activities > 99.9% on day 3 post-treatment.

10 The second experiment consists of administration of divided 3 x 3 mg/kg and 3 x 1 mg/kg po doses administered on days 1, 2, and 3 post-infection. On day 4 post-infection, blood smears of all animals were prepared and stained with Giemsa. Parasitemia was determined microscopically, and the difference between the mean value of the control group (taken as 100%) and those of the experimental groups was calculated and expressed as percent reduction. Compounds were administered orally in the SSV vehicle. The results
15 are shown in Table 8.

	3x3 mg/kg			3x1 mg/kg	
	Activity (%)	Survival (days)	Cures	Activity (%)	Survival (days)
OZ	p.o. SSV			p. . SSV	
209	100	16.4	0\5	99.51	9.4
271	99.99	16.2	0\5	87	8.8
277	100	14	0\5	83	9.4
279	100	14.8	0\5	83	8.8
281	100	12.4	0\5	92	13
288	99	10.2	0\5	49	8.4
289	100	17.2	0\5	41	7.4
290	93	10.6	0\5	14	6.8
296	94	9.4	0\5	49	7.8
297	89	9.4	0\5	22	6.4
298	99.99	16.4	0\5	93	11
301	100	23	1\5	58	8.8
302	99.51	13.4	0\5	87	13.4
305	99.91	12.2	0\5	87	9.6
306	99.75	7.6	0\5	85	11
309	99	9.2	0\5	66	9.4
315	99.99	22	0\5	81	12.2
317	100	16.8	0\5	73	11.4
319	99.97	11.2	0\5	92	13
320	96	9.6	0\5	50	8.6
323	99.95	14.4	0\5	66	14.4
329	100	27	2\5	99.86	11
330	99	12.6	0\5	45	9.2
333	99	10.2	0\5	64	9.4
335	99.99	15.4	0\5	98	10
336	100	20.8	0\5	99.14	10.4
337	99.98	14.4	0\5	96	9.4
338	100	25.6	0\5	98	9.4
339	100	27	3\5	97	9.2
CQ	99.54	10	0\5	25	7.2
MFQ	98	12	0\5	2	6.2
AM	86	9.4	0\5	51	7.2
AS	78	9.4	0\5	39	6.8

As shown by Table 8, at the 3 x 3 mg/kg dose, ten trioxolanes, together with the previously reported OZ209, had activities of 100% and produced high survival numbers.

5 Of these, OZ301, OZ329, and OZ339 cured 1/5, 2/5, and 3/5 of the infected mice, respectively. At the 3 x 1 mg/kg dose, most of the trioxolanes were more potent than the reference antimalarial drugs; ten of these had activities $\geq 90\%$. OZ209, OZ329, and OZ336 were the only trioxolanes with activities greater than 99% at the 3 x 1 mg/kg dose.

Prophylactic activities of the compounds were compared after administering po single dose of 100 mg/kg to different groups of five animals at various times before infection. All groups including an untreated control group, were then infected at the same time. Parasitemia was determined for each animal on day 3 post-infection, and percent of reduction of the level of parasitemia compared to levels for animals given no drug is determined. The results are shown in Table 10.

Table 9

10

				Prophylactic Activity (%)									
	AM	AS	CQ	MFQ	209	256	271	277	279	281			
72 h -				99.97	99.92	13	99.89	9	14	8			
48 h -			57.49	99.92	99.9	29	99.98	7	27	45			
24 h -	0	6.28	99.92	100	100	82	100	25	97	99.23			
0 h	100	92.44	100	100	100	100	100	100	100	100			

15 The unique prophylactic property of OZ209 (3-day protection, same as MFQ) was found also for OZ271.

It should be appreciated that the spiro and dispiro 1,2,4-trioxolane compositions of this invention may contain trioxolanes within the scope of the formulas described above, or prodrugs or analogues of these compounds or a racemic mixture of either the D or the L form. The invention is also intended to include all biologically active salt forms of the compounds. Also, minor dosage and formulation modifications of the composition and the ranges expressed herein may be made and still come within the scope and spirit of the present invention.

Having described the invention with reference to particular compositions, theories of effectiveness, and the like, it will be apparent to those of skill in the art that it is not intended that the invention be limited by such illustrative embodiments or mechanisms, and that modifications can be made without departing from the scope or spirit of the invention, as defined by the appended claims. It is intended that all such obvious modifications and

variations be included within the scope of the present invention as defined in the appended claims. The claims are meant to cover the claimed components and steps in any sequence which is effective to meet the objectives there intended, unless the context specifically indicates to the contrary.

5 All articles cited herein and in the following list are hereby expressly incorporated in their entirety by reference.

CITATIONS

de Almeida Barbosa, L.-C. et al., The Design, Synthesis and Biological Evaluation of Some Stable Ozonides With Anti-malarial Activity. *J. Chem. Soc. Perkin Trans. I*, **1996**, 1101-1105.

10 de Almeida Barbosa, L.-C. et al., Synthesis of Some Stable Oozonides With Anti-malarial Activity. *J. Chem. Soc. Perkin Trans. I*, **1992**, 3251-3252.

15 Cammenga, H.K. et al., Basic principles of thermoanalytical techniques and their applications in preparative chemistry. Angew. Chem. Int. Ed. Engl. 1995, 34, 1171-1187.

Cumming, J.N. et al., Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action. Adv. Pharmacol. 1997, 37, 254-297.

20 Dhingra, V.K. et al., Current Status of Artemisinin and Its Derivatives As Antimalarial Drugs. *Life Sci.* **2000**, 66, 279-300.

Dong, Y.; Vennerstrom, J.L. Peroxidic Antimalarials. *Expert Opin. Ther. Patents* **2001**, 11, 1753-1760.

25 Fishwick, J., et al., The Toxicity of Artemisinin and Related Compounds on Neuronal and Glial Cells in Culture. Chem.-Biol. Interact. 1995, 96, 263-271.

30 Griesbaum, K. et al., Diozonides from coozonolyses of suitable *O*-methyl oximes and ketones. Tetrahedron 1997a, 53, 5463-5470.

Griesbaum, K. et al., Ozonolyses of *O*-alkylated ketoximes in the presence of carbonyl groups: a facile access to ozonides. Liebigs Ann./Recueil. 1997b, 1381-1390.

35 Jefford, C. Peroxidic Antimalarials. Adv. Drug Res. 1997, 29, 271-325.

Kashima, C. et al., Ozonolysis of Five-Membered Heterocycles. *J. Het. Chem.* **1987**, 24, 637-639.

40 Meshnick, S.R. et al., Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol. Rev. 1996, 60, 301-315.

Park, B.K. et al., Safety Assessment of Peroxide Antimalarials: Clinical and Chemical Perspectives. *Br. J. Clin. Pharmacol.* 1998, 46, 521-529.

5 Titulaer, H.A.C., Zuidema, J., and Lugt, C.B. Formulation and pharmacokinetics of artemisinin and its derivatives. *Int. J. Pharmaceut.* 1991, 69, 83-92.

van Agtmael, M.A. et al., Artemisinin Drugs In the Treatment of Malaria: From Medicinal Herb to Registered Medication. *Trends Pharmacol. Sci.* 1999, 20, 199-205.

10 Vennerstrom, J.L. et al., Synthesis and Antimalarial Activity of Sixteen Dispiro-1,2,4,5-tetraoxane Analogs of WR 148999: Alkyl Substituted 7,8,15,16-Tetraoxadispiro[5.2.5.2]hexadecanes. *J. Med. Chem.* 2000, 43, 2753-2758.

15 Vroman, J.A. et al., Current Progress in the Chemistry, Medicinal Chemistry and Drug Design of Artemisinin Based Antimalarials. *Curr. Pharm. Design* 1999, 5, 101-138.

Wesche, D.L. et al., Neurotoxicity of artemisinin analogs in vitro. *Antimicrob. Agents. Chemother.* 1994, 38, 1813-1819.

20 White, N.J. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. *Trans. R. Soc. Trop. Med. Hyg.* 1994, 88, 41-43.